{"8fef15d7ac429bda4de730b663a2d95bbd19a50d": [["IntroductionGiven that animal pathogens (in particular viruses) are considered a significant source of emerging human infections (Cleaveland et al., 2001) , the identification and optimal characterisation of novel organisms affecting both domestic and wild animal populations is central to protecting both human and animal health.", [["human infections", "DISEASE", 112, 128], ["human", "ORGANISM", 112, 117], ["human", "ORGANISM", 306, 311], ["human", "SPECIES", 112, 117], ["human", "SPECIES", 306, 311], ["human", "SPECIES", 112, 117], ["human", "SPECIES", 306, 311], ["animal pathogens", "PROBLEM", 23, 39], ["emerging human infections", "PROBLEM", 103, 128], ["the identification", "TEST", 157, 175], ["novel organisms", "PROBLEM", 208, 223], ["significant", "OBSERVATION_MODIFIER", 81, 92]]], ["Recent outbreaks of human infection caused by influenza H7N7 virus transmitted from poultry (Koopmans et al., 2004) and H1N1 virus transmitted from pigs (Dawood et al., 2009; Itoh et al., 2009 ) are cases in point, highlighting the need for ongoing, vigilant epidemiological surveillance of such pathogens in animal populations.", [["human infection", "DISEASE", 20, 35], ["influenza H7N7 virus transmitted from poultry", "DISEASE", 46, 91], ["human", "ORGANISM", 20, 25], ["influenza H7N7 virus", "ORGANISM", 46, 66], ["H1N1 virus", "ORGANISM", 120, 130], ["pigs", "ORGANISM", 148, 152], ["human", "SPECIES", 20, 25], ["influenza H7N7 virus", "SPECIES", 46, 66], ["H1N1 virus", "SPECIES", 120, 130], ["pigs", "SPECIES", 148, 152], ["human", "SPECIES", 20, 25], ["influenza H7N7 virus", "SPECIES", 46, 66], ["H1N1 virus", "SPECIES", 120, 130], ["pigs", "SPECIES", 148, 152], ["human infection", "PROBLEM", 20, 35], ["influenza H7N7 virus", "PROBLEM", 46, 66], ["H1N1 virus", "PROBLEM", 120, 130], ["vigilant epidemiological surveillance", "TEST", 250, 287], ["such pathogens", "PROBLEM", 291, 305], ["infection", "OBSERVATION", 26, 35]]], ["Moreover, epidemiological studies strongly suggest that novel infectious agents remain to be discovered (Woolhouse et al., 2008) and may be contributing to a host of cancers, autoimmune disorders, and degenerative diseases in humans (Relman, 1999; Dalton-Griffin and Kellam, 2009 ).", [["cancers", "ANATOMY", 166, 173], ["cancers", "DISEASE", 166, 173], ["autoimmune disorders", "DISEASE", 175, 195], ["degenerative diseases", "DISEASE", 201, 222], ["cancers", "CANCER", 166, 173], ["humans", "ORGANISM", 226, 232], ["humans", "SPECIES", 226, 232], ["humans", "SPECIES", 226, 232], ["epidemiological studies", "TEST", 10, 33], ["novel infectious agents", "PROBLEM", 56, 79], ["cancers", "PROBLEM", 166, 173], ["autoimmune disorders", "PROBLEM", 175, 195], ["degenerative diseases in humans", "PROBLEM", 201, 232], ["infectious", "OBSERVATION", 62, 72], ["cancers", "OBSERVATION", 166, 173], ["degenerative", "OBSERVATION_MODIFIER", 201, 213], ["diseases", "OBSERVATION", 214, 222]]], ["Similar, yet-to-be-identified viruses may be contributing to the pathogenesis of similar diseases in animals.IntroductionViruses can be identified by a wide range of techniques.", [["viruses", "PROBLEM", 30, 37], ["similar diseases in animals", "PROBLEM", 81, 108], ["IntroductionViruses", "TREATMENT", 109, 128], ["viruses", "OBSERVATION", 30, 37], ["may be contributing", "UNCERTAINTY", 38, 57], ["similar", "OBSERVATION_MODIFIER", 81, 88], ["diseases", "OBSERVATION", 89, 97]]], ["Traditional methods include electron microscopy, cell culture, inoculation studies and serology (Storch, 2007) .", [["cell", "ANATOMY", 49, 53], ["cell", "CELL", 49, 53], ["electron microscopy", "TEST", 28, 47], ["cell culture", "TEST", 49, 61], ["inoculation studies", "TEST", 63, 82], ["serology", "TEST", 87, 95]]], ["Whereas many of the viruses known today were first identified by these techniques, the methods have limitations.", [["the viruses", "PROBLEM", 16, 27], ["these techniques", "TEST", 65, 81], ["viruses", "OBSERVATION", 20, 27]]], ["For instance, many viruses cannot be cultivated in the laboratory and can only be characterised by molecular methods (Amann et al., 1995) , and in recent years we have seen the increasing use of these techniques in pathogen discovery (Fig. 1 ).IntroductionOne such approach uses sequence information from known pathogens to identify related but undiscovered agents through cross-hybridisation.", [["many viruses", "PROBLEM", 14, 26], ["these techniques", "TREATMENT", 195, 211], ["known pathogens", "PROBLEM", 305, 320], ["viruses", "OBSERVATION", 19, 26]]], ["Another advance has involved PCR amplification of the pathogen genome, where there is complete knowledge of the pathogen to be amplified (conventional PCR), or where this information is limited (degenerate PCR).", [["pathogen genome", "DNA", 54, 69], ["PCR amplification", "TEST", 29, 46], ["the pathogen genome", "PROBLEM", 50, 69], ["the pathogen", "PROBLEM", 108, 120], ["conventional PCR", "TEST", 138, 154], ["pathogen genome", "OBSERVATION", 54, 69]]], ["Other PCR methods such as sequence-independent single primer amplification, degenerate oligonucleotide primed PCR, random PCR and rolling circle amplification, also have the capacity to detect completely novel pathogens.IntroductionHybridisation and PCR-based methods are more effective if the sample to be analysed is first enriched for virus, a process achieved by removing host and other contaminating nucleic acids.", [["nucleic acids", "CHEMICAL", 405, 418], ["nucleic acids", "SIMPLE_CHEMICAL", 405, 418], ["Other PCR methods", "TEST", 0, 17], ["independent single primer amplification", "TREATMENT", 35, 74], ["degenerate oligonucleotide primed PCR", "TEST", 76, 113], ["random PCR", "TEST", 115, 125], ["rolling circle amplification", "TREATMENT", 130, 158], ["the capacity", "PROBLEM", 170, 182], ["completely novel pathogens", "PROBLEM", 193, 219], ["IntroductionHybridisation", "TREATMENT", 220, 245], ["PCR-based methods", "TREATMENT", 250, 267], ["the sample", "TEST", 290, 300], ["virus", "PROBLEM", 338, 343], ["other contaminating nucleic acids", "TREATMENT", 385, 418], ["pathogens", "OBSERVATION", 210, 219]]], ["The end result of most hybridisation and PCR methods are amplified products that require definitive identification by sequencing.", [["most hybridisation and PCR methods", "PROBLEM", 18, 52]]], ["Advances in sequencing that have facilitated virus discovery include the arrival of 'next or second generation sequencing', which can generate very large amounts of sequence data.IntroductionTechnological advances have also resulted in the development of metagenomics, the culture-independent study of the collective set of microbial populations (microbiome) in a sample by analysing the sample's nucleotide sequence content (Petrosino et al., 2009) .", [["sample", "ANATOMY", 364, 370], ["nucleotide", "CHEMICAL", 397, 407], ["nucleotide", "CHEMICAL", 397, 407], ["microbial populations", "CELL", 324, 345], ["the culture", "TEST", 269, 280], ["independent study", "TEST", 281, 298], ["the sample's nucleotide sequence content", "TEST", 384, 424]]], ["The different microorganisms constituting a microbiome can include bacteria, fungi (mostly yeasts) and viruses.", [["The different microorganisms", "PROBLEM", 0, 28], ["bacteria", "PROBLEM", 67, 75], ["fungi", "PROBLEM", 77, 82], ["viruses", "PROBLEM", 103, 110], ["different", "OBSERVATION_MODIFIER", 4, 13], ["microorganisms", "OBSERVATION", 14, 28]]], ["Examples of microbiomes in mammalian biology include the microbial populations inhabiting the human intestine or mucosal surfaces both in health and disease.IntroductionTo date, the study of the viral microbiome (virome) has been applied to a range of biological and environmental samples including human (Breitbart et al., 2003; Zhang et al., 2006; Finkbeiner et al., 2008) and equine (Cann et al., 2005) intestinal contents, bat guano , sea water (Breitbart et al., 2002; Angly et al., 2006; Williamson et al., 2008) , marine sediment (Breitbart et al., 2004) , fresh water (Breitbart et al., 2009; Djikeng et al., 2009) , hot springs (Schoenfeld et al., 2008) , soil (Fierer et al., 2007) and plants (Coetzee et al., 2010) .", [["intestine", "ANATOMY", 100, 109], ["mucosal surfaces", "ANATOMY", 113, 129], ["intestinal", "ANATOMY", 406, 416], ["human", "ORGANISM", 94, 99], ["intestine", "ORGAN", 100, 109], ["mucosal surfaces", "MULTI-TISSUE_STRUCTURE", 113, 129], ["human", "ORGANISM", 299, 304], ["equine", "ORGANISM", 379, 385], ["intestinal", "ORGAN", 406, 416], ["human", "SPECIES", 94, 99], ["human", "SPECIES", 299, 304], ["human", "SPECIES", 94, 99], ["human", "SPECIES", 299, 304], ["disease", "PROBLEM", 149, 156], ["the study", "TEST", 178, 187], ["human intestine", "ANATOMY", 94, 109], ["mucosal surfaces", "OBSERVATION", 113, 129], ["disease", "OBSERVATION", 149, 156], ["intestinal", "ANATOMY", 406, 416]]], ["Early results from a large initiative to describe the humane microbiome associated with health and disease have recently been published (Nelson et al., 2010) , and such findings, together with those of other studies, are likely to lead to the discovery of a wealth of previously unknown viruses.IntroductionThis review describes the current molecular techniques available for the detection of viruses infecting animals and humans.", [["humans", "ORGANISM", 423, 429], ["humans", "SPECIES", 423, 429], ["humans", "SPECIES", 423, 429], ["disease", "PROBLEM", 99, 106], ["other studies", "TEST", 202, 215], ["viruses", "PROBLEM", 393, 400], ["large", "OBSERVATION_MODIFIER", 21, 26], ["viruses", "OBSERVATION", 287, 294], ["viruses", "OBSERVATION", 393, 400]]], ["We begin by discussing hybridisation and PCR-based methods and describe advances that have facilitated the detection of completely novel viruses.", [["hybridisation", "TEST", 23, 36], ["PCR", "TEST", 41, 44], ["completely novel viruses", "PROBLEM", 120, 144], ["viruses", "OBSERVATION", 137, 144]]], ["Advances in sequencing methodology and data analysis, such as transcriptome subtraction, are also appraised.", [["data analysis", "TEST", 39, 52], ["transcriptome subtraction", "TREATMENT", 62, 87]]], ["The review concludes with an assessment of the problems encountered when attempting to attribute disease causality to a newly discovered virus.Microarray techniquesMicroarrays consist of high-density oligonucleotide probes (or segments of DNA) immobilised on a solid surface.", [["solid surface", "ANATOMY", 261, 274], ["DNA", "CELLULAR_COMPONENT", 239, 242], ["an assessment", "TEST", 26, 39], ["the problems", "PROBLEM", 43, 55], ["disease causality", "PROBLEM", 97, 114], ["a newly discovered virus", "PROBLEM", 118, 142], ["Microarray techniques", "TEST", 143, 164], ["Microarrays", "TEST", 164, 175], ["high-density oligonucleotide probes", "TREATMENT", 187, 222], ["segments of DNA)", "PROBLEM", 227, 243], ["high-density", "OBSERVATION_MODIFIER", 187, 199], ["oligonucleotide probes", "OBSERVATION", 200, 222], ["immobilised", "OBSERVATION_MODIFIER", 244, 255], ["solid", "OBSERVATION_MODIFIER", 261, 266], ["surface", "OBSERVATION_MODIFIER", 267, 274]]], ["Any complementary sequences (labelled with fluorescent nucleotides) in a test sample hybridise to the probe on the microarray.", [["nucleotides", "CHEMICAL", 55, 66], ["complementary sequences", "DNA", 4, 27], ["Any complementary sequences", "TEST", 0, 27], ["fluorescent nucleotides", "TEST", 43, 66], ["a test sample", "TEST", 71, 84]]], ["The results of hybridisation are detected and quantified by fluorescence-based detection and thus the relative abundance of nucleic acid sequences in a sample can be determined (Clewley, 2004) .Microarray techniquesTwo types of microarray techniques are commonly used for virus identification.", [["nucleic acid", "CHEMICAL", 124, 136], ["hybridisation", "TEST", 15, 28], ["fluorescence-based detection", "TEST", 60, 88], ["nucleic acid sequences", "PROBLEM", 124, 146], ["Microarray techniques", "TEST", 194, 215], ["microarray techniques", "TREATMENT", 228, 249], ["virus identification", "TEST", 272, 292]]], ["The first uses short oligonucleotide probes (sensitive to single-base mismatches) to detect or identify known, or sub-types of known, viruses.", [["short oligonucleotide probes", "TREATMENT", 15, 43], ["single-base mismatches", "TREATMENT", 58, 80], ["viruses", "PROBLEM", 134, 141], ["viruses", "OBSERVATION", 134, 141]]], ["Such a technique has been used to discriminate between human herpes viruses (for example Foldes-Papp et al., 2004) .", [["herpes viruses", "DISEASE", 61, 75], ["human", "ORGANISM", 55, 60], ["herpes viruses", "ORGANISM", 61, 75], ["human", "SPECIES", 55, 60], ["human herpes viruses", "SPECIES", 55, 75], ["a technique", "TREATMENT", 5, 16], ["human herpes viruses", "PROBLEM", 55, 75]]], ["The second type of microarray method employs long oligonucleotide probes (60 or 70 bp) that allow for sequence mismatches (Wang et al., 2002) .", [["long oligonucleotide probes", "DNA", 45, 72], ["long oligonucleotide probes", "TREATMENT", 45, 72]]], ["Microarray applications have been used in the discovery of novel animal viruses such as a coronavirus in a Beluga whale (Mihindukulasuriya et al., 2008) , the bornavirus that causes proventricular dilation disease in wild psittacine birds (Kistler et al., 2008) , and an enterovirus associated with tongue erosions in bottle-nose dolphins (Nollens et al., 2009) .", [["proventricular", "ANATOMY", 182, 196], ["tongue", "ANATOMY", 299, 305], ["coronavirus", "DISEASE", 90, 101], ["proventricular dilation disease", "DISEASE", 182, 213], ["enterovirus", "DISEASE", 271, 282], ["tongue erosions", "DISEASE", 299, 314], ["coronavirus", "ORGANISM", 90, 101], ["Beluga whale", "ORGANISM", 107, 119], ["bornavirus", "ORGANISM", 159, 169], ["psittacine birds", "ORGANISM", 222, 238], ["enterovirus", "ORGANISM", 271, 282], ["tongue", "ORGANISM_SUBDIVISION", 299, 305], ["coronavirus", "SPECIES", 90, 101], ["Beluga whale", "SPECIES", 107, 119], ["Microarray applications", "TREATMENT", 0, 23], ["novel animal viruses", "PROBLEM", 59, 79], ["a coronavirus", "PROBLEM", 88, 101], ["the bornavirus", "PROBLEM", 155, 169], ["proventricular dilation disease", "PROBLEM", 182, 213], ["an enterovirus", "PROBLEM", 268, 282], ["tongue erosions", "PROBLEM", 299, 314], ["proventricular dilation", "OBSERVATION", 182, 205], ["enterovirus", "OBSERVATION", 271, 282], ["tongue", "ANATOMY", 299, 305], ["erosions", "OBSERVATION", 306, 314], ["nose dolphins", "ANATOMY", 325, 338]]], ["In human medicine they have been used to characterise SARS-CoV (Wang et al., 2003) , and to identify novel coronaviruses and rhinoviruses in asthmatics (Kistler et al., 2007) , gammaretrovirus in prostate tissue (Urisman et al., 2006) and cardioviruses in the gastro-intestinal tract .Microarray techniquesMicroarray technology is a powerful tool as it screens for a large number of potential pathogens simultaneously (Wang et al., 2002; Palacios et al., 2007; Xiao-Ping et al., 2009) .", [["prostate tissue", "ANATOMY", 196, 211], ["gastro-intestinal tract", "ANATOMY", 260, 283], ["SARS", "DISEASE", 54, 58], ["coronaviruses and rhinoviruses", "DISEASE", 107, 137], ["human", "ORGANISM", 3, 8], ["SARS-CoV", "ORGANISM", 54, 62], ["coronaviruses", "ORGANISM", 107, 120], ["rhinoviruses", "ORGANISM", 125, 137], ["prostate tissue", "TISSUE", 196, 211], ["intestinal tract", "ORGAN", 267, 283], ["human", "SPECIES", 3, 8], ["human", "SPECIES", 3, 8], ["SARS-CoV", "SPECIES", 54, 62], ["novel coronaviruses", "PROBLEM", 101, 120], ["rhinoviruses", "PROBLEM", 125, 137], ["asthmatics", "PROBLEM", 141, 151], ["gammaretrovirus in prostate tissue", "PROBLEM", 177, 211], ["cardioviruses", "TREATMENT", 239, 252], ["Microarray techniques", "TEST", 285, 306], ["it screens", "TEST", 350, 360], ["potential pathogens", "PROBLEM", 383, 402], ["rhinoviruses", "OBSERVATION", 125, 137], ["prostate tissue", "ANATOMY", 196, 211], ["gastro", "ANATOMY", 260, 266], ["intestinal tract", "ANATOMY", 267, 283], ["large", "OBSERVATION_MODIFIER", 367, 372]]], ["The method does have limitations however, as the process of interpreting hybridisation signals is not a trivial one, often involving the empirical characterisation of signals produced by known viruses and the development of specialised software (Urisman et al., 2005) .", [["known viruses", "PROBLEM", 187, 200], ["viruses", "OBSERVATION", 193, 200]]], ["Furthermore, microarray techniques utilise probes with a finite specificity for a particular pathogen or small group of pathogens so that novel or highly divergent strains or viruses can be difficult to detect.", [["a finite specificity", "TEST", 55, 75], ["a particular pathogen", "PROBLEM", 80, 101], ["small group of pathogens", "PROBLEM", 105, 129], ["highly divergent strains", "PROBLEM", 147, 171], ["viruses", "PROBLEM", 175, 182], ["small", "OBSERVATION_MODIFIER", 105, 110]]], ["Non-specific binding of test material to hybridisation probes can also result in loss of test sensitivity.", [["Non-specific binding of test material", "PROBLEM", 0, 37], ["hybridisation probes", "TEST", 41, 61], ["loss of test sensitivity", "PROBLEM", 81, 105]]], ["Despite these limitations, microarrays have proven extremely effective in novel pathogen discovery.Subtractive hybridisationThis form of hybridisation identifies sequence differences between two related samples and is based on the principle of removing common nucleic acid sequences from two samples while leaving differing sequences intact.", [["samples", "ANATOMY", 203, 210], ["samples", "ANATOMY", 292, 299], ["nucleic acid", "CHEMICAL", 260, 272], ["samples", "CANCER", 203, 210], ["microarrays", "TEST", 27, 38], ["Subtractive hybridisation", "TREATMENT", 99, 124], ["hybridisation identifies sequence differences", "PROBLEM", 137, 182], ["common nucleic acid sequences", "PROBLEM", 253, 282], ["hybridisation", "OBSERVATION", 137, 150]]], ["Such a process can be applied to any pair of nucleic acid sources such as 'treated' vs. 'untreated' or 'diseased' vs. 'undiseased' tissue, or to samples obtained prior to and after experimental infection (Muerhoff et al., 1997) .Subtractive hybridisationSubtractive hybridisation uses two nucleic acid sources termed 'tester' and 'driver' with only the tester containing pathogen sequences (Ambrose and Clewley, 2006) .", [["tissue", "ANATOMY", 131, 137], ["samples", "ANATOMY", 145, 152], ["nucleic acid", "CHEMICAL", 45, 57], ["infection", "DISEASE", 194, 203], ["nucleic acid", "CHEMICAL", 289, 301], ["undiseased' tissue", "TISSUE", 119, 137], ["nucleic acid sources", "PROBLEM", 45, 65], ["'diseased'", "PROBLEM", 103, 113], ["'undiseased' tissue", "PROBLEM", 118, 137], ["experimental infection", "PROBLEM", 181, 203], ["Subtractive hybridisationSubtractive hybridisation", "TREATMENT", 229, 279], ["two nucleic acid sources", "TREATMENT", 285, 309], ["infection", "OBSERVATION", 194, 203]]], ["DNA in both the tester and driver is digested by restriction enzymes and adaptors are ligated to the DNA fragments from the tester sample only.", [["sample", "ANATOMY", 131, 137], ["DNA", "CELLULAR_COMPONENT", 0, 3], ["DNA", "CELLULAR_COMPONENT", 101, 104], ["restriction enzymes", "PROTEIN", 49, 68], ["adaptors", "PROTEIN", 73, 81], ["DNA fragments", "DNA", 101, 114], ["DNA", "PROBLEM", 0, 3], ["adaptors", "TREATMENT", 73, 81], ["the tester sample", "TEST", 120, 137]]], ["The two DNA populations are mixed, denatured and annealed to form three types of molecule: (1) tester/tester; (2) hybrids of tester/driver, and (3) driver/driver.", [["DNA", "CELLULAR_COMPONENT", 8, 11], ["The two DNA populations", "PROBLEM", 0, 23], ["tester/tester", "TEST", 95, 108], ["two", "OBSERVATION_MODIFIER", 4, 7], ["DNA", "OBSERVATION_MODIFIER", 8, 11], ["populations", "OBSERVATION_MODIFIER", 12, 23], ["mixed", "OBSERVATION_MODIFIER", 28, 33]]], ["The tester/tester molecules should now be enriched for pathogen, which are preferentially and exponentially amplified by primers specific for the adaptors present on both DNA strands.", [["DNA", "CELLULAR_COMPONENT", 171, 174], ["adaptors", "PROTEIN", 146, 154], ["The tester/tester molecules", "TREATMENT", 0, 27], ["pathogen", "PROBLEM", 55, 63]]], ["The tester/driver molecules, which only contain an adaptor on one DNA strand, undergo linear amplification but are then removed by enzymatic digestion.", [["DNA", "CELLULAR_COMPONENT", 66, 69], ["an adaptor", "TREATMENT", 48, 58], ["linear amplification", "TREATMENT", 86, 106], ["linear", "OBSERVATION_MODIFIER", 86, 92], ["amplification", "OBSERVATION", 93, 106]]], ["Sufficiently enriched in this way, the tester sample is sequenced and the pathogen identified.Subtractive hybridisationAn example of a subtractive hybridisation method is representational difference analysis (RDA) (Lisitsyn et al., 1993) .", [["the tester sample", "TEST", 35, 52], ["the pathogen", "PROBLEM", 70, 82], ["a subtractive hybridisation method", "TREATMENT", 133, 167]]], ["Despite its impressive performance in model systems, RDA has had limited success in the discovery of novel viruses, largely due to the requirement for two highly matched nucleic acid sources.", [["RDA", "CHEMICAL", 53, 56], ["nucleic acid", "CHEMICAL", 170, 182], ["RDA", "SIMPLE_CHEMICAL", 53, 56], ["novel viruses", "PROBLEM", 101, 114], ["two highly matched nucleic acid sources", "PROBLEM", 151, 190], ["impressive", "OBSERVATION_MODIFIER", 12, 22], ["viruses", "OBSERVATION", 107, 114]]], ["Restriction enzyme digestion also leads to an increased DNA complexity and the risk of inefficient subtractive hybridisation, a particular problem with samples containing large amounts of host DNA, such as serum or plasma.", [["samples", "ANATOMY", 152, 159], ["serum", "ANATOMY", 206, 211], ["plasma", "ANATOMY", 215, 221], ["DNA", "CELLULAR_COMPONENT", 56, 59], ["DNA", "CELLULAR_COMPONENT", 193, 196], ["serum", "ORGANISM_SUBSTANCE", 206, 211], ["plasma", "ORGANISM_SUBSTANCE", 215, 221], ["Restriction enzyme digestion", "PROBLEM", 0, 28], ["an increased DNA complexity", "PROBLEM", 43, 70], ["inefficient subtractive hybridisation", "PROBLEM", 87, 124], ["host DNA", "PROBLEM", 188, 196], ["serum or plasma", "TEST", 206, 221], ["increased", "OBSERVATION_MODIFIER", 46, 55], ["DNA complexity", "OBSERVATION", 56, 70], ["inefficient", "OBSERVATION_MODIFIER", 87, 98], ["subtractive hybridisation", "OBSERVATION", 99, 124], ["large", "OBSERVATION_MODIFIER", 171, 176], ["amounts", "OBSERVATION_MODIFIER", 177, 184], ["host DNA", "OBSERVATION", 188, 196]]], ["Despite these limitations, RDA has been used to identify the agent causing Kaposi's sarcoma (human herpesvirus-8) (Chang et al., 1994) , torque teno or transfusion-transmitted virus (TTV) (Nishizawa et al., 1997) and the hepatitis GBV-A and GBV-B viruses (Simons et al., 1995b) .Degenerate PCRConventional PCR is frequently used to identify or exclude the presence of a virus in samples.", [["samples", "ANATOMY", 379, 386], ["Kaposi's sarcoma", "DISEASE", 75, 91], ["transfusion-transmitted virus (TTV)", "DISEASE", 152, 187], ["hepatitis GBV", "DISEASE", 221, 234], ["RDA", "SIMPLE_CHEMICAL", 27, 30], ["Kaposi's sarcoma", "ORGANISM", 75, 91], ["human herpesvirus-8", "ORGANISM", 93, 112], ["transfusion-transmitted virus", "ORGANISM", 152, 181], ["TTV", "ORGANISM", 183, 186], ["hepatitis GBV-A", "ORGANISM", 221, 236], ["GBV-B viruses", "ORGANISM", 241, 254], ["samples", "CANCER", 379, 386], ["human", "SPECIES", 93, 98], ["herpesvirus", "SPECIES", 99, 110], ["human herpesvirus-8", "SPECIES", 93, 112], ["TTV", "SPECIES", 183, 186], ["hepatitis GBV-A", "SPECIES", 221, 236], ["GBV-B viruses", "SPECIES", 241, 254], ["Kaposi's sarcoma", "PROBLEM", 75, 91], ["human herpesvirus", "TEST", 93, 110], ["torque teno", "PROBLEM", 137, 148], ["transfusion", "TREATMENT", 152, 163], ["transmitted virus", "PROBLEM", 164, 181], ["TTV", "TEST", 183, 186], ["the hepatitis GBV", "TEST", 217, 234], ["GBV", "TEST", 241, 244], ["Degenerate PCRConventional PCR", "TEST", 279, 309], ["a virus in samples", "PROBLEM", 368, 386], ["Kaposi", "OBSERVATION", 75, 81], ["sarcoma", "OBSERVATION", 84, 91], ["virus", "OBSERVATION", 370, 375]]], ["Given that the method relies on the annealing of specific primers complementary to the pathogen's genomic sequence of interest, it is unsuitable for the detection of novel viruses where there are marked sequence differences from the primers.", [["pathogen's genomic sequence", "DNA", 87, 114], ["novel viruses", "PROBLEM", 166, 179], ["marked sequence differences from the primers", "PROBLEM", 196, 240], ["viruses", "OBSERVATION", 172, 179], ["marked", "OBSERVATION_MODIFIER", 196, 202]]], ["Prior knowledge of the viral sequence is therefore a pre-requisite.", [["the viral sequence", "PROBLEM", 19, 37]]], ["An alternative PCR method, degenerate PCR, uses primers designed to anneal to highly-conserved sequence regions shared by related viruses.Degenerate PCRBecause these regions are almost never completely conserved, primers generally include some degeneracy that permits binding to all or the most common known variants on the conserved sequence (Rose et al., 1998) .", [["An alternative PCR method", "TEST", 0, 25], ["degenerate PCR", "PROBLEM", 27, 41], ["primers", "TREATMENT", 48, 55], ["Degenerate PCRBecause these regions", "PROBLEM", 138, 173], ["some degeneracy", "PROBLEM", 239, 254], ["viruses", "OBSERVATION", 130, 137]]], ["The overall aim is to achieve a balance between covering all possible viral variants within a family (i.e. primers with high degeneracy) and creating an unwieldy number of different primers.", [["viral variants", "PROBLEM", 70, 84], ["viral variants", "OBSERVATION", 70, 84]]], ["At high levels of degeneracy, only a small proportion of primers are able to prime DNA synthesis, whereas a large proportion of the remaining primers will be able to anneal but, because of sequence mismatches, will be refractory to PCR extension.", [["DNA", "CELLULAR_COMPONENT", 83, 86], ["a small proportion of primers", "PROBLEM", 35, 64], ["DNA synthesis", "PROBLEM", 83, 96], ["the remaining primers", "PROBLEM", 128, 149], ["sequence mismatches", "PROBLEM", 189, 208], ["PCR extension", "TEST", 232, 245], ["small", "OBSERVATION_MODIFIER", 37, 42], ["large", "OBSERVATION_MODIFIER", 108, 113]]], ["The maximum level of degeneracy is usually fixed at approximately 256, and degeneracy can be reduced by using codon usage tables (Wada et al., 1992) and inter-codon dinucleotide frequencies (Smith et al., 1983) .Degenerate PCRDegenerate primers are used to detect viruses, including novel viruses, from existing sufficiently homologous virus families.", [["dinucleotide", "CHEMICAL", 165, 177], ["Degenerate PCRDegenerate primers", "PROBLEM", 212, 244], ["viruses", "PROBLEM", 264, 271], ["novel viruses", "PROBLEM", 283, 296], ["maximum", "OBSERVATION_MODIFIER", 4, 11], ["degeneracy", "OBSERVATION", 21, 31], ["fixed", "OBSERVATION_MODIFIER", 43, 48], ["viruses", "OBSERVATION", 264, 271], ["viruses", "OBSERVATION", 289, 296]]], ["Such primers have been used in the identification of pig endogenous retrovirus (PERV) (Patience et al., 1997) , numerous macaque gammaherpesviruses (Van Devanter et al., 1996; Rose et al., 1997) , a novel alphaherpesvirus associated with death in rabbits (Jin et al., 2008) , and a novel chimpanzee polyomavirus (Johne et al., 2005) .", [["alphaherpesvirus", "DISEASE", 205, 221], ["death", "DISEASE", 238, 243], ["chimpanzee polyomavirus", "DISEASE", 288, 311], ["pig endogenous retrovirus", "ORGANISM", 53, 78], ["PERV", "ORGANISM", 80, 84], ["macaque", "ORGANISM", 121, 128], ["alphaherpesvirus", "CANCER", 205, 221], ["rabbits", "ORGANISM", 247, 254], ["chimpanzee", "ORGANISM", 288, 298], ["polyomavirus", "ORGANISM", 299, 311], ["pig", "SPECIES", 53, 56], ["rabbits", "SPECIES", 247, 254], ["chimpanzee polyomavirus", "SPECIES", 288, 311], ["pig", "SPECIES", 53, 56], ["PERV", "SPECIES", 80, 84], ["rabbits", "SPECIES", 247, 254], ["Such primers", "PROBLEM", 0, 12], ["pig endogenous retrovirus", "TREATMENT", 53, 78], ["a novel alphaherpesvirus", "PROBLEM", 197, 221], ["death in rabbits", "PROBLEM", 238, 254], ["a novel chimpanzee polyomavirus", "PROBLEM", 280, 311], ["macaque gammaherpesviruses", "OBSERVATION", 121, 147]]], ["Novel viruses infecting humans detected using this technique include hepatitis G virus (Simons et al., 1995a) , a hantavirus (sin nombre virus) (Nichol et al., 1993) , coronaviruses (Sampath et al., 2005) , and parainfluenza viruses 1-3 (Corne et al., 1999) .Sequence-independent single primer amplification (SISPA)Sequence-independent amplification of viral nucleic acid avoids the potential limitations of other methods, particularly the lack of microarray hybridisation due to genetic divergence from known viruses, the absence of a matched sample for subtractive hybridisation and where PCR amplification using conventional or degenerate primers fails.", [["hepatitis G", "DISEASE", 69, 80], ["hantavirus", "DISEASE", 114, 124], ["parainfluenza viruses", "DISEASE", 211, 232], ["nucleic acid", "CHEMICAL", 359, 371], ["humans", "ORGANISM", 24, 30], ["hepatitis G virus", "ORGANISM", 69, 86], ["hantavirus", "ORGANISM", 114, 124], ["sin nombre virus", "ORGANISM", 126, 142], ["coronaviruses", "ORGANISM", 168, 181], ["parainfluenza", "ORGANISM", 211, 224], ["humans", "SPECIES", 24, 30], ["hepatitis G virus", "SPECIES", 69, 86], ["parainfluenza", "SPECIES", 211, 224], ["humans", "SPECIES", 24, 30], ["hepatitis G virus", "SPECIES", 69, 86], ["hantavirus (sin nombre virus", "SPECIES", 114, 142], ["Novel viruses infecting humans", "PROBLEM", 0, 30], ["this technique", "TREATMENT", 46, 60], ["hepatitis G virus", "PROBLEM", 69, 86], ["a hantavirus", "PROBLEM", 112, 124], ["coronaviruses", "PROBLEM", 168, 181], ["parainfluenza viruses", "PROBLEM", 211, 232], ["Sequence", "TEST", 259, 267], ["viral nucleic acid", "PROBLEM", 353, 371], ["other methods", "TEST", 408, 421], ["microarray hybridisation", "PROBLEM", 448, 472], ["genetic divergence", "PROBLEM", 480, 498], ["known viruses", "PROBLEM", 504, 517], ["subtractive hybridisation", "TREATMENT", 555, 580], ["PCR amplification", "TEST", 591, 608], ["conventional or degenerate primers", "TREATMENT", 615, 649], ["viruses", "OBSERVATION", 6, 13], ["parainfluenza viruses", "OBSERVATION", 211, 232], ["viruses", "OBSERVATION", 510, 517]]], ["The advantages of these methods are their ability to detect novel viruses highly divergent from those already known, their relative speed and simplicity of use and their lack of bias in identifying particular groups of viruses (Delwart, 2007) .Sequence-independent single primer amplification (SISPA)A sequence-independent amplification technique termed sequence-independent single primer amplification (SISPA) was introduced almost two decades ago to identify viral nucleic acid of unknown sequence present in low amounts .", [["nucleic acid", "CHEMICAL", 467, 479], ["these methods", "TREATMENT", 18, 31], ["novel viruses", "PROBLEM", 60, 73], ["Sequence", "TEST", 244, 252], ["A sequence", "TEST", 300, 310], ["viral nucleic acid", "TEST", 461, 479], ["nucleic acid", "OBSERVATION", 467, 479], ["low amounts", "OBSERVATION_MODIFIER", 511, 522]]], ["SISPA was used first to sequence the norovirus genome from human faeces (Matsui et al., 1991) , in addition to an astrovirus (Matsui et al., 1993) and a rotavirus (Lambden et al., 1992) infecting humans.", [["rotavirus", "DISEASE", 153, 162], ["norovirus", "ORGANISM", 37, 46], ["human", "ORGANISM", 59, 64], ["faeces", "ORGANISM_SUBDIVISION", 65, 71], ["astrovirus", "ORGANISM", 114, 124], ["rotavirus", "ORGANISM", 153, 162], ["humans", "ORGANISM", 196, 202], ["SISPA", "PROTEIN", 0, 5], ["norovirus genome", "DNA", 37, 53], ["human", "SPECIES", 59, 64], ["rotavirus", "SPECIES", 153, 162], ["humans", "SPECIES", 196, 202], ["human", "SPECIES", 59, 64], ["humans", "SPECIES", 196, 202], ["an astrovirus", "PROBLEM", 111, 124]]], ["Originally the SISPA method involved endonuclease digestion of DNA, followed by directional ligation of an asymmetric adaptor or primer on to both ends of the DNA molecule .", [["DNA", "CELLULAR_COMPONENT", 63, 66], ["DNA", "CELLULAR_COMPONENT", 159, 162], ["SISPA", "DNA", 15, 20], ["asymmetric adaptor", "PROTEIN", 107, 125], ["DNA molecule", "PROTEIN", 159, 171], ["the SISPA method", "TREATMENT", 11, 27], ["endonuclease digestion of DNA", "PROBLEM", 37, 66], ["directional ligation", "TREATMENT", 80, 100], ["an asymmetric adaptor", "TREATMENT", 104, 125], ["asymmetric", "OBSERVATION_MODIFIER", 107, 117], ["adaptor", "OBSERVATION", 118, 125], ["DNA molecule", "OBSERVATION", 159, 171]]], ["Common end sequences of the adaptor allowed the DNA to be amplified in a subsequent PCR reaction using a complementary single primer.", [["DNA", "CELLULAR_COMPONENT", 48, 51], ["the adaptor", "TREATMENT", 24, 35], ["the DNA", "PROBLEM", 44, 51], ["a subsequent PCR reaction", "PROBLEM", 71, 96], ["a complementary single primer", "TREATMENT", 103, 132]]], ["Due to the low complexity of a viral genome, enzymatic digestion produces a large amount of a limited number of fragments.", [["fragments", "ANATOMY", 112, 121], ["viral genome", "DNA", 31, 43], ["a viral genome", "PROBLEM", 29, 43], ["enzymatic digestion", "PROBLEM", 45, 64], ["low complexity", "OBSERVATION_MODIFIER", 11, 25], ["viral genome", "OBSERVATION", 31, 43], ["enzymatic digestion", "OBSERVATION", 45, 64], ["large", "OBSERVATION_MODIFIER", 76, 81], ["amount", "OBSERVATION_MODIFIER", 82, 88], ["limited", "OBSERVATION_MODIFIER", 94, 101], ["number", "OBSERVATION_MODIFIER", 102, 108], ["fragments", "OBSERVATION", 112, 121]]], ["After amplification these are visible as discrete bands on an agarose gel and can be sequenced and identified (Allander et al., 2001) .", [["agarose", "SIMPLE_CHEMICAL", 62, 69], ["discrete bands", "PROBLEM", 41, 55], ["an agarose gel", "TREATMENT", 59, 73], ["discrete", "OBSERVATION_MODIFIER", 41, 49], ["bands", "OBSERVATION_MODIFIER", 50, 55]]], ["Since animal and bacterial genomes are larger and more complex, restriction digestion generates many different-sized fragments, the amplification of which can result in 'smears' on agarose gel.Sequence-independent single primer amplification (SISPA)One of the disadvantages of sequence-independent amplification techniques is the contemporaneous amplification of 'contaminating' host and bacterial nucleic acid.", [["fragments", "ANATOMY", 117, 126], ["nucleic acid", "CHEMICAL", 398, 410], ["agarose", "SIMPLE_CHEMICAL", 181, 188], ["host", "CELL", 379, 383], ["animal and bacterial genomes", "DNA", 6, 34], ["animal and bacterial genomes", "PROBLEM", 6, 34], ["restriction digestion", "PROBLEM", 64, 85], ["many different-sized fragments", "PROBLEM", 96, 126], ["agarose gel", "TREATMENT", 181, 192], ["Sequence", "TEST", 193, 201], ["'contaminating' host", "TREATMENT", 363, 383], ["bacterial nucleic acid", "TREATMENT", 388, 410], ["bacterial genomes", "OBSERVATION", 17, 34], ["larger", "OBSERVATION_MODIFIER", 39, 45], ["more complex", "OBSERVATION_MODIFIER", 50, 62], ["many", "OBSERVATION_MODIFIER", 96, 100], ["different", "OBSERVATION_MODIFIER", 101, 110], ["sized", "OBSERVATION_MODIFIER", 111, 116], ["fragments", "OBSERVATION", 117, 126], ["nucleic acid", "OBSERVATION", 398, 410]]], ["Enriching methods that reduce such 'background' genomic material include filtration, ultra-centrifugation, density-gradient ultra-centrifugation and enzymatic digestion of non-viral nucleic acids using DNAse and RNAse (Delwart, 2007) .", [["nucleic acids", "CHEMICAL", 182, 195], ["DNAse", "GENE_OR_GENE_PRODUCT", 202, 207], ["RNAse", "GENE_OR_GENE_PRODUCT", 212, 217], ["DNAse", "PROTEIN", 202, 207], ["RNAse", "PROTEIN", 212, 217], ["Enriching methods", "TREATMENT", 0, 17], ["such 'background' genomic material", "PROBLEM", 30, 64], ["filtration", "TREATMENT", 73, 83], ["ultra-centrifugation", "TREATMENT", 85, 105], ["density-gradient ultra-centrifugation", "PROBLEM", 107, 144], ["enzymatic digestion", "TREATMENT", 149, 168], ["non-viral nucleic acids", "TREATMENT", 172, 195], ["DNAse and RNAse", "TREATMENT", 202, 217]]], ["These techniques take advantage of the differential protection afforded to the virus genome by nucleocapsids and capsids.", [["nucleocapsids", "ANATOMY", 95, 108], ["nucleocapsids", "CELLULAR_COMPONENT", 95, 108], ["capsids", "CELLULAR_COMPONENT", 113, 120], ["virus genome", "DNA", 79, 91], ["the differential protection", "TREATMENT", 35, 62], ["the virus genome", "TREATMENT", 75, 91]]], ["However, as viral nucleic acid not protected by such capsids is removed by the purification process and not amplified, some potential assay sensitivity is lost.", [["nucleic acid", "CHEMICAL", 18, 30], ["viral nucleic acid", "TEST", 12, 30], ["such capsids", "TREATMENT", 48, 60], ["some potential assay sensitivity", "TEST", 119, 151]]], ["Furthermore, the random nature of the amplification reaction means that great care must be taken to maintain PCR integrity and prevent crosscontamination.Sequence-independent single primer amplification (SISPA)The original SISPA method has now been modified to include steps to detect both RNA and DNA viruses, to enrich for virus, and to remove host genomic and contaminating nucleic acid (Allander et al., 2001; Djikeng et al., 2008) .", [["crosscontamination", "DISEASE", 135, 153], ["nucleic acid", "CHEMICAL", 377, 389], ["DNA", "CELLULAR_COMPONENT", 298, 301], ["the amplification reaction", "PROBLEM", 34, 60], ["PCR integrity", "TEST", 109, 122], ["crosscontamination", "PROBLEM", 135, 153], ["Sequence", "TEST", 154, 162], ["both RNA and DNA viruses", "PROBLEM", 285, 309], ["virus", "PROBLEM", 325, 330]]], ["Novel human and animal viruses detected in clinical samples using these modified methods include parvoviruses (Allander et al., 2001; Jones et al., 2005) , a coronavirus (van der Hoek et al., 2004) , an adenovirus (Jones et al., 2007a) , an orthoreovirus , a picornavirus (Jones et al., 2007b) , and a porcine pestivirus (Kirkland et al., 2007) .Degenerate oligonucleotide primed PCR (DOP-PCR)This sequence-independent amplification technique, termed degenerate oligonucleotide primed PCR (DOP-PCR), was initially developed for genome mapping studies (Telenius et al., 1992) , but has more recently been modified to detect viral genomic material (Nanda et al., 2008) .", [["samples", "ANATOMY", 52, 59], ["coronavirus", "DISEASE", 158, 169], ["human", "ORGANISM", 6, 11], ["samples", "CANCER", 52, 59], ["parvoviruses", "ORGANISM", 97, 109], ["coronavirus", "ORGANISM", 158, 169], ["adenovirus", "ORGANISM", 203, 213], ["porcine", "ORGANISM", 302, 309], ["human", "SPECIES", 6, 11], ["porcine", "SPECIES", 302, 309], ["human", "SPECIES", 6, 11], ["Novel human and animal viruses", "PROBLEM", 0, 30], ["these modified methods", "TREATMENT", 66, 88], ["parvoviruses", "PROBLEM", 97, 109], ["a porcine pestivirus", "TREATMENT", 300, 320], ["Degenerate oligonucleotide primed PCR", "TEST", 346, 383], ["DOP", "TEST", 385, 388], ["This sequence", "TEST", 393, 406], ["independent amplification technique", "TEST", 407, 442], ["termed degenerate oligonucleotide primed PCR (DOP-PCR", "TEST", 444, 497], ["genome mapping studies", "TEST", 528, 550], ["viral genomic material", "PROBLEM", 623, 645]]], ["DOP-PCR uses primers with a short (4-6 nucleotide) 3 0 -anchor sequence which typically occur every 256 and 4096 bp, respectively, preceded by a non-specific degenerate sequence of 6-8 nucleotides for random priming.", [["DOP", "CHEMICAL", 0, 3], ["nucleotides", "CHEMICAL", 185, 196], ["DOP", "SIMPLE_CHEMICAL", 0, 3], ["non-specific degenerate sequence", "DNA", 145, 177], ["DOP", "TEST", 0, 3], ["primers", "TEST", 13, 20], ["anchor sequence", "TEST", 56, 71], ["bp", "TEST", 113, 115], ["a non-specific degenerate sequence", "PROBLEM", 143, 177], ["random priming", "TREATMENT", 201, 215]]], ["Immediately upstream of the non-specific degenerate sequence, each primer also contains a defined 5 0 -sequence of 10 nucleotides.", [["nucleotides", "CHEMICAL", 118, 129], ["non-specific degenerate sequence", "DNA", 28, 60], ["5 0 -sequence", "DNA", 98, 111], ["the non-specific degenerate sequence", "PROBLEM", 24, 60]]], ["Because of the degenerate sequence, each reaction includes a mixture of several thousand different primers.Degenerate oligonucleotide primed PCR (DOP-PCR)At low stringency during the first few DOP-PCR amplification cycles, at least 12 consecutive nucleotides from the 3 0 end of the primer anneal to DNA sequences on the PCR template.", [["DOP", "CHEMICAL", 193, 196], ["DOP", "CHEMICAL", 193, 196], ["nucleotides", "CHEMICAL", 247, 258], ["DNA", "CELLULAR_COMPONENT", 300, 303], ["3 0 end", "DNA", 268, 275], ["DNA sequences", "DNA", 300, 313], ["PCR template", "DNA", 321, 333], ["the degenerate sequence", "PROBLEM", 11, 34], ["each reaction", "PROBLEM", 36, 49], ["several thousand different primers", "TREATMENT", 72, 106], ["Degenerate oligonucleotide primed PCR", "TEST", 107, 144], ["DOP", "TEST", 146, 149], ["low stringency", "PROBLEM", 157, 171], ["DOP-PCR amplification cycles", "TREATMENT", 193, 221], ["the primer anneal", "TREATMENT", 279, 296], ["DNA sequences", "TEST", 300, 313], ["the PCR template", "TREATMENT", 317, 333], ["low stringency", "OBSERVATION_MODIFIER", 157, 171]]], ["In subsequent cycles at higher stringency, these initial PCR products are amplified further using the same primer population.", [["PCR products", "DNA", 57, 69], ["higher stringency", "PROBLEM", 24, 41], ["these initial PCR products", "TREATMENT", 43, 69], ["the same primer population", "TREATMENT", 98, 124], ["higher stringency", "OBSERVATION_MODIFIER", 24, 41]]], ["DOP-PCR, when followed by sequencing of the product, has the advantage of facilitating the detection of both RNA and DNA viruses without a priori knowledge of the infectious agent (Nanda et al., 2008) .Random PCRThis further, alternative sequence-independent amplification technique is known as 'random' PCR (Froussard, 1992) .", [["DOP", "CHEMICAL", 0, 3], ["DOP", "SIMPLE_CHEMICAL", 0, 3], ["DNA", "CELLULAR_COMPONENT", 117, 120], ["DOP-PCR", "TEST", 0, 7], ["the detection", "TEST", 87, 100], ["both RNA and DNA viruses", "PROBLEM", 104, 128], ["alternative sequence", "TEST", 226, 246], ["independent amplification technique", "TREATMENT", 247, 282], ["infectious", "OBSERVATION", 163, 173]]], ["The method is commonly used to amplify and label probes with fluorescent dyes for microarray analysis but has also been used in the identification of novel viruses.", [["fluorescent dyes", "TEST", 61, 77], ["microarray analysis", "TEST", 82, 101], ["novel viruses", "PROBLEM", 150, 163], ["viruses", "OBSERVATION", 156, 163]]], ["Unlike SISPA, random PCR has no requirement for an adaptor ligation step and compared with 'conventional' PCR, which utilises a pair of complementary 'forward' and 'reverse' primers to amplify DNA in both directions, random PCR utilises two different primers and two separate PCR reactions.", [["DNA", "CELLULAR_COMPONENT", 193, 196], ["SISPA", "DNA", 7, 12], ["reverse' primers", "DNA", 165, 181], ["random PCR", "TEST", 14, 24], ["an adaptor ligation step", "TREATMENT", 48, 72], ["'conventional' PCR", "TEST", 91, 109], ["'reverse' primers", "TREATMENT", 164, 181], ["random PCR", "TEST", 217, 227], ["two different primers", "TREATMENT", 237, 258], ["two separate PCR reactions", "PROBLEM", 263, 289]]], ["The single primer used in the first PCR reaction has a defined sequence at its 5 0 end, followed by a degenerate hexamer or heptamer sequence at the 3 0 end.", [["5 0 end", "DNA", 79, 86], ["heptamer sequence", "DNA", 124, 141], ["3 0 end", "DNA", 149, 156], ["The single primer", "TREATMENT", 0, 17], ["the first PCR reaction", "TEST", 26, 48], ["a degenerate hexamer or heptamer sequence", "PROBLEM", 100, 141]]], ["A second PCR reaction is then performed with a specific primer complementary to the 5 0 defined region of the first primer thus enabling amplification of products formed in the first reaction.Random PCRRandom PCR has been used extensively for the detection of both DNA and RNA viruses and is currently the molecular method most commonly used to identify unknown viruses.", [["DNA", "CELLULAR_COMPONENT", 265, 268], ["5 0 defined region", "DNA", 84, 102], ["PCRRandom PCR", "DNA", 199, 212], ["A second PCR reaction", "TEST", 0, 21], ["amplification of products", "TREATMENT", 137, 162], ["the first reaction", "PROBLEM", 173, 191], ["Random PCRRandom PCR", "TEST", 192, 212], ["the detection", "TEST", 243, 256], ["both DNA", "PROBLEM", 260, 268], ["RNA viruses", "PROBLEM", 273, 284], ["RNA viruses", "OBSERVATION", 273, 284], ["viruses", "OBSERVATION", 362, 369]]], ["Viruses infecting animals identified using this technique include a dicistrovirus associated with 'honey-bee colony collapse disorder' (Cox-Foster et al., 2007) , a seal picornavirus , and circular DNA viruses in the faeces of wild-living chimpanzees (Blinkova et al., 2010) .", [["colony", "ANATOMY", 109, 115], ["faeces", "ANATOMY", 217, 223], ["dicistrovirus", "DISEASE", 68, 81], ["collapse disorder", "DISEASE", 116, 133], ["DNA", "CELLULAR_COMPONENT", 198, 201], ["faeces", "ORGANISM_SUBDIVISION", 217, 223], ["chimpanzees", "ORGANISM", 239, 250], ["Viruses infecting animals", "PROBLEM", 0, 25], ["this technique", "TREATMENT", 43, 57], ["colony collapse disorder", "PROBLEM", 109, 133], ["a seal picornavirus", "PROBLEM", 163, 182], ["circular DNA viruses", "PROBLEM", 189, 209], ["colony collapse", "OBSERVATION", 109, 124], ["seal", "ANATOMY", 165, 169], ["picornavirus", "OBSERVATION", 170, 182]]], ["Random PCR has also proved successful in detecting novel viruses infecting humans including a parvovirus (Allander et al., 2005) , a coronavirus , and a polyomavirus in patients with respiratory tract disease (Allander et al., 2007) , a parechovirus (Li et al., 2009c) , a picornavirus (Li et al., 2009b) , and a bocavirus in patients with diarrhoea ), a human gammapapillomavirus in an patient with encephalitis (Li et al., 2009a) , and several viruses in children with acute flaccid paralysis Victoria et al., 2009) .Rolling circle amplification (RCA)A 'rolling circle' sequence-independent amplification technique makes use of the property of circular DNA molecules such as plasmids or viral genomes replicating through a rolling circle mechanism.", [["respiratory tract", "ANATOMY", 183, 200], ["gammapapillomavirus", "ANATOMY", 361, 380], ["plasmids", "ANATOMY", 677, 685], ["parvovirus", "DISEASE", 94, 104], ["coronavirus", "DISEASE", 133, 144], ["polyomavirus", "DISEASE", 153, 165], ["respiratory tract disease", "DISEASE", 183, 208], ["bocavirus", "DISEASE", 313, 322], ["diarrhoea", "DISEASE", 340, 349], ["human gammapapillomavirus", "DISEASE", 355, 380], ["encephalitis", "DISEASE", 400, 412], ["acute flaccid paralysis", "DISEASE", 471, 494], ["humans", "ORGANISM", 75, 81], ["parvovirus", "ORGANISM", 94, 104], ["coronavirus", "ORGANISM", 133, 144], ["polyomavirus", "ORGANISM", 153, 165], ["patients", "ORGANISM", 169, 177], ["patients", "ORGANISM", 326, 334], ["human", "ORGANISM", 355, 360], ["gammapapillomavirus", "CANCER", 361, 380], ["patient", "ORGANISM", 387, 394], ["children", "ORGANISM", 457, 465], ["DNA", "CELLULAR_COMPONENT", 655, 658], ["circular DNA molecules", "PROTEIN", 646, 668], ["plasmids", "DNA", 677, 685], ["viral genomes", "DNA", 689, 702], ["humans", "SPECIES", 75, 81], ["coronavirus", "SPECIES", 133, 144], ["patients", "SPECIES", 169, 177], ["patients", "SPECIES", 326, 334], ["human", "SPECIES", 355, 360], ["patient", "SPECIES", 387, 394], ["children", "SPECIES", 457, 465], ["humans", "SPECIES", 75, 81], ["human", "SPECIES", 355, 360], ["Random PCR", "TEST", 0, 10], ["novel viruses infecting humans", "PROBLEM", 51, 81], ["a parvovirus", "PROBLEM", 92, 104], ["a coronavirus", "PROBLEM", 131, 144], ["a polyomavirus", "PROBLEM", 151, 165], ["respiratory tract disease", "PROBLEM", 183, 208], ["a parechovirus", "PROBLEM", 235, 249], ["a picornavirus (Li et al.", "TEST", 271, 296], ["a bocavirus", "PROBLEM", 311, 322], ["diarrhoea", "PROBLEM", 340, 349], ["a human gammapapillomavirus", "TREATMENT", 353, 380], ["encephalitis", "PROBLEM", 400, 412], ["acute flaccid paralysis", "PROBLEM", 471, 494], ["A 'rolling circle' sequence", "TREATMENT", 553, 580], ["independent amplification technique", "TREATMENT", 581, 616], ["circular DNA molecules", "TREATMENT", 646, 668], ["plasmids", "TREATMENT", 677, 685], ["viral genomes", "PROBLEM", 689, 702], ["a rolling circle mechanism", "TREATMENT", 723, 749], ["viruses", "OBSERVATION", 57, 64], ["parvovirus", "OBSERVATION", 94, 104], ["coronavirus", "OBSERVATION", 133, 144], ["polyomavirus", "OBSERVATION", 153, 165], ["respiratory tract", "ANATOMY", 183, 200], ["encephalitis", "OBSERVATION", 400, 412], ["acute", "OBSERVATION_MODIFIER", 471, 476], ["flaccid", "OBSERVATION_MODIFIER", 477, 484], ["paralysis", "OBSERVATION", 485, 494], ["viral genomes", "OBSERVATION", 689, 702]]], ["RCA mimics this natural process without requiring prior knowledge of the viral sequence, utilising random hexamer primers that bind at multiple locations on a circular DNA template, and a polymerase enzyme, such as bacteriophage F29 DNA polymerase.Rolling circle amplification (RCA)The polymerase enzyme has a strong strand-displacing capability, high processivity (approximately 70 000 bases/binding event), and proof-reading activity (Esteban et al., 1993) .", [["RCA", "MULTI-TISSUE_STRUCTURE", 0, 3], ["DNA", "CELLULAR_COMPONENT", 168, 171], ["bacteriophage F29", "GENE_OR_GENE_PRODUCT", 215, 232], ["DNA", "CELLULAR_COMPONENT", 233, 236], ["RCA", "PROTEIN", 0, 3], ["viral sequence", "DNA", 73, 87], ["circular DNA template", "DNA", 159, 180], ["polymerase enzyme", "PROTEIN", 188, 205], ["bacteriophage F29 DNA polymerase", "PROTEIN", 215, 247], ["polymerase enzyme", "PROTEIN", 286, 303], ["the viral sequence", "TEST", 69, 87], ["random hexamer primers", "TREATMENT", 99, 121], ["a circular DNA template", "TREATMENT", 157, 180], ["a polymerase enzyme", "TEST", 186, 205], ["The polymerase enzyme", "TEST", 282, 303], ["a strong strand-displacing capability", "PROBLEM", 308, 345], ["high processivity", "PROBLEM", 347, 364], ["high processivity", "OBSERVATION_MODIFIER", 347, 364]]], ["When the polymerase enzyme comes 'full circle' on a circular viral genome it displaces its 5 0 end and continues to extend the new strand multiple times around the DNA circle.", [["DNA", "CELLULAR_COMPONENT", 164, 167], ["polymerase enzyme", "PROTEIN", 9, 26], ["circular viral genome", "DNA", 52, 73], ["5 0 end", "DNA", 91, 98], ["the polymerase enzyme", "TEST", 5, 26], ["a circular viral genome", "PROBLEM", 50, 73], ["circular", "OBSERVATION_MODIFIER", 52, 60], ["viral genome", "OBSERVATION", 61, 73], ["new", "OBSERVATION_MODIFIER", 127, 130], ["strand", "OBSERVATION", 131, 137], ["DNA circle", "OBSERVATION", 164, 174]]], ["Random primers can then anneal to the displaced strand and convert it to double-stranded DNA (Dean et al., 2001) .", [["DNA", "CELLULAR_COMPONENT", 89, 92], ["double-stranded DNA", "DNA", 73, 92], ["Random primers", "PROBLEM", 0, 14], ["the displaced strand", "PROBLEM", 34, 54], ["displaced", "OBSERVATION_MODIFIER", 38, 47], ["strand", "OBSERVATION", 48, 54]]], ["By using multiply-primed RCA, unknown circular DNA templates can be exponentially amplified.", [["RCA", "MULTI-TISSUE_STRUCTURE", 25, 28], ["DNA", "CELLULAR_COMPONENT", 47, 50], ["RCA", "DNA", 25, 28], ["circular DNA templates", "DNA", 38, 60], ["multiply-primed RCA", "TREATMENT", 9, 28], ["circular DNA templates", "TREATMENT", 38, 60], ["RCA", "ANATOMY", 25, 28], ["circular DNA", "OBSERVATION", 38, 50]]], ["The long, doublestranded DNA products can then be cut with a restriction enzyme to release linear fragments, sequenced and identified, the length of the circle.Rolling circle amplification (RCA)Although technically more demanding than other methods of sequence-independent amplification, the RCA approach has facilitated the identification of a novel variant of bovine papillomavirus type-1 (Rector et al., 2004b) and of novel papillomaviruses in a Florida manatee (Rector et al., 2004a) .", [["fragments", "ANATOMY", 98, 107], ["bovine papillomavirus type", "DISEASE", 362, 388], ["papillomaviruses", "DISEASE", 427, 443], ["DNA", "CELLULAR_COMPONENT", 25, 28], ["bovine papillomavirus type-1", "ORGANISM", 362, 390], ["papillomaviruses", "ORGANISM", 427, 443], ["doublestranded DNA products", "PROTEIN", 10, 37], ["restriction enzyme", "PROTEIN", 61, 79], ["RCA", "DNA", 292, 295], ["bovine", "SPECIES", 362, 368], ["bovine papillomavirus type-1", "SPECIES", 362, 390], ["The long, doublestranded DNA products", "TREATMENT", 0, 37], ["a restriction enzyme", "TREATMENT", 59, 79], ["linear fragments", "PROBLEM", 91, 107], ["bovine papillomavirus type", "TREATMENT", 362, 388], ["linear", "OBSERVATION_MODIFIER", 91, 97], ["fragments", "OBSERVATION", 98, 107], ["length", "OBSERVATION_MODIFIER", 139, 145], ["RCA", "ANATOMY", 190, 193], ["RCA", "ANATOMY", 292, 295]]], ["This method has also yielded the full genomic sequences of polyomaviruses (Johne et al., 2006b) , an anellovirus (Niel et al., 2005) , circoviruses (Johne et al., 2006a) and wasp polydnavirus (Espagne et al., 2004) .", [["wasp polydnavirus", "DISEASE", 174, 191], ["polyomaviruses", "ORGANISM", 59, 73], ["polyomaviruses", "PROBLEM", 59, 73]]], ["Through the use of a combination of RCA and SISPA, nine anelloviruses found in human plasma and cat saliva have been detected and characterised (Biagini et al., 2007) .Sequencing methodsMost hybridisation and PCR methods generate products that require definitive identification by sequencing.", [["plasma", "ANATOMY", 85, 91], ["anelloviruses", "GENE_OR_GENE_PRODUCT", 56, 69], ["human", "ORGANISM", 79, 84], ["plasma", "ORGANISM_SUBSTANCE", 85, 91], ["cat", "ORGANISM", 96, 99], ["saliva", "ORGANISM_SUBSTANCE", 100, 106], ["RCA", "DNA", 36, 39], ["SISPA", "PROTEIN", 44, 49], ["anelloviruses", "PROTEIN", 56, 69], ["human plasma", "CELL_TYPE", 79, 91], ["human", "SPECIES", 79, 84], ["cat", "SPECIES", 96, 99], ["human", "SPECIES", 79, 84], ["cat", "SPECIES", 96, 99], ["RCA and SISPA", "TREATMENT", 36, 49], ["nine anelloviruses", "TREATMENT", 51, 69], ["human plasma", "TEST", 79, 91], ["Sequencing methods", "TEST", 168, 186], ["Most hybridisation and PCR methods generate products", "PROBLEM", 186, 238], ["definitive identification", "TEST", 252, 277], ["RCA", "ANATOMY", 36, 39]]], ["This method is based on the DNA polymerase-dependent synthesis of a complementary DNA strand in the presence of natural 2 0 -doexynucleotides (dNTPs) and 2 0 ,3 0 -didoexynucleotides (ddNTPs) that serve as non-reversible synthesis terminators (Sanger et al., 1977) .", [["2 0 -doexynucleotides", "CHEMICAL", 120, 141], ["dNTPs", "CHEMICAL", 143, 148], ["2 0 ,3 0 -didoexynucleotides", "CHEMICAL", 154, 182], ["2 0 -doexynucleotides", "CHEMICAL", 120, 141], ["dNTPs", "CHEMICAL", 143, 148], ["2 0 ,3 0 -didoexynucleotides", "CHEMICAL", 154, 182], ["DNA", "CELLULAR_COMPONENT", 28, 31], ["DNA", "CELLULAR_COMPONENT", 82, 85], ["2 0 -doexynucleotides", "SIMPLE_CHEMICAL", 120, 141], ["dNTPs", "SIMPLE_CHEMICAL", 143, 148], ["2 0 ,3 0 -didoexynucleotides", "SIMPLE_CHEMICAL", 154, 182], ["ddNTPs", "SIMPLE_CHEMICAL", 184, 190], ["DNA polymerase", "PROTEIN", 28, 42], ["complementary DNA strand", "DNA", 68, 92], ["ddNTPs", "DNA", 184, 190], ["non-reversible synthesis terminators", "DNA", 206, 242], ["the DNA polymerase", "TEST", 24, 42], ["dependent synthesis", "PROBLEM", 43, 62], ["a complementary DNA strand", "PROBLEM", 66, 92], ["dNTPs", "TEST", 143, 148]]], ["A limitation of this technique in terms of virus identification can be the requirement to clone viral sequences into bacteria prior to sequencing, although direct sequencing of PCR products can also be employed.", [["clone viral sequences", "DNA", 90, 111], ["PCR products", "PROTEIN", 177, 189], ["this technique", "TREATMENT", 16, 30], ["virus identification", "PROBLEM", 43, 63], ["clone viral sequences", "TEST", 90, 111], ["bacteria", "PROBLEM", 117, 125], ["sequencing", "TEST", 135, 145], ["PCR products", "TREATMENT", 177, 189]]], ["When cloning is performed using this method, host-related bias can occur (Hall, 2007) , and, as only a relatively limited number of clones can be sequenced, methods to enrich for virus prior to amplification are required.Sequencing methodsRecently, use of the Sanger method has been partially succeeded by 'next generation sequencing' technologies that circumvent the need for cloning by using highly efficient in vitro DNA amplification (Morozova and Marra, 2008) .", [["clones", "CELL", 132, 138], ["DNA", "CELLULAR_COMPONENT", 420, 423], ["this method", "TREATMENT", 32, 43], ["virus", "PROBLEM", 179, 184], ["Sequencing methods", "TEST", 221, 239], ["the Sanger method", "TREATMENT", 256, 273], ["vitro DNA amplification", "TREATMENT", 414, 437]]], ["Next generation sequencing technology includes the 454 pyrosequencing-based instrument (Roche Applied Sciences), genome analysers (Illumina) and the SOLiD system (Applied Biosystems).", [["the 454 pyrosequencing-based instrument", "TREATMENT", 47, 86], ["genome analysers (Illumina)", "TREATMENT", 113, 140], ["the SOLiD system", "TREATMENT", 145, 161], ["SOLiD system", "ANATOMY", 149, 161]]], ["This approach dramatically increases cost-effective sequence throughput, albeit at the expense of sequence read-length.Sequencing methodsCompared to read-lengths in the region of up to 900 bp produced by modern automated Sanger instruments, read-lengths of approximately 76-106 bp are generated by Illumina and of 250-400 bp by 454 technology.", [["bp", "TEST", 189, 191], ["lengths", "TEST", 246, 253], ["bp", "TEST", 278, 280], ["Illumina", "TEST", 298, 306], ["bp", "TEST", 322, 324], ["dramatically", "OBSERVATION_MODIFIER", 14, 26], ["increases", "OBSERVATION_MODIFIER", 27, 36]]], ["The comparatively short read-length of next generation sequencing technologies is however compensated for by the large number of 'reads' generated.", [["large", "OBSERVATION_MODIFIER", 113, 118]]], ["Typically 100 kilobases of sequence data are produced from a modern Sanger instrument with 454 sequencing capable of generating up to 400 megabases of data, and Illumina sequencing technology can produce up to 20 gigabases of sequence data/run (Metzker, 2010) .BioinformaticsSeveral different approaches have been used to analyse data produced by sequencing methods.", [["sequence data", "TEST", 27, 40], ["Illumina sequencing technology", "TEST", 161, 191], ["sequence data", "TEST", 226, 239]]], ["To date, the majority of novel viruses have been discovered using Basic Local Alignment Search Tool (BLAST) programmes that compare detected nucleotide sequences to those in a database, and rely on the fact that novel viruses have some homology to known viruses.", [["nucleotide", "CHEMICAL", 141, 151], ["novel viruses", "PROBLEM", 25, 38], ["nucleotide sequences", "TEST", 141, 161], ["a database", "TEST", 174, 184], ["novel viruses", "PROBLEM", 212, 225], ["viruses", "OBSERVATION", 31, 38], ["viruses", "OBSERVATION", 254, 261]]], ["Detecting distant viral relatives or completely new viruses can however be problematic.", [["completely new viruses", "PROBLEM", 37, 59], ["new", "OBSERVATION_MODIFIER", 48, 51], ["viruses", "OBSERVATION", 52, 59]]], ["For instance, a proportion of sequences (5-30%) derived from animal samples by sequence-independent amplification methods, and an even greater fraction of sequences derived from environmental samples, do not have nucleotide or amino acid sequences similar to those of viruses listed in existing databases (Delwart, 2007) .", [["samples", "ANATOMY", 68, 75], ["samples", "ANATOMY", 192, 199], ["nucleotide", "CHEMICAL", 213, 223], ["amino acid", "CHEMICAL", 227, 237], ["nucleotide", "CHEMICAL", 213, 223], ["amino acid", "CHEMICAL", 227, 237], ["amino acid", "AMINO_ACID", 227, 237], ["sequences", "TEST", 30, 39], ["environmental samples", "TEST", 178, 199], ["nucleotide or amino acid sequences", "PROBLEM", 213, 247]]], ["However, using these methods, viruses have been identified that are distantly related to known viruses.BioinformaticsSeveral approaches can be used to increase the likelihood of identifying virus, including 'querying' translated DNA sequences against a translated DNA database, as evolutionary relationships remain detectable for longer at the amino acid than at the nucleotide level.", [["amino acid", "CHEMICAL", 344, 354], ["amino acid", "CHEMICAL", 344, 354], ["nucleotide", "CHEMICAL", 367, 377], ["DNA", "CELLULAR_COMPONENT", 229, 232], ["DNA", "CELLULAR_COMPONENT", 264, 267], ["amino acid", "AMINO_ACID", 344, 354], ["DNA sequences", "DNA", 229, 242], ["these methods", "TEST", 15, 28], ["viruses", "PROBLEM", 30, 37], ["known viruses", "PROBLEM", 89, 102], ["virus", "PROBLEM", 190, 195], ["DNA sequences", "TEST", 229, 242], ["a translated DNA database", "PROBLEM", 251, 276], ["the amino acid", "TEST", 340, 354], ["viruses", "OBSERVATION", 95, 102], ["virus", "OBSERVATION", 190, 195]]], ["The computational generation of theoretical ancestral sequences, and their subsequent use in sequence similarity searches, may also improve identification of highly divergent viral sequences (Delwart, 2007) .", [["viral sequences", "DNA", 175, 190]]], ["Computational biologists have also developed new ingenious algorithms and techniques to analyse data produced by next generation sequencing to aid the identification of novel viruses (Wooley et al., 2010) .BioinformaticsBefore viruses are identified, the hybridisation and PCR methods previously described generally require both an initial step, to enrich for virus, and an amplification step ( Fig. 2A) .", [["novel viruses", "PROBLEM", 169, 182], ["viruses", "PROBLEM", 227, 234], ["the hybridisation and PCR methods", "TEST", 251, 284], ["virus", "PROBLEM", 360, 365], ["an amplification step", "TEST", 371, 392]]], ["Enrichment can result in loss of viral nucleic acid thus reducing test sensitivity, and amplification can generate bias towards a dominant (potentially host-derived) sequence.", [["nucleic acid", "CHEMICAL", 39, 51], ["loss of viral nucleic acid", "PROBLEM", 25, 51], ["test sensitivity", "TEST", 66, 82], ["viral nucleic acid", "OBSERVATION", 33, 51]]], ["A method known as transcriptome subtraction has been developed for viral discovery (Weber et al., 2002) with the advantage that it can be performed without the need for enrichment or amplification (Fig. 2B) .", [["A method", "TREATMENT", 0, 8], ["transcriptome subtraction", "TREATMENT", 18, 43], ["enrichment or amplification (Fig", "TREATMENT", 169, 201]]], ["Transcriptome subtraction is based on the principal that genes are transcribed (expressed) to produce mRNA, which can be converted in vitro to single-stranded DNA product complementary DNA (cDNA).", [["DNA", "CELLULAR_COMPONENT", 159, 162], ["DNA", "CELLULAR_COMPONENT", 185, 188], ["cDNA", "CELLULAR_COMPONENT", 190, 194], ["mRNA", "RNA", 102, 106], ["single-stranded DNA product complementary DNA", "DNA", 143, 188], ["cDNA", "DNA", 190, 194], ["Transcriptome subtraction", "TREATMENT", 0, 25], ["single-stranded DNA product", "TREATMENT", 143, 170]]], ["The sequencing of this cDNA, rather than genomic DNA, therefore allows the transcribed portion of the genome to be analysed.", [["DNA", "CELLULAR_COMPONENT", 49, 52], ["cDNA", "DNA", 23, 27], ["genomic DNA", "DNA", 41, 52], ["this cDNA", "TEST", 18, 27], ["genomic DNA", "PROBLEM", 41, 52]]], ["In view of the large number of transcripts present, sequencing is usually performed using next generation technologies.BioinformaticsThe technique works on the assumption that a sample infected with a virus would contain host and viral transcripts.", [["sample", "ANATOMY", 178, 184], ["viral transcripts", "RNA", 230, 247], ["next generation technologies", "TREATMENT", 90, 118], ["a sample infected", "PROBLEM", 176, 193], ["a virus", "TREATMENT", 199, 206], ["viral transcripts", "TREATMENT", 230, 247], ["large", "OBSERVATION_MODIFIER", 15, 20], ["number", "OBSERVATION_MODIFIER", 21, 27], ["viral transcripts", "OBSERVATION", 230, 247]]], ["Host transcript sequences are aligned and subtracted from public databases; in the case of a human sample, these include reference sequences such as the human RefSeq RNA, mitochondrial or assembled chromosome sequences in the National Centre for Biotechnology Information (NCBI) databases.", [["mitochondrial", "ANATOMY", 171, 184], ["chromosome", "ANATOMY", 198, 208], ["human", "ORGANISM", 93, 98], ["human", "ORGANISM", 153, 158], ["mitochondrial", "CELLULAR_COMPONENT", 171, 184], ["chromosome", "CELLULAR_COMPONENT", 198, 208], ["human RefSeq RNA", "RNA", 153, 169], ["mitochondrial or assembled chromosome sequences", "DNA", 171, 218], ["human", "SPECIES", 93, 98], ["human", "SPECIES", 153, 158], ["human", "SPECIES", 93, 98], ["human", "SPECIES", 153, 158], ["public databases", "TEST", 58, 74], ["a human sample", "TEST", 91, 105]]], ["After aligning and subtracting human sequences against databases, non-matched virus-enriched se-quences will remain and can be further studied.", [["human", "ORGANISM", 31, 36], ["human sequences", "DNA", 31, 46], ["human", "SPECIES", 31, 36], ["human", "SPECIES", 31, 36], ["subtracting human sequences", "TEST", 19, 46], ["non-matched virus", "TREATMENT", 66, 83]]], ["With the completion of the sequencing of several animal genomes, transcriptome subtraction techniques are applicable to a variety of other species, and the possibility exists to use both public databases and subtraction against un-infected control material.BioinformaticsA transcriptome subtraction method has been used to identify a previously unknown polyomavirus in human Merkel cell carcinoma (Feng et al., 2008) and to identify an uncharacterised arenavirus associated with three transplant-related deaths (Palacios et al., 2008) .", [["Merkel cell carcinoma", "ANATOMY", 375, 396], ["Merkel cell carcinoma", "DISEASE", 375, 396], ["arenavirus", "DISEASE", 452, 462], ["deaths", "DISEASE", 504, 510], ["polyomavirus", "ORGANISM", 353, 365], ["human", "ORGANISM", 369, 374], ["Merkel cell carcinoma", "CANCER", 375, 396], ["arenavirus", "ORGANISM", 452, 462], ["human", "SPECIES", 369, 374], ["human", "SPECIES", 369, 374], ["transcriptome subtraction techniques", "TREATMENT", 65, 101], ["public databases", "TEST", 187, 203], ["subtraction", "TEST", 208, 219], ["un-infected control material", "TREATMENT", 228, 256], ["BioinformaticsA transcriptome subtraction method", "TREATMENT", 257, 305], ["a previously unknown polyomavirus in human Merkel cell carcinoma", "PROBLEM", 332, 396], ["an uncharacterised arenavirus", "PROBLEM", 433, 462], ["infected", "OBSERVATION", 231, 239], ["polyomavirus", "OBSERVATION", 353, 365], ["Merkel cell carcinoma", "OBSERVATION", 375, 396], ["arenavirus", "OBSERVATION", 452, 462]]], ["This technique has the advantage of being able to identify very small amounts of virus, as in the case of the polyomavirus detailed above, only 10 viral transcripts/cell were present.", [["cell", "ANATOMY", 165, 169], ["polyomavirus", "ORGANISM", 110, 122], ["cell", "CELL", 165, 169], ["viral transcripts", "RNA", 147, 164], ["This technique", "TREATMENT", 0, 14], ["very small amounts of virus", "PROBLEM", 59, 86], ["the polyomavirus", "PROBLEM", 106, 122], ["10 viral transcripts/cell", "PROBLEM", 144, 169], ["virus", "OBSERVATION", 81, 86], ["polyomavirus", "OBSERVATION", 110, 122]]], ["Given that each cell contains approximately 1 million host transcripts, only a small proportion of the cellular RNA is virus-derived.", [["cell", "ANATOMY", 16, 20], ["cellular", "ANATOMY", 103, 111], ["cell", "CELL", 16, 20], ["cellular", "CELL", 103, 111], ["cellular RNA", "RNA", 103, 115], ["the cellular RNA", "PROBLEM", 99, 115], ["small", "OBSERVATION_MODIFIER", 79, 84], ["cellular RNA", "OBSERVATION", 103, 115]]], ["Providing every cell is infected, even at very low levels, 10 million sequence 'reads' gives a >99.99% probability of detecting at least one viral sequence (Fig. 3) .", [["cell", "ANATOMY", 16, 20], ["cell", "CELL", 16, 20], ["viral sequence", "DNA", 141, 155], ["infected", "OBSERVATION", 24, 32]]], ["Such a large number of reads is readily obtainable using next generation technology such as the Illumina platform.", [["next generation technology", "TREATMENT", 57, 83], ["large", "OBSERVATION_MODIFIER", 7, 12]]], ["However the technique does have limitations in that if only 1/10 cells is infected, or a sequencing methodology is used which produces only 50 000 sequence reads, the probabilities of detecting viral sequence decrease to approximately 60% and 5%, respectively.Identification of viral sequences and proof of causationWhile many newly identified viruses infecting animals and humans were initially found in patients with particular clinical signs or symptoms, most have not been causally associated with particular diseases.", [["cells", "ANATOMY", 65, 70], ["cells", "CELL", 65, 70], ["animals", "ORGANISM", 362, 369], ["humans", "ORGANISM", 374, 380], ["patients", "ORGANISM", 405, 413], ["viral sequences", "DNA", 278, 293], ["humans", "SPECIES", 374, 380], ["patients", "SPECIES", 405, 413], ["humans", "SPECIES", 374, 380], ["a sequencing methodology", "TEST", 87, 111], ["viral sequence decrease", "PROBLEM", 194, 217], ["viral sequences", "TEST", 278, 293], ["particular clinical signs", "PROBLEM", 419, 444], ["symptoms", "PROBLEM", 448, 456], ["particular diseases", "PROBLEM", 502, 521], ["viral", "OBSERVATION", 194, 199], ["decrease", "OBSERVATION_MODIFIER", 209, 217], ["viral", "OBSERVATION", 278, 283], ["viruses", "OBSERVATION", 344, 351]]], ["The detection of viruses in such contexts may merely reflect the presence of a virus in a sample or the ability of a virus to replicate within a particular disease environment, rather than the virus directly causing the disease.", [["sample", "ANATOMY", 90, 96], ["viruses", "PROBLEM", 17, 24], ["a virus", "PROBLEM", 77, 84], ["a virus", "PROBLEM", 115, 122], ["a particular disease environment", "PROBLEM", 143, 175], ["the virus", "PROBLEM", 189, 198], ["the disease", "PROBLEM", 216, 227], ["viruses", "OBSERVATION", 17, 24], ["virus", "OBSERVATION", 79, 84], ["disease", "OBSERVATION", 220, 227]]], ["For example, although several infectious agents have been found in samples from human patients with multiple sclerosis (Johnson et al., 1984; Challoner et al., 1995; Perron et al., 1997; Thacker et al., 2006) , causal roles in pathogenesis have never been attributed (Munz et al., 2009) .", [["samples", "ANATOMY", 67, 74], ["multiple sclerosis", "DISEASE", 100, 118], ["samples", "CANCER", 67, 74], ["human", "ORGANISM", 80, 85], ["patients", "ORGANISM", 86, 94], ["human", "SPECIES", 80, 85], ["patients", "SPECIES", 86, 94], ["human", "SPECIES", 80, 85], ["several infectious agents", "PROBLEM", 22, 47], ["multiple sclerosis", "PROBLEM", 100, 118], ["several", "OBSERVATION_MODIFIER", 22, 29], ["infectious", "OBSERVATION", 30, 40], ["multiple", "OBSERVATION_MODIFIER", 100, 108], ["sclerosis", "OBSERVATION", 109, 118]]], ["Similarly, herpes simplex virus type-2 (HSV-2) was strongly implicated as the cause of cervical cancer in humans for many years until human papilloma virus DNA was identified in biopsies (Durst et al., 1983) .", [["cervical cancer", "ANATOMY", 87, 102], ["biopsies", "ANATOMY", 178, 186], ["herpes simplex virus", "DISEASE", 11, 31], ["cervical cancer", "DISEASE", 87, 102], ["herpes simplex virus type-2", "ORGANISM", 11, 38], ["HSV-2", "ORGANISM", 40, 45], ["cervical cancer", "CANCER", 87, 102], ["humans", "ORGANISM", 106, 112], ["human papilloma virus", "ORGANISM", 134, 155], ["DNA", "CELLULAR_COMPONENT", 156, 159], ["biopsies", "TISSUE", 178, 186], ["herpes simplex virus type-2", "SPECIES", 11, 38], ["humans", "SPECIES", 106, 112], ["human", "SPECIES", 134, 139], ["herpes simplex virus type-2 (HSV-2", "SPECIES", 11, 45], ["humans", "SPECIES", 106, 112], ["human papilloma virus", "SPECIES", 134, 155], ["herpes simplex virus type", "TEST", 11, 36], ["HSV", "TEST", 40, 43], ["cervical cancer", "PROBLEM", 87, 102], ["human papilloma virus DNA", "PROBLEM", 134, 159], ["biopsies", "TEST", 178, 186], ["herpes", "OBSERVATION", 11, 17], ["simplex virus", "OBSERVATION", 18, 31], ["cervical", "ANATOMY", 87, 95], ["cancer", "OBSERVATION", 96, 102], ["papilloma", "OBSERVATION", 140, 149]]], ["Henle-Koch postulates are a well known set of criteria that must be fulfilled by a microorganism for it to be proven as the cause of disease.", [["a microorganism", "PROBLEM", 81, 96], ["disease", "PROBLEM", 133, 140], ["disease", "OBSERVATION", 133, 140]]], ["The ability to culture viruses in vitro and the detection of antibodies against viruses led to new proposals for the demonstration of causality (Rivers, 1937) .", [["antibodies", "PROTEIN", 61, 71], ["culture viruses", "TEST", 15, 30], ["the detection", "TEST", 44, 57], ["antibodies", "PROBLEM", 61, 71], ["viruses", "PROBLEM", 80, 87]]], ["Advances in technology have resulted in new challenges to the assigning of causation and sequence-based approaches to virus identification have led to the formulation of guidelines defining the relationship between the presence of viral sequences and disease (Fredericks and Relman, 1996) .", [["virus identification", "TEST", 118, 138], ["viral sequences", "PROBLEM", 231, 246], ["disease", "PROBLEM", 251, 258], ["new", "OBSERVATION_MODIFIER", 40, 43], ["viral", "OBSERVATION", 231, 236]]], ["Such guidelines have been used to link hepatitis C virus (HCV) with non-A, non-B hepatitis (Kuo et al., 1989) , and human herpesvirus-8 with Kaposi's sarcoma (Moore and Chang, 1995; Noel et al., 1996) , but are often ignored in the race to assign significance to virus discovery.Identification of viral sequences and proof of causationIn infectious disease research a balance must be struck between the prompt identification of highly significant new human pathogens such as pandemic swine H1N1 influenza (Dawood et al., 2009) , and clearly defining the more tenuous connection between xenotropic murine leukaemia virus-related virus (XMRV) and chronic fatigue syndrome (Lombardi et al., 2009) .", [["Kaposi's sarcoma", "ANATOMY", 141, 157], ["hepatitis C", "DISEASE", 39, 50], ["non-B hepatitis", "DISEASE", 75, 90], ["Kaposi's sarcoma", "DISEASE", 141, 157], ["infectious disease", "DISEASE", 338, 356], ["swine H1N1 influenza", "DISEASE", 484, 504], ["xenotropic murine leukaemia virus", "DISEASE", 586, 619], ["chronic fatigue syndrome", "DISEASE", 645, 669], ["hepatitis C virus", "ORGANISM", 39, 56], ["HCV", "ORGANISM", 58, 61], ["non-A", "ORGANISM", 68, 73], ["non-B hepatitis", "ORGANISM", 75, 90], ["human herpesvirus-8", "ORGANISM", 116, 135], ["Kaposi's sarcoma", "ORGANISM", 141, 157], ["human", "ORGANISM", 451, 456], ["swine H1N1 influenza", "ORGANISM", 484, 504], ["xenotropic murine leukaemia virus-related virus", "ORGANISM", 586, 633], ["XMRV", "ORGANISM", 635, 639], ["viral sequences", "DNA", 297, 312], ["hepatitis C virus", "SPECIES", 39, 56], ["human", "SPECIES", 116, 121], ["human", "SPECIES", 451, 456], ["swine H1N1 influenza", "SPECIES", 484, 504], ["murine", "SPECIES", 597, 603], ["leukaemia virus-related virus", "SPECIES", 604, 633], ["hepatitis C virus", "SPECIES", 39, 56], ["HCV", "SPECIES", 58, 61], ["human herpesvirus-8", "SPECIES", 116, 135], ["human", "SPECIES", 451, 456], ["murine leukaemia virus-related virus", "SPECIES", 597, 633], ["XMRV", "SPECIES", 635, 639], ["hepatitis C virus (HCV", "PROBLEM", 39, 61], ["B hepatitis", "PROBLEM", 79, 90], ["human herpesvirus", "TEST", 116, 133], ["Kaposi's sarcoma", "PROBLEM", 141, 157], ["viral sequences", "TEST", 297, 312], ["significant new human pathogens", "PROBLEM", 435, 466], ["pandemic swine H1N1 influenza", "PROBLEM", 475, 504], ["xenotropic murine leukaemia virus", "PROBLEM", 586, 619], ["related virus (XMRV)", "PROBLEM", 620, 640], ["chronic fatigue syndrome", "PROBLEM", 645, 669], ["hepatitis", "OBSERVATION", 81, 90], ["sarcoma", "OBSERVATION", 150, 157], ["viral", "OBSERVATION", 297, 302], ["infectious", "OBSERVATION_MODIFIER", 338, 348], ["xenotropic murine leukaemia virus", "OBSERVATION", 586, 619], ["chronic", "OBSERVATION_MODIFIER", 645, 652], ["fatigue syndrome", "OBSERVATION", 653, 669]]], ["Epidemiological, immunological and sequence-based criteria should support any proposed link between an infectious organism and the disease under study.", [["an infectious organism", "PROBLEM", 100, 122], ["the disease under study", "PROBLEM", 127, 150], ["infectious", "OBSERVATION", 103, 113]]], ["Establishing causality must also involve an appreciation of the full range of genetic diversity of the viral species, as it is well established that distinct viral genotypes or even minor genetic variations can result in large changes in viral pathogenicity.ConclusionsViral identification is an ever-evolving discipline where new technologies are likely to have significant impact over the coming decades.", [["the viral species", "PROBLEM", 99, 116], ["distinct viral genotypes", "PROBLEM", 149, 173], ["large changes in viral pathogenicity", "PROBLEM", 221, 257], ["Viral identification", "TEST", 269, 289], ["viral species", "OBSERVATION", 103, 116], ["large", "OBSERVATION_MODIFIER", 221, 226], ["viral pathogenicity", "OBSERVATION", 238, 257], ["significant", "OBSERVATION_MODIFIER", 363, 374], ["impact", "OBSERVATION", 375, 381]]], ["The further development of hybridisation and PCR-based methods, the increased availability of next generation sequencing, improvements in transcriptome subtraction methods, continued expansion of viral and animal genome databases, and improved bioinformatic tools will all facilitate the acceleration of this identification process.Conflict of interest statementNeither of the authors of this paper has a financial or personal relationship with other people or organisations that could inappropriately influence or bias the content of the paper.", [["people", "ORGANISM", 451, 457], ["people", "SPECIES", 451, 457], ["hybridisation and PCR", "TEST", 27, 48], ["next generation sequencing", "TREATMENT", 94, 120], ["transcriptome subtraction methods", "TREATMENT", 138, 171], ["viral and animal genome databases", "PROBLEM", 196, 229], ["viral", "OBSERVATION_MODIFIER", 196, 201]]]], "PMC4165553": [["IntroductionInfluenza virus causes substantial burden of illness in all age groups during regular epidemics and occasional pandemics [1].", [["Influenza virus", "DISEASE", 12, 27], ["illness", "DISEASE", 57, 64], ["Influenza virus", "ORGANISM", 12, 27], ["Influenza virus", "SPECIES", 12, 27], ["Influenza virus", "SPECIES", 12, 27], ["IntroductionInfluenza virus", "PROBLEM", 0, 27], ["illness", "PROBLEM", 57, 64]]], ["Children often face the highest risk of infections during epidemics, because of higher levels of person-to-person contact and therefore greater exposure [2] as well as lower immunity due to fewer previous infections.", [["infections", "DISEASE", 40, 50], ["infections", "DISEASE", 205, 215], ["Children", "ORGANISM", 0, 8], ["Children", "SPECIES", 0, 8], ["person", "SPECIES", 97, 103], ["person", "SPECIES", 107, 113], ["infections", "PROBLEM", 40, 50], ["fewer previous infections", "PROBLEM", 190, 215], ["infections", "OBSERVATION", 40, 50], ["infections", "OBSERVATION", 205, 215]]], ["Influenza vaccination is effective in reducing the risk of influenza virus infection and illness [3].IntroductionIn Hong Kong, children between 6 months and 6 years of age as well as those with an underlying condition rendering them at increased risk for complications from influenza virus infection are recommended to receive influenza vaccination each year [4].", [["Influenza", "DISEASE", 0, 9], ["influenza virus infection", "DISEASE", 59, 84], ["illness", "DISEASE", 89, 96], ["influenza virus infection", "DISEASE", 274, 299], ["influenza virus", "ORGANISM", 59, 74], ["children", "ORGANISM", 127, 135], ["influenza virus", "ORGANISM", 274, 289], ["influenza virus", "SPECIES", 59, 74], ["children", "SPECIES", 127, 135], ["influenza virus", "SPECIES", 274, 289], ["influenza virus", "SPECIES", 59, 74], ["influenza virus", "SPECIES", 274, 289], ["Influenza vaccination", "TREATMENT", 0, 21], ["influenza virus infection", "PROBLEM", 59, 84], ["an underlying condition", "PROBLEM", 194, 217], ["complications", "PROBLEM", 255, 268], ["influenza virus infection", "PROBLEM", 274, 299], ["influenza vaccination", "TREATMENT", 327, 348], ["influenza virus", "OBSERVATION", 59, 74]]], ["The Hong Kong government provides a subsidy for influenza vaccination for children between 6 months and less than 6 years, while children with an underlying condition can receive free influenza vaccination [5].", [["influenza", "DISEASE", 48, 57], ["influenza", "DISEASE", 184, 193], ["children", "ORGANISM", 74, 82], ["children", "ORGANISM", 129, 137], ["children", "SPECIES", 74, 82], ["children", "SPECIES", 129, 137], ["influenza vaccination", "TREATMENT", 48, 69], ["an underlying condition", "PROBLEM", 143, 166], ["free influenza vaccination", "TREATMENT", 179, 205]]], ["The Northern Hemisphere vaccine is used in Hong Kong.IntroductionInfluenza vaccine effectiveness (VE) can vary from year to year, and it is important to continually monitor VE to confirm that vaccination is providing adequate protection and to identify factors affecting VE.", [["The Northern Hemisphere vaccine", "TREATMENT", 0, 31], ["IntroductionInfluenza vaccine effectiveness", "TREATMENT", 53, 96], ["vaccination", "TREATMENT", 192, 203]]], ["The test negative design is an approach to estimating influenza VE from observational data based on recruitment of cases with acute respiratory infection, and comparison of vaccine coverage among the cases testing positive for influenza virus versus coverage among the cases testing negative for influenza virus [6].", [["respiratory", "ANATOMY", 132, 143], ["acute respiratory infection", "DISEASE", 126, 153], ["influenza virus", "DISEASE", 227, 242], ["influenza virus", "DISEASE", 296, 311], ["influenza virus", "ORGANISM", 296, 311], ["influenza virus", "SPECIES", 296, 311], ["influenza virus", "SPECIES", 227, 242], ["influenza virus", "SPECIES", 296, 311], ["The test", "TEST", 0, 8], ["estimating influenza VE", "PROBLEM", 43, 66], ["observational data", "TEST", 72, 90], ["acute respiratory infection", "PROBLEM", 126, 153], ["vaccine coverage", "TREATMENT", 173, 189], ["the cases testing", "TEST", 196, 213], ["influenza virus", "PROBLEM", 227, 242], ["the cases testing", "TEST", 265, 282], ["influenza virus", "PROBLEM", 296, 311], ["acute", "OBSERVATION_MODIFIER", 126, 131], ["respiratory", "ANATOMY", 132, 143], ["infection", "OBSERVATION", 144, 153]]], ["The design has some similarities to a case\u2013control study, but one major difference is the absence of a group of patients prospectively identified and recruited specifically as controls in most such studies.", [["patients", "ORGANISM", 112, 120], ["patients", "SPECIES", 112, 120], ["a case\u2013control study", "TEST", 36, 56]]], ["An exception is in test-negative studies conducted retrospectively, when laboratory results can be included in the case definition and a separate group of patients with negative laboratory results for influenza can be recruited [7].", [["influenza", "DISEASE", 201, 210], ["patients", "ORGANISM", 155, 163], ["patients", "SPECIES", 155, 163], ["influenza", "PROBLEM", 201, 210]]], ["The majority of test-negative studies reported in the literature have been conducted in outpatient settings in temperate locations [10], [11], [12], [13], [14].", [["[12]", "SIMPLE_CHEMICAL", 143, 147], ["[13]", "SIMPLE_CHEMICAL", 149, 153], ["test", "TEST", 16, 20]]], ["We have conducted systematic surveillance of the hospitalization burden of influenza among children in Hong Kong since 1997 [15], [16], [17], and here we use the test-negative approach to estimate influenza VE in this population.", [["influenza", "DISEASE", 75, 84], ["children", "ORGANISM", 91, 99], ["children", "SPECIES", 91, 99], ["influenza", "PROBLEM", 75, 84], ["the test", "TEST", 158, 166], ["influenza VE", "PROBLEM", 197, 209], ["influenza", "OBSERVATION", 197, 206]]], ["This study provided a better estimate of VE against the more severe outcome of influenza.Subjects ::: MethodsOur study was based in Queen Mary Hospital and Pamela Youde Nethersole Eastern Hospital, the only 2 public hospitals on Hong Kong Island in Hong Kong with acute paediatric services.", [["influenza", "DISEASE", 79, 88], ["This study", "TEST", 0, 10], ["influenza", "PROBLEM", 79, 88], ["acute paediatric services", "TREATMENT", 264, 289], ["influenza", "OBSERVATION", 79, 88]]], ["Children 6 months to 17 years of age admitted to the general wards of either of these hospitals with a febrile acute respiratory infection, defined as fever measured \u226538 \u00b0C with any respiratory symptom such as cough, runny nose, or sore throat were eligible for inclusion in this study.", [["respiratory", "ANATOMY", 117, 128], ["respiratory", "ANATOMY", 182, 193], ["acute respiratory infection", "DISEASE", 111, 138], ["fever", "DISEASE", 151, 156], ["cough", "DISEASE", 210, 215], ["runny nose", "DISEASE", 217, 227], ["sore throat", "DISEASE", 232, 243], ["Children", "ORGANISM", 0, 8], ["Children", "SPECIES", 0, 8], ["a febrile acute respiratory infection", "PROBLEM", 101, 138], ["fever", "PROBLEM", 151, 156], ["any respiratory symptom", "PROBLEM", 178, 201], ["cough", "PROBLEM", 210, 215], ["runny nose", "PROBLEM", 217, 227], ["sore throat", "PROBLEM", 232, 243], ["this study", "TEST", 275, 285], ["febrile", "OBSERVATION_MODIFIER", 103, 110], ["acute", "OBSERVATION_MODIFIER", 111, 116], ["respiratory", "ANATOMY", 117, 128], ["infection", "OBSERVATION", 129, 138]]], ["Children with risk factors for potentially severe respiratory infections like prematurity or chronic lung disease were not excluded.", [["respiratory", "ANATOMY", 50, 61], ["lung", "ANATOMY", 101, 105], ["respiratory infections", "DISEASE", 50, 72], ["prematurity", "DISEASE", 78, 89], ["chronic lung disease", "DISEASE", 93, 113], ["Children", "ORGANISM", 0, 8], ["lung", "ORGAN", 101, 105], ["Children", "SPECIES", 0, 8], ["risk factors", "PROBLEM", 14, 26], ["potentially severe respiratory infections", "PROBLEM", 31, 72], ["prematurity", "PROBLEM", 78, 89], ["chronic lung disease", "PROBLEM", 93, 113], ["severe", "OBSERVATION_MODIFIER", 43, 49], ["respiratory", "ANATOMY", 50, 61], ["infections", "OBSERVATION", 62, 72], ["prematurity", "OBSERVATION", 78, 89], ["chronic", "OBSERVATION_MODIFIER", 93, 100], ["lung", "ANATOMY", 101, 105], ["disease", "OBSERVATION", 106, 113], ["not excluded", "UNCERTAINTY", 119, 131]]], ["Nasopharyngeal aspirates were obtained from all patients and tested for influenza A and B virus by immunofluorescence and culture for seasonal influenza A and B virus, and additional RT-PCR for influenza A(H1N1)pdm09 virus.", [["Nasopharyngeal aspirates", "ANATOMY", 0, 24], ["Nasopharyngeal aspirates", "MULTI-TISSUE_STRUCTURE", 0, 24], ["patients", "ORGANISM", 48, 56], ["influenza A", "ORGANISM", 72, 83], ["B virus", "ORGANISM", 88, 95], ["seasonal influenza A", "ORGANISM", 134, 154], ["B virus", "ORGANISM", 159, 166], ["influenza A(H1N1)pdm09 virus", "ORGANISM", 194, 222], ["patients", "SPECIES", 48, 56], ["influenza A and B virus", "SPECIES", 143, 166], ["influenza A(H1N1", "SPECIES", 194, 210], ["influenza A", "SPECIES", 72, 83], ["B virus", "SPECIES", 88, 95], ["seasonal influenza A", "SPECIES", 134, 154], ["B virus", "SPECIES", 159, 166], ["influenza A(H1N1)pdm09 virus", "SPECIES", 194, 222], ["Nasopharyngeal aspirates", "TEST", 0, 24], ["influenza", "PROBLEM", 72, 81], ["B virus", "PROBLEM", 88, 95], ["immunofluorescence", "TEST", 99, 117], ["culture", "TEST", 122, 129], ["seasonal influenza A and B virus", "PROBLEM", 134, 166], ["additional RT-PCR", "TEST", 172, 189], ["influenza", "PROBLEM", 194, 203], ["H1N1", "PROBLEM", 206, 210], ["pdm09 virus", "PROBLEM", 211, 222], ["aspirates", "OBSERVATION", 15, 24]]], ["Influenza vaccination history within 6 months of hospitalization was elicited from the parents or legal guardians of patients using a standardized questionnaire administered by research personnel.", [["Influenza", "DISEASE", 0, 9], ["patients", "ORGANISM", 117, 125], ["patients", "SPECIES", 117, 125], ["Influenza vaccination", "TREATMENT", 0, 21]]], ["The study period was between October 2009 and September 2013.Subjects ::: MethodsThe study protocol was approved by the Institutional Review Board of the University of Hong Kong which waived the need for written consent since viral investigation was a routine diagnostic test carried out as part of routine care, any patient information was delinked from individual patient identification to maintain patient confidentiality, and participation by responding to the questionnaire was voluntary and indicative of consent.Definition of vaccination status ::: MethodsVaccinated children were those who had received trivalent inactivated influenza vaccine (TIV) within the 6 months prior to admission in a regimen and dosage appropriate for age and influenza vaccination history according to the recommendations of the Advisory Committee on Immunization Practices, with the last dose more than 2 weeks before hospitalization [18].", [["patient", "ORGANISM", 317, 324], ["patient", "ORGANISM", 366, 373], ["patient", "ORGANISM", 401, 408], ["children", "ORGANISM", 574, 582], ["patient", "SPECIES", 317, 324], ["patient", "SPECIES", 366, 373], ["patient", "SPECIES", 401, 408], ["children", "SPECIES", 574, 582], ["TIV", "SPECIES", 652, 655], ["Methods", "TREATMENT", 74, 81], ["The study protocol", "TEST", 81, 99], ["viral investigation", "TEST", 226, 245], ["a routine diagnostic test", "TEST", 250, 275], ["routine care", "TREATMENT", 299, 311], ["trivalent inactivated influenza vaccine", "TREATMENT", 611, 650], ["a regimen", "TREATMENT", 699, 708], ["influenza vaccination history", "TREATMENT", 744, 773], ["Immunization Practices", "TREATMENT", 836, 858]]], ["Children who should receive 2 doses of TIV but only received 1 dose, or were vaccinated within 2 weeks of hospitalization were categorized as unvaccinated.", [["Children", "ORGANISM", 0, 8], ["Children", "SPECIES", 0, 8], ["TIV", "TREATMENT", 39, 42]]], ["For the first study year of 1 October 2009 through 30 September 2010, children who had received 1 dose of the monovalent H1N1pdm09 vaccine within 6 months and at least 2 weeks prior to hospitalization were considered vaccinated.Outcome definition ::: MethodsNPA specimens were tested for influenza A virus by direct antigen detection by direct immunofluorescence (IF) and virus culture in all recruited patients at the Virology Laboratory at the Queen Mary Hospital, Hong Kong and at the Public Health Laboratory Centre, Hong Kong.", [["specimens", "ANATOMY", 262, 271], ["children", "ORGANISM", 70, 78], ["influenza A virus", "ORGANISM", 288, 305], ["patients", "ORGANISM", 403, 411], ["children", "SPECIES", 70, 78], ["influenza A virus", "SPECIES", 288, 305], ["patients", "SPECIES", 403, 411], ["influenza A virus", "SPECIES", 288, 305], ["the monovalent H1N1pdm09 vaccine", "TREATMENT", 106, 138], ["MethodsNPA specimens", "TEST", 251, 271], ["influenza", "PROBLEM", 288, 297], ["direct immunofluorescence", "TEST", 337, 362], ["virus culture", "TEST", 372, 385]]], ["The direct immunofluorescence antigen test was carried out as previously described using IMAGENTM respiratory screen and typing reagents (Oxoid Ely Ltd., UK) [19].", [["The direct immunofluorescence antigen test", "TEST", 0, 42], ["IMAGENTM respiratory screen", "TEST", 89, 116], ["typing reagents", "TEST", 121, 136]]], ["All the specimens found positive in the respiratory screen with a pooled IF reagent were further identified using antibody reagents to the individual virus (influenza A or B, respiratory syncytial virus, parainfluenza virus types 1, 2, 3 and adenovirus) using the IMAGEN\u2122 typing kit.", [["specimens", "ANATOMY", 8, 17], ["influenza A or B", "DISEASE", 157, 173], ["respiratory syncytial virus", "DISEASE", 175, 202], ["parainfluenza", "DISEASE", 204, 217], ["influenza A or B, respiratory syncytial virus", "ORGANISM", 157, 202], ["parainfluenza virus types 1", "ORGANISM", 204, 231], ["adenovirus", "ORGANISM", 242, 252], ["respiratory syncytial virus", "SPECIES", 175, 202], ["parainfluenza virus", "SPECIES", 204, 223], ["respiratory syncytial virus", "SPECIES", 175, 202], ["adenovirus", "SPECIES", 242, 252], ["All the specimens", "TEST", 0, 17], ["the respiratory screen", "TEST", 36, 58], ["antibody reagents", "TREATMENT", 114, 131], ["the individual virus", "PROBLEM", 135, 155], ["influenza", "PROBLEM", 157, 166], ["respiratory syncytial virus", "PROBLEM", 175, 202], ["parainfluenza virus types", "PROBLEM", 204, 229], ["adenovirus", "PROBLEM", 242, 252], ["positive", "OBSERVATION", 24, 32], ["respiratory syncytial", "ANATOMY", 175, 196]]], ["To culture the respiratory viruses, MDCK, LLC-MK2, HEp-2 C and RD cell monolayers in culture tubes were inoculated with 150 \u03bcl of the nasopharyngeal aspirate-virus transport medium suspension and the virus isolation was carried out as previously described [20].Outcome definition ::: MethodsIn addition, during the pandemic wave in 2009, the NPA samples were tested for influenza A(H1N1)pdm09 by RT-PCR.", [["MDCK", "ANATOMY", 36, 40], ["HEp-2 C", "ANATOMY", 51, 58], ["RD cell monolayers", "ANATOMY", 63, 81], ["culture tubes", "ANATOMY", 85, 98], ["NPA samples", "ANATOMY", 342, 353], ["MDCK", "CELL", 36, 40], ["LLC-MK2", "CELL", 42, 49], ["HEp-2 C", "CELL", 51, 58], ["RD cell monolayers", "CELL", 63, 81], ["culture tubes", "CELL", 85, 98], ["NPA samples", "CANCER", 342, 353], ["influenza A(H1N1)pdm09", "ORGANISM", 370, 392], ["MDCK, LLC-MK2, HEp-2 C and RD cell monolayers", "CELL_LINE", 36, 81], ["influenza A(H1N1)pdm09", "SPECIES", 370, 392], ["culture", "TEST", 3, 10], ["the respiratory viruses", "TEST", 11, 34], ["MDCK", "TEST", 36, 40], ["LLC", "TEST", 42, 45], ["MK2", "TEST", 46, 49], ["HEp", "TEST", 51, 54], ["RD cell monolayers", "TEST", 63, 81], ["culture tubes", "TREATMENT", 85, 98], ["the nasopharyngeal aspirate", "TEST", 130, 157], ["virus transport medium suspension", "TREATMENT", 158, 191], ["the virus isolation", "TREATMENT", 196, 215], ["the NPA samples", "TEST", 338, 353], ["influenza", "PROBLEM", 370, 379], ["pdm09", "PROBLEM", 387, 392], ["RT", "TEST", 396, 398], ["PCR", "TEST", 399, 402], ["respiratory viruses", "OBSERVATION", 15, 34], ["LLC", "ANATOMY", 42, 45], ["HEp", "ANATOMY", 51, 54], ["cell monolayers", "OBSERVATION", 66, 81], ["nasopharyngeal", "ANATOMY", 134, 148]]], ["Total nucleic acid from 250 \u03bcl NPA was extracted by using NucliSens easyMAG instrument (bioMerieux, Netherlands) according to the manufacturer's instruction and previously described.", [["nucleic acid", "CHEMICAL", 6, 18], ["NPA", "CHEMICAL", 31, 34], ["Total nucleic acid", "TREATMENT", 0, 18]]], ["Nucleic acid was recovered in 55 \u03bcl elution buffer and was kept at \u221280 \u00b0C until use.", [["Nucleic acid", "CHEMICAL", 0, 12], ["Nucleic acid", "SIMPLE_CHEMICAL", 0, 12], ["Nucleic acid", "TEST", 0, 12], ["acid", "OBSERVATION_MODIFIER", 8, 12]]], ["The diagnosis of influenza A virus was performed by RT-PCR targeting the M gene as previously described [19], [21], [22].", [["influenza A virus", "DISEASE", 17, 34], ["influenza A virus", "ORGANISM", 17, 34], ["M gene", "DNA", 73, 79], ["influenza A virus", "SPECIES", 17, 34], ["influenza A virus", "SPECIES", 17, 34], ["influenza A virus", "PROBLEM", 17, 34], ["PCR", "TEST", 55, 58], ["influenza", "OBSERVATION", 17, 26]]], ["Real-time one-step RT-PCR assays were used for the detection of pandemic A(H1N1)pdm09 virus using Invitrogen SuperScript III Platinum One-Step Quantitative Kit in a 7500 Sequence Detection System (Applied Biosystem, Foster City, CA, USA) [23].", [["pandemic A(H1N1)pdm09 virus", "ORGANISM", 64, 91], ["pandemic A(H1N1)pdm09 virus", "SPECIES", 64, 91], ["step RT-PCR assays", "TEST", 14, 32], ["pandemic A(H1N1)pdm09 virus", "PROBLEM", 64, 91], ["Invitrogen", "TREATMENT", 98, 108]]], ["Briefly, 5 \u03bcl of eluted RNA was amplified in a 25 \u03bcl reaction containing 0.5 \u03bcl Superscript III Reverse Transcriptase/Platinum Taq DNA polymerase (Invitrogen), 0.05 \u03bcl ROX reference dye (25 \u03bcM), 12.5 \u03bcl of 2\u00d7 reaction buffer, 800 nmol/l each of forward primer (5\u2032-CCAAAGCTCAGCAAATCCTACAT-3\u2032), reverse primer (5\u2032-GATGGTGAATGCCCCATAGC-3\u2032), and probe 200 nmol/l (Fam-TGATAAAGGGAAAGAAGTCCT-MGB).", [["ROX", "CHEMICAL", 168, 171], ["DNA", "CELLULAR_COMPONENT", 131, 134], ["eluted RNA", "RNA", 17, 27], ["Platinum Taq DNA polymerase", "PROTEIN", 118, 145], ["reverse primer", "DNA", 293, 307], ["eluted RNA", "TREATMENT", 17, 27], ["a 25 \u03bcl reaction", "TREATMENT", 45, 61], ["Reverse Transcriptase/Platinum Taq DNA polymerase (Invitrogen)", "TREATMENT", 96, 158], ["forward primer", "TEST", 245, 259], ["CCAAAGCTCAGCAAATCCTACAT", "TEST", 264, 287], ["GATGGTGAATGCCCCATAGC", "TEST", 312, 332], ["probe", "TEST", 342, 347], ["Fam-TGATAAAGGGAAAGAAGTCCT", "TEST", 360, 385]]], ["Reactions were first incubated at 50 \u00b0C for 30 min, followed by 95 \u00b0C for 2 min, and were then thermal cycled for 50 cycles (95 \u00b0C for 15 s, 55 \u00b0C for 30 s).Statistical analysis ::: MethodsPatients who met the inclusion criteria and consented to participate were included in our study.", [["our study", "TEST", 275, 284]]], ["We used conditional logistic regression models [7], [24], [25], matching on calendar week to account for potential bias due to changes in vaccine coverage over time, and adjusting for age, age-squared (to allow for non-linear effect of age) and sex [26].", [["potential bias", "PROBLEM", 105, 119], ["changes in vaccine coverage", "TREATMENT", 127, 154]]], ["VE was estimated as 1 minus the adjusted conditional odds ratio.", [["VE", "TEST", 0, 2]]], ["VE was estimated against influenza A and B combined, and for specific types and subtypes (excluding patients positive for the other types/subtypes of influenza from the control group).", [["influenza", "DISEASE", 150, 159], ["B", "CANCER", 41, 42], ["patients", "ORGANISM", 100, 108], ["patients", "SPECIES", 100, 108], ["VE", "TEST", 0, 2], ["influenza", "PROBLEM", 25, 34], ["influenza", "PROBLEM", 150, 159]]], ["VE was estimated overall, and for each of the four study years, and for various age strata.", [["VE", "TEST", 0, 2], ["overall", "OBSERVATION_MODIFIER", 17, 24]]], ["The overall estimates and the 2009\u20132010 estimates of VE for seasonal vaccination were adjusted for receipt of monovalent A(H1N1)pdm09 vaccine.", [["A(H1N1)pdm09", "ORGANISM", 121, 133], ["seasonal vaccination", "TREATMENT", 60, 80], ["monovalent A(H1N1)pdm09 vaccine", "TREATMENT", 110, 141]]], ["In sensitivity analyses we examined VE with alternative comparison groups based on detection or non-detection of other respiratory viruses in patients testing negative for influenza.ResultsBetween 1 October 2009 and 30 September 2013, we recruited 5399 children of whom 451 (8.4%) tested positive for influenza A virus and 211 (3.9%) tested positive for influenza B virus.", [["respiratory viruses", "DISEASE", 119, 138], ["influenza", "DISEASE", 172, 181], ["influenza A virus", "DISEASE", 301, 318], ["influenza B", "DISEASE", 354, 365], ["patients", "ORGANISM", 142, 150], ["children", "ORGANISM", 253, 261], ["influenza A virus", "ORGANISM", 301, 318], ["influenza B virus", "ORGANISM", 354, 371], ["patients", "SPECIES", 142, 150], ["children", "SPECIES", 253, 261], ["influenza A virus", "SPECIES", 301, 318], ["influenza B virus", "SPECIES", 354, 371], ["influenza A virus", "SPECIES", 301, 318], ["influenza B virus", "SPECIES", 354, 371], ["sensitivity analyses", "TEST", 3, 23], ["other respiratory viruses", "PROBLEM", 113, 138], ["patients testing", "TEST", 142, 158], ["influenza", "PROBLEM", 172, 181], ["influenza A virus", "PROBLEM", 301, 318], ["influenza B virus", "PROBLEM", 354, 371], ["respiratory viruses", "OBSERVATION", 119, 138]]], ["The timeline of recruitment of patients is shown in Fig. 1.", [["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39], ["recruitment", "OBSERVATION_MODIFIER", 16, 27]]], ["As previously shown [15], [16], [17], influenza activity and pediatric hospitalization are not limited to the winter peak in Hong Kong.", [["[16]", "SIMPLE_CHEMICAL", 26, 30], ["influenza activity", "PROBLEM", 38, 56]]], ["The majority (80.8%) of children were 5 years or younger of age, and there were more males than females although there was no significant gender difference between those who tested positive or negative for influenza (Table 1).", [["influenza", "DISEASE", 206, 215], ["children", "ORGANISM", 24, 32], ["children", "SPECIES", 24, 32], ["influenza", "PROBLEM", 206, 215], ["no", "UNCERTAINTY", 123, 125], ["significant", "OBSERVATION_MODIFIER", 126, 137]]], ["9.0% of test-negative patients reported receipt of influenza vaccination in the preceding 6 months, compared to 4.8% of the patients that tested positive for influenza A or B virus (p< 0.001).", [["influenza A or B", "DISEASE", 158, 174], ["patients", "ORGANISM", 22, 30], ["patients", "ORGANISM", 124, 132], ["influenza A", "ORGANISM", 158, 169], ["B virus", "ORGANISM", 173, 180], ["patients", "SPECIES", 22, 30], ["patients", "SPECIES", 124, 132], ["B virus", "SPECIES", 173, 180], ["test", "TEST", 8, 12], ["influenza vaccination", "TREATMENT", 51, 72], ["influenza", "PROBLEM", 158, 167], ["B virus", "PROBLEM", 173, 180]]], ["Among patients between 6 months and 2 years of age, 6.9% reported receipt of influenza vaccination in the preceding 6 months, compared to 12.3% among children 3\u20135 years and 10.8% among children 6\u201317 years.", [["influenza", "DISEASE", 77, 86], ["patients", "ORGANISM", 6, 14], ["children", "ORGANISM", 150, 158], ["children", "ORGANISM", 185, 193], ["patients", "SPECIES", 6, 14], ["children", "SPECIES", 150, 158], ["children", "SPECIES", 185, 193], ["influenza vaccination", "TREATMENT", 77, 98]]], ["Parents were unable to recall the exact dates of vaccination but the history of vaccination given showed that children received TIV well into January.", [["children", "ORGANISM", 110, 118], ["children", "SPECIES", 110, 118], ["vaccination", "TREATMENT", 49, 60], ["vaccination", "TREATMENT", 80, 91], ["TIV", "TREATMENT", 128, 131]]], ["This appears to be a common practice in Hong Kong that is different from places like the US where the main annual influenza vaccination happens over a couple of months in October and November in the fall.ResultsOf the 5399 patients, 857 (15.9%) tested negative for influenza and were recruited in calendar weeks when there were no test-positive patients (Fig. 1).", [["influenza", "DISEASE", 114, 123], ["influenza", "DISEASE", 265, 274], ["patients", "ORGANISM", 223, 231], ["patients", "ORGANISM", 345, 353], ["patients", "SPECIES", 223, 231], ["patients", "SPECIES", 345, 353], ["the US", "TEST", 85, 91], ["the main annual influenza vaccination", "TREATMENT", 98, 135], ["influenza", "PROBLEM", 265, 274], ["test", "TEST", 331, 335], ["appears to be", "UNCERTAINTY", 5, 18], ["different", "OBSERVATION_MODIFIER", 58, 67], ["main", "OBSERVATION_MODIFIER", 102, 106], ["influenza", "OBSERVATION", 114, 123]]], ["These patients were excluded from our estimation of VE, and 4542 patients remained for analysis of VE.", [["patients", "ORGANISM", 6, 14], ["patients", "ORGANISM", 65, 73], ["patients", "SPECIES", 6, 14], ["patients", "SPECIES", 65, 73], ["our estimation of VE", "TEST", 34, 54], ["analysis", "TEST", 87, 95], ["VE", "TEST", 99, 101]]], ["The overall VE was 61.7% (95% confidence interval, CI: 43.0%, 74.2%) against influenza A and B combined, based on reported receipt of seasonal influenza vaccination in the preceding 6 months comparing test-positive to test-negative patients (Table 2).", [["patients", "ORGANISM", 232, 240], ["patients", "SPECIES", 232, 240], ["The overall VE", "TEST", 0, 14], ["CI", "TEST", 51, 53], ["influenza", "PROBLEM", 77, 86], ["seasonal influenza vaccination", "PROBLEM", 134, 164], ["test", "TEST", 201, 205], ["test", "TEST", 218, 222]]], ["Estimated VE was 56.9% (95% CI: 29.2%, 73.8%) for influenza A and 68.8% (95% CI: 41.6%, 83.3%) for influenza B. We examined VE for the four separate study years and found generally similar estimates, with the highest point estimates of VE in the 80% range in 2010\u20132011 and 2012\u20132013 (Fig. 2).", [["influenza A", "DISEASE", 50, 61], ["influenza A", "SPECIES", 50, 61], ["Estimated VE", "TEST", 0, 12], ["CI", "TEST", 28, 30], ["influenza A", "TEST", 50, 61], ["CI", "TEST", 77, 79], ["influenza B.", "PROBLEM", 99, 111], ["VE", "TEST", 236, 238]]], ["Both years had circulation of all 3 influenza types and subtypes that largely matched the vaccine viruses.", [["all 3 influenza types", "PROBLEM", 30, 51]]], ["There was a suggestion of lower VE in 2011\u20132012.", [["lower", "ANATOMY_MODIFIER", 26, 31]]], ["This year included a major influenza A H3N2 season with the circulating virus antigenically distinct from the 2011\u20132012 vaccine virus A/Perth/16/2009 (Fig. 1).", [["influenza A H3N2", "ORGANISM", 27, 43], ["influenza A H3N2", "SPECIES", 27, 43], ["A H3N2", "SPECIES", 37, 43], ["2011\u20132012 vaccine virus A/Perth/16/2009", "SPECIES", 110, 149], ["a major influenza A H3N2 season", "PROBLEM", 19, 50], ["the circulating virus antigenically", "PROBLEM", 56, 91], ["influenza", "OBSERVATION", 27, 36]]], ["This was also a year with high activity of influenza viruses throughout most of the year.", [["influenza viruses", "DISEASE", 43, 60], ["influenza viruses", "ORGANISM", 43, 60], ["high activity of influenza viruses", "PROBLEM", 26, 60], ["high activity", "OBSERVATION_MODIFIER", 26, 39], ["influenza viruses", "OBSERVATION", 43, 60]]], ["In 2009\u20132010 the seasonal TIV did not include the new pandemic virus and a separate monovalent H1N1pdm09 vaccine was used with low uptake in the community.", [["H1N1pdm09", "CHEMICAL", 95, 104], ["H1N1pdm09", "SPECIES", 95, 104], ["the seasonal TIV", "TREATMENT", 13, 29], ["the new pandemic virus", "PROBLEM", 46, 68], ["a separate monovalent H1N1pdm09 vaccine", "TREATMENT", 73, 112]]], ["In that year, the estimated VE of the monovalent vaccine against influenza A was 48.1% (95% CI: \u2212344.1%, 93.9%).ResultsType/subtype-specific VE estimates are shown in Fig. 3.", [["influenza A", "DISEASE", 65, 76], ["influenza A", "SPECIES", 65, 76], ["the estimated VE", "TEST", 14, 30], ["the monovalent vaccine", "TREATMENT", 34, 56], ["influenza A", "TEST", 65, 76], ["CI", "TEST", 92, 94], ["ResultsType", "TEST", 112, 123], ["subtype-specific VE estimates", "TEST", 124, 153]]], ["The point estimate of VE was lower for H3N2 (36.6%; 95% CI: \u221225.5%, 67.9%) compared to H1N1pdm (71.5%; 95% CI: 39.4%, 86.6%) and B (68.8%; 95% CI: 41.6%, 83.3%).", [["H3N2", "DISEASE", 39, 43], ["H1N1pdm", "DISEASE", 87, 94], ["VE", "TEST", 22, 24], ["H3N2", "PROBLEM", 39, 43], ["CI", "TEST", 56, 58], ["H1N1pdm", "TEST", 87, 94], ["CI", "TEST", 107, 109], ["B", "TEST", 129, 130], ["CI", "TEST", 143, 145]]], ["In some years for some subtypes we estimated VE of 100% with very wide confidence intervals because none of the admitted children testing positive for that influenza type/subtype reported receipt of TIV (Fig. 3).", [["influenza type", "DISEASE", 156, 170], ["children", "ORGANISM", 121, 129], ["children", "SPECIES", 121, 129], ["estimated VE", "TEST", 35, 47], ["children testing", "TEST", 121, 137], ["influenza type/subtype", "PROBLEM", 156, 178]]], ["Age-specific VE estimates are shown in Fig. 4.", [["Age-specific VE estimates", "TEST", 0, 25]]], ["The point estimate of VE was lower for children 6 months to 2 years of age compared to older children but the difference was not statistically significant.ResultsIn our primary analysis, we assessed VE comparing test-positive patients to all test-negative patients.", [["children", "ORGANISM", 39, 47], ["children", "ORGANISM", 93, 101], ["patients", "ORGANISM", 226, 234], ["patients", "ORGANISM", 256, 264], ["children", "SPECIES", 39, 47], ["children", "SPECIES", 93, 101], ["patients", "SPECIES", 226, 234], ["patients", "SPECIES", 256, 264], ["VE comparing test", "TEST", 199, 216], ["all test", "TEST", 238, 246]]], ["In sensitivity analyses, VE was similar when comparing only to the test-negative patients that were also negative for other respiratory viruses, or when comparing only to the test-negative patients that were positive for non-influenza respiratory viruses (Table 2).DiscussionOur 4-year study covered at least 11 periods of influenza activity in Hong Kong, including the emergence of A(H1N1)pdm09 (Fig. 1).", [["respiratory viruses", "DISEASE", 124, 143], ["non-influenza respiratory viruses", "DISEASE", 221, 254], ["influenza", "DISEASE", 323, 332], ["patients", "ORGANISM", 81, 89], ["patients", "ORGANISM", 189, 197], ["A(H1N1)pdm09", "ORGANISM", 383, 395], ["patients", "SPECIES", 81, 89], ["patients", "SPECIES", 189, 197], ["A(H1N1)pdm09", "SPECIES", 383, 395], ["sensitivity analyses", "TEST", 3, 23], ["VE", "TEST", 25, 27], ["the test", "TEST", 63, 71], ["other respiratory viruses", "PROBLEM", 118, 143], ["the test", "TEST", 171, 179], ["non-influenza respiratory viruses", "PROBLEM", 221, 254], ["influenza activity", "PROBLEM", 323, 341], ["respiratory", "ANATOMY", 124, 135], ["viruses", "OBSERVATION", 136, 143], ["influenza activity", "OBSERVATION", 323, 341]]], ["The overall VE of the TIV against influenza hospitalization was 61.7% (95% CI: 43.0%, 74.2%).", [["influenza", "DISEASE", 34, 43], ["influenza", "PROBLEM", 34, 43], ["CI", "TEST", 75, 77]]], ["A recently published study from Australia of children presenting to a tertiary pediatric hospital conducted between 2008 and 2012 also showed a VE of 64.7% (95% CI: 33.7%, 81.2%) [27].", [["children", "ORGANISM", 45, 53], ["children", "SPECIES", 45, 53], ["a VE", "TEST", 142, 146], ["CI", "TEST", 161, 163]]], ["However, most of the subjects were recruited in the Emergency Department with a smaller proportion from inpatients.", [["subjects", "ORGANISM", 21, 29]]], ["They also excluded subjects enrolled in 2009 from VE calculation.", [["VE calculation", "TEST", 50, 64]]], ["The overall VE for the monovalent A(H1N1)pdm09 vaccine in our study was 48.1% (95% CI: \u2212344.1%, 93.9%), which was somewhat lower than reported elsewhere [28].", [["A(H1N1)pdm09", "ORGANISM", 34, 46], ["pdm09 vaccine", "TREATMENT", 41, 54], ["our study", "TEST", 58, 67], ["CI", "TEST", 83, 85]]], ["The time interval between receipt of the monovalent vaccine and hospitalization in children who tested positive during the first pandemic season may not be adequate for mounting an immunologic response.", [["children", "ORGANISM", 83, 91], ["children", "SPECIES", 83, 91], ["the monovalent vaccine", "TREATMENT", 37, 59]]], ["In contrast, in 2010\u20132011 when A(H1N1)pdm09 was included in the TIV, VE was very high: 84.2% (95% CI: 43.9%, 95.6%).DiscussionThe VE against H3N2 appeared to be low in this study.", [["A(H1N1)pdm09", "ORGANISM", 31, 43], ["H3N2", "ORGANISM", 141, 145], ["TIV", "SPECIES", 64, 67], ["pdm09", "PROBLEM", 38, 43], ["the TIV", "TEST", 60, 67], ["VE", "TEST", 69, 71], ["CI", "TEST", 98, 100], ["H3N2", "PROBLEM", 141, 145], ["this study", "TEST", 168, 178]]], ["This could be due to the vaccine mismatches in the years 2009\u20132010 [29] and 2011\u20132012 in this study.", [["the vaccine mismatches", "PROBLEM", 21, 43], ["this study", "TEST", 89, 99]]], ["Studies from several countries also showed low to moderate VE for the 2011\u20132012 season for H3N2 in adults and children when there was also antigenic mismatch with the vaccine [13], [14], [30], [31].", [["H3N2", "DISEASE", 91, 95], ["children", "ORGANISM", 110, 118], ["children", "SPECIES", 110, 118], ["Studies", "TEST", 0, 7], ["H3N2", "PROBLEM", 91, 95], ["antigenic mismatch", "PROBLEM", 139, 157], ["the vaccine", "TREATMENT", 163, 174]]], ["However, the circulating H3N2 strain in 2012\u20132013 in Hong Kong was matched to the vaccine while VE was still poor.", [["H3N2 strain", "ORGANISM", 25, 36], ["the circulating H3N2 strain", "PROBLEM", 9, 36], ["the vaccine", "TREATMENT", 78, 89], ["H3N2", "OBSERVATION", 25, 29]]], ["One possible explanation was that the epidemic in 2012\u20132013 was very late, peaking in September (Fig. 1) and therefore VE may have been low due to waning post-vaccination immunity [11], [31].", [["VE", "TEST", 119, 121], ["possible explanation was", "UNCERTAINTY", 4, 28]]], ["A study from the UK showed that the VE for H3N2 in 2011/12 showed waning intra-seasonal protection [32].", [["A study", "TEST", 0, 7], ["the UK", "TEST", 13, 19], ["the VE", "TEST", 32, 38], ["H3N2", "PROBLEM", 43, 47]]], ["VE was moderate in the first three months of the season but reduced in the second three months even when there was antigenic match.", [["VE", "TEST", 0, 2], ["moderate", "OBSERVATION_MODIFIER", 7, 15]]], ["We only captured vaccination history within 6 months but did not have information on vaccination within 3 months, while influenza vaccines are typically administered between October and January prior to the winter influenza season in Hong Kong.", [["influenza", "DISEASE", 214, 223], ["vaccination", "TREATMENT", 85, 96], ["influenza vaccines", "TREATMENT", 120, 138]]], ["The H3N2 epidemics in this 4-year study were in the summer and fall and largely mismatched with the vaccine strains.", [["H3N2", "DISEASE", 4, 8], ["The H3N2 epidemics", "PROBLEM", 0, 18], ["the vaccine strains", "TREATMENT", 96, 115], ["H3N2", "OBSERVATION", 4, 8]]], ["Our finding of VE against H3N2 may not be generalized.DiscussionVE against influenza B hospitalization was 68.8% overall (95% CI: 41.6%, 83.3%).", [["H3N2", "DISEASE", 26, 30], ["influenza B", "DISEASE", 75, 86], ["H3N2", "ORGANISM", 26, 30], ["influenza B", "ORGANISM", 75, 86], ["H3N2", "PROBLEM", 26, 30], ["influenza", "PROBLEM", 75, 84], ["CI", "TEST", 126, 128], ["may not be", "UNCERTAINTY", 31, 41], ["generalized", "OBSERVATION_MODIFIER", 42, 53]]], ["This was surprisingly good considering the circulating influenza B lineages of Victoria:Yamagata was at a 4:6 ratio in the largest influenza B epidemic in this study in 2012, with the TIV including a Victoria lineage virus.", [["influenza B", "DISEASE", 131, 142], ["the largest influenza B epidemic", "PROBLEM", 119, 151], ["this study", "TEST", 155, 165], ["the TIV", "TREATMENT", 180, 187], ["largest", "OBSERVATION_MODIFIER", 123, 130], ["influenza", "OBSERVATION", 131, 140], ["lineage virus", "OBSERVATION", 209, 222]]], ["Specifically, the VE against influenza B in 2012 in a 60% mismatch season was 65.8% (95% CI: 16.8%, 85.9%).", [["influenza B", "DISEASE", 29, 40], ["the VE", "TEST", 14, 20], ["influenza B", "TEST", 29, 40], ["CI", "TEST", 89, 91]]], ["The VE seen appears to be higher than that of 38% (95% CI: 4, 60) for a poor match season according to a meta-analysis of controlled trials of TIV in children and non-elderly adults [33].", [["children", "ORGANISM", 150, 158], ["children", "SPECIES", 150, 158], ["The VE", "TEST", 0, 6], ["CI", "TEST", 55, 57], ["TIV", "TREATMENT", 143, 146], ["appears to be", "UNCERTAINTY", 12, 25], ["higher", "OBSERVATION_MODIFIER", 26, 32]]], ["Other studies have also shown suboptimal VE in the situation of a mismatch season [34], [35].", [["Other studies", "TEST", 0, 13]]], ["One explanation of the difference seen between ours and the previous studies may be that since the prevalence of cross-protective antibody is a function of previous priming by antigenically related strains or subtypes, children in Hong Kong with high influenza activity are more likely to have been primed by both influenza B lineages.", [["influenza B", "DISEASE", 314, 325], ["children", "ORGANISM", 219, 227], ["Hong Kong", "ORGANISM", 231, 240], ["influenza B", "ORGANISM", 314, 325], ["cross-protective antibody", "PROTEIN", 113, 138], ["influenza B lineages", "CELL_TYPE", 314, 334], ["children", "SPECIES", 219, 227], ["the previous studies", "TEST", 56, 76], ["cross-protective antibody", "TREATMENT", 113, 138], ["high influenza activity", "PROBLEM", 246, 269]]], ["A study from Canada showed an adjusted VE of 55% (95% CI: 32%, 70%) against a mismatched influenza B for 2007\u20132008 in adults and children which also demonstrated some cross-protection [36].", [["children", "ORGANISM", 129, 137], ["children", "SPECIES", 129, 137], ["A study", "TEST", 0, 7], ["an adjusted VE", "TEST", 27, 41], ["CI", "TEST", 54, 56], ["a mismatched influenza B", "PROBLEM", 76, 100], ["influenza", "OBSERVATION", 89, 98]]], ["The quadrivalent influenza vaccine that contains both B lineages has been licensed and recommended for use in the US for the 2013\u20132014 season [18].", [["influenza", "DISEASE", 17, 26], ["B lineages", "CELL", 54, 64], ["B lineages", "CELL_TYPE", 54, 64], ["The quadrivalent influenza vaccine", "TREATMENT", 0, 34]]], ["A multinational VE study of the quadrivalent influenza vaccine against \u2018moderate-to-severe\u2019 PCR-confirmed influenza was recently published [37].", [["influenza", "DISEASE", 45, 54], ["influenza", "DISEASE", 106, 115], ["A multinational VE study", "TEST", 0, 24], ["the quadrivalent influenza vaccine", "TREATMENT", 28, 62], ["\u2018moderate-to-severe\u2019 PCR", "PROBLEM", 71, 95], ["influenza", "PROBLEM", 106, 115]]], ["Surprisingly, the VE against moderate to severe influenza B disease, defined as a body temperature higher than 39 \u00b0C, otitis media, lower respiratory tract illness, or myositis, encephalitis, seizure or myocarditis, was only 46.5 (95% CI: 34.1, 78.7) in a season with almost exclusively the Victoria lineage.", [["body", "ANATOMY", 82, 86], ["lower respiratory tract", "ANATOMY", 132, 155], ["influenza B disease", "DISEASE", 48, 67], ["otitis", "DISEASE", 118, 124], ["respiratory tract illness", "DISEASE", 138, 163], ["myositis", "DISEASE", 168, 176], ["encephalitis", "DISEASE", 178, 190], ["seizure", "DISEASE", 192, 199], ["myocarditis", "DISEASE", 203, 214], ["body", "ORGANISM_SUBDIVISION", 82, 86], ["tract", "ORGANISM_SUBDIVISION", 150, 155], ["moderate to severe influenza B disease", "PROBLEM", 29, 67], ["a body temperature", "TEST", 80, 98], ["otitis media", "PROBLEM", 118, 130], ["lower respiratory tract illness", "PROBLEM", 132, 163], ["myositis", "PROBLEM", 168, 176], ["encephalitis", "PROBLEM", 178, 190], ["seizure", "PROBLEM", 192, 199], ["myocarditis", "PROBLEM", 203, 214], ["CI", "TEST", 235, 237], ["moderate", "OBSERVATION_MODIFIER", 29, 37], ["severe", "OBSERVATION_MODIFIER", 41, 47], ["influenza", "OBSERVATION", 48, 57], ["B disease", "OBSERVATION", 58, 67], ["lower", "ANATOMY_MODIFIER", 132, 137], ["respiratory tract", "ANATOMY", 138, 155], ["myositis", "OBSERVATION", 168, 176], ["encephalitis", "OBSERVATION", 178, 190], ["myocarditis", "OBSERVATION", 203, 214]]], ["Further vaccine effectiveness studies comparing the quadrivalent and trivalent vaccines will have to be conducted to determine whether the theoretical advantage of inclusion of strains from both B lineages could be translated to a real improvement in VE.DiscussionWe previously reported an increased risk of non-influenza respiratory virus infections among children 6\u201317 years of age who received influenza vaccination [38], implying that the estimates of VE from test-negative studies might vary depending on the choice of comparison group [39].", [["non-influenza respiratory virus infections", "DISEASE", 308, 350], ["B lineages", "CELL", 195, 205], ["non-influenza respiratory virus", "ORGANISM", 308, 339], ["children", "ORGANISM", 357, 365], ["B lineages", "CELL_TYPE", 195, 205], ["children", "SPECIES", 357, 365], ["quadrivalent", "SPECIES", 52, 64], ["non-influenza respiratory virus", "SPECIES", 308, 339], ["Further vaccine effectiveness studies", "TEST", 0, 37], ["the quadrivalent and trivalent vaccines", "TREATMENT", 48, 87], ["strains", "PROBLEM", 177, 184], ["non-influenza respiratory virus infections", "PROBLEM", 308, 350], ["influenza vaccination", "TREATMENT", 397, 418], ["VE from test", "TEST", 456, 468], ["increased", "OBSERVATION_MODIFIER", 290, 299], ["respiratory virus", "OBSERVATION", 322, 339]]], ["We therefore examined the difference in VE estimates using alternative comparison groups but did not find any major differences in this study of hospitalization (Table 2), in which the majority of patients were 5 years of age or younger.", [["patients", "ORGANISM", 197, 205], ["patients", "SPECIES", 197, 205]]], ["A similar observation was also reported in the US in children below 5 years of age seeking ambulatory care or admitted to hospital [40].DiscussionThis is the first study of VE in a geographic site outside areas with sharp peaks of influenza season in the winter.", [["influenza", "DISEASE", 231, 240], ["children", "ORGANISM", 53, 61], ["children", "SPECIES", 53, 61], ["the first study", "TEST", 154, 169], ["influenza", "PROBLEM", 231, 240], ["sharp", "OBSERVATION_MODIFIER", 216, 221], ["influenza", "OBSERVATION", 231, 240]]], ["Unlike most influenza VE studies, our study was conducted year round.", [["most influenza VE studies", "TEST", 7, 32], ["our study", "TEST", 34, 43]]], ["This allowed us to capture all influenza hospitalization.", [["influenza", "DISEASE", 31, 40], ["all influenza hospitalization", "TREATMENT", 27, 56], ["influenza", "OBSERVATION", 31, 40]]], ["This is particularly relevant for areas with prolonged or multiple influenza A seasons, as well as for influenza B epidemics that can occur any time of the year.", [["influenza B", "DISEASE", 103, 114], ["influenza B", "ORGANISM", 103, 114], ["multiple influenza A seasons", "PROBLEM", 58, 86], ["influenza B epidemics", "PROBLEM", 103, 124], ["multiple", "OBSERVATION_MODIFIER", 58, 66], ["influenza", "OBSERVATION", 67, 76]]], ["Another strength of our study includes matching test-positive patients with test-negative patients recruited in the same week which may be particularly important when influenza activity is not concentrated in a few weeks.", [["patients", "ORGANISM", 62, 70], ["patients", "ORGANISM", 90, 98], ["patients", "SPECIES", 62, 70], ["patients", "SPECIES", 90, 98], ["our study", "TEST", 20, 29], ["matching test", "TEST", 39, 52], ["test", "TEST", 76, 80], ["influenza activity", "PROBLEM", 167, 185]]], ["Furthermore, we have shown that our results are robust even when using different criteria to define the \u201ctest negative\u201d group (Table 2), viz. influenza negative, negative for all viruses tested or those positive for other viruses.DiscussionOne limitation of this analysis was the use of immunofluorescence and virus culture to identify other respiratory viruses leading to a lack of sensitivity to identify some rhinoviruses and some other non-influenza viruses (e.g. human coronaviruses, human metapneumovirus).", [["respiratory viruses", "DISEASE", 342, 361], ["rhinoviruses", "DISEASE", 412, 424], ["rhinoviruses", "ORGANISM", 412, 424], ["non-influenza viruses", "ORGANISM", 440, 461], ["human", "ORGANISM", 468, 473], ["coronaviruses", "ORGANISM", 474, 487], ["human", "ORGANISM", 489, 494], ["metapneumovirus", "ORGANISM", 495, 510], ["human", "SPECIES", 468, 473], ["human", "SPECIES", 489, 494], ["metapneumovirus", "SPECIES", 495, 510], ["human coronaviruses", "SPECIES", 468, 487], ["human metapneumovirus", "SPECIES", 489, 510], ["the \u201ctest", "TEST", 100, 109], ["viz. influenza", "TEST", 137, 151], ["all viruses", "PROBLEM", 175, 186], ["other viruses", "PROBLEM", 216, 229], ["this analysis", "TEST", 258, 271], ["immunofluorescence", "TEST", 287, 305], ["virus culture", "TEST", 310, 323], ["other respiratory viruses", "PROBLEM", 336, 361], ["sensitivity", "PROBLEM", 383, 394], ["some rhinoviruses", "PROBLEM", 407, 424], ["some other non-influenza viruses", "PROBLEM", 429, 461], ["human coronaviruses", "PROBLEM", 468, 487], ["human metapneumovirus", "PROBLEM", 489, 510], ["respiratory viruses", "OBSERVATION", 342, 361], ["rhinoviruses", "OBSERVATION", 412, 424]]], ["The direct immunofluorescence antigen tests for respiratory viruses only identified 7 respiratory viruses including influenza A, influenza A, RSV, parainfluenza 1, parainfluenza 2, parainfluenza 3 and adenovirus [19].", [["respiratory viruses", "DISEASE", 48, 67], ["respiratory viruses", "DISEASE", 86, 105], ["influenza A", "DISEASE", 116, 127], ["influenza A, RSV, parainfluenza 1, parainfluenza 2, parainfluenza 3", "DISEASE", 129, 196], ["influenza A", "ORGANISM", 116, 127], ["influenza A", "ORGANISM", 129, 140], ["RSV", "ORGANISM", 142, 145], ["parainfluenza 1", "ORGANISM", 147, 162], ["parainfluenza 2", "ORGANISM", 164, 179], ["parainfluenza 3", "ORGANISM", 181, 196], ["adenovirus", "ORGANISM", 201, 211], ["RSV", "SPECIES", 142, 145], ["parainfluenza", "SPECIES", 147, 160], ["parainfluenza", "SPECIES", 164, 177], ["parainfluenza", "SPECIES", 181, 194], ["influenza A", "SPECIES", 129, 140], ["RSV", "SPECIES", 142, 145], ["The direct immunofluorescence antigen tests", "TEST", 0, 43], ["respiratory viruses", "PROBLEM", 48, 67], ["7 respiratory viruses", "PROBLEM", 84, 105], ["influenza", "PROBLEM", 116, 125], ["influenza", "PROBLEM", 129, 138], ["RSV", "PROBLEM", 142, 145], ["parainfluenza", "PROBLEM", 147, 160], ["parainfluenza", "PROBLEM", 164, 177], ["parainfluenza", "PROBLEM", 181, 194], ["adenovirus", "PROBLEM", 201, 211], ["respiratory viruses", "OBSERVATION", 86, 105]]], ["To culture respiratory viruses, it is able to isolate more respiratory viruses but lack of sensitivity to certain viruses such as human metapneumovirus [compared to RT-PCR for HMPV, sensitivity of culture is 13.6% (unpublished data)], or unable to recover such as rhinovirus type C [41] or unable to isolate human coronaviruses [42].DiscussionFurthermore, our reliance on virus culture and immunofluorescence assays rather than RT-PCR may have led to some under-detection of influenza-positive patients and consequent underestimation of VE.", [["respiratory viruses", "DISEASE", 11, 30], ["respiratory viruses", "DISEASE", 59, 78], ["human metapneumovirus", "DISEASE", 130, 151], ["influenza-positive", "DISEASE", 475, 493], ["human", "ORGANISM", 130, 135], ["metapneumovirus", "ORGANISM", 136, 151], ["HMPV", "ORGANISM", 176, 180], ["rhinovirus type C", "ORGANISM", 264, 281], ["human", "ORGANISM", 308, 313], ["influenza", "ORGANISM", 475, 484], ["patients", "ORGANISM", 494, 502], ["human", "SPECIES", 130, 135], ["metapneumovirus", "SPECIES", 136, 151], ["human", "SPECIES", 308, 313], ["patients", "SPECIES", 494, 502], ["human metapneumovirus", "SPECIES", 130, 151], ["HMPV", "SPECIES", 176, 180], ["human coronaviruses", "SPECIES", 308, 327], ["culture respiratory viruses", "PROBLEM", 3, 30], ["more respiratory viruses", "PROBLEM", 54, 78], ["sensitivity", "PROBLEM", 91, 102], ["certain viruses", "PROBLEM", 106, 121], ["human metapneumovirus", "PROBLEM", 130, 151], ["RT", "TEST", 165, 167], ["PCR", "TEST", 168, 171], ["HMPV", "PROBLEM", 176, 180], ["sensitivity", "TEST", 182, 193], ["culture", "TEST", 197, 204], ["rhinovirus type C", "PROBLEM", 264, 281], ["unable to isolate human coronaviruses", "PROBLEM", 290, 327], ["virus culture", "TEST", 372, 385], ["immunofluorescence assays", "TEST", 390, 415], ["RT-PCR", "TEST", 428, 434], ["influenza", "PROBLEM", 475, 484], ["respiratory viruses", "OBSERVATION", 11, 30]]], ["A second limitation is that vaccination history in the preceding 6 months was self-reported and there may have been some misclassification bias leading to underestimation or overestimation of VE overall, while as mentioned above we did not collect data on exact date of vaccination.", [["some misclassification bias", "PROBLEM", 116, 143], ["vaccination", "TREATMENT", 270, 281]]], ["We also did not have information on comorbidity.", [["comorbidity", "PROBLEM", 36, 47]]], ["In addition, our definition of the vaccination status to be those receiving vaccine within 6 months of hospitalization may falsely bias toward higher VE in a setting where the influenza season lasts for many months.", [["influenza", "DISEASE", 176, 185], ["vaccine", "TREATMENT", 76, 83], ["the influenza season", "PROBLEM", 172, 192]]], ["Given that it may not be feasible to vaccinate more than once each year, true VE late in the influenza season may be lower than our estimates for children vaccinated in the November\u2013December period as recommended in Hong Kong.", [["influenza", "DISEASE", 93, 102], ["children", "ORGANISM", 146, 154], ["children", "SPECIES", 146, 154]]], ["Finally, our definition of the vaccination status to be those who had received vaccine within 6 months of hospitalization precluded assessment of VE for the whole year in line with the practice of annual influenza vaccination.DiscussionIn conclusion, we found that influenza vaccination was effective in preventing hospitalizations associated with confirmed influenza A and B virus infections in children.", [["influenza", "DISEASE", 265, 274], ["influenza A and B virus infections", "DISEASE", 358, 392], ["influenza A", "ORGANISM", 358, 369], ["B virus", "ORGANISM", 374, 381], ["children", "ORGANISM", 396, 404], ["B virus", "SPECIES", 374, 381], ["children", "SPECIES", 396, 404], ["influenza A", "SPECIES", 358, 369], ["B virus", "SPECIES", 374, 381], ["vaccine", "TREATMENT", 79, 86], ["assessment", "TEST", 132, 142], ["annual influenza vaccination", "TREATMENT", 197, 225], ["influenza vaccination", "TREATMENT", 265, 286], ["influenza", "PROBLEM", 358, 367], ["B virus infections", "PROBLEM", 374, 392]]], ["Vaccine effectiveness varied by year correlating with vaccine match although the impact of a mismatched B lineage is less clear.", [["B lineage", "ANATOMY", 104, 113], ["B lineage", "CELL", 104, 113], ["mismatched B lineage", "CELL_TYPE", 93, 113], ["Vaccine effectiveness", "TREATMENT", 0, 21], ["vaccine", "TREATMENT", 54, 61], ["a mismatched B lineage", "TREATMENT", 91, 113], ["less", "OBSERVATION_MODIFIER", 117, 121], ["clear", "OBSERVATION", 122, 127]]], ["Protection against hospitalization also appeared to decrease when an epidemic happens late in the year.", [["Protection", "TREATMENT", 0, 10], ["decrease", "OBSERVATION_MODIFIER", 52, 60]]], ["In our analyses, we chose to match test-positive and test-negative patients by calendar week to allow fairer estimation of VE given changing vaccine coverage during the course of the year.", [["patients", "ORGANISM", 67, 75], ["patients", "SPECIES", 67, 75], ["test", "TEST", 35, 39], ["test", "TEST", 53, 57], ["VE", "TREATMENT", 123, 125], ["changing vaccine coverage", "TREATMENT", 132, 157]]], ["This approach may be particularly valuable in subtropical and tropical settings with prolonged influenza activity.", [["prolonged influenza activity", "PROBLEM", 85, 113], ["influenza activity", "OBSERVATION", 95, 113]]]], "298c524267fbee64a96708488f68c90ad382b2c9": [["Response to \"The imaginary 'Asian Super Consumer': A critique of demand reduction campaigns for the illegal wildlife trade.\"", [["demand reduction campaigns", "TREATMENT", 65, 91]]]], "918502b9ff6b04705babfc9e08f9b0f7c7ece9cc": [["BackgroundLongitudinal cohort studies play a central role in advancing understanding of the onset and progression of physical and mental health problems.", [["progression of physical and mental health problems", "PROBLEM", 102, 152]]], ["Cohort studies assess, and often compare, the incidence of a condition within a group of people who share common characteristics (e.g., being born in the same year) [1] .", [["people", "ORGANISM", 89, 95], ["people", "SPECIES", 89, 95], ["Cohort studies assess", "TEST", 0, 21]]], ["A key advantage of longitudinal cohort studies over other research designs is that repeated measures data temporally orders exposures and outcomes to facilitate causal inference [2] .", [["longitudinal cohort studies", "TEST", 19, 46]]], ["However, significant and systematic attrition can reduce the generalisability of outcomes and the statistical power to detect effects of interest [3] .", [["significant and systematic attrition", "PROBLEM", 9, 45], ["significant", "OBSERVATION_MODIFIER", 9, 20]]], ["Systematic attrition in longitudinal research occurs most often in older, non-white male participants with limited education and/or multiple health problems [4] .", [["participants", "SPECIES", 89, 101], ["Systematic attrition", "PROBLEM", 0, 20], ["attrition", "OBSERVATION_MODIFIER", 11, 20]]], ["Long duration and repeated assessments can also increase attrition due to the significant burden on participants [4] .", [["participants", "SPECIES", 100, 112], ["repeated assessments", "TEST", 18, 38]]], ["Given the expense of longitudinal cohort studies, effective strategies that engage and retain cohort participants are critical to the integrity of research outcomes [5, 6] .BackgroundIn the last decade, longitudinal data collection methods and cohort retention strategies have evolved considerably.", [["participants", "SPECIES", 101, 113], ["longitudinal cohort studies", "TEST", 21, 48], ["effective strategies", "TREATMENT", 50, 70], ["longitudinal data collection methods", "PROBLEM", 203, 239], ["cohort retention strategies", "TREATMENT", 244, 271], ["considerably", "OBSERVATION_MODIFIER", 285, 297]]], ["Established retention strategies within longitudinal cohort studies include: cash or gift incentives, sending reminder letters to participants, re-sending surveys, and offering alternative methods of data collection (for a review, see [6] ).", [["participants", "SPECIES", 130, 142], ["longitudinal cohort studies", "TEST", 40, 67], ["retention", "OBSERVATION_MODIFIER", 12, 21]]], ["Booker et al. [6] demonstrated that these strategies were effective in longitudinal cohort studies that used the traditional data collection methods of postal surveys, face-to-face visits (home or on-site), and telephone interviews or surveys.", [["longitudinal cohort studies", "TEST", 71, 98], ["postal surveys", "TEST", 152, 166]]], ["However, these cohort retention strategies may not be as well suited to contemporary methods of collecting longitudinal data, such as web and mobile surveys [9] , wearable sensors (e.g., FitBits) [10] , short message services (SMS) [11] , and groupware systems (e.g., video conferencing) [12] .", [["these cohort retention strategies", "TREATMENT", 9, 42], ["collecting longitudinal data", "TEST", 96, 124]]], ["Novel methods of engaging participants such as web advertising [13] , social media [14] , and electronic reminders [15] , are also now being employed in cohort studies using both traditional and modern longitudinal data collection methods.BackgroundA systematic review on the effectiveness of established and emerging cohort retention strategies in longitudinal cohort studies would provide guidance to researchers and funders on maximising cohort maintenance within these high investment programs of research.", [["participants", "SPECIES", 26, 38], ["cohort studies", "TEST", 153, 167], ["emerging cohort retention strategies", "TREATMENT", 309, 345], ["longitudinal cohort studies", "TEST", 349, 376], ["maximising cohort maintenance", "TREATMENT", 430, 459]]], ["Booker et al. [6] conducted a narrative review of retention strategies in longitudinal cohort studies, including incentives, reminders, repeat visits/questionnaires, and alternative methods of data collection, finding that incentives and reminder strategies improved cohort retention.", [["retention strategies", "TREATMENT", 50, 70], ["longitudinal cohort studies", "TEST", 74, 101], ["data collection", "TEST", 193, 208], ["cohort retention", "PROBLEM", 267, 283]]], ["However, this review was limited by the small number of studies identified for each retention strategy, which resulted in the identification of a restricted breadth of retention strategies and the inability to synthesise findings empirically.BackgroundFurther, Booker et al. [6] did not include research completed after 2006 and thus were unable to investigate emerging cohort retention strategies.", [["studies", "TEST", 56, 63], ["each retention strategy", "PROBLEM", 79, 102], ["retention strategies", "TREATMENT", 168, 188], ["emerging cohort retention strategies", "TREATMENT", 361, 397], ["small", "OBSERVATION_MODIFIER", 40, 45], ["restricted", "OBSERVATION_MODIFIER", 146, 156], ["breadth", "OBSERVATION_MODIFIER", 157, 164], ["retention strategies", "OBSERVATION", 168, 188]]], ["Brueton et al. [16] completed a more recent review of retention strategies that included both established and emerging digital data collection retention strategies.", [["retention strategies", "TREATMENT", 54, 74], ["retention strategies", "TREATMENT", 143, 163]]], ["However, the authors specifically excluded longitudinal cohort studies and instead focused on participant retention in intervention trials.", [["longitudinal cohort studies", "TEST", 43, 70], ["intervention trials", "TREATMENT", 119, 138]]], ["Differences between intervention and longitudinal cohort studies, such as research design factors (e.g., study duration) and the motivations of the participants in joining or withdrawing from studies, may impact the usefulness of retention strategies across both study designs [4, 6] .BackgroundA review of retention strategies reported in modern longitudinal cohort studies is pertinent and timely, given the emergence of digital retention strategies alongside established retention methods.", [["participants", "SPECIES", 148, 160], ["intervention", "TREATMENT", 20, 32], ["longitudinal cohort studies", "TEST", 37, 64], ["studies", "TEST", 192, 199], ["retention strategies", "TREATMENT", 230, 250], ["retention strategies", "TREATMENT", 307, 327], ["modern longitudinal cohort studies", "TEST", 340, 374], ["digital retention strategies", "TREATMENT", 423, 451], ["established retention methods", "TREATMENT", 462, 491]]], ["Maximising cohort retention in longitudinal research can reduce the administration costs of conducting research, improve the efficiency of research processes, and reduce outcome biases for studies by adopting an evidence-based cohort retention framework.", [["Maximising cohort retention", "PROBLEM", 0, 27], ["studies", "TEST", 189, 196], ["retention", "OBSERVATION", 18, 27]]], ["In this review, we aimed to: (i) identify retention strategies used in recent longitudinal cohort studies; (ii) examine whether retention rate was moderated by different study or participant characteristics (i.e., number of waves, study duration, sample size, population type, gender, age, country); (iii) estimate the retention rate in studies that use specific retention strategies, and contrast this retention rate with studies that do not use specific retention strategies; (iv) examine whether retention rate is associated with the number of retention strategies used; (v) examine which retention strategies were the strongest independent predictors of retention rate; and (vi) contrast the retention rate based on whether studies utilised emerging or established strategies.", [["retention strategies", "TREATMENT", 42, 62], ["recent longitudinal cohort studies", "TEST", 71, 105], ["retention rate", "PROBLEM", 128, 142], ["study duration", "TEST", 231, 245], ["the retention rate", "TEST", 315, 333], ["specific retention strategies", "TREATMENT", 354, 383], ["this retention rate", "TEST", 398, 417], ["specific retention strategies", "TREATMENT", 447, 476], ["retention rate", "PROBLEM", 499, 513], ["retention strategies", "TREATMENT", 547, 567], ["retention rate", "TEST", 658, 672], ["the retention rate", "TEST", 692, 710], ["size", "OBSERVATION_MODIFIER", 254, 258]]], ["Moreover, to ensure that recent innovations in retention strategies were identified, this review focused on literature published within the past 10 years.Search strategyA systematic review was performed as per the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [18] .", [["recent innovations in retention strategies", "PROBLEM", 25, 67], ["A systematic review", "TEST", 169, 188], ["Systematic Reviews", "TEST", 244, 262]]], ["Second, the reference lists of all articles selected for review were manually searched.Inclusion and exclusion criteriaThe inclusion and exclusion criteria were determined prior to implementing the search strategy.", [["exclusion criteria", "TEST", 137, 155], ["the search strategy", "TREATMENT", 194, 213]]], ["Articles were included in the review if: (i) the article described a cohort study, which was defined as a representative sample of a group or population who share a common experience or condition [2] , (ii) the article reported at least one wave of follow-up data collection with a participant/ proxy, (iii) participant retention data were reported, and (iv) retention strategies were reported.", [["a cohort study", "TEST", 67, 81], ["iv) retention strategies", "TREATMENT", 355, 379]]], ["Articles were excluded if: (i) the article was not available in English; (ii) the article was not published in a peer-reviewed publication (e.g., conference abstracts or dissertations); and, (iii) the article's research design was cross-sectional, involved data linkage only, or the article was a clinical or non-clinical trial evaluating the effectiveness of treatment regimens or intervention/prevention programmes (for an existing review of retention in intervention studies, see (12) ).Study selection, data extraction, and quality assessmentThe search strategy resulted in 9225 articles after removing duplicates.", [["treatment regimens", "TREATMENT", 360, 378], ["intervention/prevention programmes", "TREATMENT", 382, 416], ["intervention studies", "TEST", 457, 477], ["Study selection", "TEST", 490, 505], ["data extraction", "TEST", 507, 522], ["quality assessment", "TEST", 528, 546]]], ["Data were extracted and summarised for each of the 141 articles on: (i) the research design, including baseline sample population and sample size, the number of data collection waves reported, and the duration in years between the first and last waves of data collection; (ii) the cohort demographics, including mean sample age at baseline (or age range if mean age was not reported), proportion of male participants, country of cohort participants, and whether the cohort was clinical or non-clinical; and (iii) retention data, including the retention rate between baseline and the final data collection wave reported, and the specific retention strategies.", [["participants", "SPECIES", 404, 416], ["participants", "SPECIES", 436, 448], ["baseline sample population", "PROBLEM", 103, 129], ["sample size", "TEST", 134, 145], ["the retention rate", "TEST", 539, 557], ["size", "OBSERVATION_MODIFIER", 141, 145]]], ["Finally, we examined the suitability of each article in addressing the current study's research question.", [["the current study", "TEST", 67, 84]]], ["No articles were excluded on the basis of this quality assessment.Statistical methodWe used meta-analysis (and meta-regression) to address the aims of the study.", [["this quality assessment", "TEST", 42, 65], ["meta-analysis", "TEST", 92, 105], ["the study", "TEST", 151, 160], ["articles", "OBSERVATION", 3, 11]]], ["Meta-analyses were conducted using the Metafor package v1.9.8 [19] in R software v3.3.1 [20] .", [["the Metafor package v", "TEST", 35, 56]]], ["The retention rate, defined as the number of individuals who remained in the study at the last wave of data collection as a proportion of the total number of participants recruited at the baseline assessment, was the primary effect size measure of interest.", [["participants", "SPECIES", 158, 170], ["The retention rate", "TEST", 0, 18], ["the study", "TEST", 73, 82], ["the baseline assessment", "TEST", 184, 207], ["retention rate", "OBSERVATION", 4, 18], ["total", "OBSERVATION_MODIFIER", 142, 147], ["number", "OBSERVATION_MODIFIER", 148, 154], ["size", "OBSERVATION_MODIFIER", 232, 236]]], ["All meta-analyses were conducted using inverse variance weighting, with random effects specified to account for between study heterogeneity.", [["All meta-analyses", "TEST", 0, 17], ["inverse variance weighting", "TEST", 39, 65], ["study heterogeneity", "TEST", 120, 139]]], ["A binomial-normal model (with logit link) was used as the basis for analysis, which is appropriate when the effect size of interest is measured as a proportion.", [["A binomial", "TEST", 0, 10], ["analysis", "TEST", 68, 76], ["normal model", "OBSERVATION_MODIFIER", 11, 23]]], ["Meta-analyses were conducted when at least two independent studies contributed to the meta-analysis.Statistical methodTo examine the effect of gender on retention rate, we created a binary variable to denote studies as comprising a higher proportion of either male or female samples (Proportion of male participants in \"male\" grouping: M(SD) = 73.6%(0.20); Proportion of female participants in \"female\" grouping: M(SD) = 75.0%(0.21)).", [["participants", "SPECIES", 303, 315], ["participants", "SPECIES", 378, 390], ["Meta-analyses", "TEST", 0, 13], ["the meta-analysis", "TEST", 82, 99], ["retention rate", "TEST", 153, 167], ["studies", "TEST", 208, 215]]], ["To examine the effect of country development level on retention rate, each study country was categorised as either high or low development level by using a mean-split of each nation's Human Development Indexa measure of relative opportunity for longevity, education, and income, with a score range of 0 (low) to 1 (high) (Low HDI group M(SD) = 0.66(0.10); High HDI group M(SD) = 0.92(0.02)) [22] .", [["Human", "ORGANISM", 184, 189], ["Human", "SPECIES", 184, 189], ["retention rate", "TEST", 54, 68], ["each study", "TEST", 70, 80], ["a score range", "TEST", 284, 297]]], ["Retention strategies were coded as either established or emerging, depending on their presence or absence in any of the earlier systematic reviews on participant retention strategies [4, 6, 16, 17] .", [["Retention strategies", "TREATMENT", 0, 20]]], ["Finally, all meta-regressions adjusted for study duration and number of waves (except when these were specifically examined as predictor variables), given these were deemed to be likely confounding variables in analyses.Cohort, participant, and article characteristicsThe 141 articles identified for review described 143 cohorts (41 clinical and 102 non-clinical).", [["study duration", "TEST", 43, 57]]], ["Overall the mean sample size reported in the first wave of each article was 3585 participants (range = 30 to 61,895).", [["participants", "SPECIES", 81, 93], ["the mean sample size", "TEST", 8, 28], ["mean", "OBSERVATION_MODIFIER", 12, 16], ["size", "OBSERVATION_MODIFIER", 24, 28]]], ["Articles reported a mean retention rate of 73.5% (SD = 20.1%), with 4.6 waves (SD = 8.0), over 4.3 years (SD = 5.0).", [["a mean retention rate", "TEST", 18, 39], ["SD", "TEST", 50, 52], ["SD", "TEST", 79, 81]]], ["The average baseline participant age was 30.0 years (SD = 22.0), and the average baseline proportion of male participants across samples was 40% (SD = 0.30).", [["participants", "ORGANISM", 109, 121], ["participant", "SPECIES", 21, 32], ["participants", "SPECIES", 109, 121], ["SD", "TEST", 146, 148]]], ["Studies were conducted in 28 different countries with a mean Human Development Index of 0.79 (SD = 0.15), indicating that studies were more likely to be conducted in countries with high-levels human development.", [["Human", "ORGANISM", 61, 66], ["human", "ORGANISM", 193, 198], ["Human", "SPECIES", 61, 66], ["human", "SPECIES", 193, 198], ["human", "SPECIES", 193, 198], ["Studies", "TEST", 0, 7], ["a mean Human Development Index", "TEST", 54, 84], ["SD", "TEST", 94, 96]]], ["Cohort attrition/retention was identified as a specific research question or objective of interest in 55 of the 141 articles, indicating that most articles were not focused on participant retention.", [["Cohort attrition/retention", "PROBLEM", 0, 26]]], ["Retention-focused articles reported significantly more retention strategies than non-retention-focused articles (non-retention-focused: M(SD) = 3.3(3.1); retention-focused: M(SD) = 11.0(7.02); t (141) = \u2212 9.00, p < .001); however, no differences were found for the study sample size, number of waves, study duration, or retention rate.", [["significantly more retention strategies", "PROBLEM", 36, 75], ["non-retention", "TEST", 81, 94], ["non-retention", "TEST", 113, 126], ["t", "TEST", 193, 194], ["p", "TEST", 211, 212], ["the study", "TEST", 261, 270], ["study duration", "TEST", 301, 315], ["retention rate", "TEST", 320, 334], ["size", "OBSERVATION_MODIFIER", 278, 282]]], ["High heterogeneity was identified in all results, as expected given the diversity of research questions, methodologies, and cohorts across articles [21] .Relationship between retention rate and study or participant characteristicsTo examine whether retention rate was moderated by study characteristics (i.e., number of waves, study duration, sample size, study focus on retention strategies or not) or by participant characteristics (i.e., population type, gender, age, country development level), a series of meta-regressions was performed, one for each characteristic under examination.", [["High heterogeneity", "PROBLEM", 0, 18], ["retention rate", "TEST", 175, 189], ["retention rate", "TEST", 249, 263], ["study duration", "TEST", 327, 341], ["sample size", "TEST", 343, 354], ["retention strategies", "TREATMENT", 371, 391], ["examination", "TEST", 577, 588], ["heterogeneity", "OBSERVATION", 5, 18]]], ["Retention rate was not moderated by: number of waves 14 to \u2212 0.20]; p < .01)).", [["Retention rate", "TEST", 0, 14]]], ["Namely, cohorts with more female participants (median retention = 81.5%, 95%CI [77.6% to 84.9%]) reported higher retention rates than articles with more male participants (medianRelationship between retention rate and retention strategy typesA total of 95 retention strategies was identified, with an average of 6.2 strategies per article (SD = 6.2).", [["participants", "SPECIES", 33, 45], ["participants", "SPECIES", 158, 170], ["median retention", "TEST", 47, 63], ["CI", "TEST", 76, 78], ["higher retention rates", "PROBLEM", 106, 128], ["retention rate", "TEST", 199, 213]]], ["The most common retention strategies were: cash/voucher incentives to complete a follow-up assessment (n = 59), sending a postcard or letter reminder to complete a follow-up assessment (n = 43), and offering participants alternative methods of data collection, such as completing an interview face-to-face or over the phone (n = 36).", [["participants", "SPECIES", 208, 220], ["a follow-up assessment", "TEST", 79, 101], ["a follow-up assessment", "TEST", 162, 184]]], ["Retention strategies were grouped into four main retention strategy domains: (i) barrier-reduction strategies, such as offering childcare services, assistance with parking and transport, and engaging a participant sub-sample to evaluate data collection methods for the next wave; (ii) community-building strategies, such as creating a recognisable study brand via logos and colour schemes, giving away study merchandise to create a sense of project community (e.g., t-shirts with study logo), and sharing study results, news and events with participants via newsletters, social media, and feedback reports; (iii) strategies to improve follow-up rates within each wave, including cash or voucher incentives for varying levels of assessment completion, and use of phone calls, SMS, house visits, mail and email reminders to participants to complete assessments; and (iv) tracing strategies, such as collecting the details of alternative contact persons for each participant at baseline, using public or non-public records to find updated contact information for participants, and collecting detailed participant contact information via a locator document (e.g. full name, address, social security number, phone numbers, email addresses, etc.).", [["participants", "SPECIES", 541, 553], ["participants", "SPECIES", 822, 834], ["persons", "SPECIES", 943, 950], ["participants", "SPECIES", 1060, 1072], ["Retention strategies", "TREATMENT", 0, 20], ["barrier-reduction strategies", "TREATMENT", 81, 109], ["collection methods", "TEST", 242, 260], ["sharing study", "TEST", 497, 510], ["complete assessments", "TEST", 838, 858], ["iv) tracing strategies", "TREATMENT", 865, 887], ["main", "OBSERVATION_MODIFIER", 44, 48], ["retention strategy", "OBSERVATION", 49, 67]]], ["The most commonly reported category was strategies to improve follow-up rates within waves, identified 306 times within the 143 cohorts, followed by barrier-reduction strategies (adopted 268 times), community-building strategies (adopted 181 times), and tracing strategies (adopted 138 times).", [["barrier-reduction strategies", "TREATMENT", 149, 177]]], ["Table 2 presents the retention strategies used, grouped by retention strategy domain.", [["the retention strategies", "TREATMENT", 17, 41]]], ["It compares the retention rate for those studies that did, or did not utilise a specific retention strategy type or domain.", [["those studies", "TEST", 35, 48]]], ["Of the 95 individual retention strategies examined, three demonstrated moderation of the retention rate.", [["the retention rate", "TEST", 85, 103], ["retention rate", "OBSERVATION", 89, 103]]], ["First, improved retention was associated with offering participants alternative methods of data collection (e.g., completing an interview face-to-face or over the phone) (median retention using strategy = 86.1%; median retention not using strategy = 76.3%; b = 0.24, p = .01), and having participants complete a locator document at baseline (median retention using strategy = 90.9%; median retention not using strategy = 78.1%; b = 0.49, p = 0.02).", [["participants", "SPECIES", 55, 67], ["participants", "SPECIES", 288, 300], ["data collection", "TEST", 91, 106], ["strategy", "TEST", 194, 202], ["median retention", "TEST", 212, 228], ["strategy", "TEST", 239, 247], ["b", "TEST", 257, 258], ["p", "TEST", 267, 268], ["strategy", "TEST", 365, 373], ["median retention", "TEST", 383, 399], ["strategy", "TEST", 410, 418], ["b", "TEST", 428, 429], ["p", "TEST", 438, 439], ["improved", "OBSERVATION_MODIFIER", 7, 15], ["retention", "OBSERVATION", 16, 25]]], ["Finally, lower retention was associated with use of phone call reminders to participants to complete a follow-up wave (median retention using strategy = 72.7%; median retention not using strategy = 80.6%; b = 0.25, p = .05).", [["participants", "SPECIES", 76, 88], ["strategy", "TEST", 142, 150], ["median retention", "TEST", 160, 176], ["strategy", "TEST", 187, 195], ["b", "TEST", 205, 206]]], ["There was weak evidence against the null hypothesis of no moderation effect for a further three strategies.", [["the null hypothesis", "PROBLEM", 32, 51], ["a further three strategies", "TREATMENT", 80, 106], ["no", "UNCERTAINTY", 55, 57]]], ["This included having consistent research team members (median retention using strategy = 87.3%; median retention not using strategy = 78.1%; b = 0.67, p = .09); offering site and home visits for data collection (median retention using strategy = 83.9%; median retention not using strategy = 77.4%; b = 0.46, p = .07); and sending participants thank you, birthday or holiday cards (median retention using strategy = 84.9%; median retention not using strategy = 77.5%; b = 0.50, p = .07).", [["participants", "SPECIES", 330, 342], ["strategy", "TEST", 78, 86], ["strategy", "TEST", 123, 131], ["b", "TEST", 141, 142], ["p", "TEST", 151, 152], ["data collection", "TEST", 195, 210], ["strategy", "TEST", 235, 243], ["median retention", "TEST", 253, 269], ["strategy", "TEST", 280, 288], ["b", "TEST", 298, 299], ["p", "TEST", 308, 309], ["strategy", "TEST", 404, 412], ["median retention", "TEST", 422, 438], ["strategy", "TEST", 449, 457], ["b", "TEST", 467, 468], ["p", "TEST", 477, 478]]], ["There was no evidence to support a moderated retention rate by any other specific retention strategy type.Relationship between retention rate and retention strategy typesTo examine whether the specific strategy domains of barrier-reduction, community-building, follow-up/reminder, and tracing retention strategies were associated with retention rate, a binary variable was created for each domain that denoted whether a study did or did not utilise one or more specific strategy types within that domain.", [["a moderated retention rate", "PROBLEM", 33, 59], ["retention rate and retention strategy types", "TREATMENT", 127, 170], ["barrier-reduction", "TREATMENT", 222, 239], ["tracing retention strategies", "TREATMENT", 285, 313], ["retention rate", "PROBLEM", 335, 349], ["a study", "TEST", 418, 425], ["no evidence to", "UNCERTAINTY", 10, 24], ["moderated", "OBSERVATION_MODIFIER", 35, 44], ["retention", "OBSERVATION", 45, 54], ["retention rate", "OBSERVATION", 127, 141], ["retention strategy", "OBSERVATION", 146, 164]]], ["As shown in Table 2 , after controlling for study duration and number of waves, studies that utilised any barrier-reduction strategy had higher retention rates than those that did not use a barrier strategy (median retention using barrier strategies = 81.1%; median retention not using barrier strategies = 70.7%; b = 0.61, p = .01).", [["study duration", "TEST", 44, 58], ["studies", "TEST", 80, 87], ["any barrier-reduction strategy", "TREATMENT", 102, 132], ["higher retention rates", "PROBLEM", 137, 159], ["a barrier strategy", "TREATMENT", 188, 206], ["barrier strategies", "TREATMENT", 231, 249], ["barrier strategies", "TEST", 286, 304], ["b", "TEST", 314, 315]]], ["Again after controlling for the study duration and number of waves, surprisingly, articles that reported use of at least one follow-up/reminder strategy had lower retention rates when compared to studies that did not utilise any follow-up/reminder (median retention using follow-up/reminder strategies = 76.4%; median retention not using follow-up/reminder strategies = 86.1%; b = \u2212 0.32, p < .01).", [["the study duration", "TEST", 28, 46], ["lower retention rates", "PROBLEM", 157, 178], ["strategies", "TEST", 291, 301], ["strategies", "TEST", 357, 367], ["b", "TEST", 377, 378]]], ["No relationships were found between retention rate and the use of any community-building or tracing retention strategies.Relationship between retention rate and number of strategies usedTo examine whether the cumulative number of retention strategies was associated with retention rate, we meta-regressed retention rate on to continuous variables representing the cumulative number of strategies used across strategy domains, and then within each domain separately.", [["tracing retention strategies", "TREATMENT", 92, 120], ["retention rate", "TREATMENT", 142, 156], ["retention strategies", "PROBLEM", 230, 250], ["retention rate", "PROBLEM", 271, 285], ["meta-regressed retention rate", "PROBLEM", 290, 319]]], ["Greater number of retention strategies used (across all domains) was not associated with higher retention rate (b = 0.02; 95%CI [\u2212 0.12 to 0.05], p = .21).", [["retention strategies", "TREATMENT", 18, 38], ["higher retention rate", "PROBLEM", 89, 110], ["CI", "TEST", 125, 127], ["p", "TEST", 146, 147], ["retention strategies", "OBSERVATION", 18, 38]]], ["When examined within each domain, controlling for study duration and number of waves, we found accumulation of barrier-reduction strategies was associated with higher retention (b = 0.", [["study duration", "TEST", 50, 64], ["barrier-reduction strategies", "TREATMENT", 111, 139], ["higher retention", "PROBLEM", 160, 176], ["accumulation", "OBSERVATION_MODIFIER", 95, 107]]], ["12Identifying strongest independent predictors of retention rateThree separate meta-regression models were estimated to examine strongest predictors of retention rate within strategy domains and types.", [["retention rate", "TREATMENT", 50, 64], ["retention rate", "PROBLEM", 152, 166]]], ["Table 3 -Model 1 shows that when examining retention strategy types as cumulative variables for each domain, barrier-reduction was independently associated with higher retention (b = 0.17; 95%CI [0.03 to 0.31]; p = .02) and follow-up strategies was independently associated with lower retention (b = \u2212 0.15; 95%CI [\u2212 0.29 to \u2212 0.01]; p = .04) beyond the effects of other retention strategy types.", [["barrier-reduction", "TREATMENT", 109, 126], ["higher retention", "PROBLEM", 161, 177], ["CI", "TEST", 192, 194], ["p", "TEST", 211, 212], ["lower retention", "PROBLEM", 279, 294], ["CI", "TEST", 311, 313], ["other retention strategy types", "TREATMENT", 365, 395], ["retention", "OBSERVATION", 371, 380]]], ["By contrast, Table 3 -Model 2 demonstrates that when the retention rate was regressed on to all the binary indicator variables denoting whether the study did or did not utilise at least one strategy within that domain, only the use of follow-up/reminder strategies was independently associated with reduced retention rate (b = \u2212 0.83; 95%CI [\u2212 1.4 to \u2212 0.27]; p < .01).Identifying strongest independent predictors of retention rateFinally, we investigated whether the associations between individual strategies and retention rate remained after controlling for other effective individual strategies in a single model (see Table 3 Model 3).", [["the retention rate", "TEST", 53, 71], ["the study", "TEST", 144, 153], ["reduced retention rate", "PROBLEM", 299, 321], ["CI", "TEST", 338, 340], ["\u2212", "TEST", 342, 343], ["retention rate", "TEST", 515, 529]]], ["A meta-regression model was created by entering only individual retention strategies that were associated with a retention rate at the p < .10 level (as discussed in [23, 24] ).", [["A meta-regression model", "TEST", 0, 23], ["a retention rate", "TEST", 111, 127], ["retention strategies", "OBSERVATION", 64, 84]]], ["Offering participants alternative methods of data collection was associated with improved retention, whilst the use of phone call reminders was associated with re-Relationship between retention rate and emerging strategiesThe final group-level analysis investigated the association between emerging retention strategies and retention rates.", [["participants", "SPECIES", 9, 21], ["retention rate", "TREATMENT", 184, 198], ["emerging strategies", "TREATMENT", 203, 222], ["The final group-level analysis", "TEST", 222, 252], ["emerging retention strategies", "TREATMENT", 290, 319], ["retention rates", "TREATMENT", 324, 339], ["retention strategies", "OBSERVATION", 299, 319], ["retention rates", "OBSERVATION", 324, 339]]], ["Within these 95 retention strategies, 44 emerging strategies were identified, including the application of social media and SMS to assist in tracing participants lost to follow-up, and the application of study websites and social media profiles for keeping participants up-to-date with the study's news and events.", [["participants", "SPECIES", 149, 161], ["participants", "SPECIES", 257, 269], ["social media", "TREATMENT", 107, 119]]], ["Meta-regressions demonstrated that articles reporting a higher frequency of emerging retention strategies had higher retention, after controlling for study duration and number of waves (b = 0.08; 95%CI [0.01 to 0.16]; p = .03).", [["higher retention", "PROBLEM", 110, 126], ["study duration", "TEST", 150, 164], ["CI", "TEST", 199, 201], ["p", "TEST", 218, 219], ["higher", "OBSERVATION_MODIFIER", 56, 62], ["higher retention", "OBSERVATION", 110, 126]]], ["Despite this, there was no difference in overall retention rates between those articles that did and did not report the use of emerging retention strategies (median retention using emerging strategies = 80.1%; median retention not using emerging strategies = 75.0%; b = 0.27, p = .27).DiscussionThis study aimed to identify retention strategies employed in longitudinal cohort studies during the past decade, and to examine their effectiveness.", [["emerging retention strategies", "TREATMENT", 127, 156], ["emerging strategies", "TREATMENT", 181, 200], ["emerging strategies", "TEST", 237, 256], ["b", "TEST", 266, 267], ["p", "TEST", 276, 277], ["This study", "TEST", 295, 305], ["retention strategies", "TREATMENT", 324, 344], ["longitudinal cohort studies", "TEST", 357, 384], ["no", "UNCERTAINTY", 24, 26], ["difference", "OBSERVATION_MODIFIER", 27, 37], ["overall retention", "OBSERVATION", 41, 58]]], ["We identified 143 longitudinal cohort studies that described retention strategies and outcomes, resulting in 95 different retention strategies.", [["longitudinal cohort studies", "TEST", 18, 45], ["different retention strategies", "TREATMENT", 112, 142], ["retention strategies", "OBSERVATION", 122, 142]]], ["We then investigated whether study or participant characteristics moderated retention, the relationship between retention rate and retention strategy type, and whether new cohort retention strategies have emerged since previous reviews.", [["moderated retention", "PROBLEM", 66, 85], ["retention rate and retention strategy type", "TREATMENT", 112, 154], ["new cohort retention strategies", "PROBLEM", 168, 199], ["retention strategy", "OBSERVATION", 131, 149]]], ["In so doing, this study is the first meta-analysis of retention strategies conducted in longitudinal cohort studies.", [["this study", "TEST", 13, 23], ["retention strategies", "TREATMENT", 54, 74], ["longitudinal cohort studies", "TEST", 88, 115]]], ["This research particularly complements the previous narrative review that investigated cohort retention strategies in longitudinal research [6] , and the wider literature investigating participant retention strategies across health research designs (e.g., 4, 16, 17) .", [["cohort retention strategies", "TREATMENT", 87, 114]]], ["Such research has important implications for maximising cohort retention and reducing research administration costs, which will subsequently improve the efficacy and quality of health research.", [["maximising cohort retention", "PROBLEM", 45, 72], ["reducing research administration costs", "TREATMENT", 77, 115]]], ["We first investigated how study or participant characteristics may influence cohort retention.", [["influence cohort retention", "PROBLEM", 67, 93]]], ["Study characteristics included sample size, study duration, number of waves, and country development level -none of which were associated with retention rate.", [["Study characteristics", "TEST", 0, 21], ["sample size", "TEST", 31, 42], ["study duration", "TEST", 44, 58], ["retention rate", "TEST", 143, 157], ["size", "OBSERVATION_MODIFIER", 38, 42]]], ["We found that cohort studies with a higher proportion of male participants had lower retention rates than studies with a higher proportion of female participants; no associations were found for participants' age or cohort type.", [["participants", "SPECIES", 62, 74], ["participants", "SPECIES", 149, 161], ["participants", "SPECIES", 194, 206], ["cohort studies", "TEST", 14, 28], ["lower retention rates", "PROBLEM", 79, 100]]], ["While difficulties in retaining male participants are well-documented in previous research (e.g., 4, 20, 21) , our study noted that cohorts with a higher proportion of male participants were also more likely to be clinical samples than cohorts with a higher proportion of female participants.", [["participants", "ORGANISM", 173, 185], ["participants", "SPECIES", 37, 49], ["participants", "SPECIES", 173, 185], ["participants", "SPECIES", 279, 291], ["our study", "TEST", 111, 120]]], ["In addition, cohorts with a higher proportion of male participants were also disproportionately focused on high-risk groups, such as substance use and men who have sex with men (e.g., the Bangkok Men who have Sex with Men Cohort Study (BMCS) [25] and the International Multicenter ADHD Genetics (IMAGE) study [26] ).", [["ADHD", "DISEASE", 281, 285], ["men", "ORGANISM", 151, 154], ["men", "ORGANISM", 173, 176], ["participants", "SPECIES", 54, 66], ["men", "SPECIES", 151, 154], ["men", "SPECIES", 173, 176]]], ["Thus, the difficulties in retention reported in this study and the wider literature could potentially be attributed to the differential impact of these clinical issues that affect men more than women.", [["men", "ORGANISM", 180, 183], ["women", "ORGANISM", 194, 199], ["men", "SPECIES", 180, 183], ["women", "SPECIES", 194, 199], ["the difficulties in retention", "PROBLEM", 6, 35], ["this study", "TEST", 48, 58]]], ["Researchers working with hard-to-retain populations, such as men in particular clinical groupings, may benefit from investigating what retention strategies work within their specific populations and settings beyond the core retention strategies identified in this review.DiscussionSecond, we investigated the relationship between retention rate and retention strategies.", [["men", "ORGANISM", 61, 64], ["men", "SPECIES", 61, 64], ["the core retention strategies", "TREATMENT", 215, 244], ["retention rate", "TREATMENT", 330, 344], ["retention strategies", "TREATMENT", 349, 369], ["retention strategies", "OBSERVATION", 349, 369]]], ["We identified 95 different retention strategies, grouped thematically into four classes: barrier-reduction, community-building, follow-up, and tracing.", [["different retention strategies", "TREATMENT", 17, 47], ["barrier-reduction", "TREATMENT", 89, 106], ["retention strategies", "OBSERVATION", 27, 47], ["reduction", "OBSERVATION_MODIFIER", 97, 106]]], ["Specific strategies associated with improved retention rates included the barrier-reduction strategy of offering alternative methods of data collection to participants (e.g., completing an interview over the phone or in person); and the tracing strategy of collecting detailed contact information from participants at baseline via a locator document.", [["participants", "SPECIES", 155, 167], ["person", "SPECIES", 220, 226], ["participants", "SPECIES", 302, 314], ["improved retention rates", "PROBLEM", 36, 60], ["the barrier-reduction strategy", "TREATMENT", 70, 100]]], ["Further, weak evidence was found for one community-building and two further barrier-reduction strategies: (i) sending participants thank you, birthday or holiday cards; (ii) having consistent research team members, and; (iii) offering site and home visits for data collection.DiscussionOverall, barrier-reduction strategies emerged as the strongest predictor of improved retention.", [["participants", "SPECIES", 118, 130], ["two further barrier-reduction strategies", "TREATMENT", 64, 104], ["data collection", "TEST", 260, 275], ["barrier-reduction strategies", "TREATMENT", 295, 323]]], ["Barrier-reduction strategies may be particularly useful in longitudinal research given participants are likely to experience significant changes in their capacity to remain involved across the study's duration (typically years).", [["participants", "ORGANISM", 87, 99], ["participants", "SPECIES", 87, 99], ["Barrier-reduction strategies", "TREATMENT", 0, 28], ["significant changes in their capacity", "PROBLEM", 125, 162]]], ["Follow-up/reminder strategies, such as incentives and reminders, were associated with significantly poorer retention.", [["significantly poorer retention", "PROBLEM", 86, 116]]], ["This result was surprising, given that the previous review investigating retention strategies in longitudinal cohort studies found the opposite, that use of these follow-up/reminder strategies resulted in improved retention rates [6] .", [["retention strategies", "TREATMENT", 73, 93], ["longitudinal cohort studies", "TEST", 97, 124], ["improved retention rates", "PROBLEM", 205, 229]]], ["The lack of support for follow-up/reminder strategies found in the current review could be due to a number of extraneous variables including: (i) timing: studies may have implemented this strategy after other retention efforts proved ineffective; (ii) participant burden: the studies using follow-up/reminder strategies may have involved a high data collection burden (e.g., long surveys); (iii) sampling: studies using follow-up/reminder strategies may be over-represented in studies of difficult-to-retain populations, such as men.", [["men", "ORGANISM", 529, 532], ["men", "SPECIES", 529, 532], ["the studies", "TEST", 272, 283], ["a high data collection burden", "PROBLEM", 338, 367]]], ["However, these explanations are unlikely, given that follow-up/reminder strategies were identified in most of the cohorts included in this review Alternatively, participants may perhaps view follow-up/reminder strategies as the research team \"badgering\" them to complete assessments, thereby damaging rapport.", [["participants", "SPECIES", 161, 173], ["complete assessments", "TEST", 262, 282]]], ["This negative perspective of follow-up/reminder strategies may be further exacerbated if the research team has not implemented sufficient barrier-reduction strategies to help make it easier for participants to remain involved in the study.", [["participants", "SPECIES", 194, 206], ["sufficient barrier-reduction strategies", "TREATMENT", 127, 166], ["the study", "TEST", 229, 238]]], ["Future research could consider investigating participants' perspectives of retention strategies in longitudinal cohort studies, ensuring that both active and inactive participants are included, to better understand the costs and benefits of different approaches.", [["participants", "ORGANISM", 167, 179], ["participants", "SPECIES", 45, 57], ["participants", "SPECIES", 167, 179], ["retention strategies", "TREATMENT", 75, 95], ["longitudinal cohort studies", "TEST", 99, 126]]], ["Interestingly, the current study found that simply adding more cohort retention strategies did not result in higher retention rates.", [["the current study", "TEST", 15, 32], ["higher retention rates", "PROBLEM", 109, 131], ["higher retention", "OBSERVATION", 109, 125]]], ["These results contradict the findings of Robinson et al. [17] and Davis et al. [4] , who both found that the use of more retention strategies across multiple classes was associated with improved retention rates.", [["improved retention rates", "PROBLEM", 186, 210], ["improved retention", "OBSERVATION", 186, 204]]], ["However, neither study specifically examined participant retention in longitudinal cohort studies, and both synthesised their retention results using a narrative rather than meta-analytic approach.", [["neither study", "TEST", 9, 22], ["longitudinal cohort studies", "TEST", 70, 97], ["meta-analytic approach", "TREATMENT", 174, 196]]], ["Given that the implementation of retention strategies can be costly in terms of both time and money, the overall number of strategies employed is important to evaluate.", [["retention strategies", "TREATMENT", 33, 53]]], ["The interaction of quantity of retention strategies used and provision of flexibility needs to be better understood, given research protocols that accommodate the changing lives of participants should remain a key focus of retention efforts.", [["participants", "SPECIES", 181, 193], ["retention strategies", "TREATMENT", 31, 51], ["research protocols", "TREATMENT", 123, 141]]], ["Finally, we examined whether studies utilising new or emerging retention strategies had improved retention compared with studies using established strategies.", [["studies", "TEST", 121, 128]]], ["Of the 95 retention strategies described in the included articles, 44 were identified as an emerging retention strategy that had not yet been described in extant systematic reviews examining participant retention [4, 6, 16, 17] .", [["the 95 retention strategies", "TREATMENT", 3, 30], ["an emerging retention strategy", "TREATMENT", 89, 119]]], ["Emerging strategies included using social media and SMS to assist in tracing participants lost to follow-up, and the use of study websites and social media profiles for keeping participants up-to-date with study news and events.", [["participants", "SPECIES", 77, 89], ["participants", "SPECIES", 177, 189], ["social media", "TREATMENT", 35, 47]]], ["Emerging retention strategies were endorsed by only a handful of studies, and the use of a single emerging strategy was not significantly associated with retention rate.", [["a single emerging strategy", "TREATMENT", 89, 115]]], ["However, we found that studies that employed more emerging retention strategies were associated with improved retention rates.", [["improved retention rates", "PROBLEM", 101, 125]]], ["Importantly, emerging strategies were identified across all four retention strategy domains (barrier-reduction, community-building, follow-up/reminder, and tracing), demonstrating that the association between emerging strategies and improvements in retention are due to the use of modern technology to help achieve core cohort engagement goals.", [["barrier-reduction", "TREATMENT", 93, 110], ["modern technology", "TREATMENT", 281, 298], ["core cohort engagement goals", "TREATMENT", 315, 343]]], ["Thus, we recommend that researchers continue to innovate their retention efforts, particularly where such strategies may reduce participant burden.DiscussionThe current study has a number of limitations.", [["The current study", "TEST", 157, 174]]], ["First, the number of articles that focused on reporting retention strategies in detail was proportionally low compared to the number of articles that did not focus on reporting retention strategies.", [["reporting retention strategies", "TREATMENT", 167, 197]]], ["Although retention strategies were identified within 143 longitudinal cohorts, only 55 included cohort retention as a key focus area.", [["retention strategies", "PROBLEM", 9, 29], ["cohort retention", "PROBLEM", 96, 112]]], ["Very few articles (n = 12) were identified that reported strategy-specific retention rates within the longitudinal cohort studies.", [["specific retention rates", "PROBLEM", 66, 90], ["the longitudinal cohort studies", "TEST", 98, 129]]], ["The number of retention strategies reported by articles ranged from one to 32, with 35 of the 141 articles describing only one retention strategy.", [["one retention strategy", "TREATMENT", 123, 145], ["retention strategies", "OBSERVATION", 14, 34]]], ["Longitudinal cohort studies should aim to publish protocol papers that delineate their cohort retention strategies, and ensure that the protocol is updated as retention efforts evolve.DiscussionSecond, net retention rates were calculated by the difference between the first and last wave of data collection reported in the article.", [["Longitudinal cohort studies", "TEST", 0, 27], ["their cohort retention strategies", "TREATMENT", 81, 114], ["the protocol", "TREATMENT", 132, 144], ["net retention rates", "PROBLEM", 202, 221], ["data collection", "TEST", 291, 306]]], ["Where specified, ineligible participants (e.g., participants recruited after the first wave, or deceased participants) were excluded from the retention rate calculation.", [["participants", "ORGANISM", 28, 40], ["participants", "SPECIES", 28, 40], ["participants", "SPECIES", 48, 60], ["participants", "SPECIES", 105, 117], ["the retention rate calculation", "TEST", 138, 168]]], ["However, some articles did not provide detailed information on the eligibility of the sample at the final wave, and thus it is possible that the retention rates calculated for some studies may be slightly inaccurate.", [["the retention rates", "TEST", 141, 160], ["some studies", "TEST", 176, 188], ["slightly inaccurate", "PROBLEM", 196, 215]]], ["This limitation could be addressed by researchers providing details on the eligibility of their samples at each wave.DiscussionThird, high levels of heterogeneity were reported for most analyses in this study.", [["this study", "TEST", 198, 208]]], ["This may best be explained by two factors.", [["may best be explained", "UNCERTAINTY", 5, 26]]], ["First, we expected to identify high heterogeneity given the diversity of research questions, methodologies, and cohorts reported across articles.", [["high heterogeneity", "PROBLEM", 31, 49]]], ["Second, only a small number of studies were eligible for most meta-regressions in this paper, which reduces the precision of heterogeneity estimates [27] .", [["studies", "TEST", 31, 38], ["small", "OBSERVATION_MODIFIER", 15, 20]]], ["This limitation could be addressed in future work, which could aim to investigate the effectiveness of different retention strategies within different subgroups.DiscussionFinally, by nature of synthesising retention results across different samples and settings, the current study is unable to disaggregate nuanced effects of various retention strategies across specific contexts and populations, given results are pooled across multiple studies.", [["different retention strategies", "TREATMENT", 103, 133], ["the current study", "TEST", 263, 280], ["various retention strategies", "TREATMENT", 326, 354], ["multiple studies", "TEST", 429, 445]]], ["The current study did address this broadly by investigating the effects of study and sample characteristics on retention.DiscussionA final point to note is that available to researchers are a range of statistical or methodological approaches that can minimise potential biases introduced with attrition.", [["The current study", "TEST", 0, 17], ["study", "TEST", 75, 80]]], ["Whilst beyond the scope of this paper, these approaches include formal statistical methods for addressing missingness due to attrition such as multiple imputation or full information maximum likelihood methods [28, 29] .", [["formal statistical methods", "TREATMENT", 64, 90], ["missingness", "PROBLEM", 106, 117]]], ["Moreover, researchers may address attrition methodologically by using replacement sampling approaches that recruit new participants into a study to replace those who have dropped out, based on shared characteristics measured in the original sampling frame [30, 31] .", [["participants", "SPECIES", 119, 131], ["replacement sampling approaches", "TREATMENT", 70, 101], ["a study", "TEST", 137, 144]]], ["All these methods provide useful avenues to address attrition once any employed retention strategies have been used to retain the largest proportion of the original sample as possible.ConclusionsOverall, this study has important implications for the retention efforts of longitudinal cohort studies.", [["any employed retention strategies", "TREATMENT", 67, 100], ["this study", "TEST", 204, 214], ["longitudinal cohort studies", "TEST", 271, 298]]], ["Projects should invest both time and funding into matching retention strategies to the sample prior to implementation, including careful consideration of unintended burden for participants.", [["participants", "SPECIES", 176, 188]]], ["Finally, given the high number of emerging retention strategies identified, longitudinal research methods clearly continue to evolve.", [["emerging retention strategies", "TREATMENT", 34, 63], ["longitudinal research methods", "TREATMENT", 76, 105], ["retention strategies", "OBSERVATION", 43, 63]]], ["Longitudinal cohort studies may benefit from open and regular protocol revision to incorporate new strategies, particularly where these strategies may offer greater flexibility to participants.Additional fileAdditional file 1: Table S1 .", [["participants", "SPECIES", 180, 192], ["Longitudinal cohort studies", "TEST", 0, 27], ["open and regular protocol revision", "TREATMENT", 45, 79], ["new strategies", "TREATMENT", 95, 109], ["S1", "ANATOMY", 233, 235]]]], "3c7eb421011c8c1830e74bce684d0393f503345a": [["IntroductionEnteroviruses (EVs) present a major burden for human health and health care systems worldwide, with large outbreaks consisting of hundreds of thousands of hospitalized cases occurring periodically [1] .", [["EVs", "ANATOMY", 27, 30], ["Enteroviruses", "GENE_OR_GENE_PRODUCT", 12, 25], ["EVs", "MULTI-TISSUE_STRUCTURE", 27, 30], ["human", "ORGANISM", 59, 64], ["human", "SPECIES", 59, 64], ["human", "SPECIES", 59, 64]]], ["EVs are associated with a wide variety of symptoms, ranging from mild respiratory diseases to severe neurological infections, leading potentially to death [2] .", [["EVs", "ANATOMY", 0, 3], ["respiratory", "ANATOMY", 70, 81], ["neurological", "ANATOMY", 101, 113], ["respiratory diseases", "DISEASE", 70, 90], ["neurological infections", "DISEASE", 101, 124], ["death", "DISEASE", 149, 154], ["EVs", "MULTI-TISSUE_STRUCTURE", 0, 3], ["a wide variety of symptoms", "PROBLEM", 24, 50], ["mild respiratory diseases", "PROBLEM", 65, 90], ["severe neurological infections", "PROBLEM", 94, 124], ["mild", "OBSERVATION_MODIFIER", 65, 69], ["respiratory diseases", "OBSERVATION", 70, 90], ["severe", "OBSERVATION_MODIFIER", 94, 100], ["neurological", "OBSERVATION_MODIFIER", 101, 113], ["infections", "OBSERVATION", 114, 124]]], ["These single-stranded RNA viruses that belong to the Picornaviridae family possess a relatively small genome size ranging from 7.2 to 8.5 kb.", [["Picornaviridae", "GENE_OR_GENE_PRODUCT", 53, 67], ["Picornaviridae family", "PROTEIN", 53, 74], ["These single-stranded RNA viruses", "PROBLEM", 0, 33], ["a relatively small genome size", "PROBLEM", 83, 113], ["RNA viruses", "OBSERVATION", 22, 33], ["relatively", "OBSERVATION_MODIFIER", 85, 95], ["small", "OBSERVATION_MODIFIER", 96, 101], ["genome", "OBSERVATION", 102, 108], ["size", "OBSERVATION_MODIFIER", 109, 113]]], ["For routine diagnostics, EV presence is generally determined by real-time, reverse-transcription PCR (qRT-PCR) assays, complemented by partial sequencing of the VP1-VP4 coding regions for genotyping [2, 3] .", [["VP1-VP4 coding regions", "DNA", 161, 183], ["routine diagnostics", "TEST", 4, 23], ["transcription PCR", "TEST", 83, 100], ["qRT", "TEST", 102, 105], ["the VP1", "TEST", 157, 164], ["genotyping", "TEST", 188, 198]]], ["Due to the lack of proofreading mechanism in RNA replication, EV genomes are highly variable and the likely subject of within-and between-genome recombinations [4, 5] .", [["EV genomes", "ORGANISM", 62, 72], ["EV genomes", "DNA", 62, 72], ["proofreading mechanism", "PROBLEM", 19, 41], ["RNA replication", "TREATMENT", 45, 60], ["EV genomes", "TEST", 62, 72]]], ["Therefore, when diagnostic tests solely rely on PCR using conserved primer sequences, false-negative results cannot be excluded.", [["conserved primer sequences", "DNA", 58, 84], ["diagnostic tests", "TEST", 16, 32], ["PCR", "TEST", 48, 51], ["conserved primer sequences", "TEST", 58, 84], ["cannot be excluded", "UNCERTAINTY", 109, 127]]], ["There is thus a need to generalize the assessment of EV diversity and evolution via a whole-genome approach, rather than from the limited information gained from sequencing single genomic regions.IntroductionThe main limitation towards a general adoption of whole-genome sequencing (WGS) for better EV characterization and better understanding of their evolution and epidemiology is mostly of a technological nature: WGS approaches are more expensive, technically demanding and hence time consuming than standard molecular assays.", [["single genomic regions", "DNA", 173, 195], ["the assessment", "TEST", 35, 49], ["a whole-genome approach", "TREATMENT", 84, 107], ["better EV characterization", "TEST", 292, 318], ["standard molecular assays", "TEST", 504, 529]]], ["As such, they are generally not routinely used in diagnostic laboratories.", [["diagnostic laboratories", "TEST", 50, 73]]], ["In the case of RNA viruses, the challenge is even more exacerbated because various molecular steps (RNA purification, extraction, cDNA synthesis, and optionally amplification) add to the turnaround time and final cost of the assays.", [["RNA viruses", "PROBLEM", 15, 26], ["RNA purification", "TREATMENT", 100, 116], ["extraction", "TREATMENT", 118, 128], ["cDNA synthesis", "TREATMENT", 130, 144], ["the assays", "TEST", 221, 231], ["RNA viruses", "OBSERVATION", 15, 26]]], ["Clinical WGS applications are mostly based on Sanger sequencing and on second-generation sequencing platforms, with Illumina MiSeq/HiSeq (Illumina, San Diego, CA, USA) and Ion Torrent machines leading the market, as benchtop sequencing technologies enable high-throughput sequencing at an affordable price per sample when samples are multiplexed [6] .", [["samples", "ANATOMY", 322, 329], ["Clinical WGS applications", "TREATMENT", 0, 25], ["Sanger sequencing", "TEST", 46, 63], ["Illumina MiSeq", "TREATMENT", 116, 130], ["CA, USA", "TREATMENT", 159, 166], ["Ion Torrent machines", "TREATMENT", 172, 192], ["benchtop sequencing technologies", "TEST", 216, 248]]], ["Third-generation sequencers, i.e., SMRT technology (Pacific Biosciences, Menlo Park, CA, USA) and nanopore sequencing (Oxford Nanopore Technologies (ONT), Oxford, UK), have recently emerged as complement to or replacement of second-generation sequencers, by enabling the sequencing of single, long DNA molecules, a feature that is particularly attractive in the context of sequencing full-length viral genomes [7] .IntroductionNanopore sequencing technology has been successfully applied to genome sequencing of RNA viruses.", [["DNA", "CELLULAR_COMPONENT", 298, 301], ["SMRT", "PROTEIN", 35, 39], ["nanopore sequencing", "TEST", 98, 117], ["replacement of second-generation sequencers", "TREATMENT", 210, 253], ["single, long DNA molecules", "PROBLEM", 285, 311], ["IntroductionNanopore sequencing technology", "TREATMENT", 415, 457], ["RNA viruses", "PROBLEM", 512, 523], ["RNA viruses", "OBSERVATION", 512, 523]]], ["Based on viruses propagated on cell lines, viral transcriptomes have been examined by nanopore sequencing, for instance for porcine circovirus [8] , herpes simplex virus [9] , hepatitis C virus [10] , cultured influenza virus A, and human cytomegalovirus (HCMV) [11] .", [["cell lines", "ANATOMY", 31, 41], ["herpes simplex virus", "DISEASE", 149, 169], ["hepatitis C", "DISEASE", 176, 187], ["influenza virus A", "DISEASE", 210, 227], ["human cytomegalovirus", "DISEASE", 233, 254], ["cell lines", "CELL", 31, 41], ["porcine circovirus [8] ,", "ORGANISM", 124, 148], ["herpes simplex virus [9] ,", "ORGANISM", 149, 175], ["hepatitis C virus", "ORGANISM", 176, 193], ["cultured influenza virus A", "ORGANISM", 201, 227], ["human", "ORGANISM", 233, 238], ["cytomegalovirus", "ORGANISM", 239, 254], ["HCMV", "ORGANISM", 256, 260], ["cell lines", "CELL_LINE", 31, 41], ["porcine circovirus", "SPECIES", 124, 142], ["herpes simplex virus", "SPECIES", 149, 169], ["hepatitis C virus", "SPECIES", 176, 193], ["influenza virus", "SPECIES", 210, 225], ["human", "SPECIES", 233, 238], ["cytomegalovirus", "SPECIES", 239, 254], ["porcine circovirus", "SPECIES", 124, 142], ["herpes simplex virus", "SPECIES", 149, 169], ["hepatitis C virus", "SPECIES", 176, 193], ["influenza virus A", "SPECIES", 210, 227], ["human cytomegalovirus", "SPECIES", 233, 254], ["HCMV", "SPECIES", 256, 260], ["viruses", "PROBLEM", 9, 16], ["cell lines", "TREATMENT", 31, 41], ["viral transcriptomes", "TREATMENT", 43, 63], ["porcine circovirus", "PROBLEM", 124, 142], ["herpes simplex virus", "PROBLEM", 149, 169], ["hepatitis C virus", "PROBLEM", 176, 193], ["cultured influenza virus A", "PROBLEM", 201, 227], ["human cytomegalovirus", "PROBLEM", 233, 254], ["viruses", "OBSERVATION", 9, 16], ["cell lines", "OBSERVATION", 31, 41]]], ["Additionally, nanopore sequencing has been used successfully to sequence whole EV genomes from viral cDNA extracted from cell cultures: in their proof-of-concept study [12] , the authors demonstrated that nanopore sequencing could be applied for rapid routine whole-genome sequencing of EV with sufficient accuracy compared to Sanger sequencing.", [["cell cultures", "ANATOMY", 121, 134], ["cell cultures", "CELL", 121, 134], ["EV genomes", "DNA", 79, 89], ["viral cDNA", "DNA", 95, 105], ["cell cultures", "CELL_LINE", 121, 134], ["nanopore sequencing", "TREATMENT", 14, 33], ["viral cDNA", "TEST", 95, 105], ["cell cultures", "TEST", 121, 134], ["nanopore sequencing", "TREATMENT", 205, 224], ["Sanger sequencing", "TEST", 327, 344]]], ["Metagenomic nanopore sequencing of influenza virus was performed directly from randomly amplified viral cDNA obtained from clinical respiratory samples [13] .", [["respiratory samples", "ANATOMY", 132, 151], ["influenza virus", "ORGANISM", 35, 50], ["viral cDNA", "DNA", 98, 108], ["influenza virus", "SPECIES", 35, 50], ["influenza virus", "SPECIES", 35, 50], ["Metagenomic nanopore sequencing", "PROBLEM", 0, 31], ["influenza virus", "PROBLEM", 35, 50], ["viral cDNA", "TEST", 98, 108], ["clinical respiratory samples", "TEST", 123, 151], ["influenza virus", "OBSERVATION", 35, 50]]], ["Furthermore, ONT has presented a new, potentially revolutionary nanopore sequencing application, which allows sequencing of RNA molecules directly, i.e., without the pre-requirement of cDNA synthesis or PCR amplification [14] .", [["ONT", "CHEMICAL", 13, 16], ["RNA molecules", "PROTEIN", 124, 137], ["cDNA", "DNA", 185, 189], ["revolutionary nanopore sequencing application", "TREATMENT", 50, 95], ["RNA molecules", "PROBLEM", 124, 137], ["cDNA synthesis", "TREATMENT", 185, 199], ["PCR amplification", "TREATMENT", 203, 220]]], ["This method, direct RNA sequencing (DRS), yields full-length, strand-specific RNA sequences and enables the direct detection of nucleotide modifications in native RNA molecules.", [["nucleotide", "CHEMICAL", 128, 138], ["nucleotide", "CHEMICAL", 128, 138], ["RNA sequences", "DNA", 78, 91], ["native RNA molecules", "PROTEIN", 156, 176], ["strand-specific RNA sequences", "TEST", 62, 91], ["the direct detection", "TEST", 104, 124], ["nucleotide modifications in native RNA molecules", "PROBLEM", 128, 176], ["RNA molecules", "OBSERVATION", 163, 176]]], ["DRS has been used in several studies, including human poly(A) transcriptome [15] and DNA virus transcriptome, such as HSV herpes simplex virus type 1 (HSV-1) during productive infection of primary cell [16] .", [["primary cell", "ANATOMY", 189, 201], ["DRS", "DISEASE", 0, 3], ["HSV herpes simplex virus", "DISEASE", 118, 142], ["infection", "DISEASE", 176, 185], ["human", "ORGANISM", 48, 53], ["poly(A) transcriptome [15]", "GENE_OR_GENE_PRODUCT", 54, 80], ["DNA", "CELLULAR_COMPONENT", 85, 88], ["HSV herpes simplex virus type 1", "ORGANISM", 118, 149], ["HSV-1", "ORGANISM", 151, 156], ["cell", "CELL", 197, 201], ["human", "SPECIES", 48, 53], ["HSV herpes simplex virus type 1", "SPECIES", 118, 149], ["HSV-1", "SPECIES", 151, 156], ["human", "SPECIES", 48, 53], ["HSV herpes simplex virus type 1", "SPECIES", 118, 149], ["HSV-1", "SPECIES", 151, 156], ["human poly(A) transcriptome", "TREATMENT", 48, 75], ["DNA virus transcriptome", "TREATMENT", 85, 108], ["HSV herpes simplex virus type", "PROBLEM", 118, 147], ["productive", "OBSERVATION_MODIFIER", 165, 175], ["infection", "OBSERVATION", 176, 185]]], ["DRS was also used for sequencing RNA genomes of, e.g., Pseudorabies virus propagated on immortalized porcine kidney epithelial cell line [17] , influenza A virus (H1N1) from infected chicken eggs [18] , human Coronaviruses viral RNAs produced in cell cultures [19] , and many other examples of complete sequencing of multiple, single-stranded RNA (ssRNA) viruses obtained with or without poly(A)-tailing of RNA viruses obtained from cell cultures [20] .IntroductionHere, in a proof-of-concept study, we apply nanopore DRS to EV-positive stool samples and show that whole RNA genomes of enteroviruses can be retrieved with enough genomic information for the characterization of the infectious agents.", [["kidney epithelial cell line", "ANATOMY", 109, 136], ["eggs", "ANATOMY", 191, 195], ["cell cultures", "ANATOMY", 246, 259], ["cell cultures", "ANATOMY", 433, 446], ["stool samples", "ANATOMY", 537, 550], ["influenza A", "DISEASE", 144, 155], ["poly(A", "CHEMICAL", 388, 394], ["Pseudorabies virus", "ORGANISM", 55, 73], ["porcine", "ORGANISM", 101, 108], ["kidney epithelial cell line [17] ,", "ORGANISM", 109, 143], ["influenza A virus", "ORGANISM", 144, 161], ["H1N1", "ORGANISM", 163, 167], ["chicken", "ORGANISM", 183, 190], ["human", "ORGANISM", 203, 208], ["cell cultures", "CELL", 246, 259], ["cell cultures", "CELL", 433, 446], ["stool", "ORGANISM", 537, 542], ["enteroviruses", "ORGANISM", 586, 599], ["RNA genomes", "DNA", 33, 44], ["immortalized porcine kidney epithelial cell line", "CELL_LINE", 88, 136], ["human Coronaviruses viral RNAs", "RNA", 203, 233], ["porcine", "SPECIES", 101, 108], ["influenza A virus", "SPECIES", 144, 161], ["chicken", "SPECIES", 183, 190], ["human", "SPECIES", 203, 208], ["Pseudorabies virus", "SPECIES", 55, 73], ["influenza A virus", "SPECIES", 144, 161], ["chicken", "SPECIES", 183, 190], ["human", "SPECIES", 203, 208], ["sequencing RNA genomes", "PROBLEM", 22, 44], ["Pseudorabies virus", "PROBLEM", 55, 73], ["immortalized porcine kidney epithelial cell line", "TREATMENT", 88, 136], ["influenza A virus (H1N1", "PROBLEM", 144, 167], ["infected chicken eggs", "TREATMENT", 174, 195], ["human Coronaviruses viral RNAs", "PROBLEM", 203, 233], ["cell cultures", "TEST", 246, 259], ["complete sequencing", "TEST", 294, 313], ["multiple, single-stranded RNA (ssRNA) viruses", "PROBLEM", 317, 362], ["RNA viruses", "PROBLEM", 407, 418], ["cell cultures", "TEST", 433, 446], ["concept study", "TEST", 485, 498], ["stool samples", "TEST", 537, 550], ["whole RNA genomes of enteroviruses", "PROBLEM", 565, 599], ["the infectious agents", "TREATMENT", 677, 698], ["kidney", "ANATOMY", 109, 115], ["epithelial cell line", "OBSERVATION", 116, 136], ["multiple", "OBSERVATION_MODIFIER", 317, 325], ["enteroviruses", "OBSERVATION", 586, 599], ["infectious", "OBSERVATION", 681, 691]]], ["We further analyze the metatranscriptomic data provided by the DRS approach and compare it with that obtained by Illumina MiSeq sequencing of the same samples.Sample DescriptionIn this study, we used three independent patient stool samples (E590, E372, E026), which were sent for enterovirus diagnostics to the clinical diagnostic laboratory of the Institute for Infection Diseases, Bern, Switzerland.", [["samples", "ANATOMY", 151, 158], ["samples", "ANATOMY", 232, 239], ["Infection Diseases", "DISEASE", 363, 381], ["patient", "ORGANISM", 218, 225], ["enterovirus", "ORGANISM", 280, 291], ["patient", "SPECIES", 218, 225], ["enterovirus", "SPECIES", 280, 291], ["this study", "TEST", 180, 190], ["enterovirus diagnostics", "TEST", 280, 303], ["Infection Diseases", "PROBLEM", 363, 381], ["Infection", "OBSERVATION", 363, 372]]], ["The samples were collected in 2017 (E590, E372) and 2018 (E026) and had a cycle threshold (Ct) value of 23.0 (E590), 18.8 (E372) and 22.5 (E026) via real-time PCR using enterovirus-specific primers (see description below).", [["samples", "ANATOMY", 4, 11], ["enterovirus", "ORGANISM", 169, 180], ["enterovirus-specific primers", "DNA", 169, 197], ["The samples", "TEST", 0, 11], ["a cycle threshold", "TEST", 72, 89], ["Ct) value", "TEST", 91, 100], ["real-time PCR", "TEST", 149, 162], ["enterovirus", "PROBLEM", 169, 180]]], ["Ethics approval was granted on 8 March 2018 by the Swiss Ethics committee on research involving humans to conduct sequencing of enteroviruses in clinical samples stored in the IFIK biobank (BASEC-Nr: Req-2018-00158).Routine Diagnostic ApproachAfter homogenization with a sterile pipette, approximately 0.5 g of stool sample was added to 4 mL of transport medium [21] containing 5-10 glass beads (diameter 2 mm; Merck AG, Zug, Switzerland).", [["samples", "ANATOMY", 154, 161], ["stool sample", "ANATOMY", 311, 323], ["enteroviruses", "DISEASE", 128, 141], ["humans", "ORGANISM", 96, 102], ["enteroviruses", "ORGANISM", 128, 141], ["humans", "SPECIES", 96, 102], ["humans", "SPECIES", 96, 102], ["enteroviruses", "PROBLEM", 128, 141], ["clinical samples", "TEST", 145, 161], ["Routine Diagnostic ApproachAfter homogenization", "TREATMENT", 216, 263], ["a sterile pipette", "TREATMENT", 269, 286], ["stool sample", "TREATMENT", 311, 323], ["transport medium", "TREATMENT", 345, 361], ["5-10 glass beads (diameter", "TREATMENT", 378, 404], ["Merck AG", "TREATMENT", 411, 419], ["enteroviruses", "OBSERVATION", 128, 141]]], ["After 30 s of vortexing, the suspension was centrifuged for 5 min at 3350 g and the resulting supernatant was filtered through a pore size of 0.2 \u00b5m with 20% penicillin/streptomycin (Biochrom, Berlin, Germany).", [["supernatant", "ANATOMY", 94, 105], ["pore", "ANATOMY", 129, 133], ["penicillin", "CHEMICAL", 158, 168], ["streptomycin", "CHEMICAL", 169, 181], ["penicillin", "CHEMICAL", 158, 168], ["streptomycin", "CHEMICAL", 169, 181], ["penicillin", "SIMPLE_CHEMICAL", 158, 168], ["streptomycin", "SIMPLE_CHEMICAL", 169, 181], ["vortexing", "TREATMENT", 14, 23], ["the suspension", "TREATMENT", 25, 39], ["a pore size", "TREATMENT", 127, 138], ["20% penicillin", "TREATMENT", 154, 168], ["streptomycin", "TREATMENT", 169, 181], ["size", "OBSERVATION_MODIFIER", 134, 138]]], ["This preparation was further extracted on the EasyMAG platform (bioM\u00e9rieux, Geneva, Switzerland) for real-time PCR and with TRIzol LS Reagent (Thermo Fisher Scientific, Reinach, Switzerland) for Illumina MiSeq sequencing ( Figure 1 ).Routine Diagnostic ApproachAfter homogenization with a sterile pipette, approximately 0.5 g of stool sample was added to 4 mL of transport medium [21] containing 5-10 glass beads (diameter 2 mm; Merck AG, Zug, Switzerland).", [["stool sample", "ANATOMY", 329, 341], ["TRIzol LS Reagent", "TREATMENT", 124, 141], ["Illumina MiSeq sequencing", "TREATMENT", 195, 220], ["Routine Diagnostic ApproachAfter homogenization", "TREATMENT", 234, 281], ["a sterile pipette", "TREATMENT", 287, 304], ["stool sample", "TREATMENT", 329, 341], ["transport medium", "TREATMENT", 363, 379], ["5-10 glass beads (diameter", "TREATMENT", 396, 422], ["Merck AG", "TREATMENT", 429, 437]]], ["After 30 s of vortexing, the suspension was centrifuged for 5 min at 3350 g and the resulting supernatant was filtered through a pore size of 0.2 \u00b5m with 20% penicillin/streptomycin (Biochrom, Berlin, Germany).", [["supernatant", "ANATOMY", 94, 105], ["pore", "ANATOMY", 129, 133], ["penicillin", "CHEMICAL", 158, 168], ["streptomycin", "CHEMICAL", 169, 181], ["penicillin", "CHEMICAL", 158, 168], ["streptomycin", "CHEMICAL", 169, 181], ["penicillin", "SIMPLE_CHEMICAL", 158, 168], ["streptomycin", "SIMPLE_CHEMICAL", 169, 181], ["vortexing", "TREATMENT", 14, 23], ["the suspension", "TREATMENT", 25, 39], ["a pore size", "TREATMENT", 127, 138], ["20% penicillin", "TREATMENT", 154, 168], ["streptomycin", "TREATMENT", 169, 181], ["size", "OBSERVATION_MODIFIER", 134, 138]]], ["This preparation was further extracted on the EasyMAG platform (bioM\u00e9rieux, Geneva, Switzerland) for real-time PCR and with TRIzol LS Reagent (Thermo Fisher Scientific, Reinach, Switzerland) for Illumina MiSeq sequencing ( Figure 1 ).", [["TRIzol LS Reagent", "TREATMENT", 124, 141], ["Illumina MiSeq sequencing", "TREATMENT", 195, 220]]], ["The workflow used for diagnostic assays is indicated by greyed boxes and that followed for NGS techniques by white boxes.RNA Extraction and PurificationA total of 750 \u00b5L of TRIzol LS Reagent (Thermo Fisher Scientific) was added per 250 \u00b5L of stool suspension in PBS.", [["stool", "ORGANISM_SUBSTANCE", 242, 247], ["greyed boxes", "DNA", 56, 68], ["diagnostic assays", "TEST", 22, 39], ["NGS techniques", "TEST", 91, 105], ["RNA Extraction", "TREATMENT", 121, 135], ["PurificationA", "TEST", 140, 153], ["TRIzol LS Reagent", "TREATMENT", 173, 190], ["stool suspension in PBS", "TREATMENT", 242, 265]]], ["Following homogenization by pipetting, the sample was transferred to Phasemaker tubes (Thermo Fisher Scientific).", [["sample", "ANATOMY", 43, 49]]], ["After incubation for 5 min, 200 \u00b5L of chloroform was added, and the tubes were shaken vigorously by hand for 15 s.", [["tubes", "ANATOMY", 68, 73], ["hand", "ANATOMY", 100, 104], ["chloroform", "CHEMICAL", 38, 48], ["chloroform", "CHEMICAL", 38, 48], ["chloroform", "SIMPLE_CHEMICAL", 38, 48], ["tubes", "ORGANISM_SUBSTANCE", 68, 73], ["hand", "ORGANISM_SUBDIVISION", 100, 104], ["chloroform", "TREATMENT", 38, 48], ["the tubes", "TREATMENT", 64, 73], ["tubes", "OBSERVATION", 68, 73]]], ["After 15 min incubation, the sample was centrifuged for 5 min at 16,000 g, at 4 \u00b0C. The aqueous phase was transferred to a new tube and 10 \u00b5g of carrier RNase-free glycogen (Thermo Fisher Scientific) was added, followed by 500 \u00b5L isopropanol.", [["sample", "ANATOMY", 29, 35], ["glycogen", "CHEMICAL", 164, 172], ["isopropanol", "CHEMICAL", 230, 241], ["isopropanol", "CHEMICAL", 230, 241], ["tube", "TISSUE", 127, 131], ["RNase", "GENE_OR_GENE_PRODUCT", 153, 158], ["glycogen", "SIMPLE_CHEMICAL", 164, 172], ["RNase", "PROTEIN", 153, 158], ["a new tube", "TREATMENT", 121, 131], ["carrier RNase-free glycogen (Thermo Fisher Scientific)", "TREATMENT", 145, 199], ["isopropanol", "TREATMENT", 230, 241]]], ["After incubation for 10 min, the sample was centrifuged for 10 min at 12,000 g, at 4 \u00b0C, and the supernatant was discarded.", [["sample", "ANATOMY", 33, 39], ["supernatant", "ANATOMY", 97, 108], ["the supernatant", "TREATMENT", 93, 108]]], ["The total RNA precipitate was resuspended in 1 mL of 75% ethanol.", [["ethanol", "CHEMICAL", 57, 64], ["ethanol", "CHEMICAL", 57, 64], ["ethanol", "SIMPLE_CHEMICAL", 57, 64], ["The total RNA precipitate", "TREATMENT", 0, 25]]], ["The sample was vortexed briefly, and then centrifuged for 5 min at 7500 \u00d7 g, at 4 \u00b0C. The supernatant was discarded and the RNA pellet was air-dried for 10 min, before being resuspended in 20 \u00b5L of RNA storage solution (Thermo Fisher Scientific).", [["sample", "ANATOMY", 4, 10], ["supernatant", "ANATOMY", 90, 101], ["The supernatant", "TREATMENT", 86, 101], ["the RNA pellet", "TREATMENT", 120, 134], ["RNA storage solution", "TREATMENT", 198, 218], ["RNA pellet", "OBSERVATION", 124, 134]]], ["After incubation at 60 \u00b0C for 10 min, the RNA sample was either used directly in downstream applications, or stored at \u221280 \u00b0C. Alternatively, total nucleic acid extraction was performed with NUCLISENS easyMAG from 200 \u00b5L of the routine diagnostic stool preparation, to which 2.5 \u00b5L carrier RNA (Qiagen AG, Hombrechtikon, Switzerland) was added and eluted in 110 \u00b5L.", [["nucleic acid", "CHEMICAL", 148, 160], ["the RNA sample", "TREATMENT", 38, 52], ["total nucleic acid extraction", "TREATMENT", 142, 171], ["NUCLISENS easyMAG", "TREATMENT", 191, 208], ["the routine diagnostic stool preparation", "TREATMENT", 224, 264], ["2.5 \u00b5L carrier RNA", "TREATMENT", 275, 293], ["Qiagen AG, Hombrechtikon, Switzerland)", "TREATMENT", 295, 333]]], ["This extract was used for real-time PCR and Sanger genotyping.Pre-Treatment (Chloroform/Beads/Centrifugation)We used the WHO-recommended protocol for pre-treating stool samples for enterovirus RNA isolation (Enterovirus surveillance guidelines, [22] ) adapted from Nix et al. 2006 [23] as follows: a low amount (0.5 to 1 g) of stool sample was added to PBS (Thermo Fisher Scientific) up to 1 mL volume, to which 0.3 g of glass beads (2 mm diameter, Merck) and 0.5 mL of chloroform (AppliChem, Aesch, Switzerland) were added.", [["extract", "ANATOMY", 5, 12], ["stool samples", "ANATOMY", 163, 176], ["stool sample", "ANATOMY", 327, 339], ["chloroform", "CHEMICAL", 470, 480], ["Chloroform", "CHEMICAL", 77, 87], ["chloroform", "CHEMICAL", 470, 480], ["Chloroform", "SIMPLE_CHEMICAL", 77, 87], ["enterovirus", "ORGANISM", 181, 192], ["stool", "ORGANISM", 327, 332], ["chloroform", "SIMPLE_CHEMICAL", 470, 480], ["enterovirus", "SPECIES", 181, 192], ["This extract", "TREATMENT", 0, 12], ["Sanger genotyping", "TEST", 44, 61], ["Pre-Treatment (Chloroform/Beads/Centrifugation", "TREATMENT", 62, 108], ["stool samples", "TEST", 163, 176], ["enterovirus RNA isolation", "PROBLEM", 181, 206], ["stool sample", "TEST", 327, 339], ["glass beads (2 mm diameter, Merck)", "TREATMENT", 421, 455], ["chloroform", "TREATMENT", 470, 480], ["AppliChem", "TREATMENT", 482, 491], ["Aesch", "TREATMENT", 493, 498]]], ["The mixture was shaken vigorously using a TissueLyser (Qiagen AG) for 20 min at maximum speed.", [["a TissueLyser (Qiagen AG)", "TREATMENT", 40, 65]]], ["The suspension was centrifuged at 1500 \u00d7 g for 20 min at 4 \u00b0C, and approximately 1 mL of the supernatant was transferred to a new 1.5 mL tube and continued with RNA extraction.", [["supernatant", "ANATOMY", 93, 104], ["tube", "TISSUE", 137, 141], ["The suspension", "TREATMENT", 0, 14], ["a new 1.5 mL tube", "TREATMENT", 124, 141], ["RNA extraction", "TREATMENT", 161, 175], ["suspension", "OBSERVATION_MODIFIER", 4, 14], ["tube", "OBSERVATION", 137, 141]]], ["For DRS of sample E590, RNA was extracted using easyMAG, while for E372 and E026, the TRIzol LS method was used (see supplementary material Table S1 ).RNA Extraction and PurificationA total of 750 \u00b5L of TRIzol LS Reagent (Thermo Fisher Scientific) was added per 250 \u00b5L of stool suspension in PBS.", [["stool", "ORGANISM_SUBSTANCE", 272, 277], ["easyMAG", "TREATMENT", 48, 55], ["the TRIzol LS method", "TREATMENT", 82, 102], ["RNA Extraction", "TREATMENT", 151, 165], ["PurificationA", "TEST", 170, 183], ["TRIzol LS Reagent", "TREATMENT", 203, 220], ["stool suspension in PBS", "TREATMENT", 272, 295]]], ["Following homogenization by pipetting, the sample was transferred to Phasemaker tubes (Thermo Fisher Scientific).", [["sample", "ANATOMY", 43, 49]]], ["After incubation for 5 min, 200 \u00b5L of chloroform was added, and the tubes were shaken vigorously by hand for 15 s.", [["tubes", "ANATOMY", 68, 73], ["hand", "ANATOMY", 100, 104], ["chloroform", "CHEMICAL", 38, 48], ["chloroform", "CHEMICAL", 38, 48], ["chloroform", "SIMPLE_CHEMICAL", 38, 48], ["tubes", "ORGANISM_SUBSTANCE", 68, 73], ["hand", "ORGANISM_SUBDIVISION", 100, 104], ["chloroform", "TREATMENT", 38, 48], ["the tubes", "TREATMENT", 64, 73], ["tubes", "OBSERVATION", 68, 73]]], ["After 15 min incubation, the sample was centrifuged for 5 min at 16,000\u00d7 g, at 4 \u2022 C. The aqueous phase was transferred to a new tube and 10 \u00b5g of carrier RNase-free glycogen (Thermo Fisher Scientific) was added, followed by 500 \u00b5L isopropanol.", [["sample", "ANATOMY", 29, 35], ["glycogen", "CHEMICAL", 166, 174], ["isopropanol", "CHEMICAL", 232, 243], ["isopropanol", "CHEMICAL", 232, 243], ["tube", "TISSUE", 129, 133], ["RNase", "GENE_OR_GENE_PRODUCT", 155, 160], ["glycogen", "SIMPLE_CHEMICAL", 166, 174], ["RNase", "PROTEIN", 155, 160], ["a new tube", "TREATMENT", 123, 133], ["carrier RNase-free glycogen (Thermo Fisher Scientific)", "TREATMENT", 147, 201], ["isopropanol", "TREATMENT", 232, 243]]], ["After incubation for 10 min, the sample was centrifuged for 10 min at 12,000\u00d7 g, at 4 \u2022 C, and the supernatant was discarded.", [["sample", "ANATOMY", 33, 39], ["supernatant", "ANATOMY", 99, 110], ["the supernatant", "TREATMENT", 95, 110]]], ["The total RNA precipitate was resuspended in 1 mL of 75% ethanol.", [["ethanol", "CHEMICAL", 57, 64], ["ethanol", "CHEMICAL", 57, 64], ["ethanol", "SIMPLE_CHEMICAL", 57, 64], ["The total RNA precipitate", "TREATMENT", 0, 25]]], ["The sample was vortexed briefly, and then centrifuged for 5 min at 7500\u00d7 g, at 4 \u2022 C. The supernatant was discarded and the RNA pellet was air-dried for 10 min, before being resuspended in 20 \u00b5L of RNA storage solution (Thermo Fisher Scientific).", [["sample", "ANATOMY", 4, 10], ["supernatant", "ANATOMY", 90, 101], ["The supernatant", "TREATMENT", 86, 101], ["the RNA pellet", "TREATMENT", 120, 134], ["RNA storage solution", "TREATMENT", 198, 218]]], ["After incubation at 60 \u2022 C for 10 min, the RNA sample was either used directly in downstream applications, or stored at \u221280 \u2022 C. Alternatively, total nucleic acid extraction was performed with NUCLISENS easyMAG from 200 \u00b5L of the routine diagnostic stool preparation, to which 2.5 \u00b5L carrier RNA (Qiagen AG, Hombrechtikon, Switzerland) was added and eluted in 110 \u00b5L.", [["sample", "ANATOMY", 47, 53], ["nucleic acid", "CHEMICAL", 150, 162], ["the RNA sample", "TEST", 39, 53], ["total nucleic acid extraction", "TREATMENT", 144, 173], ["NUCLISENS easyMAG", "TREATMENT", 193, 210], ["the routine diagnostic stool preparation", "TREATMENT", 226, 266], ["2.5 \u00b5L carrier RNA", "TREATMENT", 277, 295], ["Qiagen AG, Hombrechtikon, Switzerland)", "TREATMENT", 297, 335]]], ["This extract was used for real-time PCR and Sanger genotyping.Pre-Treatment (Chloroform/Beads/Centrifugation)We used the WHO-recommended protocol for pre-treating stool samples for enterovirus RNA isolation (Enterovirus surveillance guidelines, [22] ) adapted from Nix et al. 2006 [23] as follows: a low amount (0.5 to 1 g) of stool sample was added to PBS (Thermo Fisher Scientific) up to 1 mL volume, to which 0.3 g of glass beads (2 mm diameter, Merck) and 0.5 mL of chloroform (AppliChem, Aesch, Switzerland) were added.", [["extract", "ANATOMY", 5, 12], ["stool samples", "ANATOMY", 163, 176], ["stool sample", "ANATOMY", 327, 339], ["chloroform", "CHEMICAL", 470, 480], ["Chloroform", "CHEMICAL", 77, 87], ["chloroform", "CHEMICAL", 470, 480], ["Chloroform", "SIMPLE_CHEMICAL", 77, 87], ["enterovirus", "ORGANISM", 181, 192], ["stool", "ORGANISM", 327, 332], ["chloroform", "SIMPLE_CHEMICAL", 470, 480], ["enterovirus", "SPECIES", 181, 192], ["This extract", "TREATMENT", 0, 12], ["Sanger genotyping", "TEST", 44, 61], ["Pre-Treatment (Chloroform/Beads/Centrifugation", "TREATMENT", 62, 108], ["stool samples", "TEST", 163, 176], ["enterovirus RNA isolation", "PROBLEM", 181, 206], ["stool sample", "TEST", 327, 339], ["glass beads (2 mm diameter, Merck)", "TREATMENT", 421, 455], ["chloroform", "TREATMENT", 470, 480], ["AppliChem", "TREATMENT", 482, 491], ["Aesch", "TREATMENT", 493, 498]]], ["The mixture was shaken vigorously using a TissueLyser (Qiagen AG) for 20 min at maximum speed.", [["a TissueLyser (Qiagen AG)", "TREATMENT", 40, 65]]], ["The suspension was centrifuged at 1500\u00d7 g for 20 min at 4 \u2022 C, and approximately 1 mL of the supernatant was transferred to a new 1.5 mL tube and continued with RNA extraction.", [["supernatant", "ANATOMY", 93, 104], ["tube", "TISSUE", 137, 141], ["The suspension", "TREATMENT", 0, 14], ["a new 1.5 mL tube", "TREATMENT", 124, 141], ["RNA extraction", "TREATMENT", 161, 175], ["suspension", "OBSERVATION_MODIFIER", 4, 14], ["tube", "OBSERVATION", 137, 141]]], ["For DRS of sample E590, RNA was extracted using easyMAG, while for E372 and E026, the TRIzol LS method was used (see supplementary material Table S1 ).Real-Time RT PCROne-step RT-PCR was performed with the AgPath-ID one-step kit (Ambion, Reinach, Switzerland) using published primers and probes [24] , following the protocol described previously [25] .", [["easyMAG", "TREATMENT", 48, 55], ["the TRIzol LS method", "TREATMENT", 82, 102], ["PCR", "TEST", 179, 182], ["the protocol", "TREATMENT", 312, 324]]], ["Primers and probes were synthesized at Microsynth AG, Balgach, Switzerland.Enterovirus GenotypingGenotyping of the samples was performed by VP1 amplicon Sanger sequencing as described previously [23, 25] and carried out at Microsynth.Nanopore SequencingFor nanopore sequencing, we followed the manufacturer's instructions of the protocol for kit SQK-RNA001 (version DRS_9026_v1_revN_15Dec2016), but substituted Superscript III with Superscript IV (Thermo Fisher Scientific).", [["samples", "ANATOMY", 115, 122], ["Enterovirus", "ORGANISM", 75, 86], ["samples", "CANCER", 115, 122], ["Microsynth", "DNA", 223, 233], ["Superscript IV", "PROTEIN", 432, 446], ["Enterovirus", "PROBLEM", 75, 86], ["the samples", "TEST", 111, 122]]], ["The input RNA and amounts loaded on flow cells for each experiment are specified in Table S1 .", [["cells", "ANATOMY", 41, 46], ["cells", "CELL", 41, 46], ["flow cells", "CELL_TYPE", 36, 46], ["flow cells", "TREATMENT", 36, 46], ["flow cells", "OBSERVATION", 36, 46], ["S1", "ANATOMY", 90, 92]]], ["Quantification was performed using a Qubit RNA HS assay kit (RNA) or DNA HS assay (cDNA) kit on a Qubit fluorometer 3.0 (Thermo Fisher Scientific).", [["DNA", "CELLULAR_COMPONENT", 69, 72], ["Quantification", "TEST", 0, 14], ["DNA HS assay", "TEST", 69, 81], ["a Qubit fluorometer", "TREATMENT", 96, 115]]], ["The reverse-transcribed and adapted RNA was loaded onto R9.4.1 flowcells and sequenced on MinION sequencer.", [["R9", "DNA", 56, 58], ["adapted RNA", "TREATMENT", 28, 39], ["MinION sequencer", "TEST", 90, 106]]], ["Each DRS run was conducted with a new, previously unused flowcell.Illumina MiSeq.", [["flowcell", "ANATOMY", 57, 65], ["flowcell", "CANCER", 57, 65], ["Illumina MiSeq", "TREATMENT", 66, 80]]], ["Primer Design for Coxsackievirus A6 cDNA SynthesisThe following three specific primers for Coxsackievirus A6 were designed for this project to hybridize to Coxsackievirus A6 sequence KJ541158:Illumina MiSeq.", [["Coxsackievirus A6", "ORGANISM", 91, 108], ["Coxsackievirus A6 sequence", "DNA", 156, 182], ["Coxsackievirus A6", "SPECIES", 18, 35], ["Coxsackievirus A6", "SPECIES", 91, 108], ["Coxsackievirus A6 sequence KJ541158", "SPECIES", 156, 191], ["Coxsackievirus", "PROBLEM", 18, 32], ["Coxsackievirus A6", "PROBLEM", 91, 108]]], ["Primer Design for Coxsackievirus A6 cDNA Synthesis2588R_A6: 5 -CCCGTTTCTGCCGCTT-3 adapted from primer 292 by Oberste et al. [26] ; 5672R_A6: 5 -ATATCTCTGAATTTCTCATT-3 adapted from primer HEV.3C.d1 by Bessaud et al. [27] ; EV-3UTR1_A6_rc: 5 -CATATTCACGACCAGATTCCTGGTG-3 (this study).", [["Coxsackievirus A6", "ORGANISM", 18, 35], ["primer 292", "DNA", 95, 105], ["primer HEV.3C.d1", "DNA", 180, 196], ["Coxsackievirus A6", "SPECIES", 18, 35], ["Coxsackievirus A6 cDNA Synthesis", "TEST", 18, 50], ["-CCCGTTTCTGCCGCTT", "TEST", 62, 79], ["ATATCTCTGAATTTCTCATT", "TEST", 144, 164], ["this study", "TEST", 270, 280]]], ["All primers were synthesized at Microsynth.cDNA Synthesis for Illumina MiSeqFirst-strand synthesis was performed with the SuperScript IV First-Strand Synthesis System as follows: for reverse transcription, a reaction mixture was prepared containing 0.5 \u00b5L of the specific primers EV-3UTR1_A6_rc, 2588R_A6, 5672R_A6 (10 \u00b5M), or 1 \u00b5L of random hexamers (50 \u00b5M) or 1 \u00b5L of oligo(dT) 20 (50 \u00b5M) together with 1 \u00b5L of 10 mM dNTP mix and filled with RNA extract and DEPC-treated water to a total volume of 13 \u00b5L.", [["oligo(dT) 20", "CHEMICAL", 370, 382], ["dNTP", "CHEMICAL", 419, 423], ["DEPC", "CHEMICAL", 460, 464], ["dNTP", "CHEMICAL", 419, 423], ["DEPC", "CHEMICAL", 460, 464], ["oligo(dT) 20", "SIMPLE_CHEMICAL", 370, 382], ["DEPC", "SIMPLE_CHEMICAL", 460, 464], ["All primers", "TREATMENT", 0, 11], ["Microsynth.cDNA Synthesis", "TREATMENT", 32, 57], ["Illumina MiSeqFirst", "TREATMENT", 62, 81], ["strand synthesis", "TREATMENT", 82, 98], ["the SuperScript IV First-Strand Synthesis System", "TREATMENT", 118, 166], ["reverse transcription", "TREATMENT", 183, 204], ["a reaction mixture", "TREATMENT", 206, 224], ["random hexamers", "TREATMENT", 335, 350], ["oligo(dT)", "TREATMENT", 370, 379], ["10 mM dNTP mix", "TREATMENT", 413, 427], ["RNA extract", "TREATMENT", 444, 455], ["DEPC", "TREATMENT", 460, 464], ["a total volume", "TEST", 482, 496]]], ["After heating at 65 \u2022 C for 5 min and snap cooling, a mixture of 4 \u00b5L SSIV Buffer, 1 \u00b5L 100 mM DTT, 1 \u00b5L ribonuclease inhibitor and 1 \u00b5L SuperScript IV reverse transcriptase (200 U/\u00b5L) were added.", [["DTT", "CHEMICAL", 95, 98], ["DTT", "CHEMICAL", 95, 98], ["DTT", "SIMPLE_CHEMICAL", 95, 98], ["ribonuclease", "GENE_OR_GENE_PRODUCT", 105, 117], ["reverse transcriptase", "PROTEIN", 152, 173], ["snap cooling", "TREATMENT", 38, 50], ["a mixture of 4 \u00b5L SSIV Buffer", "TREATMENT", 52, 81], ["1 \u00b5L ribonuclease inhibitor", "TREATMENT", 100, 127], ["1 \u00b5L SuperScript IV reverse transcriptase", "TREATMENT", 132, 173], ["U/\u00b5L)", "TREATMENT", 179, 184]]], ["The samples were incubated for 10 min at 50 \u2022 C and 10 min at 80 \u2022 C (preceded by 10 min at 23 \u2022 C when containing random hexamer primers).", [["samples", "ANATOMY", 4, 11], ["random hexamer primers", "TREATMENT", 115, 137]]], ["Subsequently, 1 \u00b5L of E. coli RNase H (2 U/\u00b5L) was added and incubated at 37 \u2022 C for 20 min.", [["E. coli", "ORGANISM", 22, 29], ["RNase H", "GENE_OR_GENE_PRODUCT", 30, 37], ["E. coli", "SPECIES", 22, 29], ["E. coli", "SPECIES", 22, 29], ["E. coli RNase H", "TREATMENT", 22, 37], ["U/\u00b5L)", "TREATMENT", 41, 46]]], ["To this mixture, 10 \u00b5L of second-strand synthesis reaction buffer NEBNext (New England Biolabs (NEB), Ipswich, MA, USA), 5 \u00b5L NEBNext Second-Strand Synthesis Enzyme Mix and 44 \u00b5L of nuclease-free water were added.", [["NEBNext", "CHEMICAL", 66, 73], ["nuclease", "PROTEIN", 182, 190], ["second-strand synthesis reaction", "TREATMENT", 26, 58], ["New England Biolabs (NEB", "TREATMENT", 75, 99], ["Strand Synthesis Enzyme Mix", "TREATMENT", 141, 168], ["nuclease-free water", "TREATMENT", 182, 201]]], ["The reaction mixture was incubated at 16 \u2022 C for 60 min.", [["The reaction mixture", "PROBLEM", 0, 20]]], ["Clean up with 144 \u00b5L of Agencourt AMPure XP magnetic beads (Beckman Coulter, Nyon, Switzerland) was performed according to the manufacturer's instructions, with an elution volume of 35 \u00b5L for samples E372 and E026 and 47 \u00b5L for sample E590.", [["samples", "ANATOMY", 192, 199], ["an elution volume", "TEST", 161, 178]]], ["For the first sample E590, an additional end-prep step was performed, but that step was later removed in the protocol as it was deemed unnecessary: to 45 \u00b5L of the elution, 7 \u00b5L of Ultra II End-Prep buffer (NEB), 3 \u00b5L of Ultra II End-Prep enzyme mix (NEB), and 5 \u00b5L of nuclease-free water were added and the mixture was incubated for 5 min at 20 \u2022 C and 5 min at 65 \u2022 C. After an additional purification step using 60 \u00b5L of Agencourt AMPure XP magnetic beads, the cDNA was eluted in 20 \u00b5L of nuclease-free water.Illumina MiSeq SequencingLibraries were prepared from unamplified cDNA using Nextera XT DNA Library Prep kit (E590) and Nextera DNA Flex Library Prep kit (E372, E026) (Illumina), and sequenced using an Illumina MiSeq benchtop sequencer generating 2 \u00d7 150 bp paired-end reads (v2), according to the manufacturer's protocols.", [["water", "SIMPLE_CHEMICAL", 283, 288], ["DNA", "CELLULAR_COMPONENT", 600, 603], ["DNA", "CELLULAR_COMPONENT", 640, 643], ["nuclease", "PROTEIN", 269, 277], ["cDNA", "DNA", 464, 468], ["nuclease", "PROTEIN", 492, 500], ["unamplified cDNA", "DNA", 566, 582], ["an additional end-prep step", "TREATMENT", 27, 54], ["Ultra II End-Prep buffer (NEB)", "TREATMENT", 181, 211], ["Ultra II End", "TREATMENT", 221, 233], ["Prep enzyme mix (NEB", "TREATMENT", 234, 254], ["nuclease-free water", "TREATMENT", 269, 288], ["an additional purification step", "TREATMENT", 377, 408], ["Agencourt AMPure XP magnetic beads", "TREATMENT", 424, 458], ["the cDNA", "TREATMENT", 460, 468], ["nuclease-free water", "TREATMENT", 492, 511], ["Illumina MiSeq SequencingLibraries", "TREATMENT", 512, 546], ["an Illumina MiSeq benchtop sequencer", "TREATMENT", 711, 747], ["the manufacturer's protocols", "TREATMENT", 806, 834]]], ["Sequencing was performed at the Next-Generation Sequencing Platform of the Inselspital, Bern, Switzerland.Bioinformatic AnalysisRaw FAST5 files produced by MinION sequencing were basecalled under the high accuracy mode using the ONT basecaller Guppy version 3.2.2 with the parameter: \"guppy_basecaller --input_path PATH --recursive --save_path PATH --qscore_filtering --min_qscore 7 --flowcell FLO-MIN106 --kit SQK-RNA001 --cpu_threads_per_caller 4 -num_callers 4\".", [["AnalysisRaw FAST5 files", "DNA", 120, 143], ["MIN106", "PROTEIN", 398, 404], ["Sequencing", "TEST", 0, 10], ["the ONT basecaller Guppy version", "TREATMENT", 225, 257], ["flowcell FLO", "TREATMENT", 385, 397]]], ["Statistics for nanopore sequencing output are summarized in Table S2 .", [["nanopore sequencing output", "TEST", 15, 41]]], ["We did not perform any adapter trimming due to the inaccuracy of the RNA basecaller when calling DNA adapter sequences, which results in unreliable identification [19] , but do not expect it to impair our downstream analysis, as basecalled nanopore reads were classified using BLASTN against the NCBI's nucleotide (nt) database (downloaded 03.10.2019), using BLAST version 2.6.0.", [["nucleotide", "CHEMICAL", 303, 313], ["nucleotide", "CHEMICAL", 303, 313], ["DNA", "CELLULAR_COMPONENT", 97, 100], ["DNA adapter sequences", "DNA", 97, 118], ["NCBI's nucleotide (nt) database", "DNA", 296, 327], ["any adapter trimming", "TREATMENT", 19, 39], ["our downstream analysis", "TEST", 201, 224], ["BLAST version", "TEST", 359, 372]]], ["BLAST results were classified using MEGAN (v. 6.12.3, [28] ), with the blast2rma parameters \"c false --m 10 --ms 50 --me 0.01 --mpi 0 --top 10 --supp 0.05 --sup 1 --alg naive --mrc 0 --mrefc 0 --ram readCount --a2t nucl_acc2tax-Jul2019.abin\".", [["MEGAN", "TEST", 36, 41], ["the blast2rma parameters", "TEST", 67, 91], ["false --m", "OBSERVATION", 95, 104]]], ["RNA sequences were mapped to the best-scoring reference genome (whole-genome reference with highest bit-score in BLASTN output) using minimap2 (version 2.5-r601-dirty, [29] ).", [["reference genome", "DNA", 46, 62], ["minimap2", "DNA", 134, 142], ["RNA sequences", "TEST", 0, 13], ["BLASTN output", "TEST", 113, 126], ["version", "TEST", 144, 151]]], ["For Illumina MiSeq data (Table S3) , adapter trimming was performed with bbduk.sh from the BBMap package (v 37.80, [30] ), and human and rRNA reads were removed by mapping reads against the corresponding databases (GRCh18 genome, cDNA and ncRNA, and SILVA 132 LSU SSU https://www.arb-silva.de/documentation/release-132/) using minimap2 [29] .", [["human", "ORGANISM", 127, 132], ["Illumina MiSeq data", "DNA", 4, 23], ["BBMap package", "DNA", 91, 104], ["human and rRNA reads", "RNA", 127, 147], ["GRCh18 genome", "DNA", 215, 228], ["cDNA", "DNA", 230, 234], ["ncRNA", "DNA", 239, 244], ["SILVA 132 LSU SSU", "DNA", 250, 267], ["human", "SPECIES", 127, 132], ["human", "SPECIES", 127, 132], ["Illumina MiSeq data", "TEST", 4, 23], ["adapter trimming", "TREATMENT", 37, 53], ["ncRNA", "TEST", 239, 244]]], ["Non-human, non-rRNA reads were then assembled using SPAdes (parameters: -k 55 --rna --only-assembler; version 3.11.0; [31] ).", [["Non-human, non-rRNA reads", "DNA", 0, 25], ["--rna", "TEST", 78, 83]]], ["The resulting contigs were subsequently analyzed using BLASTN and MEGAN as described for nanopore data.", [["MEGAN", "DNA", 66, 71], ["BLASTN", "TREATMENT", 55, 61], ["MEGAN", "TREATMENT", 66, 71]]], ["Sequence identity between Illumina MiSeq and nanopore DRS enterovirus genome consensus sequences was calculated using legacy BLAST 2.2.9.", [["Illumina MiSeq", "DNA", 26, 40], ["nanopore DRS enterovirus genome consensus sequences", "DNA", 45, 96], ["Sequence identity", "TEST", 0, 17], ["Illumina MiSeq", "TEST", 26, 40], ["nanopore DRS enterovirus genome consensus sequences", "TEST", 45, 96], ["legacy BLAST", "TEST", 118, 130]]], ["Coverage information was generated using BBMap and plots created using R statistical computing environment (version 3.6.0).Data AvailabilityAfter removal of any human reads, all Illumina MiSeq sequencing data (FASTQ), raw and basecalled ONT data (FAST5 and FASTQ, respectively), and Sanger sequences were deposited in the European Nucleotide Archive (ENA) under the project reference PRJEB38758.ResultsDRS was performed with enterovirus-positive stool samples with similar viral load (Ct values between 18 and 23) in three independent experiments, consisting of samples from three different patients.", [["stool samples", "ANATOMY", 446, 459], ["samples", "ANATOMY", 562, 569], ["human", "ORGANISM", 161, 166], ["enterovirus", "ORGANISM", 425, 436], ["stool", "ORGANISM", 446, 451], ["patients", "ORGANISM", 591, 599], ["human reads", "DNA", 161, 172], ["FAST5", "DNA", 247, 252], ["FASTQ", "DNA", 257, 262], ["Sanger sequences", "DNA", 283, 299], ["human", "SPECIES", 161, 166], ["patients", "SPECIES", 591, 599], ["human", "SPECIES", 161, 166], ["removal", "TREATMENT", 146, 153], ["any human reads", "TEST", 157, 172], ["Sanger sequences", "TEST", 283, 299], ["ResultsDRS", "TEST", 395, 405], ["enterovirus", "PROBLEM", 425, 436], ["positive stool samples", "PROBLEM", 437, 459], ["similar viral load", "PROBLEM", 465, 483], ["Ct values", "TEST", 485, 494], ["viral load", "OBSERVATION", 473, 483]]], ["The samples were prepared using the WHO-recommended protocol for viral enrichment using chloroform/bead treatment, followed by RNA extraction using TRIzol or easyMAG (Table S1) .", [["samples", "ANATOMY", 4, 11], ["chloroform", "CHEMICAL", 88, 98], ["chloroform", "CHEMICAL", 88, 98], ["chloroform", "SIMPLE_CHEMICAL", 88, 98], ["viral enrichment", "TREATMENT", 65, 81], ["chloroform/bead treatment", "TREATMENT", 88, 113], ["RNA extraction", "TREATMENT", 127, 141], ["TRIzol", "TREATMENT", 148, 154], ["easyMAG", "TREATMENT", 158, 165]]], ["We sequenced the total polyadenylated RNA using DRS on a MinION Nanopore sequencer.", [["total polyadenylated RNA", "RNA", 17, 41], ["a MinION Nanopore sequencer", "TREATMENT", 55, 82]]], ["The runs were continued until there was only negligible sequencing output or until the maximum recommended duration of the run was reached.", [["negligible sequencing output", "PROBLEM", 45, 73]]], ["For validation purposes, all three samples were also subjected to cDNA sequencing using Illumina MiSeq from samples prepared by the routine diagnostic procedure (Figure 1 ).", [["samples", "ANATOMY", 35, 42], ["samples", "ANATOMY", 108, 115], ["Illumina MiSeq", "DNA", 88, 102], ["validation purposes", "TEST", 4, 23], ["Illumina MiSeq", "TREATMENT", 88, 102], ["the routine diagnostic procedure", "TREATMENT", 128, 160]]], ["The cDNA was produced with either genotype specific primers (E590), or with both oligo-dT primers and random hexamers (E372, E026).Sample E590DRS reads from extracted RNA were obtained up to 7 h after the beginning of the sequencing run, and sequencing was stopped after 12 h.", [["cDNA", "DNA", 4, 8], ["genotype specific primers", "DNA", 34, 59], ["E590", "DNA", 61, 65], ["oligo-dT primers", "DNA", 81, 97], ["E590DRS reads", "DNA", 138, 151], ["both oligo-dT primers", "TREATMENT", 76, 97], ["sequencing", "TEST", 242, 252]]], ["Out of a total output of 137,834 raw nanopore reads, 9213 reads were successfully basecalled into RNA sequences, with an average length of 1128 bases (range 1-7112 bases).", [["137,834 raw nanopore reads", "DNA", 25, 51], ["RNA sequences", "DNA", 98, 111], ["a total output", "TEST", 7, 21], ["RNA sequences", "TEST", 98, 111]]], ["More than 98% of basecalled RNA reads (9065 reads) were taxonomically classified using BLASTN against the NCBI's nucleotide (nt) database.", [["nucleotide", "CHEMICAL", 113, 123], ["nucleotide", "CHEMICAL", 113, 123], ["basecalled RNA reads", "RNA", 17, 37], ["NCBI's nucleotide (nt) database", "DNA", 106, 137], ["BLASTN", "TREATMENT", 87, 93]]], ["The large majority (>98%) of those hits matched eukaryotic sequences, and only 2.2% bacterial (199 reads) and 0.17% viral sequences (16 reads) ( Table 1 ).", [["eukaryotic sequences", "DNA", 48, 68], ["viral sequences", "DNA", 116, 131], ["eukaryotic sequences", "TEST", 48, 68], ["% viral sequences", "TEST", 114, 131], ["large", "OBSERVATION_MODIFIER", 4, 9], ["majority", "OBSERVATION_MODIFIER", 10, 18]]], ["The majority of eukaryotic reads were assigned to the yeast species Saccharomyces cerevisiae (8619 reads; 95%).", [["Saccharomyces cerevisiae", "ORGANISM", 68, 92], ["yeast", "SPECIES", 54, 59], ["Saccharomyces cerevisiae", "SPECIES", 68, 92], ["yeast", "SPECIES", 54, 59], ["Saccharomyces cerevisiae", "SPECIES", 68, 92], ["eukaryotic reads", "OBSERVATION", 16, 32]]], ["All other eukaryotic species had less than five reads assigned.", [["All other eukaryotic species", "PROBLEM", 0, 28], ["eukaryotic species", "OBSERVATION", 10, 28]]], ["Within the reads assigned to bacteria, the only species with notable number of reads were Escherichia coli (37 reads), Faecalibacterium prausnitzii (12 reads) or Bacteroides vulgatus (12 reads), all of which are known to be commensal species in the human gut.", [["gut", "ANATOMY", 255, 258], ["Escherichia coli", "ORGANISM", 90, 106], ["Faecalibacterium prausnitzii", "ORGANISM", 119, 147], ["Bacteroides vulgatus", "ORGANISM", 162, 182], ["human", "ORGANISM", 249, 254], ["gut", "ORGANISM_SUBDIVISION", 255, 258], ["Escherichia coli", "SPECIES", 90, 106], ["Faecalibacterium prausnitzii", "SPECIES", 119, 147], ["Bacteroides vulgatus", "SPECIES", 162, 182], ["human", "SPECIES", 249, 254], ["Escherichia coli", "SPECIES", 90, 106], ["Faecalibacterium prausnitzii", "SPECIES", 119, 147], ["Bacteroides vulgatus", "SPECIES", 162, 182], ["human", "SPECIES", 249, 254], ["bacteria", "PROBLEM", 29, 37], ["Escherichia coli", "PROBLEM", 90, 106], ["Faecalibacterium prausnitzii", "TREATMENT", 119, 147], ["Bacteroides vulgatus", "PROBLEM", 162, 182], ["commensal species in the human gut", "PROBLEM", 224, 258], ["known to be", "UNCERTAINTY", 212, 223], ["commensal species", "OBSERVATION", 224, 241], ["human gut", "ANATOMY", 249, 258]]], ["As far as viral sequences were concerned, all 16 (0.18% of 9065) reads matched the Enterovirus genus, species EV-A ( Table 2 ).", [["viral sequences", "TEST", 10, 25], ["the Enterovirus genus", "PROBLEM", 79, 100], ["Enterovirus genus", "OBSERVATION", 83, 100]]], ["Alignment of the RNA sequences to the best-scoring reference genome (Coxsackievirus A6 KJ541158; Figure 2 ) demonstrated that the long reads covered almost the entire genome of Coxsackievirus A6, with one single read covering alone 98.5% of the reference genome (with only 110 bases missing at the 5 end).", [["Coxsackievirus A6 KJ541158", "ORGANISM", 69, 95], ["Coxsackievirus A6", "ORGANISM", 177, 194], ["RNA sequences", "DNA", 17, 30], ["reference genome", "DNA", 51, 67], ["reference genome", "DNA", 245, 261], ["Coxsackievirus A6 KJ541158", "SPECIES", 69, 95], ["Coxsackievirus A6", "SPECIES", 177, 194], ["the RNA sequences", "TEST", 13, 30], ["Coxsackievirus", "TEST", 69, 83], ["KJ", "TEST", 87, 89]]], ["The top two longest RNA sequences (7112 and 5397 bases long) were obtained within the first hour of sequencing, and most of the larger sequences (>2 kb) were obtained within the first 3 h of sequencing.", [["RNA sequences", "DNA", 20, 33], ["longest RNA sequences", "TEST", 12, 33], ["sequencing", "TEST", 100, 110], ["the larger sequences", "TEST", 124, 144]]], ["After 3 h of sequencing, sequences matching enterovirus were all <900 bases long.Sample E590Classical amplicon sequencing of the VP1 region was attempted for sample E590, but it did not yield good results.", [["sample", "ANATOMY", 158, 164], ["enterovirus", "ORGANISM", 44, 55], ["VP1", "ORGANISM", 129, 132], ["VP1 region", "DNA", 129, 139], ["sequences matching enterovirus", "TEST", 25, 55], ["Sample", "TEST", 81, 87], ["the VP1 region", "TREATMENT", 125, 139], ["VP1", "ANATOMY", 129, 132]]], ["In order to confirm genotype identification obtained via DRS and to obtain a highly accurate whole-genome enterovirus sequence, we also subjected sample E590 to cDNA sequencing using Illumina MiSeq.", [["enterovirus", "ORGANISM", 106, 117], ["Illumina MiSeq", "DNA", 183, 197], ["genotype identification", "TEST", 20, 43], ["Illumina MiSeq", "TREATMENT", 183, 197]]], ["MiSeq sequencing library preparation was performed with stool material and following the routine diagnostic pre-treatment (as opposed to chloroform/bead treatment) given that low amount of patient stool sample was available (Figure 1 ).", [["stool sample", "ANATOMY", 197, 209], ["chloroform", "CHEMICAL", 137, 147], ["chloroform", "SIMPLE_CHEMICAL", 137, 147], ["patient", "ORGANISM", 189, 196], ["patient", "SPECIES", 189, 196], ["MiSeq sequencing library preparation", "TREATMENT", 0, 36], ["stool material", "TREATMENT", 56, 70], ["the routine diagnostic pre-treatment", "TEST", 85, 121], ["chloroform/bead treatment", "TREATMENT", 137, 162], ["patient stool sample", "TEST", 189, 209]]], ["For this sample, an enterovirus-targeted approach was chosen to produce the cDNA by using genotype-specific primers given that low number of reads was obtained by DRS.", [["sample", "ANATOMY", 9, 15], ["cDNA", "DNA", 76, 80], ["this sample", "TEST", 4, 15], ["an enterovirus", "PROBLEM", 17, 31], ["genotype-specific primers", "TREATMENT", 90, 115]]], ["After removal of reads mapping to human genome and bacterial rRNA, metatranscriptomic reads were assembled into contigs and further subjected to BLASTN similarity analysis against sequences in the nt database, and the top hits were taxonomically summarized using MEGAN.", [["human", "ORGANISM", 34, 39], ["human genome", "DNA", 34, 46], ["bacterial rRNA", "DNA", 51, 65], ["metatranscriptomic reads", "DNA", 67, 91], ["nt database", "DNA", 197, 208], ["top hits", "DNA", 218, 226], ["MEGAN", "DNA", 263, 268], ["human", "SPECIES", 34, 39], ["human", "SPECIES", 34, 39], ["removal of reads mapping", "TREATMENT", 6, 30], ["bacterial rRNA", "PROBLEM", 51, 65], ["metatranscriptomic reads", "TREATMENT", 67, 91], ["BLASTN similarity analysis", "TEST", 145, 171], ["the nt database", "TEST", 193, 208], ["MEGAN", "TREATMENT", 263, 268], ["bacterial rRNA", "OBSERVATION", 51, 65]]], ["Most contigs of sample E590 were classified as bacteria (38) or viruses (17) ( Table 1 ).", [["sample", "ANATOMY", 16, 22], ["sample E590", "TEST", 16, 27], ["bacteria", "PROBLEM", 47, 55], ["viruses", "PROBLEM", 64, 71]]], ["Such differences in species composition when compared to the results of the DRS run may be explained by the genotype-specific approach used for cDNA synthesis and different pre-treatment of the sample.Sample E372Based on the promising results obtained for sample E590, the DRS transcriptomic approach was repeated on two other clinical samples: For the DRS of RNA extracted from sample E372, the total yield of the sequencing run was 58,548 reads (14.84 Mb) after 12 h of sequencing.", [["cDNA synthesis", "TREATMENT", 144, 158], ["the sample", "TEST", 190, 200], ["the DRS transcriptomic approach", "TREATMENT", 269, 300], ["sequencing", "TEST", 472, 482], ["species", "OBSERVATION_MODIFIER", 20, 27], ["composition", "OBSERVATION_MODIFIER", 28, 39]]], ["A total of 31,636 reads passed basecalling, with an average length of 144.4 bases (range of 2-4,276).", [["an average length", "TEST", 49, 66], ["average", "OBSERVATION_MODIFIER", 52, 59], ["length", "OBSERVATION_MODIFIER", 60, 66]]], ["Only 42% (13,297) of the basecalled sequences were taxonomically classified using BLASTN.", [["basecalled sequences", "DNA", 25, 45], ["the basecalled sequences", "TEST", 21, 45]]], ["Interestingly, there was a drastic difference in read composition as compared to the first sample (E590), and the majority of reads classified as of bacterial origin (97.5%, 12,967), and only very few reads matched to eukaryotic (10, 0.8%) or archaeal (5, 0.4%) species.", [["sample", "ANATOMY", 91, 97], ["a drastic difference", "PROBLEM", 25, 45], ["bacterial origin", "PROBLEM", 149, 165], ["eukaryotic", "TEST", 218, 228], ["archaeal", "TEST", 243, 251], ["drastic", "OBSERVATION_MODIFIER", 27, 34], ["difference", "OBSERVATION_MODIFIER", 35, 45], ["bacterial origin", "OBSERVATION_MODIFIER", 149, 165]]], ["For bacteria, DRS reads were assigned to a large variety of species.", [["DRS reads", "DNA", 14, 23], ["bacteria", "PROBLEM", 4, 12], ["DRS reads", "TEST", 14, 23], ["a large variety of species", "PROBLEM", 41, 67], ["large", "OBSERVATION_MODIFIER", 43, 48], ["variety", "OBSERVATION_MODIFIER", 49, 56], ["species", "OBSERVATION", 60, 67]]], ["The most prominent phyla were Bacteroidetes (4,518 reads) and Proteobacteria (717 reads).", [["Bacteroidetes", "PROBLEM", 30, 43], ["Proteobacteria", "TEST", 62, 76], ["most prominent", "OBSERVATION_MODIFIER", 4, 18], ["phyla", "OBSERVATION_MODIFIER", 19, 24], ["Bacteroidetes", "OBSERVATION", 30, 43]]], ["For E026, the coverage plot was produced by using the assembled contig sequence of the Illumina sequencing run (oligo-dT primers) as reads did not map well to any reference EV genome sequence.", [["E026", "DNA", 4, 8], ["assembled contig sequence", "DNA", 54, 79], ["oligo-dT primers", "DNA", 112, 128], ["EV genome sequence", "DNA", 173, 191], ["the coverage plot", "TREATMENT", 10, 27], ["the Illumina sequencing", "TEST", 83, 106], ["oligo-dT primers", "TREATMENT", 112, 128]]], ["For samples E372 and E026, Illumina MiSeq reads based on cDNA produced with oligo-dT and random hexamers are indicated by light and dark grey lines, respectively.", [["samples", "ANATOMY", 4, 11], ["oligo-dT", "CHEMICAL", 76, 84], ["E026", "CELL", 21, 25], ["Illumina MiSeq reads", "DNA", 27, 47], ["cDNA", "DNA", 57, 61], ["oligo-dT and random hexamers", "DNA", 76, 104], ["samples", "TEST", 4, 11], ["Illumina MiSeq reads", "TEST", 27, 47], ["cDNA", "TEST", 57, 61], ["oligo", "TEST", 76, 81], ["random hexamers", "TREATMENT", 89, 104], ["dark", "OBSERVATION", 132, 136], ["grey lines", "OBSERVATION", 137, 147]]], ["All viral sequences matched again uniquely to EV sequences.", [["viral sequences", "DNA", 4, 19], ["EV sequences", "DNA", 46, 58], ["All viral sequences", "TEST", 0, 19], ["EV sequences", "TEST", 46, 58]]], ["However, MEGAN analyses revealed the presence of two enterovirus species consisting of EV-A (8 contigs; contigs lengths ranging from 130 to 3164 bases) and EV-B (8 contigs; contigs lengths ranging from 241 to 2845 bases) in the cDNA sample, of which the majority of contigs were assigned to Coxsackievirus A6 and Echovirus 18 ( Table 2 ).", [["sample", "ANATOMY", 233, 239], ["EV-A", "CANCER", 87, 91], ["EV-B", "GENE_OR_GENE_PRODUCT", 156, 160], ["Coxsackievirus A6", "ORGANISM", 291, 308], ["Echovirus 18", "ORGANISM", 313, 325], ["MEGAN", "PROTEIN", 9, 14], ["EV-B", "DNA", 156, 160], ["EV-A", "SPECIES", 87, 91], ["Coxsackievirus A6", "SPECIES", 291, 308], ["MEGAN analyses", "TEST", 9, 23], ["two enterovirus species", "PROBLEM", 49, 72], ["EV", "TEST", 87, 89], ["contigs lengths", "TEST", 104, 119], ["EV", "TEST", 156, 158], ["contigs lengths", "TEST", 173, 188], ["the cDNA sample", "TEST", 224, 239], ["contigs", "TEST", 266, 273], ["Coxsackievirus", "TEST", 291, 305], ["Echovirus", "TEST", 313, 322], ["enterovirus species", "OBSERVATION", 53, 72]]], ["Mapping of the viral sequences to a VP1 database confirmed the presence of these two genotypes and the identification was verified by using the online RIVM bioinformatic platform [32] .", [["viral sequences", "DNA", 15, 30], ["the viral sequences", "TEST", 11, 30], ["a VP1 database", "TEST", 34, 48]]], ["Alignment of the reads to the closest reference genome sequences revealed that the coverage of CV-A6 was 96% with an average depth of 7.8 (\u00b14.5), while for Echovirus 18, only 68% of the reference genome was covered (Figure 2) .", [["CV-A6", "CELL", 95, 100], ["reference genome sequences", "DNA", 38, 64], ["reference genome", "DNA", 186, 202], ["CV-A6", "SPECIES", 95, 100], ["CV", "TEST", 95, 97], ["an average depth", "TEST", 114, 130], ["Echovirus", "TEST", 156, 165]]], ["The consensus sequence for CV-A6 obtained by Illumina MiSeq was 94.0% identical (6926/7368), with 2% gaps (167/7368), to the consensus sequence obtained by DRS sequencing.Sample E372Based on the promising results obtained for sample E590, the DRS transcriptomic approach was repeated on two other clinical samples: For the DRS of RNA extracted from sample E372, the total yield of the sequencing run was 58,548 reads (14.84 Mb) after 12 h of sequencing.", [["consensus sequence", "DNA", 4, 22], ["A6", "DNA", 30, 32], ["consensus sequence", "DNA", 125, 143], ["The consensus sequence", "TEST", 0, 22], ["CV", "TEST", 27, 29], ["Illumina MiSeq", "TEST", 45, 59], ["the consensus sequence", "TEST", 121, 143], ["the DRS transcriptomic approach", "TREATMENT", 239, 270], ["sequencing", "TEST", 442, 452]]], ["A total of 31,636 reads passed basecalling, with an average length of 144.4 bases (range of 2-4276).", [["an average length", "TEST", 49, 66], ["average", "OBSERVATION_MODIFIER", 52, 59], ["length", "OBSERVATION_MODIFIER", 60, 66]]], ["Only 42% (13, 297) of the basecalled sequences were taxonomically classified using BLASTN.", [["basecalled sequences", "DNA", 26, 46], ["the basecalled sequences", "TEST", 22, 46]]], ["Interestingly, there was a drastic difference in read composition as compared to the first sample (E590), and the majority of reads classified as of bacterial origin (97.5%, 12,967), and only very few reads matched to eukaryotic (10, 0.8%) or archaeal (5, 0.4%) species.", [["sample", "ANATOMY", 91, 97], ["a drastic difference", "PROBLEM", 25, 45], ["bacterial origin", "PROBLEM", 149, 165], ["eukaryotic", "TEST", 218, 228], ["archaeal", "TEST", 243, 251], ["drastic", "OBSERVATION_MODIFIER", 27, 34], ["difference", "OBSERVATION_MODIFIER", 35, 45], ["bacterial origin", "OBSERVATION_MODIFIER", 149, 165]]], ["For bacteria, DRS reads were assigned to a large variety of species.", [["DRS reads", "DNA", 14, 23], ["bacteria", "PROBLEM", 4, 12], ["DRS reads", "TEST", 14, 23], ["a large variety of species", "PROBLEM", 41, 67], ["large", "OBSERVATION_MODIFIER", 43, 48], ["variety", "OBSERVATION_MODIFIER", 49, 56], ["species", "OBSERVATION", 60, 67]]], ["The most prominent phyla were Bacteroidetes (4518 reads) and Proteobacteria (717 reads).", [["Bacteroidetes", "PROBLEM", 30, 43], ["Proteobacteria", "TEST", 61, 75], ["most prominent", "OBSERVATION_MODIFIER", 4, 18], ["phyla", "OBSERVATION_MODIFIER", 19, 24], ["Bacteroidetes", "OBSERVATION", 30, 43]]], ["As seen for the previous sample, only matches to the Enterovirus genus were found.", [["Enterovirus", "DISEASE", 53, 64], ["Enterovirus", "ORGANISM", 53, 64], ["the previous sample", "TEST", 12, 31], ["the Enterovirus genus", "PROBLEM", 49, 70], ["Enterovirus genus", "OBSERVATION", 53, 70]]], ["Although many more viral reads were found in comparison to sample E590, they were, with an average of 1192 bases, much shorter, and with a range of 106-4276.", [["bases", "ANATOMY_MODIFIER", 107, 112], ["shorter", "OBSERVATION_MODIFIER", 119, 126]]], ["No reads spanned the complete genome sequence of any known EV species or genotype, and altogether could cover 59% of the reference genome sequence (Figure 2 ).", [["reference genome sequence", "DNA", 121, 146], ["any known EV species", "PROBLEM", 49, 69]]], ["Short fragment lengths might result from increased fragmentation of the viral RNA during extraction or library preparation.", [["viral RNA", "RNA", 72, 81], ["Short fragment lengths", "PROBLEM", 0, 22], ["increased fragmentation", "PROBLEM", 41, 64], ["the viral RNA", "PROBLEM", 68, 81], ["library preparation", "TREATMENT", 103, 122], ["lengths", "OBSERVATION_MODIFIER", 15, 22], ["increased", "OBSERVATION_MODIFIER", 41, 50], ["fragmentation", "OBSERVATION", 51, 64], ["viral RNA", "OBSERVATION", 72, 81]]], ["Due to the directional sequencing used in the DRS process of nanopore sequencing, higher coverage at the 3' end of the sequence may be obtained, and fragments without poly-A tail cannot be sequenced.", [["3' end", "CELLULAR_COMPONENT", 105, 111], ["poly-A tail", "GENE_OR_GENE_PRODUCT", 167, 178], ["3' end", "DNA", 105, 111], ["poly-A tail", "DNA", 167, 178], ["nanopore sequencing", "TREATMENT", 61, 80], ["the sequence", "TEST", 115, 127]]], ["Therefore fragmented, incomplete RNA molecules may hinder the recovery of the 5 end of the RNA genome.", [["RNA molecules", "PROTEIN", 33, 46], ["5 end", "RNA", 78, 83], ["RNA genome", "DNA", 91, 101], ["incomplete RNA molecules", "PROBLEM", 22, 46], ["fragmented", "OBSERVATION_MODIFIER", 10, 20], ["incomplete", "OBSERVATION_MODIFIER", 22, 32], ["RNA molecules", "OBSERVATION", 33, 46], ["RNA genome", "OBSERVATION", 91, 101]]], ["Nevertheless, although the covered region did not span the VP1 region, we were able to identify the enterovirus as Echovirus 30 by genomic similarity to the best-scoring reference genome sequence.", [["enterovirus", "DISEASE", 100, 111], ["VP1 region", "DNA", 59, 69], ["reference genome sequence", "DNA", 170, 195], ["the enterovirus", "PROBLEM", 96, 111], ["Echovirus", "PROBLEM", 115, 124], ["VP1 region", "ANATOMY", 59, 69]]], ["This species identification was independently confirmed by a standard genotyping approach that uses Sanger-based sequencing of the partial VP1 amplicon.Sample E372The cDNA from sample E372 was also sequenced by Illumina MiSeq, although in this case with non-specific primers for cDNA synthesis for a more unbiased approach towards EV detection and not to miss possible EV co-infections.", [["E372", "CHEMICAL", 159, 163], ["E372", "CHEMICAL", 159, 163], ["VP1 amplicon", "DNA", 139, 151], ["cDNA", "DNA", 167, 171], ["E372", "DNA", 184, 188], ["Illumina MiSeq", "DNA", 211, 225], ["a standard genotyping approach", "TREATMENT", 59, 89], ["Sanger-based sequencing", "TREATMENT", 100, 123], ["the partial VP1 amplicon", "TREATMENT", 127, 151], ["Sample", "TEST", 152, 158], ["The cDNA from sample E372", "TEST", 163, 188], ["non-specific primers", "PROBLEM", 254, 274], ["cDNA synthesis", "PROBLEM", 279, 293], ["EV detection", "TEST", 331, 343], ["EV co-infections", "PROBLEM", 369, 385], ["VP1 amplicon", "OBSERVATION", 139, 151], ["co-infections", "OBSERVATION", 372, 385]]], ["Both oligo-dT and random hexamer primers were used to ensure a better chance of obtaining the full genome, with the idea that oligo-dT may lead to results more comparable to those of DRS due to polyadenylation requirements, and random hexamers may offer better chance of obtaining a well-covered 5' end of the enterovirus genome.", [["oligo-dT", "CHEMICAL", 5, 13], ["oligo-dT", "CHEMICAL", 126, 134], ["DRS", "DISEASE", 183, 186], ["oligo-dT", "SIMPLE_CHEMICAL", 5, 13], ["oligo-dT", "GENE_OR_GENE_PRODUCT", 126, 134], ["enterovirus", "ORGANISM", 310, 321], ["oligo-dT and random hexamer primers", "DNA", 5, 40], ["5' end", "DNA", 296, 302], ["enterovirus genome", "DNA", 310, 328], ["Both oligo-dT", "TREATMENT", 0, 13], ["random hexamer primers", "TREATMENT", 18, 40], ["dT", "PROBLEM", 132, 134], ["polyadenylation requirements", "PROBLEM", 194, 222], ["random hexamers", "TREATMENT", 228, 243], ["the enterovirus genome", "PROBLEM", 306, 328], ["enterovirus genome", "OBSERVATION", 310, 328]]], ["The distribution of contigs assigned on the domain level did not vary much between random hexamer and oligo-dT produced cDNA: most contigs were assigned to bacteria (99.3% or 99.5%, respectively), with only a small minority mapping to eukaryotes (0.15%, 0.20%) and viruses (0.51%, 0.28%).", [["oligo-dT", "CHEMICAL", 102, 110], ["oligo-dT", "SIMPLE_CHEMICAL", 102, 110], ["oligo-dT produced cDNA", "DNA", 102, 124], ["the domain level", "TEST", 40, 56], ["random hexamer", "TEST", 83, 97], ["bacteria", "TEST", 156, 164], ["viruses", "TEST", 265, 272], ["small", "OBSERVATION_MODIFIER", 209, 214], ["minority", "OBSERVATION", 215, 223]]], ["Within bacteria, most contigs were assigned to the phyla Proteobacteria (11,120, 12,551), followed by Bacteriodetes (735, 896) and Actinobacteria (303, 381).", [["bacteria", "PROBLEM", 7, 15], ["the phyla Proteobacteria", "TEST", 47, 71], ["Bacteriodetes", "TEST", 102, 115], ["Actinobacteria", "TEST", 131, 145]]], ["Taking a closer look at all the detected viral genotypes (Table 2) , we found that, besides Echovirus 30, there were also contigs mapping to other virus genotypes, such as Rhinovirus A, and a variety of other bacterial or plant viruses, albeit only with few short contigs.", [["Echovirus 30", "ORGANISM", 92, 104], ["Rhinovirus A", "GENE_OR_GENE_PRODUCT", 172, 184], ["Rhinovirus A", "SPECIES", 172, 184], ["Echovirus", "PROBLEM", 92, 101], ["other virus genotypes", "PROBLEM", 141, 162], ["Rhinovirus A", "PROBLEM", 172, 184], ["other bacterial or plant viruses", "PROBLEM", 203, 235], ["few short contigs", "PROBLEM", 254, 271], ["Rhinovirus", "OBSERVATION", 172, 182], ["plant viruses", "OBSERVATION", 222, 235]]], ["The Echovirus 30 genome, however, was well covered with either approach (Figure 2) .", [["Echovirus 30", "ORGANISM", 4, 16], ["Echovirus 30 genome", "DNA", 4, 23], ["The Echovirus 30 genome", "PROBLEM", 0, 23], ["Echovirus", "OBSERVATION", 4, 13], ["30 genome", "OBSERVATION_MODIFIER", 14, 23]]], ["Comparison of the DRS nanopore sequencing consensus to the one obtained from Illumina MiSeq showed 97.3% identity (4211/4329), with 0.8% gaps (34/4329).Sample E026The DRS run of the RNA extract from sample E026 was stopped after the maximal run duration of 48 h.", [["sample", "ANATOMY", 199, 205], ["E026", "CHEMICAL", 159, 163], ["E026", "CHEMICAL", 206, 210], ["Illumina MiSeq", "DNA", 77, 91], ["the DRS nanopore", "TEST", 14, 30], ["Illumina MiSeq", "TEST", 77, 91], ["Sample", "TEST", 152, 158]]], ["Notably, this run had much higher output compared to the other two samples, resulting in a total of 1.56 M sequenced reads (1.78 Gb), from which 1.46 M reads passed basecalling.", [["samples", "ANATOMY", 67, 74], ["much higher output", "PROBLEM", 22, 40]]], ["The average length was also considerably higher than in previous runs with 1035 bases (range 1-7101 bases).", [["The average length", "TEST", 0, 18], ["average", "OBSERVATION_MODIFIER", 4, 11], ["length", "OBSERVATION_MODIFIER", 12, 18], ["considerably", "OBSERVATION_MODIFIER", 28, 40], ["higher", "OBSERVATION_MODIFIER", 41, 47]]], ["Although the RNA input material used for library preparation was measured to be of a similar amount for all three samples (361 ng), cDNA measurement (896 ng) before loading on the flow cell indicated that the initial RNA concentration might not have been the same.", [["cell", "ANATOMY", 185, 189], ["cell", "CELL", 185, 189], ["the RNA input material", "PROBLEM", 9, 31], ["library preparation", "TREATMENT", 41, 60], ["cDNA measurement", "TEST", 132, 148], ["the flow cell", "TEST", 176, 189], ["the initial RNA concentration", "PROBLEM", 205, 234]]], ["Overall, 91% of basecalled reads (1.41 M reads) were taxonomically classified using BLASTN.", [["basecalled reads", "DNA", 16, 32]]], ["Of those, 95.3% (1,349,407) mapped to eukaryotic sequences.", [["eukaryotic sequences", "DNA", 38, 58]]], ["As seen for sample E590, the vast majority of eukaryotic reads mapped to Saccharomyces cerevisiae (96.8%), while 4.6% (65,408) were classified as of bacterial origin, and only a negligible amount as archaea (6, 0.0004%).", [["Saccharomyces cerevisiae", "ORGANISM", 73, 97], ["Saccharomyces cerevisiae", "SPECIES", 73, 97], ["Saccharomyces cerevisiae", "SPECIES", 73, 97], ["Saccharomyces cerevisiae", "TEST", 73, 97], ["bacterial origin", "PROBLEM", 149, 165], ["bacterial origin", "OBSERVATION", 149, 165], ["negligible", "OBSERVATION_MODIFIER", 178, 188], ["amount", "OBSERVATION_MODIFIER", 189, 195], ["archaea", "OBSERVATION", 199, 206]]], ["Viral sequences comprised 0.11% (1579) of the reads, the majority of which were classified as plant viral pathogens (Table 2) , mostly belonging to the tomato mosaic virus (1274 reads, 81% of viral reads).", [["viral pathogens", "DISEASE", 100, 115], ["tomato mosaic virus", "ORGANISM", 152, 171], ["tomato mosaic virus", "SPECIES", 152, 171], ["tomato mosaic virus", "SPECIES", 152, 171], ["Viral sequences", "TEST", 0, 15], ["the reads", "TEST", 42, 51], ["plant viral pathogens", "PROBLEM", 94, 115], ["viral reads", "TEST", 192, 203], ["viral pathogens", "OBSERVATION", 100, 115]]], ["Other, more rarely detected species, included Melon necrotic spot virus (8) , and Cactus virus X (21) .", [["necrotic", "DISEASE", 52, 60], ["Melon necrotic spot virus", "ORGANISM", 46, 71], ["Cactus virus", "ORGANISM", 82, 94], ["Cactus virus", "SPECIES", 82, 94], ["Melon necrotic spot virus", "SPECIES", 46, 71], ["Cactus virus", "SPECIES", 82, 94], ["Melon necrotic spot virus", "PROBLEM", 46, 71], ["Cactus virus", "PROBLEM", 82, 94], ["necrotic", "OBSERVATION_MODIFIER", 52, 60], ["spot virus", "OBSERVATION", 61, 71]]], ["In total, 181 reads mapped to enteroviruses.", [["enteroviruses", "DISEASE", 30, 43], ["enteroviruses", "ORGANISM", 30, 43], ["enteroviruses", "PROBLEM", 30, 43]]], ["Although sequences were mapped to several genotypes, mapping the reads to the best-scoring reference genome and to a VP1 database identified genotype Echovirus 25 as the most likely and only EV genotype present in the sample.", [["reference genome", "DNA", 91, 107], ["a VP1 database", "TEST", 115, 129], ["genotype Echovirus", "PROBLEM", 141, 159], ["EV genotype", "PROBLEM", 191, 202], ["most likely", "UNCERTAINTY", 170, 181]]], ["Although there were relatively few hits to enteroviruses considering the high total output of the run, long sequences (average 1724.2, range 257-7101 bases) were observed, which covered up to 99.6% of the reference genome sequence (Figure 2 ).Sample E026Illumina sequencing of the cDNA from sample E026 produced using oligo-dT primers and random hexamers showed similar distributions on the domain level: the majority of contigs belonged to bacterial species (98.6% and 98.9%, respectively, for oligo-dT and random hexamer approaches), with a minority of reads mapping to eukaryotes (0.49%, 0.50%) and viruses (0.87%, 0.56%).", [["enteroviruses", "DISEASE", 43, 56], ["long sequences", "DNA", 103, 117], ["reference genome sequence", "DNA", 205, 230], ["cDNA", "DNA", 281, 285], ["E026", "DNA", 298, 302], ["oligo-dT primers", "DNA", 318, 334], ["relatively few hits to enteroviruses", "PROBLEM", 20, 56], ["long sequences", "TEST", 103, 117], ["Sample E026Illumina", "TEST", 243, 262], ["the cDNA", "TEST", 277, 285], ["sample E026", "TEST", 291, 302], ["oligo-dT primers", "TREATMENT", 318, 334], ["random hexamers", "TEST", 339, 354], ["similar distributions on the domain level", "PROBLEM", 362, 403], ["bacterial species", "TEST", 441, 458], ["oligo", "TEST", 495, 500], ["random hexamer approaches", "TREATMENT", 508, 533], ["viruses", "TEST", 602, 609], ["relatively", "OBSERVATION_MODIFIER", 20, 30], ["few", "OBSERVATION_MODIFIER", 31, 34], ["bacterial species", "OBSERVATION", 441, 458]]], ["This major shift from yeast to bacteria as compared to the DRS approach, which was also observed for sample E590, could be explained by the different pre-treatment using filtration with a pore size of 0.2 \u00b5m.", [["pore", "ANATOMY", 188, 192], ["yeast", "SPECIES", 22, 27], ["yeast", "SPECIES", 22, 27], ["This major shift", "PROBLEM", 0, 16], ["yeast to bacteria", "PROBLEM", 22, 39], ["filtration", "TREATMENT", 170, 180], ["a pore size", "TEST", 186, 197], ["yeast to bacteria", "OBSERVATION_MODIFIER", 22, 39], ["size", "OBSERVATION_MODIFIER", 193, 197]]], ["For E026, the genome of Echovirus 25 genotype, whose presence was also confirmed by Sanger sequencing of the VP1 gene, was well covered with both types of cDNA synthesis ( Figure 2 ).", [["Echovirus 25", "ORGANISM", 24, 36], ["VP1", "GENE_OR_GENE_PRODUCT", 109, 112], ["E026", "DNA", 4, 8], ["VP1 gene", "DNA", 109, 117], ["cDNA", "DNA", 155, 159], ["Echovirus", "PROBLEM", 24, 33], ["cDNA synthesis", "TREATMENT", 155, 169]]], ["Some contigs also mapped to another genotype, Echovirus 30, but these were only short contigs, which may have been wrongly taxonomically assigned due to the short sizes of the Illumina reads.", [["Echovirus 30", "ORGANISM", 46, 58], ["Illumina reads", "DNA", 176, 190], ["Some contigs", "PROBLEM", 0, 12], ["another genotype", "TEST", 28, 44], ["Echovirus", "TEST", 46, 55]]], ["Otherwise, we also found a variety of viral sequences, with the most prominent being the tomato mosaic viruses and other plant pathogens, reflecting the results of the DRS run.", [["tomato mosaic viruses", "ORGANISM", 89, 110], ["tomato", "SPECIES", 89, 95], ["tomato", "SPECIES", 89, 95], ["a variety of viral sequences", "PROBLEM", 25, 53], ["the tomato mosaic viruses", "PROBLEM", 85, 110], ["other plant pathogens", "PROBLEM", 115, 136], ["most prominent", "OBSERVATION_MODIFIER", 64, 78], ["mosaic viruses", "OBSERVATION", 96, 110], ["plant pathogens", "OBSERVATION", 121, 136]]], ["The consensus sequence identity for Echovirus 25 sequenced by DRS to Illumina MiSeq was calculated as 96.7% (6979/7218), with 1% gaps (104/ 7218).DiscussionUsing RNA extracted from clinical samples, we were able to repeatedly identify human enteroviruses in stool samples from three independent patients by nanopore-based DRS in this proof-of-concept study.", [["samples", "ANATOMY", 190, 197], ["stool samples", "ANATOMY", 258, 271], ["human", "ORGANISM", 235, 240], ["enteroviruses", "ORGANISM", 241, 254], ["stool samples", "ORGANISM_SUBSTANCE", 258, 271], ["patients", "ORGANISM", 295, 303], ["Echovirus 25", "DNA", 36, 48], ["human", "SPECIES", 235, 240], ["patients", "SPECIES", 295, 303], ["human", "SPECIES", 235, 240], ["The consensus sequence identity", "TEST", 0, 31], ["Echovirus", "PROBLEM", 36, 45], ["Illumina MiSeq", "TEST", 69, 83], ["clinical samples", "TEST", 181, 197], ["human enteroviruses", "PROBLEM", 235, 254], ["stool samples", "TEST", 258, 271], ["concept study", "TEST", 343, 356], ["enteroviruses", "OBSERVATION", 241, 254]]], ["Beyond identifying EV species and genotypes correctly, we showed that the approach may also provide rich metatranscriptomic information on sample composition for all life domains.", [["sample", "ANATOMY", 139, 145], ["EV species", "OBSERVATION", 19, 29]]], ["Clear differences in overall species compositions, with either yeast or bacteria dominating the majority of obtained reads, were observed between samples.", [["samples", "ANATOMY", 146, 153], ["yeast", "SPECIES", 63, 68], ["yeast", "SPECIES", 63, 68], ["overall species compositions", "PROBLEM", 21, 49], ["yeast", "PROBLEM", 63, 68], ["bacteria", "PROBLEM", 72, 80], ["overall", "OBSERVATION_MODIFIER", 21, 28], ["species compositions", "OBSERVATION", 29, 49], ["bacteria", "OBSERVATION", 72, 80]]], ["Viral reads constituted between 0.11% and 2.4% of total passed reads.", [["Viral reads", "TEST", 0, 11]]], ["By complementing DRS data with Illumina MiSeq sequencing data for the same samples, we were able to validate the obtained enterovirus sequences and added further metatranscriptomic information.", [["samples", "ANATOMY", 75, 82], ["enterovirus", "ORGANISM", 122, 133], ["enterovirus sequences", "DNA", 122, 143], ["Illumina MiSeq sequencing data", "TEST", 31, 61], ["enterovirus sequences", "TEST", 122, 143], ["further metatranscriptomic information", "TREATMENT", 154, 192]]], ["Illumina MiSeq sequencing revealed a higher diversity in viral species in these samples (Table 2) , which was not captured by the DRS approach.DiscussionIn all samples, 59% to 99.6 % of the EV reference genome sequences were covered.", [["samples", "ANATOMY", 80, 87], ["samples", "ANATOMY", 160, 167], ["EV reference genome sequences", "DNA", 190, 219], ["Illumina MiSeq sequencing", "TEST", 0, 25], ["a higher diversity in viral species", "PROBLEM", 35, 70], ["higher", "OBSERVATION_MODIFIER", 37, 43], ["diversity", "OBSERVATION_MODIFIER", 44, 53], ["viral species", "OBSERVATION", 57, 70]]], ["The average identity of the DRS consensus was 94-97% compared to the Illumina MiSeq consensus sequence.", [["DRS consensus", "DNA", 28, 41], ["Illumina MiSeq consensus sequence", "DNA", 69, 102], ["the DRS consensus", "TEST", 24, 41], ["average", "OBSERVATION_MODIFIER", 4, 11]]], ["Other studies using DRS have achieved similar values with 93-97% identity when sequencing viruses from cell culture [20, 33] , or up to 99% consensus identity for influenza A [18] .", [["cell", "ANATOMY", 103, 107], ["influenza", "DISEASE", 163, 172], ["cell", "CELL", 103, 107], ["Other studies", "TEST", 0, 13], ["sequencing viruses", "PROBLEM", 79, 97], ["cell culture", "TEST", 103, 115], ["influenza A", "PROBLEM", 163, 174]]], ["For applications with samples with low target concentration such as patient samples, getting enough sequencing depth to obtain accurate consensus sequences constitutes a challenge for the method.", [["samples", "ANATOMY", 22, 29], ["samples", "ANATOMY", 76, 83], ["patient", "ORGANISM", 68, 75], ["consensus sequences", "DNA", 136, 155], ["patient", "SPECIES", 68, 75], ["samples", "TEST", 22, 29], ["low target concentration", "TREATMENT", 35, 59], ["the method", "TREATMENT", 184, 194]]], ["The resulting consensus sequences might therefore be of limited use for applications which require high accuracy, such as phylogenomic analysis.", [["consensus sequences", "DNA", 14, 33], ["The resulting consensus sequences", "TEST", 0, 33], ["phylogenomic analysis", "TEST", 122, 143]]], ["However, for the purpose of genotype identification, the approach is sufficiently accurate, especially as it can provide long reads, which can facilitate mapping to the correct reference, and expedite downstream bioinformatic analyses.", [["genotype identification", "TEST", 28, 51]]], ["Furthermore, different EV genotypes have <75% nucleotide identity in the VP1 region [34, 35] , which makes VP1-based genotype identification possible even with the current high error rate of DRS (modal read accuracy of >90% [14] ) when considering read length above few hundred bases.DiscussionOur wet laboratory approaches were refined during the course of the study while analyzing further samples, and the experiments had to be adapted to limited patient material availability.", [["nucleotide", "CHEMICAL", 46, 56], ["nucleotide", "CHEMICAL", 46, 56], ["VP1", "GENE_OR_GENE_PRODUCT", 107, 110], ["patient", "ORGANISM", 450, 457], ["VP1 region", "DNA", 73, 83], ["patient", "SPECIES", 450, 457], ["different EV genotypes", "TEST", 13, 35], ["nucleotide identity", "TEST", 46, 65], ["VP1", "TEST", 107, 110], ["accuracy", "TEST", 207, 215], ["the study", "TEST", 358, 367], ["analyzing further samples", "TEST", 374, 399], ["VP1", "ANATOMY", 73, 76], ["region", "ANATOMY_MODIFIER", 77, 83], ["bases", "ANATOMY_MODIFIER", 278, 283]]], ["The good overall agreement in EV detection between the two NGS approaches suggests that the variability observed in number of reads and composition between samples may be attributable to the natural biological variability that may exist between the sampled patients.", [["samples", "ANATOMY", 156, 163], ["patients", "ORGANISM", 257, 265], ["patients", "SPECIES", 257, 265], ["EV detection", "TEST", 30, 42], ["the variability", "PROBLEM", 88, 103], ["good", "OBSERVATION_MODIFIER", 4, 8]]], ["Yet, finer differences in composition between samples may be explained by the sequencing technology and by the different pre-treatments of the samples: on the one hand, smaller cDNA molecules produced by the wet laboratory procedure (cDNA synthesis, bead cleaning), followed by short-read sequencing, may be easier to detect, than larger, intact RNA molecules via DRS.", [["samples", "ANATOMY", 46, 53], ["samples", "ANATOMY", 143, 150], ["samples", "CANCER", 46, 53], ["cDNA molecules", "PROTEIN", 177, 191], ["RNA molecules", "PROTEIN", 346, 359], ["smaller cDNA molecules", "PROBLEM", 169, 191], ["the wet laboratory procedure", "TREATMENT", 204, 232], ["cDNA synthesis", "TREATMENT", 234, 248], ["bead cleaning", "TREATMENT", 250, 263], ["finer", "OBSERVATION_MODIFIER", 5, 10], ["differences", "OBSERVATION_MODIFIER", 11, 22], ["smaller", "OBSERVATION_MODIFIER", 169, 176], ["cDNA molecules", "OBSERVATION", 177, 191], ["RNA molecules", "OBSERVATION", 346, 359]]], ["On the other hand, unreliable mapping and poor taxonomical identification may be produced by short reads aligning to genomic regions that are conserved among genotypes, but also by long, error-prone nanopore reads [14] aligning incorrectly to reference sequences.", [["genomic regions", "DNA", 117, 132], ["reference sequences", "DNA", 243, 262], ["unreliable mapping", "TEST", 19, 37], ["poor taxonomical identification", "PROBLEM", 42, 73]]], ["Therefore, further large-scale comparisons of the two NGS approaches would be needed to confirm or reject the hypothesis about the effect of read length on organism detectability in metagenomic or metatranscriptomic studies.DiscussionWhile enteroviruses were detected in all tested samples using DRS, it should be noted that these were all samples with relatively high viral load, i.e., low Ct values.", [["samples", "ANATOMY", 282, 289], ["samples", "ANATOMY", 340, 347], ["enteroviruses", "ORGANISM", 240, 253], ["the two NGS approaches", "TREATMENT", 46, 68], ["the hypothesis", "PROBLEM", 106, 120], ["organism detectability", "PROBLEM", 156, 178], ["metagenomic or metatranscriptomic studies", "TEST", 182, 223], ["enteroviruses", "PROBLEM", 240, 253], ["relatively high viral load", "PROBLEM", 353, 379], ["large", "OBSERVATION_MODIFIER", 19, 24]]], ["With a range of only 16-315 total reads mapping to enteroviruses for the three clinical samples, the approach was close to miss EV detection in those samples.", [["samples", "ANATOMY", 88, 95], ["samples", "ANATOMY", 150, 157], ["enteroviruses", "DISEASE", 51, 64], ["enteroviruses", "ORGANISM", 51, 64], ["enteroviruses", "TREATMENT", 51, 64]]], ["In the case of sample E590, this sensitivity issue could explain why co-infection by another enterovirus was not detected by DRS, but only by the short-read sequencing-based approach.", [["co-infection", "DISEASE", 69, 81], ["enterovirus", "DISEASE", 93, 104], ["enterovirus", "ORGANISM", 93, 104], ["this sensitivity issue", "PROBLEM", 28, 50], ["co-infection", "PROBLEM", 69, 81], ["another enterovirus", "PROBLEM", 85, 104]]], ["In a recent study on the use of DRS for identification of porcine reproductive and respiratory syndrome virus, viruses could be detected in spike-in samples with 3.4 \u00d7 10 4 viral copies and in clinical samples with 3.8 \u00d7 10 6 viral copies [33] .", [["samples", "ANATOMY", 149, 156], ["samples", "ANATOMY", 202, 209], ["porcine reproductive and respiratory syndrome", "DISEASE", 58, 103], ["porcine reproductive and respiratory syndrome virus", "ORGANISM", 58, 109], ["respiratory syndrome virus", "SPECIES", 83, 109], ["a recent study", "TEST", 3, 17], ["porcine reproductive", "PROBLEM", 58, 78], ["respiratory syndrome virus", "PROBLEM", 83, 109], ["viruses", "PROBLEM", 111, 118], ["samples", "TEST", 149, 156], ["viral copies", "TEST", 173, 185], ["clinical samples", "TEST", 193, 209], ["viral copies", "TEST", 226, 238], ["respiratory syndrome", "OBSERVATION", 83, 103]]], ["Another study has previously reported low sensitivity of nanopore sequencing in a viral metagenomic approach in patient samples with low viral titers, even when sequencing viral genomes via SISPA-based amplification [13] .", [["samples", "ANATOMY", 120, 127], ["patient", "ORGANISM", 112, 119], ["viral genomes", "DNA", 172, 185], ["SISPA", "DNA", 190, 195], ["patient", "SPECIES", 112, 119], ["Another study", "TEST", 0, 13], ["low sensitivity of nanopore sequencing", "PROBLEM", 38, 76], ["a viral metagenomic approach", "TREATMENT", 80, 108], ["patient samples", "TEST", 112, 127], ["low viral titers", "PROBLEM", 133, 149], ["SISPA", "TEST", 190, 195]]], ["An improvement in sensitivity would be necessary before attempting to sequence samples with low viral load in general.", [["samples", "ANATOMY", 79, 86], ["sequence samples", "TEST", 70, 86], ["low viral load", "PROBLEM", 92, 106], ["improvement", "OBSERVATION_MODIFIER", 3, 14]]], ["A limiting factor of the DRS approach was the amount of polyadenylated RNA used for library preparation, as in two of the sequencing runs, the full flowcell sequencing capacity was not used and the sequencing was stopped before maximal run duration, because low amounts of RNA library were loaded on the flowcell.", [["flowcell", "ANATOMY", 304, 312], ["polyadenylated RNA", "RNA", 56, 74], ["the DRS approach", "TREATMENT", 21, 37], ["polyadenylated RNA", "TREATMENT", 56, 74], ["library preparation", "TREATMENT", 84, 103], ["the full flowcell sequencing capacity", "PROBLEM", 139, 176], ["RNA library", "TREATMENT", 273, 284], ["the flowcell", "TREATMENT", 300, 312], ["polyadenylated RNA", "OBSERVATION", 56, 74]]], ["If a sufficient amount of patient samples is available to obtain enough RNA, increasing the input concentration to fulfill the recommended input of at least 500 ng polyadenylated (as opposed to total) RNA might have provided better coverage of the target genome sequences.", [["patient", "ORGANISM", 26, 33], ["500 ng polyadenylated", "RNA", 157, 178], ["total) RNA", "RNA", 194, 204], ["target genome sequences", "DNA", 248, 271], ["patient", "SPECIES", 26, 33], ["the input concentration", "TREATMENT", 88, 111], ["total) RNA", "TREATMENT", 194, 204]]], ["Additionally, results might be improved with adaptations in viral enrichment steps.", [["improved", "OBSERVATION_MODIFIER", 31, 39], ["viral enrichment steps", "OBSERVATION", 60, 82]]], ["We used a chloroform/bead pre-treatment in DRS samples for enrichment of viral capsid and although it might be efficient in enriching viral reads, it could also reduce the overall amount of RNA extracted.", [["chloroform", "CHEMICAL", 10, 20], ["chloroform", "CHEMICAL", 10, 20], ["chloroform", "SIMPLE_CHEMICAL", 10, 20], ["a chloroform/bead pre-treatment", "TREATMENT", 8, 39], ["DRS samples", "TEST", 43, 54], ["viral capsid", "PROBLEM", 73, 85], ["RNA extracted", "PROBLEM", 190, 203], ["viral capsid", "OBSERVATION", 73, 85], ["overall", "OBSERVATION_MODIFIER", 172, 179], ["amount", "OBSERVATION_MODIFIER", 180, 186], ["RNA extracted", "OBSERVATION", 190, 203]]], ["As the maximum sequencing yield of the flowcell was not always reached, perhaps milder enrichment methods might be preferable, especially if the broader diversity of pathogens is to be studied.", [["flowcell", "ANATOMY", 39, 47], ["flowcell", "CANCER", 39, 47], ["milder enrichment methods", "PROBLEM", 80, 105], ["pathogens", "PROBLEM", 166, 175], ["milder", "OBSERVATION_MODIFIER", 80, 86], ["enrichment", "OBSERVATION", 87, 97], ["pathogens", "OBSERVATION", 166, 175]]], ["Currently, the DRS method is restricted to sequencing of polyadenylated RNA.", [["polyadenylated RNA", "RNA", 57, 75], ["the DRS method", "TREATMENT", 11, 25], ["polyadenylated RNA", "PROBLEM", 57, 75], ["polyadenylated RNA", "OBSERVATION", 57, 75]]], ["However, performing polyadenylation of the total RNA fraction could expand its applications.DiscussionAnother characteristic of the DRS method is the expected sequencing bias towards the 3' end of the polyadenylated molecules [14] .", [["3' end", "DNA", 187, 193], ["the total RNA fraction", "TREATMENT", 39, 61]]], ["Hence, coverage of the 5' region of the EV genomes was generally low, which may be problematic given that the VP1 region is the main region used for EV genotyping (e.g., located at position 2207-3082 in Echovirus 30 KT353720.1).", [["VP1", "GENE_OR_GENE_PRODUCT", 110, 113], ["5' region", "DNA", 23, 32], ["EV genomes", "DNA", 40, 50], ["VP1 region", "DNA", 110, 120], ["position 2207-3082", "DNA", 181, 199], ["the EV genomes", "PROBLEM", 36, 50], ["the VP1 region", "PROBLEM", 106, 120], ["EV genotyping", "TEST", 149, 162], ["Echovirus", "TEST", 203, 212], ["main", "OBSERVATION_MODIFIER", 128, 132]]], ["Thus, correct genotyping would require around 4800 bases long RNA reads from the 3' towards the 5' end of the genome sequence.", [["4800 bases long RNA reads", "RNA", 46, 71], ["5' end", "DNA", 96, 102], ["genome sequence", "DNA", 110, 125]]], ["We encountered lesser coverage of the 5' region of the genome with sample E372, although in that instance, we were still able to identify the same genotype as found by the gold-standard VP1 PCR-based approach.", [["5' region", "DNA", 38, 47], ["lesser", "OBSERVATION_MODIFIER", 15, 21], ["coverage", "OBSERVATION_MODIFIER", 22, 30]]], ["However, unambiguous identification relies on the capsid region and its presence is crucial in case of recombinations or co-infections.", [["capsid region", "DNA", 50, 63], ["co-infections", "PROBLEM", 121, 134]]], ["Therefore, great care must be applied during extraction and library preparation to avoid shearing or degrading extracted RNA.", [["extracted RNA", "RNA", 111, 124], ["great care", "TREATMENT", 11, 21], ["extraction", "TREATMENT", 45, 55], ["library preparation", "TREATMENT", 60, 79], ["shearing", "PROBLEM", 89, 97], ["degrading extracted RNA", "PROBLEM", 101, 124]]], ["The known high variability of EV genome sequences makes it necessary to have suitable alternatives for genotype identification available if PCR-based approaches fail.", [["EV genome sequences", "DNA", 30, 49], ["The known high variability of EV genome sequences", "PROBLEM", 0, 49], ["genotype identification", "TEST", 103, 126], ["PCR", "TEST", 140, 143], ["high variability", "OBSERVATION_MODIFIER", 10, 26]]], ["In such cases, DRS of patient samples could be a valuable alternative, as the sequencing is primer independent and the sequences of long, native RNA molecules are recovered.", [["samples", "ANATOMY", 30, 37], ["patient", "ORGANISM", 22, 29], ["patient", "SPECIES", 22, 29]]], ["Additionally, as is the case with all nanopore sequencing, the data is available in real time, which can provide faster identification and a sequencing-on-demand approach to molecular assays.DiscussionOverall, our proof-of-concept study demonstrated the possibilities offered by the DRS technique for genotype identification of human enteroviruses directly from clinical samples.", [["samples", "ANATOMY", 371, 378], ["human", "ORGANISM", 328, 333], ["enteroviruses", "ORGANISM", 334, 347], ["human", "SPECIES", 328, 333], ["human", "SPECIES", 328, 333], ["all nanopore sequencing", "TREATMENT", 34, 57], ["a sequencing", "TEST", 139, 151], ["molecular assays", "TEST", 174, 190], ["concept study", "TEST", 223, 236], ["the DRS technique", "TEST", 279, 296], ["human enteroviruses", "PROBLEM", 328, 347], ["clinical samples", "TEST", 362, 378]]], ["The method requires further optimization to improve the overall sensitivity and to lower costs for possible applications in routine diagnostics.", [["further optimization", "TREATMENT", 20, 40], ["the overall sensitivity", "PROBLEM", 52, 75], ["routine diagnostics", "TEST", 124, 143]]], ["However, with the rapid advancement of the technologies, those issues will likely improve in the near future.DiscussionSupplementary Materials: The following are available online at http://www.mdpi.com/1999-4915/12/8/841/s1, Table S1 : Summary of laboratory experiments; Table S2 : Summary of nanopore sequencing data; Table S3 : Summary of Illumina sequencing data.", [["Illumina sequencing data", "TEST", 341, 365]]], ["The sponsor had no role in the design, execution, interpretation, or writing of the study.", [["the study", "TEST", 80, 89]]]], "1f7e778c5dcba7834b252eb31c9a2daee96d6cd0": [["INTRODUCTIONInfectious diseases can lead to illness, human suffering, economic costs, medical complications, hospitalization, disability, and death.", [["illness", "DISEASE", 44, 51], ["disability", "DISEASE", 126, 136], ["death", "DISEASE", 142, 147], ["human", "ORGANISM", 53, 58], ["human", "SPECIES", 53, 58], ["human", "SPECIES", 53, 58], ["INTRODUCTIONInfectious diseases", "PROBLEM", 0, 31], ["illness", "PROBLEM", 44, 51], ["medical complications", "PROBLEM", 86, 107], ["death", "PROBLEM", 142, 147]]], ["Besides sanitation and clean water, vaccines have had the greatest impact on human health and longevity (1) .", [["human", "ORGANISM", 77, 82], ["human", "SPECIES", 77, 82], ["human", "SPECIES", 77, 82], ["vaccines", "TREATMENT", 36, 44]]], ["The cost of vaccine-preventable diseases (VPD) just in the USA during 2015 was estimated at $9 billion (2) .", [["vaccine", "TREATMENT", 12, 19], ["preventable diseases (VPD)", "PROBLEM", 20, 46]]], ["From 2011-2020, one model estimated that 23.3 million deaths worldwide will have been averted by vaccines (3) .", [["deaths", "DISEASE", 54, 60]]], ["In the 2017-2018 influenza season, it is estimated that almost one million Americans were hospitalized and 90,000 died due to influenza (4) .", [["influenza", "DISEASE", 17, 26], ["influenza", "DISEASE", 126, 135], ["influenza", "PROBLEM", 126, 135]]], ["Worldwide, it is estimated that, between 2000 and 2014, 17.1 million deaths due to measles were averted by the use of the measles vaccine (5) .INTRODUCTIONWhile there are over 1,400 known species of human pathogens with more being discovered every year, in the US, licensed vaccines exist for only 26 pathogens (6) .", [["deaths", "DISEASE", 69, 75], ["measles", "DISEASE", 83, 90], ["human", "ORGANISM", 199, 204], ["human", "SPECIES", 199, 204], ["human", "SPECIES", 199, 204], ["measles", "PROBLEM", 83, 90], ["the measles vaccine", "TREATMENT", 118, 137], ["human pathogens", "PROBLEM", 199, 214], ["licensed vaccines", "TREATMENT", 265, 282]]], ["Preventing infections with vaccines is a complex, costly, and lengthy process that requires overcoming multiple challenges before resulting in a safe and effective product (Box 1).", [["infections", "DISEASE", 11, 21], ["Box 1", "PROTEIN", 173, 178], ["infections", "PROBLEM", 11, 21], ["vaccines", "TREATMENT", 27, 35], ["infections", "OBSERVATION", 11, 21]]], ["Historically, vaccine development has followed an empiric \"isolate, inactivate and inject\" paradigm, whereby the disease-causing pathogen or its disease-mediating entity (e.g., a toxin) is identified, inactivated, and injected in order to elicit a protective immune response (7) (8) (9) .", [["vaccine", "TREATMENT", 14, 21], ["an empiric \"isolate", "TREATMENT", 47, 66], ["the disease", "PROBLEM", 109, 120], ["pathogen", "PROBLEM", 129, 137], ["its disease", "PROBLEM", 141, 152], ["disease", "OBSERVATION", 113, 120]]], ["This empiric method, developed before the genetic revolution, enabled the development of many early and effective vaccines against pathogens such as influenza, tetanus, diphtheria, and pertussis.", [["influenza, tetanus, diphtheria, and pertussis", "DISEASE", 149, 194], ["This empiric method", "TREATMENT", 0, 19], ["effective vaccines", "TREATMENT", 104, 122], ["pathogens", "PROBLEM", 131, 140], ["influenza", "PROBLEM", 149, 158], ["tetanus", "PROBLEM", 160, 167], ["diphtheria", "PROBLEM", 169, 179], ["pertussis", "PROBLEM", 185, 194]]], ["In the case of viruses, including smallpox, measles, mumps, rubella, and smallpox, a parallel approach has been to substitute inactivation with attenuation.INTRODUCTIONWhile this empiric approach has led to tremendous successes, the work is far from finished; major, significant barriers remain (Figure 1 ).", [["smallpox", "DISEASE", 34, 42], ["measles, mumps, rubella, and smallpox", "DISEASE", 44, 81], ["measles", "ORGANISM", 44, 51], ["viruses", "PROBLEM", 15, 22], ["smallpox", "PROBLEM", 34, 42], ["measles", "PROBLEM", 44, 51], ["mumps", "PROBLEM", 53, 58], ["rubella", "PROBLEM", 60, 67], ["smallpox", "PROBLEM", 73, 81], ["a parallel approach", "TREATMENT", 83, 102], ["this empiric approach", "TREATMENT", 174, 195], ["viruses", "OBSERVATION", 15, 22], ["attenuation", "OBSERVATION_MODIFIER", 144, 155]]], ["This review focuses on five of these barriers: an incomplete understanding of how immunity develops, host and pathogen genetic variability, problems related to vaccine safety, and both environmental (e.g., nutrition, obesity) and geographic BOX 1 | Current Challenges Facing Vaccine Development Efforts.", [["obesity", "DISEASE", 217, 224], ["vaccine safety", "TREATMENT", 160, 174], ["obesity", "PROBLEM", 217, 224], ["Current Challenges Facing Vaccine", "TREATMENT", 249, 282]]], ["The creation of new vaccines is a slow, systematic, expensive, and laborious process that requires coordination between scientists, physicians, public health of cials, industry and vaccine developers, and society.", [["new vaccines", "TREATMENT", 16, 28], ["a slow, systematic, expensive, and laborious process", "PROBLEM", 32, 84], ["new", "OBSERVATION_MODIFIER", 16, 19], ["vaccines", "OBSERVATION", 20, 28]]], ["These shareholders must work together in order for us to overcome the listed challenges in order to successfully development safe and effective vaccines that see widespread use.INTRODUCTION\u2022 High (and increasing) costs for vaccine development (\u223c$700 million-$1 billion) \u2022 Current pathogens require more complicated vaccines \u2022 Low ef cacy of some licensed vaccines \u2022 Business models prioritize vaccines by market potential, not by public health need \u2022 Aging world population that respond poorly to most vaccines (immunosenescence)INTRODUCTION\u2022 Limited number of approved and acceptable adjuvantsINTRODUCTION\u2022 Concurrent health problems in developing world that compromise immune response (nutrition, co-infection)INTRODUCTION\u2022 Incomplete or inadequate understanding of biology, pathogenesis, and/or immunology of emerging pathogens \u2022 Inability to properly attenuate pathogens OR risk of reversion to wild type organism \u2022 Humoral immune responses do not always correlate with protection \u2022 Inappropriate/harmful immune response (formalin-inactivated RSV products) or enhanced disease upon re-infection (Dengue)INTRODUCTION\u2022 Inadequate durability of immune response (ex.", [["co-infection", "DISEASE", 699, 711], ["Dengue", "DISEASE", 1100, 1106], ["formalin", "CHEMICAL", 1026, 1034], ["formalin", "SIMPLE_CHEMICAL", 1026, 1034], ["RSV", "ORGANISM", 1047, 1050], ["RSV", "SPECIES", 1047, 1050], ["effective vaccines", "TREATMENT", 134, 152], ["vaccine development", "TREATMENT", 223, 242], ["Current pathogens", "PROBLEM", 272, 289], ["more complicated vaccines", "TREATMENT", 298, 323], ["some licensed vaccines", "TREATMENT", 341, 363], ["immune response", "PROBLEM", 671, 686], ["emerging pathogens", "PROBLEM", 812, 830], ["pathogens", "PROBLEM", 865, 874], ["wild type organism", "PROBLEM", 899, 917], ["Humoral immune responses", "TREATMENT", 920, 944], ["Inappropriate/harmful immune response", "PROBLEM", 987, 1024], ["formalin", "TEST", 1026, 1034], ["inactivated RSV products", "TREATMENT", 1035, 1059], ["enhanced disease", "PROBLEM", 1064, 1080], ["immune response", "PROBLEM", 1146, 1161]]], ["Pertussis) FIGURE 1 | Barriers to vaccine development.", [["Pertussis", "DISEASE", 0, 9], ["Pertussis", "PROBLEM", 0, 9]]], ["Vaccines are the most effective public health tool for controlling infectious diseases.", [["infectious diseases", "DISEASE", 67, 86], ["Vaccines", "TREATMENT", 0, 8], ["controlling infectious diseases", "PROBLEM", 55, 86]]], ["Despite considerable success, there is room for improvement in many current vaccines and there are a large number of new and re-emerging pathogens for which we do not have effective vaccines.", [["many current vaccines", "TREATMENT", 63, 84], ["new and re-emerging pathogens", "PROBLEM", 117, 146], ["effective vaccines", "TREATMENT", 172, 190], ["large", "OBSERVATION_MODIFIER", 101, 106], ["number", "OBSERVATION_MODIFIER", 107, 113], ["new", "OBSERVATION_MODIFIER", 117, 120], ["re-emerging", "OBSERVATION_MODIFIER", 125, 136], ["pathogens", "OBSERVATION", 137, 146]]], ["Vaccine development faces a number of challenges, many of which are presented here.", [["Vaccine", "TREATMENT", 0, 7]]], ["Developing vaccines to combat current and future pathogens will require us to overcome those challenges and recent developments in genomic technologies may provide the solutions that we need.INTRODUCTIONfactors (e.g., maintaining a cold chain in Sub-Saharan Africa, co-infection in tropical climates) that compromise vaccine usage or efficacy.", [["co-infection", "DISEASE", 266, 278], ["Developing vaccines", "TREATMENT", 0, 19], ["future pathogens", "PROBLEM", 42, 58], ["those challenges", "TREATMENT", 87, 103], ["genomic technologies", "TREATMENT", 131, 151], ["the solutions", "TREATMENT", 164, 177], ["a cold chain", "TREATMENT", 230, 242], ["co-infection in tropical climates", "TREATMENT", 266, 299]]], ["Because of these barriers, the traditional empiric approach has been ineffective for developing vaccines against hypervariable and highly complex pathogens, such as Mycobacterium tuberculosis, malaria-causing Plasmodium, hookworm, HIV, HCV, coronaviruses, among others.", [["Mycobacterium tuberculosis", "DISEASE", 165, 191], ["malaria-causing Plasmodium, hookworm, HIV, HCV, coronaviruses", "DISEASE", 193, 254], ["Mycobacterium tuberculosis", "ORGANISM", 165, 191], ["Plasmodium", "ORGANISM", 209, 219], ["hookworm", "ORGANISM", 221, 229], ["HIV", "ORGANISM", 231, 234], ["HCV", "ORGANISM", 236, 239], ["Mycobacterium tuberculosis", "SPECIES", 165, 191], ["HIV", "SPECIES", 231, 234], ["Mycobacterium tuberculosis", "SPECIES", 165, 191], ["HIV", "SPECIES", 231, 234], ["HCV", "SPECIES", 236, 239], ["the traditional empiric approach", "TREATMENT", 27, 59], ["developing vaccines", "TREATMENT", 85, 104], ["hypervariable and highly complex pathogens", "PROBLEM", 113, 155], ["Mycobacterium tuberculosis", "PROBLEM", 165, 191], ["malaria", "PROBLEM", 193, 200], ["Plasmodium", "PROBLEM", 209, 219], ["hookworm", "PROBLEM", 221, 229], ["HIV", "PROBLEM", 231, 234], ["HCV", "PROBLEM", 236, 239], ["coronaviruses", "PROBLEM", 241, 254], ["complex", "OBSERVATION_MODIFIER", 138, 145], ["pathogens", "OBSERVATION", 146, 155], ["Mycobacterium tuberculosis", "OBSERVATION", 165, 191]]], ["This is due to their complex life cycles, the ability of these pathogens to rapidly alter their surface proteins (i.e., antigenic variation) and other mechanisms by which the pathogen can evade host detection and the host immune response.", [["surface", "ANATOMY", 96, 103], ["surface proteins", "PROTEIN", 96, 112], ["their complex life cycles", "TREATMENT", 15, 40], ["these pathogens", "PROBLEM", 57, 72]]], ["Complex immunology can also be a barrier; for example, the recent demonstration of antibody-dependent disease enhancement which has hindered the development and use of the recently licensed Dengue vaccine (10) .INTRODUCTIONIn response to the challenges posed by these barriers, novel approaches such as vaccinomics (which aims to understand genomic and systems-level data to elucidate the basis of inter-individual variations in immune responses), reverse vaccinology (which uses genetic sequence information to identify immunogenic antigens), and structure-based vaccine design have been developed to take advantage of high-dimensional tools and techniques and generate novel data that can be leveraged to create new vaccine products (Figure 2 ) (11) (12) (13) .", [["Dengue", "DISEASE", 190, 196], ["Dengue", "ORGANISM", 190, 196], ["immunogenic antigens", "PROTEIN", 521, 541], ["antibody-dependent disease enhancement", "PROBLEM", 83, 121], ["the recently licensed Dengue vaccine", "TREATMENT", 168, 204], ["novel approaches", "TREATMENT", 278, 294], ["vaccinomics", "TREATMENT", 303, 314], ["immunogenic antigens", "PROBLEM", 521, 541], ["structure-based vaccine", "TREATMENT", 548, 571], ["new vaccine products", "TREATMENT", 714, 734], ["antibody", "OBSERVATION", 83, 91], ["dependent", "OBSERVATION_MODIFIER", 92, 101], ["disease", "OBSERVATION", 102, 109]]], ["In the past decade, new vaccines, including the licensed Meningococcus B vaccine, have been designed and developed using such genomics-based approaches (14, 15) .", [["Meningococcus B", "CHEMICAL", 57, 72], ["Meningococcus B vaccine", "ORGANISM", 57, 80], ["Meningococcus B vaccine", "SPECIES", 57, 80], ["Meningococcus B", "SPECIES", 57, 72], ["new vaccines", "TREATMENT", 20, 32], ["the licensed Meningococcus B vaccine", "TREATMENT", 44, 80]]], ["With the increasing sophistication and decreased expense of gene-based assays and next-generation sequencing technologies, genomics is accelerating the development of new vaccines in the twenty-first century-closely paralleling the application of genomics to other aspects of human medicine, such as individualized medicine.INTRODUCTIONGenetics has expanded far beyond the simple nucleic acid sequence of a given organism.", [["nucleic acid", "CHEMICAL", 380, 392], ["human", "ORGANISM", 276, 281], ["human", "SPECIES", 276, 281], ["human", "SPECIES", 276, 281], ["the increasing sophistication", "PROBLEM", 5, 34], ["gene-based assays", "TREATMENT", 60, 77], ["next-generation sequencing technologies", "TREATMENT", 82, 121], ["new vaccines", "TREATMENT", 167, 179], ["human medicine", "TREATMENT", 276, 290], ["individualized medicine", "TREATMENT", 300, 323], ["INTRODUCTIONGenetics", "TREATMENT", 324, 344], ["organism", "PROBLEM", 413, 421], ["increasing", "OBSERVATION_MODIFIER", 9, 19], ["sophistication", "OBSERVATION", 20, 34], ["decreased", "OBSERVATION_MODIFIER", 39, 48], ["new", "OBSERVATION_MODIFIER", 167, 170]]], ["Similarly, genomics has also expanded in scope to include the comprehensive characterization of gene expression, regulation, interdependency, pre-and post-transcriptional modifications, gene editing, epistasis, complementarity, pleiotropy, and other complex interactions (23) .INTRODUCTIONGenomics is not the only area that has undergone remarkable transformation recently in terms of the technologies and platforms that can be used to design, create, and study vaccines.", [["gene expression", "PROBLEM", 96, 111], ["pre-and post-transcriptional modifications", "PROBLEM", 142, 184], ["gene editing", "PROBLEM", 186, 198], ["epistasis", "PROBLEM", 200, 209], ["pleiotropy", "PROBLEM", 228, 238], ["study vaccines", "TREATMENT", 456, 470], ["expanded", "OBSERVATION_MODIFIER", 29, 37], ["gene expression", "OBSERVATION", 96, 111], ["remarkable", "OBSERVATION_MODIFIER", 338, 348], ["transformation", "OBSERVATION", 349, 363]]], ["Examples include the following: mass cytometry, which allows for incredibly complex immunophenotyping (24, 25) ; proteomics and mass spectrometry (26) (27) (28) (29) (30) ; and metabolomics, which has been closely linked to immunologic function and vaccine response (31) (32) (33) .", [["mass cytometry", "TEST", 32, 46], ["incredibly complex immunophenotyping", "PROBLEM", 65, 101], ["proteomics and mass spectrometry", "TEST", 113, 145], ["metabolomics", "TEST", 177, 189], ["immunologic function", "TEST", 224, 244], ["vaccine response", "TEST", 249, 265]]], ["However, in this focused review, we will explore how genomics and recent genomic technologies have impacted vaccine development and may provide solutions to both the long-standing barriers in vaccine design and the new challenges posed by new and re-emerging pathogens of public health importance.", [["recent genomic technologies", "PROBLEM", 66, 93], ["the long-standing barriers in vaccine design", "TREATMENT", 162, 206]]], ["Creative application of these tools and the biological insights that they provide are poised to truly revolutionize how we design, develop, test, and deploy vaccines (Figure 3 ).BARRIER #1: INCOMPLETE UNDERSTANDING OF HOW IMMUNITY DEVELOPSThe human immune system is incredibly complex, with multiple tissues and organs, dozens of different signaling pathways FIGURE 2 | The use of vaccinomics in new vaccine development.", [["immune system", "ANATOMY", 249, 262], ["tissues", "ANATOMY", 300, 307], ["organs", "ANATOMY", 312, 318], ["human", "ORGANISM", 243, 248], ["tissues", "TISSUE", 300, 307], ["organs", "ORGAN", 312, 318], ["human", "SPECIES", 243, 248], ["human", "SPECIES", 243, 248], ["these tools", "TEST", 24, 35], ["test", "TEST", 140, 144], ["multiple tissues and organs", "PROBLEM", 291, 318], ["vaccinomics", "TREATMENT", 381, 392], ["new vaccine development", "TREATMENT", 396, 419], ["organs", "ANATOMY", 312, 318]]], ["A wide array of genomic tools and techniques are available for researchers to study various aspects of pathogen biology and host physiology and immune response.", [["wide", "OBSERVATION_MODIFIER", 2, 6]]], ["Vaccinomics and similar approaches represent toolboxes that contain a specific assortment of laboratory assays, statistical analysis routines, bioinformatic methods, and computational models that can be used to generate an appropriate dataset and extract biologically meaningful results from the data.", [["Vaccinomics", "TREATMENT", 0, 11], ["laboratory assays", "TEST", 93, 110], ["statistical analysis routines", "TEST", 112, 141], ["bioinformatic methods", "TEST", 143, 164], ["the data", "TEST", 292, 300]]], ["GWAS, genome wide association study; bnAbs, broadly neutralizing antibodies.", [["bnAbs", "PROTEIN", 37, 42], ["neutralizing antibodies", "PROTEIN", 52, 75], ["genome wide association study", "TEST", 6, 35], ["bnAbs", "PROBLEM", 37, 42], ["broadly neutralizing antibodies", "PROBLEM", 44, 75]]], ["The results generated by genomic approaches inform each stage of vaccine development.", [["vaccine development", "TREATMENT", 65, 84]]], ["Initial genomics work plays a critical role in discovering new vaccine targets.", [["new vaccine targets", "TREATMENT", 59, 78]]], ["Finally, application of the findings assists in the design and completion of phase I-IV clinical trials.BARRIER #1: INCOMPLETE UNDERSTANDING OF HOW IMMUNITY DEVELOPS(34), hundreds of different cells (35) , thousands of different effector molecules, and an effectively infinite ability to recognize foreign antigens (36)-all of which must be \"choreographed\" effectively, kinetically, and in proper sequence.", [["cells", "ANATOMY", 193, 198], ["cells", "CELL", 193, 198], ["effector molecules", "PROTEIN", 229, 247], ["foreign antigens", "PROTEIN", 298, 314], ["IV clinical trials", "TREATMENT", 85, 103], ["different effector molecules", "PROBLEM", 219, 247], ["effector molecules", "OBSERVATION", 229, 247]]], ["Immunologists have developed a large and comprehensive (but by no means complete) catalog of the individual parts that make up the system (37) (38) (39) ; however, our reductionist understanding of how these parts collaboratively function as a \"system\" has lagged behind (40) .", [["large", "OBSERVATION_MODIFIER", 31, 36]]], ["In short, we do not comprehensively understand the rules governing the behavior of the system and therefore cannot reliably and consistently predict the outcome of a given infection or vaccination (43) .", [["infection", "DISEASE", 172, 181], ["infection", "PROBLEM", 172, 181]]], ["Developing this understanding is a critical first step in our ability to predict and eventually manipulate the immune system in order to achieve the desired outcome of protective immunity (44) .", [["immune system", "ANATOMY", 111, 124], ["immune system", "ANATOMICAL_SYSTEM", 111, 124]]], ["This is the knowledge gap that systems biology and vaccinomics paradigms seek to fill by capturing complex relationships among immune components as the host responds to infection or vaccination-rather than simple reductionist approaches to single components of the system.", [["infection", "DISEASE", 169, 178], ["vaccinomics paradigms", "TREATMENT", 51, 72], ["immune components", "TREATMENT", 127, 144], ["infection", "PROBLEM", 169, 178], ["vaccination", "TREATMENT", 182, 193], ["simple reductionist approaches", "TREATMENT", 206, 236], ["infection", "OBSERVATION", 169, 178]]], ["These studies have been made possible by our growing ability to measure increasingly larger and more complete collections of molecules.", [["These studies", "TEST", 0, 13], ["larger", "OBSERVATION_MODIFIER", 85, 91], ["more complete", "OBSERVATION_MODIFIER", 96, 109], ["collections", "OBSERVATION", 110, 121], ["molecules", "OBSERVATION", 125, 134]]], ["For example, instead of a single quantitative PCR reaction, we can use next generation sequencing to simultaneously sequence millions of different DNA or RNA molecules (45, 46) .", [["DNA", "CELLULAR_COMPONENT", 147, 150], ["RNA molecules", "PROTEIN", 154, 167], ["a single quantitative PCR reaction", "PROBLEM", 24, 58], ["different DNA or RNA molecules", "PROBLEM", 137, 167]]], ["We can characterize comprehensive changes within each cell's entire transcriptome, epigenome, proteome, metabolome, and multiple other \"-omes\" (47) (48) (49) .", [["cell", "ANATOMY", 54, 58], ["cell", "CELL", 54, 58]]], ["We can characterize the cell types and sub-types involved in the response, their phenotype, their activation state, and their biological functions (50, 51) .", [["cell", "ANATOMY", 24, 28], ["cell", "CELL", 24, 28], ["cell types", "OBSERVATION", 24, 34]]], ["We can capture the signals generated by multiple signaltransduction pathways inside each cell (52) and observe the communication occurring between cells in normal health (53) and during infection (54) .", [["cell", "ANATOMY", 89, 93], ["cells", "ANATOMY", 147, 152], ["infection", "DISEASE", 186, 195], ["cell", "CELL", 89, 93], ["cells", "CELL", 147, 152], ["infection", "PROBLEM", 186, 195]]], ["Collectively, these technologies have been applied to understanding immune function, hostpathogen interactions, pathogen genetics, and pathogenesis in unprecedented detail (55) (56) (57) (58) .BARRIER #1: INCOMPLETE UNDERSTANDING OF HOW IMMUNITY DEVELOPSA central organizing feature of these efforts is a focus on genomics, as gene expression is considered a critical first step because immune cells recognize and react to foreign antigens.", [["immune cells", "ANATOMY", 387, 399], ["immune cells", "CELL", 387, 399], ["immune cells", "CELL_TYPE", 387, 399], ["foreign antigens", "PROTEIN", 423, 439], ["immune cells", "PROBLEM", 387, 399]]], ["Consequently, each of these studies has a primary goal of understanding the transcriptomic changes that occur during the development of an immune response.", [["these studies", "TEST", 22, 35], ["the transcriptomic changes", "PROBLEM", 72, 98], ["immune response", "OBSERVATION", 139, 154]]], ["Querec et al. first applied high-throughput data to the characterization of yellow fever vaccine response in humans (59) .", [["yellow fever", "DISEASE", 76, 88], ["yellow fever", "ORGANISM", 76, 88], ["humans", "ORGANISM", 109, 115], ["yellow fever vaccine", "SPECIES", 76, 96], ["humans", "SPECIES", 109, 115], ["humans", "SPECIES", 109, 115], ["yellow fever", "PROBLEM", 76, 88]]], ["Systems analysis was used to discover a distinct molecular signature that predicted the neutralizing antibody (Ab) (i.e., TNFRS17 gene signature) and antigen-specific CD8+ T cell (i.e., C1QB and EIF2AK3 gene signature) responses to the live attenuated yellow fever vaccine YF-17D in humans with up to 100 and 90% accuracy, respectively (59) .", [["CD8+ T cell", "ANATOMY", 167, 178], ["yellow fever", "DISEASE", 252, 264], ["YF-17D", "CHEMICAL", 273, 279], ["Ab", "GENE_OR_GENE_PRODUCT", 111, 113], ["TNFRS17", "GENE_OR_GENE_PRODUCT", 122, 129], ["CD8", "GENE_OR_GENE_PRODUCT", 167, 170], ["C1QB", "GENE_OR_GENE_PRODUCT", 186, 190], ["EIF2AK3", "GENE_OR_GENE_PRODUCT", 195, 202], ["yellow fever", "ORGANISM", 252, 264], ["YF-17D", "ORGANISM", 273, 279], ["humans", "ORGANISM", 283, 289], ["neutralizing antibody", "PROTEIN", 88, 109], ["Ab", "PROTEIN", 111, 113], ["TNFRS17 gene signature", "DNA", 122, 144], ["CD8", "PROTEIN", 167, 170], ["yellow fever vaccine", "SPECIES", 252, 272], ["humans", "SPECIES", 283, 289], ["yellow fever vaccine YF-17D", "SPECIES", 252, 279], ["humans", "SPECIES", 283, 289], ["Systems analysis", "TEST", 0, 16], ["a distinct molecular signature", "PROBLEM", 38, 68], ["the neutralizing antibody", "TEST", 84, 109], ["antigen", "TEST", 150, 157], ["C1QB", "TEST", 186, 190], ["the live attenuated yellow fever vaccine", "PROBLEM", 232, 272]]], ["Because expression levels of the genes identified in this study were highly predictive of both humoral and cellmediated immune responses, these signatures can potentially function as early biomarkers of vaccine response, efficacy, and even safety.", [["expression levels of the genes", "PROBLEM", 8, 38], ["this study", "TEST", 53, 63]]], ["Similarly, Dunachie et al. identified a gene expression signature that correlates with vaccine-induced protection in a human malaria challenge model in which the expression of genes associated with IFN induction and with antigen presentation correlated with protection against malaria (60) .BARRIER #1: INCOMPLETE UNDERSTANDING OF HOW IMMUNITY DEVELOPSTranscriptomic studies can reveal important factors controlling disease susceptibility and clinical outcomes during infection or vaccination.", [["malaria", "DISEASE", 125, 132], ["malaria", "DISEASE", 277, 284], ["infection", "DISEASE", 468, 477], ["human", "ORGANISM", 119, 124], ["IFN", "GENE_OR_GENE_PRODUCT", 198, 201], ["IFN", "PROTEIN", 198, 201], ["human", "SPECIES", 119, 124], ["human", "SPECIES", 119, 124], ["a gene expression signature", "PROBLEM", 38, 65], ["vaccine", "TREATMENT", 87, 94], ["a human malaria challenge model", "TREATMENT", 117, 148], ["IFN induction", "TREATMENT", 198, 211], ["malaria", "PROBLEM", 277, 284], ["DEVELOPSTranscriptomic studies", "TEST", 344, 374], ["disease susceptibility", "PROBLEM", 416, 438], ["infection", "PROBLEM", 468, 477], ["vaccination", "TREATMENT", 481, 492], ["expression signature", "OBSERVATION", 45, 65]]], ["Through mechanisms that are not fully understood, clinical symptoms of dengue virus infection range from asymptomatic or mild disease (80%) to severe, life-threatening dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS).", [["dengue virus infection", "DISEASE", 71, 93], ["dengue hemorrhagic fever", "DISEASE", 168, 192], ["DHF", "DISEASE", 194, 197], ["dengue shock syndrome", "DISEASE", 202, 223], ["DSS", "DISEASE", 225, 228], ["dengue virus", "ORGANISM", 71, 83], ["dengue virus", "SPECIES", 71, 83], ["dengue hemorrhagic fever", "SPECIES", 168, 192], ["dengue virus", "SPECIES", 71, 83], ["clinical symptoms", "PROBLEM", 50, 67], ["dengue virus infection", "PROBLEM", 71, 93], ["asymptomatic or mild disease", "PROBLEM", 105, 133], ["life-threatening dengue hemorrhagic fever", "PROBLEM", 151, 192], ["DHF", "PROBLEM", 194, 197], ["dengue shock syndrome", "PROBLEM", 202, 223], ["mild", "OBSERVATION_MODIFIER", 121, 125], ["disease", "OBSERVATION", 126, 133], ["severe", "OBSERVATION_MODIFIER", 143, 149], ["hemorrhagic", "OBSERVATION_MODIFIER", 175, 186], ["fever", "OBSERVATION", 187, 192], ["shock syndrome", "OBSERVATION", 209, 223]]], ["Transcriptomic profiling of the central nervous system (CNS) of mice infected with dengue identified putative innate signaling pathways (IFN signaling, IL-10, GM-CSF, PDGF), antigen processing, and complement activation signatures, which suggests that innate immune responses may serve to limit dengue virus replication in the CNS and thereby reduce disease severity (61) .", [["central nervous system", "ANATOMY", 32, 54], ["CNS", "ANATOMY", 56, 59], ["CNS", "ANATOMY", 327, 330], ["dengue", "DISEASE", 83, 89], ["dengue", "DISEASE", 295, 301], ["central nervous system", "ANATOMICAL_SYSTEM", 32, 54], ["CNS", "ANATOMICAL_SYSTEM", 56, 59], ["mice", "ORGANISM", 64, 68], ["IFN", "GENE_OR_GENE_PRODUCT", 137, 140], ["IL-10", "GENE_OR_GENE_PRODUCT", 152, 157], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 159, 165], ["PDGF", "GENE_OR_GENE_PRODUCT", 167, 171], ["antigen", "GENE_OR_GENE_PRODUCT", 174, 181], ["dengue virus", "ORGANISM", 295, 307], ["CNS", "ANATOMICAL_SYSTEM", 327, 330], ["IFN", "PROTEIN", 137, 140], ["GM", "PROTEIN", 159, 161], ["CSF", "PROTEIN", 162, 165], ["PDGF", "PROTEIN", 167, 171], ["mice", "SPECIES", 64, 68], ["mice", "SPECIES", 64, 68], ["dengue", "SPECIES", 83, 89], ["dengue virus", "SPECIES", 295, 307], ["mice infected", "PROBLEM", 64, 77], ["IFN signaling", "TEST", 137, 150], ["IL", "TEST", 152, 154], ["GM", "TEST", 159, 161], ["antigen processing", "TEST", 174, 192], ["complement activation signatures", "TEST", 198, 230], ["dengue virus replication", "PROBLEM", 295, 319], ["disease severity", "PROBLEM", 350, 366], ["central", "ANATOMY_MODIFIER", 32, 39], ["nervous system", "ANATOMY", 40, 54]]], ["These findings suggest that adjuvant-mediated activation of these pathways could enhance vaccine response and/or provide therapeutic benefit.", [["adjuvant-mediated activation", "TREATMENT", 28, 56]]], ["Similar gene expression studies in humans with dengue illness suggest that a transcriptomic signature detectable as early as 1 day after infection can potentially distinguish between dengue fever and the more serious dengue hemorrhagic fever (62) .", [["dengue illness", "DISEASE", 47, 61], ["infection", "DISEASE", 137, 146], ["dengue fever", "DISEASE", 183, 195], ["dengue hemorrhagic fever", "DISEASE", 217, 241], ["humans", "ORGANISM", 35, 41], ["humans", "SPECIES", 35, 41], ["dengue hemorrhagic fever", "SPECIES", 217, 241], ["humans", "SPECIES", 35, 41], ["dengue", "SPECIES", 47, 53], ["dengue illness", "PROBLEM", 47, 61], ["a transcriptomic signature", "PROBLEM", 75, 101], ["infection", "PROBLEM", 137, 146], ["dengue fever", "PROBLEM", 183, 195], ["the more serious dengue hemorrhagic fever", "PROBLEM", 200, 241], ["hemorrhagic", "OBSERVATION_MODIFIER", 224, 235]]], ["These results inform the development of molecular diagnostics and treatment options for patients.BARRIER #1: INCOMPLETE UNDERSTANDING OF HOW IMMUNITY DEVELOPSEbola virus infection is another disease where pathogenesis is not completely understood and transcriptomic analysis has revealed important insights into Ebola disease progression.", [["DEVELOPSEbola virus infection", "DISEASE", 150, 179], ["Ebola disease", "DISEASE", 312, 325], ["patients", "ORGANISM", 88, 96], ["Ebola", "ORGANISM", 312, 317], ["patients", "SPECIES", 88, 96], ["treatment options", "TREATMENT", 66, 83], ["DEVELOPSEbola virus infection", "PROBLEM", 150, 179], ["another disease", "PROBLEM", 183, 198], ["transcriptomic analysis", "TEST", 251, 274], ["Ebola disease progression", "PROBLEM", 312, 337], ["Ebola disease", "OBSERVATION", 312, 325]]], ["Nonhuman primate survivors of experimental infection displayed upregulation of specific genes, including CCL8, compared to animals that succumbed to infection (63) .", [["infection", "DISEASE", 43, 52], ["infection", "DISEASE", 149, 158], ["primate", "ORGANISM", 9, 16], ["CCL8", "GENE_OR_GENE_PRODUCT", 105, 109], ["CCL8", "DNA", 105, 109], ["experimental infection", "PROBLEM", 30, 52], ["CCL8", "PROBLEM", 105, 109], ["infection", "PROBLEM", 149, 158], ["infection", "OBSERVATION", 43, 52], ["infection", "OBSERVATION", 149, 158]]], ["Although the study was focused on therapeutics, the findings suggest additional correlates of protection beyond the typical antibody measures.", [["the study", "TEST", 9, 18], ["protection", "TREATMENT", 94, 104], ["the typical antibody measures", "TREATMENT", 112, 141], ["typical", "OBSERVATION_MODIFIER", 116, 123], ["antibody", "OBSERVATION", 124, 132]]], ["In yet another example, microarrays have also been used to identify gene expression patterns (i.e., upregulation of NF-kB and IFNg signaling) that correlate with protection in trials with the malaria RTS,S vaccine (64) .", [["malaria RTS", "DISEASE", 192, 203], ["NF-kB", "GENE_OR_GENE_PRODUCT", 116, 121], ["IFNg", "GENE_OR_GENE_PRODUCT", 126, 130], ["NF-kB", "PROTEIN", 116, 121], ["IFNg", "PROTEIN", 126, 130], ["microarrays", "TEST", 24, 35], ["gene expression patterns", "PROBLEM", 68, 92], ["NF-kB", "TREATMENT", 116, 121], ["IFNg signaling", "PROBLEM", 126, 140], ["the malaria RTS", "PROBLEM", 188, 203]]], ["Thus, studies evaluating transcriptomic changes after infection/vaccination have provided rich insights into mechanisms of disease initiation, clinical progression, and vaccine-induced immunity (65) .", [["infection", "DISEASE", 54, 63], ["studies", "TEST", 6, 13], ["transcriptomic changes", "PROBLEM", 25, 47], ["infection/vaccination", "TREATMENT", 54, 75], ["disease initiation", "PROBLEM", 123, 141], ["clinical progression", "PROBLEM", 143, 163], ["vaccine", "TREATMENT", 169, 176], ["disease", "OBSERVATION", 123, 130]]], ["These studies have also identified potential correlates of protection and yielded predictive biomarkers that can be used to inform clinical care or to provide early go/no-go criteria for vaccine trials.BARRIER #1: INCOMPLETE UNDERSTANDING OF HOW IMMUNITY DEVELOPSSystems biology studies have also provided important insights into the generation and maintenance (i.e., durability) of immune responses to many vaccines, including seasonal influenza (trivalent inactivated influenza vaccine [TIV] and MF59adjuvanted influenza vaccine), malaria (RTS,S), meningococcal (MPSV4 and MCV4), and others (66) (67) (68) (69) (70) .", [["influenza", "DISEASE", 437, 446], ["TIV", "CHEMICAL", 489, 492], ["malaria", "DISEASE", 533, 540], ["seasonal influenza", "ORGANISM", 428, 446], ["trivalent inactivated influenza vaccine", "ORGANISM", 448, 487], ["MF59adjuvanted influenza vaccine", "ORGANISM", 498, 530], ["influenza vaccine", "SPECIES", 470, 487], ["MF59adjuvanted influenza vaccine", "SPECIES", 498, 530], ["TIV", "SPECIES", 489, 492], ["These studies", "TEST", 0, 13], ["predictive biomarkers", "TEST", 82, 103], ["vaccine trials", "TREATMENT", 187, 201], ["immune responses", "PROBLEM", 383, 399], ["many vaccines", "TREATMENT", 403, 416], ["seasonal influenza (trivalent inactivated influenza vaccine", "TREATMENT", 428, 487], ["TIV", "TREATMENT", 489, 492], ["MF59adjuvanted influenza vaccine", "TREATMENT", 498, 530], ["malaria", "PROBLEM", 533, 540]]], ["A systems biology approach comparing MF59-adjuvanted and TIV vaccine in immune-immature children (14-24-months-old, n = 90) identified significantly higher transcriptional responses to the MF59-adjuvanted vaccine and identified early innate response signatures correlated with Day 28 Ab titers (67) .", [["MF59", "CHEMICAL", 37, 41], ["MF59", "CHEMICAL", 189, 193], ["MF59", "SIMPLE_CHEMICAL", 37, 41], ["children", "ORGANISM", 88, 96], ["MF59", "GENE_OR_GENE_PRODUCT", 189, 193], ["Ab", "GENE_OR_GENE_PRODUCT", 284, 286], ["MF59", "PROTEIN", 189, 193], ["children", "SPECIES", 88, 96], ["TIV", "SPECIES", 57, 60], ["TIV vaccine", "TREATMENT", 57, 68], ["adjuvanted vaccine", "TREATMENT", 194, 212], ["Ab titers", "TEST", 284, 293]]], ["These include M16 (a module associated with TLR and inflammatory signaling); M11 (a module regulating monocyte function); M75 (a module controlling IFN-induced antiviral response); M156 (a module associated with Ab secreting cells); and S3 (a module with genes involved in immunoglobulin production).", [["monocyte", "ANATOMY", 102, 110], ["cells", "ANATOMY", 225, 230], ["TLR", "GENE_OR_GENE_PRODUCT", 44, 47], ["M11", "GENE_OR_GENE_PRODUCT", 77, 80], ["monocyte", "CELL", 102, 110], ["M75", "GENE_OR_GENE_PRODUCT", 122, 125], ["IFN", "GENE_OR_GENE_PRODUCT", 148, 151], ["M156", "GENE_OR_GENE_PRODUCT", 181, 185], ["Ab", "GENE_OR_GENE_PRODUCT", 212, 214], ["cells", "CELL", 225, 230], ["S3", "GENE_OR_GENE_PRODUCT", 237, 239], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 273, 287], ["M16", "PROTEIN", 14, 17], ["TLR", "PROTEIN", 44, 47], ["M11", "PROTEIN", 77, 80], ["M75", "PROTEIN", 122, 125], ["IFN", "PROTEIN", 148, 151], ["M156", "PROTEIN", 181, 185], ["Ab secreting cells", "CELL_TYPE", 212, 230], ["S3", "PROTEIN", 237, 239], ["immunoglobulin", "PROTEIN", 273, 287], ["inflammatory signaling", "PROBLEM", 52, 74], ["a module regulating monocyte function", "TEST", 82, 119], ["M75", "TEST", 122, 125], ["a module controlling IFN", "TREATMENT", 127, 151], ["a module", "PROBLEM", 187, 195], ["Ab secreting cells", "PROBLEM", 212, 230], ["S3", "PROBLEM", 237, 239], ["immunoglobulin production", "TREATMENT", 273, 298], ["inflammatory", "OBSERVATION_MODIFIER", 52, 64], ["S3", "ANATOMY", 237, 239]]], ["These findings may provide potentially generalizable molecular correlates of Ab production during early childhood (67) .BARRIER #1: INCOMPLETE UNDERSTANDING OF HOW IMMUNITY DEVELOPSSeveral adjuvants, such as MF59, AS01-4, TLR9 agonists, virosomes, and others have recently been licensed for use in human vaccines.", [["Ab", "GENE_OR_GENE_PRODUCT", 77, 79], ["MF59", "SIMPLE_CHEMICAL", 208, 212], ["AS01-4", "GENE_OR_GENE_PRODUCT", 214, 220], ["TLR9", "GENE_OR_GENE_PRODUCT", 222, 226], ["virosomes", "GENE_OR_GENE_PRODUCT", 237, 246], ["human", "ORGANISM", 298, 303], ["Ab", "PROTEIN", 77, 79], ["TLR9", "PROTEIN", 222, 226], ["human", "SPECIES", 298, 303], ["human", "SPECIES", 298, 303], ["Ab production", "PROBLEM", 77, 90], ["DEVELOPSSeveral adjuvants", "TREATMENT", 173, 198], ["AS01", "TEST", 214, 218], ["TLR9 agonists", "TREATMENT", 222, 235], ["virosomes", "TREATMENT", 237, 246], ["human vaccines", "TREATMENT", 298, 312], ["may provide potentially", "UNCERTAINTY", 15, 38]]], ["For example, a recent Hepatitis B vaccine (Heplisav B) incorporating a TLR9 agonist has considerably improved seroconversion rates compared to other hepatitis vaccines-particularly in subjects who normally respond poorly and slowly (71) .", [["Hepatitis B", "DISEASE", 22, 33], ["Heplisav B", "CHEMICAL", 43, 53], ["hepatitis", "DISEASE", 149, 158], ["Hepatitis B vaccine", "ORGANISM", 22, 41], ["Heplisav B", "ORGANISM", 43, 53], ["TLR9", "GENE_OR_GENE_PRODUCT", 71, 75], ["TLR9", "PROTEIN", 71, 75], ["Hepatitis B", "SPECIES", 22, 33], ["a recent Hepatitis B vaccine (Heplisav B)", "TREATMENT", 13, 54], ["a TLR9 agonist", "TREATMENT", 69, 83], ["other hepatitis vaccines", "TREATMENT", 143, 167]]], ["Similarly, the recently FDA-licensed MF59adjuvanted influenza subunit vaccine (72) induces higher antibody titers, a broader humoral response, and longer persistence of influenza Ab titers than the non-adjuvanted, standard-dose influenza vaccine in older adults.", [["influenza", "DISEASE", 169, 178], ["influenza", "DISEASE", 228, 237], ["MF59adjuvanted influenza subunit", "ORGANISM", 37, 69], ["influenza", "ORGANISM", 169, 178], ["Ab", "GENE_OR_GENE_PRODUCT", 179, 181], ["influenza", "SPECIES", 169, 178], ["licensed MF59adjuvanted influenza subunit vaccine", "TREATMENT", 28, 77], ["higher antibody titers", "PROBLEM", 91, 113], ["influenza", "PROBLEM", 169, 178], ["Ab titers", "TEST", 179, 188], ["standard-dose influenza vaccine", "TREATMENT", 214, 245], ["humoral response", "OBSERVATION", 125, 141], ["influenza", "OBSERVATION", 169, 178]]], ["This is a population that suffers the greatest burden of influenzaassociated morbidity and mortality, yet has the poorest response to standard influenza vaccines (73, 74) .", [["influenzaassociated morbidity", "PROBLEM", 57, 86], ["standard influenza vaccines", "TREATMENT", 134, 161], ["greatest", "OBSERVATION_MODIFIER", 38, 46], ["burden", "OBSERVATION_MODIFIER", 47, 53], ["morbidity", "OBSERVATION", 77, 86]]], ["A recent large study in 7,082 individuals (\u226565 years of age) demonstrated significantly higher immunogenicity (p < 0.001, seroconversion and HAI GMT) of the MF59-adjuvanted vaccine compared to standard dose influenza vaccine (75) .", [["MF59", "CHEMICAL", 157, 161], ["individuals", "ORGANISM", 30, 41], ["MF59", "GENE_OR_GENE_PRODUCT", 157, 161], ["A recent large study", "TEST", 0, 20], ["significantly higher immunogenicity", "PROBLEM", 74, 109], ["seroconversion", "TEST", 122, 136], ["HAI GMT", "TEST", 141, 148], ["the MF59", "TREATMENT", 153, 161], ["adjuvanted vaccine", "TREATMENT", 162, 180], ["standard dose influenza vaccine", "TREATMENT", 193, 224], ["large", "OBSERVATION_MODIFIER", 9, 14], ["significantly", "OBSERVATION_MODIFIER", 74, 87], ["higher", "OBSERVATION_MODIFIER", 88, 94]]], ["Similarly, the diversity, commonalities, and differences in human genetic and immune responses to two varicella zoster virus (VZV) vaccines, the live attenuated vaccine (Zostavax), and the AS01B-adjuvanted glycoprotein E vaccine (Shingrix) are being examined using systems biology approaches (31, 76) .", [["varicella zoster", "DISEASE", 102, 118], ["Zostavax", "CHEMICAL", 170, 178], ["human", "ORGANISM", 60, 65], ["varicella zoster virus", "ORGANISM", 102, 124], ["VZV", "ORGANISM", 126, 129], ["AS01B", "GENE_OR_GENE_PRODUCT", 189, 194], ["glycoprotein E vaccine", "ORGANISM", 206, 228], ["AS01B", "PROTEIN", 189, 194], ["human", "SPECIES", 60, 65], ["varicella zoster virus", "SPECIES", 102, 124], ["human", "SPECIES", 60, 65], ["varicella zoster virus", "SPECIES", 102, 124], ["VZV", "SPECIES", 126, 129], ["two varicella zoster virus (VZV) vaccines", "TREATMENT", 98, 139], ["the live attenuated vaccine", "TREATMENT", 141, 168], ["Zostavax", "TREATMENT", 170, 178], ["the AS01B-adjuvanted glycoprotein E vaccine (Shingrix)", "TREATMENT", 185, 239], ["diversity", "OBSERVATION_MODIFIER", 15, 24]]], ["These vaccines exhibit significant differential immunogenicity and significant variations in the longevity of immunologic memory.", [["These vaccines", "TREATMENT", 0, 14], ["significant differential immunogenicity", "PROBLEM", 23, 62], ["significant variations", "PROBLEM", 67, 89], ["significant", "OBSERVATION_MODIFIER", 23, 34], ["differential", "OBSERVATION_MODIFIER", 35, 47], ["immunogenicity", "OBSERVATION", 48, 62], ["significant", "OBSERVATION_MODIFIER", 67, 78], ["variations", "OBSERVATION_MODIFIER", 79, 89]]], ["Furthermore, the effect of age and immunosenescence is drastically different with these two vaccines.", [["these two vaccines", "TREATMENT", 82, 100]]], ["These clinically important differences provide an ideal system for studying the systems-level factors contributing to these differences and are likely to drastically improve our understanding of zoster immunology.", [["zoster", "DISEASE", 195, 201], ["zoster", "ORGANISM", 195, 201], ["studying the systems", "TEST", 67, 87], ["level factors", "PROBLEM", 88, 101]]], ["In fact, recent reports have highlighted the novel finding that the magnitude and durability of immune responses to zoster vaccination are dependent on the abundance of both regulatory T cells and T cells expressing checkpoint markers (e.g., PD-1) (77) .", [["regulatory T cells", "ANATOMY", 174, 192], ["T cells", "ANATOMY", 197, 204], ["zoster", "DISEASE", 116, 122], ["zoster", "ORGANISM", 116, 122], ["T cells", "CELL", 185, 192], ["T cells", "CELL", 197, 204], ["PD-1", "GENE_OR_GENE_PRODUCT", 242, 246], ["regulatory T cells", "CELL_TYPE", 174, 192], ["T cells", "CELL_TYPE", 197, 204], ["checkpoint markers", "PROTEIN", 216, 234], ["immune responses", "PROBLEM", 96, 112], ["zoster vaccination", "PROBLEM", 116, 134], ["checkpoint markers", "TEST", 216, 234], ["PD", "TEST", 242, 244]]], ["Systems studies examining the durability of immunity after measles, mumps, and rubella vaccination are in progress (78) (79) (80) (81) (82) (83) (84) .Structural VaccinologyStructural biology studies have allowed investigators to map viral epitopes onto the three-dimensional structure of pathogen proteins (85, 86) .", [["measles, mumps", "DISEASE", 59, 73], ["rubella", "DISEASE", 79, 86], ["viral epitopes", "PROTEIN", 234, 248], ["pathogen proteins", "PROTEIN", 289, 306], ["rubella", "SPECIES", 79, 86], ["Systems studies", "TEST", 0, 15], ["measles", "PROBLEM", 59, 66], ["mumps", "PROBLEM", 68, 73], ["rubella vaccination", "TEST", 79, 98], ["map viral epitopes", "TEST", 230, 248], ["pathogen proteins", "TEST", 289, 306]]], ["Antibody-antigen complexes can also be determined, providing insights into critical antibody functionality such as neutralization or have identified critical conserved regions that can be targeted for more effective immune responses (87) .", [["Antibody-antigen", "GENE_OR_GENE_PRODUCT", 0, 16], ["Antibody-antigen complexes", "PROTEIN", 0, 26], ["Antibody", "TEST", 0, 8]]], ["Insights into conformational changes with RSV have enabled investigators to develop new vaccines that avoid the limitations of historical approaches (88) and design better immunogens (89) .", [["RSV", "ORGANISM", 42, 45], ["RSV", "SPECIES", 42, 45], ["RSV", "PROBLEM", 42, 45], ["new vaccines", "TREATMENT", 84, 96]]], ["Another excellent example of structural vaccinology is the increasing use of virus-like-particles as vaccine platforms (90, 91) .Genome-Wide Association Studies (GWAS)Inter-individual variation in vaccine-specific immune response is known to be influenced by host gene polymorphisms.", [["host gene polymorphisms", "DNA", 259, 282], ["virus", "TREATMENT", 77, 82], ["vaccine platforms", "TEST", 101, 118], ["individual variation in vaccine", "TREATMENT", 173, 204], ["increasing", "OBSERVATION_MODIFIER", 59, 69]]], ["This genetic variability of the human population gave rise to vaccineimmunogenetics research focused on finding important genetic variants associated with variations in immune responses by assessing relationships between variability in immune response to vaccines and genetic factors.", [["human", "ORGANISM", 32, 37], ["human", "SPECIES", 32, 37], ["human", "SPECIES", 32, 37], ["the human population", "PROBLEM", 28, 48], ["vaccineimmunogenetics research", "TREATMENT", 62, 92], ["variations in immune responses", "PROBLEM", 155, 185], ["vaccines", "TREATMENT", 255, 263], ["genetic factors", "PROBLEM", 268, 283]]], ["Certainly, population-based candidate gene association studies of vaccine-specific immune responses are beginning to reveal and explain how-and to what degree-variations in innate and adaptive immune responses following vaccination are determined by gene polymorphisms (92, 93) .", [["gene polymorphisms", "DNA", 250, 268], ["vaccination", "TREATMENT", 220, 231]]], ["While a candidate gene approach was thought most efficient in the past decade, it is clear that a GWAS is an unbiased, agnostic approach that serves as a critical step in the research by identifying genetic variants impacting immunity and supporting a novel paradigm by which vaccine development could occur (92, 94, 95) .", [["a GWAS", "TEST", 96, 102], ["a novel paradigm", "TREATMENT", 250, 266]]], ["A GWAS allows the identification of individual and groups of genes and genetic variants (SNPs, or single nucleotide polymorphisms) that are associated with specific markers of vaccine-induced immunity.", [["SNPs", "DNA", 89, 93], ["A GWAS", "TEST", 0, 6], ["individual and groups of genes and genetic variants (SNPs", "PROBLEM", 36, 93], ["single nucleotide polymorphisms", "TREATMENT", 98, 129], ["vaccine", "TREATMENT", 176, 183]]], ["At the systems level, genotype/phenotype computational models that integrate numerous additive and epistatic marker effects are needed.", [["genotype/phenotype computational models", "PROBLEM", 22, 61], ["epistatic marker effects", "TREATMENT", 99, 123]]], ["The evidence thus far suggests that the effect of one gene/allele depends on the presence of another gene/allele that may control a phenotype (e.g., epistatic interactions).", [["allele", "DNA", 59, 65], ["allele", "DNA", 106, 112], ["another gene/allele", "PROBLEM", 93, 112], ["a phenotype (e.g., epistatic interactions", "PROBLEM", 130, 171]]], ["The integration of epistasis network analysis and functional interactions into genotype-phenotype association studies have provided important insights into smallpox vaccine-induced immunity and specifically the role of variants in RXRA (the gene encoding a vitamin A receptor) in immune responses to smallpox and other viral vaccines (96) (97) (98) .", [["vitamin A", "CHEMICAL", 257, 266], ["smallpox", "DISEASE", 300, 308], ["vitamin A", "CHEMICAL", 257, 266], ["RXRA", "GENE_OR_GENE_PRODUCT", 231, 235], ["vitamin A receptor", "GENE_OR_GENE_PRODUCT", 257, 275], ["smallpox", "ORGANISM", 300, 308], ["RXRA", "DNA", 231, 235], ["vitamin A receptor", "PROTEIN", 257, 275], ["epistasis network analysis", "TEST", 19, 45], ["smallpox vaccine", "TREATMENT", 156, 172], ["RXRA", "TREATMENT", 231, 235], ["a vitamin A receptor", "TREATMENT", 255, 275], ["immune responses", "TREATMENT", 280, 296], ["smallpox", "TREATMENT", 300, 308], ["other viral vaccines", "TREATMENT", 313, 333], ["epistasis", "OBSERVATION", 19, 28]]], ["The most thorough and efficient study for such purposes is a two-stage (discovery-replication) genome-scale analysis (99) , followed by functional studies to (1) validate which specific gene polymorphisms and pathways/gene sets have the biggest or most critical effect on inter-individual variations in immune responses among immunized subjects, and (2) identify the mechanism(s) by which these effects occur.", [["efficient study", "TEST", 22, 37], ["genome-scale analysis", "TEST", 95, 116], ["functional studies", "TEST", 136, 154], ["specific gene polymorphisms and pathways/gene sets", "PROBLEM", 177, 227], ["inter-individual variations", "PROBLEM", 272, 299]]], ["Significant work delineating the effect of gene polymorphisms on hepatitis B, measles, mumps, rubella, influenza, smallpox, and anthrax vaccine-induced immune responses has been published (98, (100) (101) (102) (103) (104) (105) (106) (107) .", [["hepatitis B", "DISEASE", 65, 76], ["measles", "DISEASE", 78, 85], ["mumps, rubella", "DISEASE", 87, 101], ["influenza", "DISEASE", 103, 112], ["smallpox", "DISEASE", 114, 122], ["anthrax", "DISEASE", 128, 135], ["hepatitis B", "ORGANISM", 65, 76], ["hepatitis B", "SPECIES", 65, 76], ["gene polymorphisms", "PROBLEM", 43, 61], ["hepatitis B", "PROBLEM", 65, 76], ["measles", "PROBLEM", 78, 85], ["mumps", "PROBLEM", 87, 92], ["rubella", "PROBLEM", 94, 101], ["influenza", "PROBLEM", 103, 112], ["smallpox", "TREATMENT", 114, 122], ["anthrax vaccine", "TREATMENT", 128, 143]]], ["Examples include the identification and replication of a CD46 measles virus receptor variant coding for a 53% reduction in Ab response to measles vaccine, which is a finding that could be used to reverse engineer a vaccine to circumvent this viral receptor genetic restriction (108) .", [["CD46", "GENE_OR_GENE_PRODUCT", 57, 61], ["Ab", "GENE_OR_GENE_PRODUCT", 123, 125], ["CD46 measles virus receptor variant", "PROTEIN", 57, 92], ["Ab", "PROTEIN", 123, 125], ["measles virus", "SPECIES", 62, 75], ["the identification", "TEST", 17, 35], ["a CD46 measles virus receptor variant", "TREATMENT", 55, 92], ["a 53% reduction", "TREATMENT", 104, 119], ["measles vaccine", "TREATMENT", 138, 153], ["a vaccine", "TREATMENT", 213, 222], ["this viral receptor genetic restriction", "TREATMENT", 237, 276]]], ["Our studies identified a SNP (rs2064479, p = 8.6 \u00d7 10 \u22128 ) in the class II HLA-DPB1 gene region associated with variations in rubellaspecific Ab titers after rubella vaccine (106) .", [["SNP", "CHEMICAL", 25, 28], ["HLA-DPB1", "GENE_OR_GENE_PRODUCT", 75, 83], ["Ab", "GENE_OR_GENE_PRODUCT", 142, 144], ["class II HLA-DPB1 gene region", "DNA", 66, 95], ["Our studies", "TEST", 0, 11], ["a SNP", "TEST", 23, 28], ["p", "TEST", 41, 42], ["DPB1 gene region", "PROBLEM", 79, 95], ["variations in rubellaspecific Ab titers", "PROBLEM", 112, 151], ["rubella vaccine", "TREATMENT", 158, 173]]], ["Additional SNPs (p \u2264 1.0 \u00d7 10 \u22127 ) in high linkage disequilibrium (LD, r 2 \u2265 0.8) of rs2064479 were also positioned near the genetic region of HLA-DPB1.", [["rs2064479", "GENE_OR_GENE_PRODUCT", 85, 94], ["HLA-DPB1", "GENE_OR_GENE_PRODUCT", 143, 151], ["HLA-DPB1", "DNA", 143, 151], ["Additional SNPs", "TEST", 0, 15], ["\u2264", "TEST", 19, 20], ["high linkage disequilibrium", "PROBLEM", 38, 65], ["LD", "TEST", 67, 69]]], ["Some of these polymorphisms were predicted to be located in miRNA binding sites.", [["miRNA binding sites", "DNA", 60, 79], ["these polymorphisms", "PROBLEM", 8, 27], ["polymorphisms", "OBSERVATION", 14, 27], ["miRNA binding sites", "OBSERVATION", 60, 79]]], ["These data validate the previous findings of HLA-DPB1 genotypes (i.e., HLA-DPB1 * 04:01 and HLA-DPB1 * 03:01) linked with rubella vaccine-specific immune response (109, 110) .", [["HLA-DPB1", "GENE_OR_GENE_PRODUCT", 45, 53], ["rubella", "ORGANISM", 122, 129], ["HLA", "TEST", 45, 48], ["DPB1 genotypes", "TEST", 49, 63], ["HLA", "TEST", 71, 74], ["HLA", "TEST", 92, 95], ["rubella vaccine", "TREATMENT", 122, 137]]], ["It has been previously demonstrated that the DPB1 * 04:01 and DPB1 * 03:01 alleles are associated with significantly higher and lower Ab responses, respectively (109, 110) .", [["DPB1 * 04:01", "GENE_OR_GENE_PRODUCT", 45, 57], ["DPB1 * 03:01", "GENE_OR_GENE_PRODUCT", 62, 74], ["DPB1 * 04:01 and DPB1 * 03:01 alleles", "DNA", 45, 82], ["significantly", "OBSERVATION_MODIFIER", 103, 116], ["higher", "OBSERVATION_MODIFIER", 117, 123], ["lower", "ANATOMY_MODIFIER", 128, 133], ["Ab responses", "OBSERVATION", 134, 146]]], ["It is highly likely that the DPB1 * 04:01 molecule presents an array of processed epitopes to CD4+ T cells different from that of the DPB1 * 03:01 allele and is therefore able to stimulate more robust rubella-specific T cell responses, which in turn elicit robust humoral immune responses.", [["T cells", "ANATOMY", 99, 106], ["rubella-specific T cell", "ANATOMY", 201, 224], ["CD4", "GENE_OR_GENE_PRODUCT", 94, 97], ["T cells", "CELL", 99, 106], ["DPB1 * 03:01", "GENE_OR_GENE_PRODUCT", 134, 146], ["rubella-specific T cell", "CELL", 201, 224], ["DPB1 * 04:01 molecule", "PROTEIN", 29, 50], ["epitopes", "PROTEIN", 82, 90], ["CD4", "PROTEIN", 94, 97], ["T cells", "CELL_TYPE", 99, 106], ["DPB1 * 03:01 allele", "DNA", 134, 153], ["T cells", "PROBLEM", 99, 106], ["highly likely", "UNCERTAINTY", 6, 19]]], ["Indeed, earlier work revealed that HLA genes/proteins are critical elements for immune responses to rubella vaccination, accounting for \u223c20% of the total genetic inter-individual variation in Ab response to rubella (109) .Genome-Wide Association Studies (GWAS)Multiple GWAS studies have shown that allele-specific HLA class I and class II genetic polymorphisms play a fundamental function in the differential generation of viral vaccine-induced immune responses (109, (111) (112) (113) (114) (115) (116) .", [["rubella", "DISEASE", 100, 107], ["rubella", "DISEASE", 207, 214], ["HLA", "GENE_OR_GENE_PRODUCT", 35, 38], ["rubella", "ORGANISM", 100, 107], ["Ab", "GENE_OR_GENE_PRODUCT", 192, 194], ["HLA class I", "GENE_OR_GENE_PRODUCT", 314, 325], ["class II", "GENE_OR_GENE_PRODUCT", 330, 338], ["HLA genes", "DNA", 35, 44], ["allele", "DNA", 298, 304], ["HLA class I and class II genetic polymorphisms", "DNA", 314, 360], ["HLA genes/proteins", "PROBLEM", 35, 53], ["critical elements", "PROBLEM", 58, 75], ["immune responses", "PROBLEM", 80, 96], ["rubella vaccination", "TEST", 100, 119], ["the total genetic inter-individual variation", "PROBLEM", 144, 188], ["rubella", "TEST", 207, 214], ["Multiple GWAS studies", "TEST", 260, 281], ["class II genetic polymorphisms", "PROBLEM", 330, 360], ["viral vaccine", "TREATMENT", 423, 436]]], ["Identifying which specific HLA alleles are associated with protective immune responses through vaccination is critical for population health and for a deeper understanding of vaccine-induced immunology and vaccine development.", [["HLA", "GENE_OR_GENE_PRODUCT", 27, 30], ["HLA alleles", "DNA", 27, 38], ["vaccine", "TREATMENT", 175, 182]]], ["We have leveraged such knowledge to identify naturally processed and HLA-presented viral-derived epitopes using mass spectrometry techniques (117) .", [["HLA", "TEST", 69, 72], ["mass spectrometry techniques", "TEST", 112, 140]]], ["Peptide identification using this approach provides the framework for the selection and use of these immunodominant pathogen epitopes as candidate vaccine targets (118) .", [["immunodominant pathogen epitopes", "PROTEIN", 101, 133], ["Peptide identification", "TEST", 0, 22], ["this approach", "TREATMENT", 29, 42], ["the selection", "TREATMENT", 70, 83], ["these immunodominant pathogen epitopes", "TREATMENT", 95, 133]]], ["Studies have illustrated several regulatory and common SNPs in the different regions of HLA genes associated with immune responses to childhood immunization, such as the capsular group C meningococcal (MenC); Haemophilus influenza type B (Hib); tetanus toxoid (TT); hepatitis B (HBV); 7-valent pneumococcal conjugate (PCV7); and the diphtheria, tetanus, and acellular pertussis (DTaP) vaccines (119, 120) .", [["Haemophilus influenza type B", "DISEASE", 209, 237], ["tetanus toxoid", "DISEASE", 245, 259], ["hepatitis B", "DISEASE", 266, 277], ["PCV7", "CHEMICAL", 318, 322], ["diphtheria, tetanus", "DISEASE", 333, 352], ["DTaP", "CHEMICAL", 379, 383], ["HLA", "GENE_OR_GENE_PRODUCT", 88, 91], ["Haemophilus influenza type B", "ORGANISM", 209, 237], ["Hib)", "ORGANISM", 239, 243], ["tetanus toxoid (TT); hepatitis B", "ORGANISM", 245, 277], ["HBV", "ORGANISM", 279, 282], ["7-valent pneumococcal conjugate", "SIMPLE_CHEMICAL", 285, 316], ["PCV7", "ORGANISM", 318, 322], ["acellular pertussis", "ORGANISM", 358, 377], ["regulatory and common SNPs", "DNA", 33, 59], ["HLA genes", "DNA", 88, 97], ["Haemophilus influenza type", "SPECIES", 209, 235], ["tetanus toxoid", "SPECIES", 245, 259], ["PCV7", "SPECIES", 318, 322], ["Haemophilus influenza type B", "SPECIES", 209, 237], ["HBV", "SPECIES", 279, 282], ["pneumococcal", "SPECIES", 294, 306], ["PCV7", "SPECIES", 318, 322], ["Studies", "TEST", 0, 7], ["common SNPs", "PROBLEM", 48, 59], ["HLA genes", "PROBLEM", 88, 97], ["immune responses", "PROBLEM", 114, 130], ["childhood immunization", "TREATMENT", 134, 156], ["the capsular group C meningococcal (MenC", "TREATMENT", 166, 206], ["Haemophilus influenza type B (Hib)", "PROBLEM", 209, 243], ["tetanus toxoid", "TREATMENT", 245, 259], ["hepatitis B (HBV)", "PROBLEM", 266, 283], ["valent pneumococcal conjugate (PCV7", "TREATMENT", 287, 322], ["the diphtheria", "PROBLEM", 329, 343], ["tetanus", "PROBLEM", 345, 352], ["acellular pertussis (DTaP) vaccines", "TREATMENT", 358, 393], ["common SNPs", "OBSERVATION", 48, 59], ["HLA genes", "OBSERVATION", 88, 97]]], ["Through studies such as these, GWAS can be used to identify critical genetic determinants of vaccine-specific immunity and assist in the development of novel vaccines that overcome these genetic restrictions.Genome-Wide Association Studies (GWAS)GWAS studies also demonstrate that multigenic effects (121, 122) including HLA and a variety of immune, innate, and adaptive gene SNPs significantly affect immune responses to vaccines (114, (123) (124) (125) (126) .", [["HLA", "GENE_OR_GENE_PRODUCT", 321, 324], ["adaptive gene SNPs", "DNA", 362, 380], ["vaccine", "TREATMENT", 93, 100], ["novel vaccines", "TREATMENT", 152, 166], ["GWAS studies", "TEST", 246, 258], ["multigenic effects", "PROBLEM", 281, 299], ["HLA", "TEST", 321, 324], ["adaptive gene SNPs", "PROBLEM", 362, 380], ["vaccines", "TEST", 422, 430], ["multigenic", "OBSERVATION_MODIFIER", 281, 291]]], ["Likewise, synergistic effects of tapasin gene polymorphisms and specific HLA class I alleles to generate stronger anti-viral CD8+ T cell responses have been observed.", [["T cell", "ANATOMY", 130, 136], ["tapasin", "CHEMICAL", 33, 40], ["tapasin", "GENE_OR_GENE_PRODUCT", 33, 40], ["HLA class I", "GENE_OR_GENE_PRODUCT", 73, 84], ["CD8", "GENE_OR_GENE_PRODUCT", 125, 128], ["T cell", "CELL", 130, 136], ["tapasin gene polymorphisms", "DNA", 33, 59], ["HLA class I alleles", "DNA", 73, 92], ["anti-viral CD8", "PROTEIN", 114, 128], ["tapasin gene polymorphisms", "TREATMENT", 33, 59]]], ["In a study of subjects with resolved or chronic hepatitis C virus (HCV) infection in UK, Germany and US, tapasin G alleles in a combination with specific HLA class IB alleles with an aspartate (Asp) at residues 114 and 156 have been associated with stronger anti-viral CD8+ T cell responses against HCV and with the outcome of HCV infection (127) .", [["T cell", "ANATOMY", 274, 280], ["chronic hepatitis C virus (HCV) infection", "DISEASE", 40, 81], ["aspartate", "CHEMICAL", 183, 192], ["Asp", "CHEMICAL", 194, 197], ["HCV infection", "DISEASE", 327, 340], ["aspartate", "CHEMICAL", 183, 192], ["Asp", "CHEMICAL", 194, 197], ["hepatitis C virus", "ORGANISM", 48, 65], ["tapasin G", "GENE_OR_GENE_PRODUCT", 105, 114], ["aspartate", "AMINO_ACID", 183, 192], ["Asp", "AMINO_ACID", 194, 197], ["CD8", "GENE_OR_GENE_PRODUCT", 269, 272], ["T cell", "CELL", 274, 280], ["HCV", "ORGANISM", 299, 302], ["HCV", "ORGANISM", 327, 330], ["tapasin G alleles", "DNA", 105, 122], ["HLA class IB alleles", "DNA", 154, 174], ["anti-viral CD8", "PROTEIN", 258, 272], ["hepatitis C virus", "SPECIES", 48, 65], ["hepatitis C virus", "SPECIES", 48, 65], ["HCV", "SPECIES", 67, 70], ["HCV", "SPECIES", 299, 302], ["HCV", "SPECIES", 327, 330], ["a study", "TEST", 3, 10], ["chronic hepatitis C virus (HCV) infection", "PROBLEM", 40, 81], ["tapasin G alleles", "TREATMENT", 105, 122], ["an aspartate (Asp) at residues", "TEST", 180, 210], ["HCV", "PROBLEM", 299, 302], ["HCV infection", "PROBLEM", 327, 340], ["chronic", "OBSERVATION_MODIFIER", 40, 47], ["hepatitis", "OBSERVATION", 48, 57], ["HCV", "OBSERVATION_MODIFIER", 327, 330], ["infection", "OBSERVATION", 331, 340]]], ["This suggests that tapasin gene polymorphisms maybe important for antigen processing and HLA class I peptide loading mechanisms (128) .", [["tapasin", "GENE_OR_GENE_PRODUCT", 19, 26], ["HLA class I", "GENE_OR_GENE_PRODUCT", 89, 100], ["tapasin gene polymorphisms", "DNA", 19, 45], ["HLA class I", "PROTEIN", 89, 100], ["tapasin gene polymorphisms", "PROBLEM", 19, 45], ["antigen processing", "PROBLEM", 66, 84], ["tapasin gene", "OBSERVATION", 19, 31]]], ["A large number of other genes and gene families (e.g., interferon response factors, pattern recognition receptors, cytokines, chemokines) have been implicated in the control of immune responses to vaccines (129) , and the literature is full of disease susceptibility studies that highlight additional genes and pathways contributing to immune responses to pathogens (130) .", [["interferon response factors", "GENE_OR_GENE_PRODUCT", 55, 82], ["pattern recognition receptors", "GENE_OR_GENE_PRODUCT", 84, 113], ["interferon response factors", "PROTEIN", 55, 82], ["pattern recognition receptors", "PROTEIN", 84, 113], ["cytokines", "PROTEIN", 115, 124], ["chemokines", "PROTEIN", 126, 136], ["interferon response factors", "TREATMENT", 55, 82], ["disease susceptibility studies", "PROBLEM", 244, 274], ["additional genes and pathways", "PROBLEM", 290, 319], ["immune responses", "PROBLEM", 336, 352], ["pathogens", "PROBLEM", 356, 365], ["large", "OBSERVATION_MODIFIER", 2, 7], ["number", "OBSERVATION_MODIFIER", 8, 14]]], ["Many of these study results are available in online databases such as this one: https://www.ebi.ac.uk/gwas/.", [["these study", "TEST", 8, 19]]], ["Genetic studies of vaccine responses have revealed effects that are both quantifiable and predictable (7, 13, 109, 114, 121, 122, (131) (132) (133) (134) (135) .", [["Genetic studies of vaccine responses", "TEST", 0, 36]]], ["Informed by such studies, the development of novel vaccines and adjuvants that specifically target innate receptors and their signaling pathways (e.g., TLR pathway), leading to higher protection rates and enhanced immune responses, is possible.BARRIER #3: PATHOGEN VARIABILITYPathogen genetic sequence variability is a major impediment to vaccine development (136) (137) (138) .", [["TLR", "GENE_OR_GENE_PRODUCT", 152, 155], ["innate receptors", "PROTEIN", 99, 115], ["TLR", "PROTEIN", 152, 155], ["novel vaccines", "TREATMENT", 45, 59], ["adjuvants", "TREATMENT", 64, 73]]], ["This can manifest in multiple ways: (1) tremendous sequence diversity among viral strainsas an example, a major challenge in the development of an effective rhinovirus vaccine is that it must elicit cross-protective immunity across over 160 different circulating rhinovirus strains (139); (2) antigenic drift or shift, as demonstrated by influenza viruses, which necessitates a yearly reformulation of influenza vaccines; (3) a complicated lifecycle during which large segments of the genome are turned on and off, as is the case with Plasmodium falciparum (Plasmodium life-cycle stages also affect the type of immune response that is required to combat the pathogen); (4) pathogens with large, complex genomes, such as Mycobacterium tuberculosis, where effective immunologic targets or immunomodulatory molecules are difficult to identify, and therefore have not been effectively dealt with; (5) vaccineinduced pressure leading to changes in serotype prevalence, as has been demonstrated with the heptavalent pneumococcal vaccine (140); (6) pathogens with rapid mutation rates, such as HIV and HCV, also complicate the issue as the antigenic targets of the immune response rapidly shift during an infection forcing the immune response to chase an ever-changing target; (7) zoonoses that cross the species barrier to infect humans (e.g., SARS-CoV, MERS-CoV, H5, SARS-CoV-2).BARRIER #3: PATHOGEN VARIABILITYThe host immune response typically recognizes and responds to a small set of immunodominant epitopes (141) .", [["influenza viruses", "DISEASE", 338, 355], ["influenza", "DISEASE", 402, 411], ["Plasmodium falciparum", "DISEASE", 535, 556], ["Mycobacterium tuberculosis", "DISEASE", 720, 746], ["HIV and HCV", "DISEASE", 1087, 1098], ["infection", "DISEASE", 1198, 1207], ["rhinovirus", "ORGANISM", 157, 167], ["rhinovirus", "ORGANISM", 263, 273], ["influenza viruses", "ORGANISM", 338, 355], ["Plasmodium falciparum", "ORGANISM", 535, 556], ["Mycobacterium tuberculosis", "ORGANISM", 720, 746], ["humans", "ORGANISM", 1324, 1330], ["SARS-CoV", "ORGANISM", 1338, 1346], ["MERS-CoV", "ORGANISM", 1348, 1356], ["H5", "ORGANISM", 1358, 1360], ["SARS-CoV-2", "ORGANISM", 1362, 1372], ["immunomodulatory molecules", "PROTEIN", 787, 813], ["immunodominant epitopes", "PROTEIN", 1483, 1506], ["Plasmodium falciparum", "SPECIES", 535, 556], ["Mycobacterium tuberculosis", "SPECIES", 720, 746], ["HIV", "SPECIES", 1087, 1090], ["humans", "SPECIES", 1324, 1330], ["Plasmodium falciparum", "SPECIES", 535, 556], ["Mycobacterium tuberculosis", "SPECIES", 720, 746], ["pneumococcal", "SPECIES", 1010, 1022], ["HIV", "SPECIES", 1087, 1090], ["HCV", "SPECIES", 1095, 1098], ["humans", "SPECIES", 1324, 1330], ["SARS-CoV", "SPECIES", 1338, 1346], ["MERS-CoV", "SPECIES", 1348, 1356], ["tremendous sequence diversity", "PROBLEM", 40, 69], ["a major challenge", "TREATMENT", 104, 121], ["an effective rhinovirus vaccine", "TREATMENT", 144, 175], ["circulating rhinovirus strains", "PROBLEM", 251, 281], ["antigenic drift or shift", "PROBLEM", 293, 317], ["influenza viruses", "PROBLEM", 338, 355], ["influenza vaccines", "TREATMENT", 402, 420], ["Plasmodium falciparum", "PROBLEM", 535, 556], ["Plasmodium life-cycle stages", "TREATMENT", 558, 586], ["immune response", "PROBLEM", 611, 626], ["the pathogen", "PROBLEM", 654, 666], ["pathogens", "PROBLEM", 673, 682], ["large, complex genomes", "PROBLEM", 688, 710], ["Mycobacterium tuberculosis", "PROBLEM", 720, 746], ["immunomodulatory molecules", "PROBLEM", 787, 813], ["vaccineinduced pressure", "TREATMENT", 897, 920], ["changes in serotype prevalence", "PROBLEM", 932, 962], ["the heptavalent pneumococcal vaccine", "TREATMENT", 994, 1030], ["pathogens", "PROBLEM", 1042, 1051], ["rapid mutation rates", "PROBLEM", 1057, 1077], ["HIV", "PROBLEM", 1087, 1090], ["HCV", "PROBLEM", 1095, 1098], ["the immune response", "PROBLEM", 1154, 1173], ["an infection", "PROBLEM", 1195, 1207], ["zoonoses", "TREATMENT", 1274, 1282], ["rhinovirus", "OBSERVATION", 157, 167], ["influenza viruses", "OBSERVATION", 338, 355], ["large", "OBSERVATION_MODIFIER", 463, 468], ["segments", "OBSERVATION_MODIFIER", 469, 477], ["genome", "OBSERVATION", 485, 491], ["large", "OBSERVATION_MODIFIER", 688, 693], ["complex genomes", "OBSERVATION", 695, 710], ["Mycobacterium tuberculosis", "OBSERVATION", 720, 746], ["infection", "OBSERVATION", 1198, 1207], ["PATHOGEN VARIABILITY", "OBSERVATION", 1386, 1406], ["host immune response", "OBSERVATION", 1410, 1430]]], ["For humoral responses, these epitopes are typically the linear or conformational areas that are readily accessible to antibodies.", [["epitopes", "PROTEIN", 29, 37], ["antibodies", "PROTEIN", 118, 128], ["humoral responses", "PROBLEM", 4, 21], ["these epitopes", "PROBLEM", 23, 37], ["linear", "OBSERVATION_MODIFIER", 56, 62]]], ["Unfortunately, these areas of the pathogen genome are often hot spots for mutation or recombination events, enabling the pathogen to evade immune responses by displaying modified surface proteins that are no longer recognized by existing antibodies, forcing the immune system to start over-an effect repeatedly demonstrated by influenza virus and HIV (142) (143) (144) (145) .", [["surface", "ANATOMY", 179, 186], ["influenza virus", "ORGANISM", 327, 342], ["pathogen genome", "DNA", 34, 49], ["modified surface proteins", "PROTEIN", 170, 195], ["antibodies", "PROTEIN", 238, 248], ["influenza virus", "SPECIES", 327, 342], ["HIV", "SPECIES", 347, 350], ["influenza virus", "SPECIES", 327, 342], ["HIV", "SPECIES", 347, 350], ["the pathogen genome", "PROBLEM", 30, 49], ["mutation", "PROBLEM", 74, 82], ["recombination events", "PROBLEM", 86, 106], ["the pathogen", "PROBLEM", 117, 129], ["modified surface proteins", "PROBLEM", 170, 195], ["influenza virus", "PROBLEM", 327, 342], ["HIV", "PROBLEM", 347, 350], ["areas", "OBSERVATION_MODIFIER", 21, 26], ["pathogen genome", "OBSERVATION", 34, 49], ["no longer", "UNCERTAINTY", 205, 214]]], ["Sequence differences between viral, bacterial, and parasite strains are often found at these locations; therefore, a neutralizing antibody specific to an epitope on the HA protein of one influenza strain will not necessarily bind to or neutralize that same site on another influenza strain.", [["neutralizing antibody", "PROTEIN", 117, 138], ["HA protein", "PROTEIN", 169, 179], ["Sequence differences", "TEST", 0, 20], ["viral, bacterial, and parasite strains", "PROBLEM", 29, 67], ["a neutralizing antibody", "PROBLEM", 115, 138], ["an epitope", "PROBLEM", 151, 161], ["the HA protein", "TREATMENT", 165, 179], ["one influenza strain", "PROBLEM", 183, 203], ["another influenza strain", "PROBLEM", 265, 289], ["bacterial", "OBSERVATION_MODIFIER", 36, 45], ["parasite strains", "OBSERVATION", 51, 67]]], ["An analogous situation exists for bacteria, where a second strain may possess entirely different virulence factors than the first.", [["virulence factors", "PROTEIN", 97, 114], ["An analogous situation", "PROBLEM", 0, 22], ["bacteria", "PROBLEM", 34, 42], ["a second strain", "PROBLEM", 50, 65], ["different virulence factors", "PROBLEM", 87, 114]]], ["The new strain may be effectively invisible to the immune response specific for the first strain.", [["The new strain", "PROBLEM", 0, 14], ["the first strain", "PROBLEM", 80, 96]]], ["In this manner, strain diversity contributes to antigenic differences that determine whether or not immune responses are cross-protective.", [["strain diversity", "PROBLEM", 16, 32], ["antigenic differences", "PROBLEM", 48, 69]]], ["Understanding the factors controlling immunodominance and how pathogens exploit this is of critical importance (146, 147) .BARRIER #3: PATHOGEN VARIABILITYBy identifying genetically conserved regions, investigators can target epitopes more likely to be present across multiple strains, thereby creating immune responses that are cross-protective.", [["epitopes", "PROTEIN", 226, 234], ["multiple strains", "PROBLEM", 268, 284]]], ["For example, the use of conserved stalk regions of the influenza hemagglutinin (HA) protein to develop universal influenza vaccines is an excellent example of this type of work.", [["influenza", "DISEASE", 113, 122], ["influenza hemagglutinin", "ORGANISM", 55, 78], ["HA", "GENE_OR_GENE_PRODUCT", 80, 82], ["conserved stalk regions", "PROTEIN", 24, 47], ["influenza hemagglutinin (HA) protein", "PROTEIN", 55, 91], ["the influenza hemagglutinin (HA) protein", "TREATMENT", 51, 91], ["universal influenza vaccines", "TREATMENT", 103, 131]]], ["Another example is the Plasmodium falciparum Reticulocyte Binding Protein Homolog 5 (PfRh5), which facilitates parasite entry into human red blood cells through binding to the Ok blood group antigen (148) .", [["red blood cells", "ANATOMY", 137, 152], ["Ok blood", "ANATOMY", 176, 184], ["Plasmodium falciparum", "DISEASE", 23, 44], ["Plasmodium falciparum", "ORGANISM", 23, 44], ["Reticulocyte Binding Protein Homolog 5", "GENE_OR_GENE_PRODUCT", 45, 83], ["PfRh5", "GENE_OR_GENE_PRODUCT", 85, 90], ["human", "ORGANISM", 131, 136], ["red blood cells", "CELL", 137, 152], ["Ok blood group antigen", "GENE_OR_GENE_PRODUCT", 176, 198], ["Plasmodium falciparum Reticulocyte Binding Protein Homolog 5", "PROTEIN", 23, 83], ["PfRh5", "PROTEIN", 85, 90], ["human red blood cells", "CELL_TYPE", 131, 152], ["Ok blood group antigen", "PROTEIN", 176, 198], ["Plasmodium falciparum", "SPECIES", 23, 44], ["human", "SPECIES", 131, 136], ["Plasmodium falciparum", "SPECIES", 23, 44], ["human", "SPECIES", 131, 136], ["the Plasmodium falciparum Reticulocyte Binding Protein Homolog", "TREATMENT", 19, 81], ["red blood cells", "TEST", 137, 152], ["blood group antigen", "TEST", 179, 198]]], ["Because the PfRh5 protein is targeted by broadly acting, parasite-neutralizing antibodies that transcend different strains, PfRh5-based vaccines have shown promise as vaccine immunogens (149) .BARRIER #3: PATHOGEN VARIABILITYGenome-sequence data is used to do the following: determine pathogen strain diversity; identify virulence factors; select conserved regions; construct vectors; create recombinant proteins, attenuate vaccine strains (149) (150) (151) (152) (153) ; and create nucleic acid-based vaccines (154, 155) , which contain specific gene sequences necessary for the in vivo expression of selected antigens.", [["PfRh5", "CHEMICAL", 124, 129], ["nucleic acid", "CHEMICAL", 483, 495], ["PfRh5", "GENE_OR_GENE_PRODUCT", 12, 17], ["PfRh5", "GENE_OR_GENE_PRODUCT", 124, 129], ["nucleic acid", "SIMPLE_CHEMICAL", 483, 495], ["PfRh5 protein", "PROTEIN", 12, 25], ["parasite-neutralizing antibodies", "PROTEIN", 57, 89], ["PfRh5", "PROTEIN", 124, 129], ["virulence factors", "PROTEIN", 321, 338], ["recombinant proteins", "PROTEIN", 392, 412], ["antigens", "PROTEIN", 611, 619], ["the PfRh5 protein", "TEST", 8, 25], ["parasite-neutralizing antibodies", "TREATMENT", 57, 89], ["transcend different strains", "TREATMENT", 95, 122], ["PfRh5-based vaccines", "TREATMENT", 124, 144], ["vaccine immunogens", "TREATMENT", 167, 185], ["pathogen strain diversity", "PROBLEM", 285, 310], ["virulence factors", "PROBLEM", 321, 338], ["create recombinant proteins", "TEST", 385, 412], ["attenuate vaccine strains", "TEST", 414, 439], ["create nucleic acid", "TEST", 476, 495], ["specific gene sequences", "TEST", 538, 561]]], ["Additionally, the identification of such virulence factors enables researchers to selectively remove regions of the pathogen genome and create safer, attenuated strains for use as live-attenuated vaccines.", [["virulence factors", "PROTEIN", 41, 58], ["pathogen genome", "DNA", 116, 131], ["such virulence factors", "PROBLEM", 36, 58], ["the pathogen genome", "PROBLEM", 112, 131], ["live-attenuated vaccines", "TREATMENT", 180, 204], ["pathogen genome", "OBSERVATION", 116, 131]]], ["For example, bubonic plague is caused by Yersinia pestis and is one of the deadliest diseases known.", [["bubonic plague", "DISEASE", 13, 27], ["Yersinia pestis", "DISEASE", 41, 56], ["Yersinia pestis", "ORGANISM", 41, 56], ["Yersinia pestis", "SPECIES", 41, 56], ["Yersinia pestis", "SPECIES", 41, 56], ["bubonic plague", "PROBLEM", 13, 27], ["Yersinia pestis", "PROBLEM", 41, 56], ["the deadliest diseases", "PROBLEM", 71, 93], ["bubonic", "OBSERVATION_MODIFIER", 13, 20], ["plague", "OBSERVATION", 21, 27], ["Yersinia pestis", "OBSERVATION", 41, 56], ["deadliest", "OBSERVATION_MODIFIER", 75, 84], ["diseases", "OBSERVATION", 85, 93]]], ["A variety of killed, whole-cell vaccines have been available since before 1900, but none are currently licensed (156) .", [["whole-cell", "ANATOMY", 21, 31], ["cell", "CELL", 27, 31], ["whole-cell vaccines", "TREATMENT", 21, 40], ["variety", "OBSERVATION_MODIFIER", 2, 9]]], ["A number of live, attenuated vaccines have been produced, but concerns regarding reversion to virulence have precluded their widespread use (156) .", [["attenuated vaccines", "TREATMENT", 18, 37], ["virulence", "PROBLEM", 94, 103]]], ["Current efforts have focused on subunit vaccines, with the subunits (typically virulence factors such as the F1 and V proteins, although other such as NlpD, Caf1 have been used) (157) being identified through genomic approaches.", [["V", "GENE_OR_GENE_PRODUCT", 116, 117], ["NlpD", "GENE_OR_GENE_PRODUCT", 151, 155], ["Caf1", "GENE_OR_GENE_PRODUCT", 157, 161], ["virulence factors", "PROTEIN", 79, 96], ["F1", "PROTEIN", 109, 111], ["V proteins", "PROTEIN", 116, 126], ["NlpD", "PROTEIN", 151, 155], ["Caf1", "PROTEIN", 157, 161], ["subunit vaccines", "TREATMENT", 32, 48], ["the subunits (typically virulence factors", "PROBLEM", 55, 96], ["the F1 and V proteins", "TEST", 105, 126]]], ["These vaccines have several advantages, including increased safety profiles, rapid induction of protective immunity, and a requirement for fewer vaccine doses (158) .", [["These vaccines", "TREATMENT", 0, 14], ["increased safety profiles", "PROBLEM", 50, 75], ["protective immunity", "TREATMENT", 96, 115], ["fewer vaccine doses", "TREATMENT", 139, 158]]], ["Unfortunately, Caf1 deletion does not always prevent lethal infection (159) , which suggests that it is not essential for virulence.", [["infection", "DISEASE", 60, 69], ["Caf1", "GENE_OR_GENE_PRODUCT", 15, 19], ["Caf1 deletion", "DNA", 15, 28], ["Caf1 deletion", "PROBLEM", 15, 28], ["lethal infection", "PROBLEM", 53, 69], ["virulence", "PROBLEM", 122, 131], ["does not always prevent", "UNCERTAINTY", 29, 52], ["lethal", "OBSERVATION_MODIFIER", 53, 59], ["infection", "OBSERVATION", 60, 69], ["not essential for", "UNCERTAINTY", 104, 121]]], ["Similarly, although it is widely assumed that LcrV antibodies are necessary for protection, some primate models indicate that this may not be true for pneumonic plague (160) .", [["pneumonic", "DISEASE", 151, 160], ["LcrV antibodies", "GENE_OR_GENE_PRODUCT", 46, 61], ["LcrV antibodies", "PROTEIN", 46, 61], ["LcrV antibodies", "TREATMENT", 46, 61], ["protection", "TREATMENT", 80, 90], ["pneumonic plague", "PROBLEM", 151, 167], ["may not be", "UNCERTAINTY", 131, 141]]], ["Another example is Rift Valley fever virus.", [["Rift Valley fever", "DISEASE", 19, 36], ["Rift Valley fever virus", "ORGANISM", 19, 42], ["Rift Valley fever virus", "SPECIES", 19, 42], ["Rift Valley fever virus", "PROBLEM", 19, 42], ["Rift", "OBSERVATION_MODIFIER", 19, 23]]], ["The Rift Valley fever non-structural protein NSs was identified as a component that could be removed from the Rift Valley fever veterinary vaccine in order to differentiate infected from vaccinated animals (161) .", [["fever", "DISEASE", 16, 21], ["fever", "DISEASE", 122, 127], ["Rift Valley fever", "ORGANISM", 4, 21], ["Rift Valley fever", "ORGANISM", 110, 127], ["Rift Valley fever non-structural protein NSs", "PROTEIN", 4, 48], ["Rift Valley fever non-structural", "SPECIES", 4, 36], ["Rift Valley fever veterinary vaccine", "SPECIES", 110, 146], ["The Rift Valley fever non-structural protein NSs", "PROBLEM", 0, 48], ["the Rift Valley fever veterinary vaccine", "TREATMENT", 106, 146], ["Rift", "OBSERVATION_MODIFIER", 4, 8], ["protein NSs", "OBSERVATION", 37, 48]]], ["Studies found that the NSs protein was a virulence factor and that removal of the protein increased animal survival from 50 to 95% (162) .", [["NSs", "GENE_OR_GENE_PRODUCT", 23, 26], ["NSs protein", "PROTEIN", 23, 34], ["virulence factor", "PROTEIN", 41, 57], ["Studies", "TEST", 0, 7], ["the NSs protein", "PROBLEM", 19, 34], ["a virulence factor", "PROBLEM", 39, 57], ["removal", "TREATMENT", 67, 74], ["the protein", "TEST", 78, 89]]], ["Virulence proteins can also be used as components of protein-based vaccines.", [["Virulence proteins", "PROTEIN", 0, 18], ["Virulence proteins", "PROBLEM", 0, 18], ["protein-based vaccines", "TREATMENT", 53, 75]]], ["Excellent examples of this are the diphtheria and tetanus toxoid vaccines that contain formaldehyde-detoxified toxins (163) , which enable recipients to develop antibodies that recognize and neutralize the native toxins, thus eliminating the major cause of pathogenesis during infection.", [["diphtheria", "DISEASE", 35, 45], ["tetanus", "DISEASE", 50, 57], ["formaldehyde", "CHEMICAL", 87, 99], ["infection", "DISEASE", 277, 286], ["formaldehyde", "CHEMICAL", 87, 99], ["tetanus toxoid", "ORGANISM", 50, 64], ["formaldehyde", "SIMPLE_CHEMICAL", 87, 99], ["recipients", "ORGANISM", 139, 149], ["antibodies", "PROTEIN", 161, 171], ["the diphtheria", "TREATMENT", 31, 45], ["tetanus toxoid vaccines", "TREATMENT", 50, 73], ["antibodies", "PROBLEM", 161, 171], ["the native toxins", "PROBLEM", 202, 219], ["pathogenesis during infection", "PROBLEM", 257, 286], ["pathogenesis", "OBSERVATION", 257, 269], ["infection", "OBSERVATION", 277, 286]]], ["Sequencing studies have also identified the role of gene sequences in meningococcal antigen expression (164) , have identified meningococcal genotypes associated with increase virulence or invasion (165, 166) , and have provided insight into immune evasion mechanisms (167) .BARRIER #3: PATHOGEN VARIABILITYFor a complex pathogen such as plasmodium, in which multiple life-cycle stages occur with very different genes (and proteins) expressed at each stage, it is important to identify the proper sets of immune targets for vaccine development.", [["meningococcal antigen", "GENE_OR_GENE_PRODUCT", 70, 91], ["Sequencing studies", "TEST", 0, 18], ["meningococcal antigen expression", "TEST", 70, 102], ["meningococcal genotypes", "PROBLEM", 127, 150], ["increase virulence", "PROBLEM", 167, 185], ["invasion", "PROBLEM", 189, 197], ["PATHOGEN", "PROBLEM", 287, 295], ["a complex pathogen", "PROBLEM", 311, 329], ["plasmodium", "PROBLEM", 338, 348], ["very different genes (and proteins)", "PROBLEM", 397, 432], ["immune targets", "TREATMENT", 505, 519], ["vaccine development", "TREATMENT", 524, 543], ["meningococcal genotypes", "OBSERVATION", 127, 150], ["increase", "OBSERVATION_MODIFIER", 167, 175], ["virulence", "OBSERVATION_MODIFIER", 176, 185], ["invasion", "OBSERVATION_MODIFIER", 189, 197]]], ["Genomic technologies have allowed investigators to \"mine\" the plasmodium genome for antigen discovery.", [["antigen", "GENE_OR_GENE_PRODUCT", 84, 91], ["plasmodium genome", "DNA", 62, 79], ["plasmodium genome", "OBSERVATION", 62, 79]]], ["In a recent study, investigators identified the UIS3 gene as essential for parasite development in the liver.", [["liver", "ANATOMY", 103, 108], ["UIS3", "GENE_OR_GENE_PRODUCT", 48, 52], ["liver", "ORGAN", 103, 108], ["UIS3 gene", "DNA", 48, 57], ["a recent study", "TEST", 3, 17], ["parasite development in the liver", "PROBLEM", 75, 108], ["parasite", "OBSERVATION", 75, 83], ["liver", "ANATOMY", 103, 108]]], ["UIS3-deficient sporozoites were created and found to infect hepatocytes but were unable to establish a blood-stage infection (168) .", [["sporozoites", "ANATOMY", 15, 26], ["hepatocytes", "ANATOMY", 60, 71], ["blood", "ANATOMY", 103, 108], ["blood-stage infection", "DISEASE", 103, 124], ["UIS3", "GENE_OR_GENE_PRODUCT", 0, 4], ["hepatocytes", "CELL", 60, 71], ["blood", "ORGANISM_SUBSTANCE", 103, 108], ["UIS3", "PROTEIN", 0, 4], ["hepatocytes", "CELL_TYPE", 60, 71], ["deficient sporozoites", "PROBLEM", 5, 26], ["a blood-stage infection", "PROBLEM", 101, 124], ["deficient sporozoites", "OBSERVATION", 5, 26], ["stage", "OBSERVATION_MODIFIER", 109, 114], ["infection", "OBSERVATION", 115, 124]]], ["Vaccination with these modified sporozoites could protect immunized animals from an infectious challenge.", [["sporozoites", "ORGANISM", 32, 43], ["Vaccination", "TREATMENT", 0, 11], ["these modified sporozoites", "TREATMENT", 17, 43], ["an infectious challenge", "PROBLEM", 81, 104], ["infectious", "OBSERVATION", 84, 94]]], ["In another study, scientists identified genes preferentially expressed by parasites capable of infecting the placenta through the CSA receptor (169) .", [["placenta", "ANATOMY", 109, 117], ["placenta", "ORGAN", 109, 117], ["CSA receptor", "GENE_OR_GENE_PRODUCT", 130, 142], ["CSA receptor", "PROTEIN", 130, 142], ["another study", "TEST", 3, 16], ["placenta", "ANATOMY", 109, 117]]], ["Just like the UIS3 example, these genes may serve as useful targets for a vaccine against malaria in pregnant women.", [["malaria", "DISEASE", 90, 97], ["UIS3", "GENE_OR_GENE_PRODUCT", 14, 18], ["women", "ORGANISM", 110, 115], ["UIS3", "DNA", 14, 18], ["women", "SPECIES", 110, 115], ["a vaccine", "TREATMENT", 72, 81], ["malaria", "PROBLEM", 90, 97]]], ["Fortunately, these approaches can also be applied to less complex pathogens.", [["less complex pathogens", "PROBLEM", 53, 75], ["pathogens", "OBSERVATION", 66, 75]]], ["A similar microarray-analysis approach identified Neisseria serogroup B genes that were upregulated during infection and were subsequently demonstrated to encode proteins targeted by protective immune responses (170) .BARRIER #4: NEW VACCINES AND VACCINE SAFETYDrivers for the use of genomics in vaccinology include not only the public health need for new vaccines, but also the need to ensure vaccine safety and the need to develop directed approaches to de-risk the costs and time involved in vaccine development.", [["infection", "DISEASE", 107, 116], ["Neisseria serogroup B", "GENE_OR_GENE_PRODUCT", 50, 71], ["Neisseria serogroup B genes", "DNA", 50, 77], ["Neisseria serogroup B", "SPECIES", 50, 71], ["Neisseria serogroup B genes", "PROBLEM", 50, 77], ["infection", "PROBLEM", 107, 116], ["NEW VACCINES", "TREATMENT", 230, 242], ["VACCINE SAFETYDrivers", "TREATMENT", 247, 268], ["genomics in vaccinology", "TREATMENT", 284, 307], ["new vaccines", "TREATMENT", 352, 364], ["vaccine safety", "TREATMENT", 394, 408], ["infection", "OBSERVATION", 107, 116]]], ["The recognition that human genetic diversity leads to variations in infectious disease expression, severity, and disease outcomes, as well as variations in vaccine response, means that immune responses to vaccines are, at some level, predictable (7) .", [["human", "ORGANISM", 21, 26], ["human", "SPECIES", 21, 26], ["human", "SPECIES", 21, 26], ["variations in infectious disease expression", "PROBLEM", 54, 97], ["severity", "PROBLEM", 99, 107], ["disease outcomes", "PROBLEM", 113, 129], ["variations in vaccine response", "PROBLEM", 142, 172], ["vaccines", "TREATMENT", 205, 213], ["infectious", "OBSERVATION_MODIFIER", 68, 78]]], ["In 2007, we developed and published the immune response network theory, which stated that immune responses to a vaccine are the \"cumulative result of non-random interactions with host genes, epigenetic phenomena, metagenomics and the microbiome, gene dominance, complementarity, epistasis, coinfections, and other factors occurring within the system as a whole\" (7, 92) .", [["coinfections", "DISEASE", 290, 302], ["host genes", "DNA", 179, 189], ["immune responses", "PROBLEM", 90, 106], ["a vaccine", "TREATMENT", 110, 119], ["non-random interactions", "PROBLEM", 150, 173], ["epigenetic phenomena", "PROBLEM", 191, 211], ["epistasis", "PROBLEM", 279, 288], ["coinfections", "PROBLEM", 290, 302]]], ["Critical to our understanding of how vaccines induce protective (or aberrant) immune responses are the ideas that such responses are not random (and hence can be predictable) and occur at the systems level (92) .", [["aberrant) immune responses", "PROBLEM", 68, 94]]], ["In turn, this led to the development of vaccinomics and systems vaccinology (7, 13, (171) (172) (173) (174) (175) (176) (177) (178) .", [["vaccinomics", "PROBLEM", 40, 51], ["systems vaccinology", "TEST", 56, 75]]], ["This emerging paradigm is an approach that utilizes the tools and insights derived from systems biology; high-dimensional, high-throughput \"omics\" technologies; and genomics (7, 13, 59, 66, 79, 175, (179) (180) (181) (182) (183) .", [["the tools", "TEST", 52, 61], ["genomics", "TEST", 165, 173]]], ["Vaccinomics leverages high-resolution data, such as transcriptomics, proteomics, and metabolomics/lipidomics/glycomics, epigenetics, etc., to derive holistic (systems-level) and mechanistic models of both protective and aberrant immune system responses (i.e., \"immune signatures\").", [["immune system", "ANATOMY", 229, 242], ["Vaccinomics leverages", "TEST", 0, 21], ["transcriptomics", "TEST", 52, 67], ["proteomics", "TEST", 69, 79], ["metabolomics/lipidomics", "TEST", 85, 108]]], ["Such high-dimensional data are utilized in a new, directed four-step vaccine-development paradigm we have described as, \"discover, characterize, validate and apply\" (13) .", [["directed four-step vaccine", "TREATMENT", 50, 76]]], ["The idea is to discover new vaccine targets through the use of genomic technologies, characterize these targets in terms of their ability to generate protective immune responses, validate the findings in genetically diverse populations, and apply such findings to new vaccine development and vaccine safety studies.BARRIER #4: NEW VACCINES AND VACCINE SAFETYThe increased public scrutiny of vaccine safety has led to several large-scale initiatives designed to enhance our understanding of what drives adverse events after vaccination.", [["new vaccine targets", "TREATMENT", 24, 43], ["genomic technologies", "TREATMENT", 63, 83], ["new vaccine development", "TREATMENT", 264, 287], ["vaccine safety studies", "TEST", 292, 314], ["NEW VACCINES", "TREATMENT", 327, 339], ["VACCINE SAFETY", "TREATMENT", 344, 358], ["vaccine safety", "TREATMENT", 391, 405], ["several large-scale initiatives", "TREATMENT", 417, 448], ["vaccination", "TREATMENT", 523, 534], ["increased", "OBSERVATION_MODIFIER", 362, 371]]], ["One such effort, the BIoVacSafe Project (http://www.biovacsafe. eu/), began in 2012 with an overall goal to improve vaccine safety monitoring and understand what drives adverse reactions to vaccines.", [["eu", "PROTEIN", 64, 66], ["vaccine safety monitoring", "TREATMENT", 116, 141], ["adverse reactions", "PROBLEM", 169, 186], ["vaccines", "TREATMENT", 190, 198]]], ["The effort had several objectives: (1) to understand early inflammatory responses after vaccination;BARRIER #4: NEW VACCINES AND VACCINE SAFETY(2) to develop biomarkers of autoimmunity; and (3) to capture the incidence of autoimmune disease in the population in order to identify those at higher risk of severe adverse events such as anaphylactic shock.", [["autoimmunity", "DISEASE", 172, 184], ["autoimmune disease", "DISEASE", 222, 240], ["anaphylactic shock", "DISEASE", 334, 352], ["NEW VACCINES", "TREATMENT", 112, 124], ["autoimmunity", "PROBLEM", 172, 184], ["autoimmune disease", "PROBLEM", 222, 240], ["severe adverse events", "PROBLEM", 304, 325], ["anaphylactic shock", "PROBLEM", 334, 352], ["autoimmune disease", "OBSERVATION", 222, 240], ["severe", "OBSERVATION_MODIFIER", 304, 310], ["adverse", "OBSERVATION", 311, 318], ["anaphylactic shock", "OBSERVATION", 334, 352]]], ["A key to this endeavor has been the use of high-dimensional systems vaccinology approaches (184) .BARRIER #4: NEW VACCINES AND VACCINE SAFETYConventional vaccines to prevent infectious diseases typically consist of killed or attenuated pathogens or of proteins from those microorganisms.", [["infectious diseases", "DISEASE", 174, 193], ["NEW VACCINES", "TREATMENT", 110, 122], ["VACCINE SAFETYConventional vaccines", "TREATMENT", 127, 162], ["infectious diseases", "PROBLEM", 174, 193], ["attenuated pathogens", "PROBLEM", 225, 245], ["proteins from those microorganisms", "PROBLEM", 252, 286]]], ["In contrast, new vaccines being developed, which are poised to make major inroads in medicine, take advantage of genomic technologies to understand which host genes are activated/silenced, which host proteins or metabolites are involved, and what leads to a long duration (durability) of the immune response in vaccinated individuals (O'Connor et al., 119) .", [["new vaccines", "TREATMENT", 13, 25], ["genomic technologies", "TREATMENT", 113, 133]]], ["The second genomic revolution in the vaccine field has to do with the vaccine constructs themselves.", [["second", "OBSERVATION_MODIFIER", 4, 10], ["genomic", "OBSERVATION_MODIFIER", 11, 18], ["revolution", "OBSERVATION_MODIFIER", 19, 29]]], ["Specifically, genomic universal influenza virus vaccines can take the form of DNA or RNA that encode desired hemagglutinins or domains thereof.", [["influenza virus", "ORGANISM", 32, 47], ["DNA", "CELLULAR_COMPONENT", 78, 81], ["hemagglutinins", "PROTEIN", 109, 123], ["influenza virus", "SPECIES", 32, 47], ["influenza virus", "SPECIES", 32, 47], ["genomic universal influenza virus vaccines", "TREATMENT", 14, 56], ["DNA or RNA", "PROBLEM", 78, 88]]], ["On administration, the genes enter cells, which then produce the proteins/components of proteins of interest.", [["cells", "ANATOMY", 35, 40], ["cells", "CELL", 35, 40], ["administration", "TREATMENT", 3, 17]]], ["Compared with manufacturing proteins in cell cultures or whole viruses in embryonated eggs, producing just DNA/RNA is possibly simpler and less expensive.", [["cell cultures", "ANATOMY", 40, 53], ["eggs", "ANATOMY", 86, 90], ["cell cultures", "CELL", 40, 53], ["DNA", "CELLULAR_COMPONENT", 107, 110], ["cell cultures", "CELL_LINE", 40, 53], ["cell cultures", "TEST", 40, 53], ["whole viruses", "PROBLEM", 57, 70], ["embryonated eggs", "PROBLEM", 74, 90], ["just DNA/RNA", "PROBLEM", 102, 114], ["cell cultures", "OBSERVATION", 40, 53], ["embryonated eggs", "OBSERVATION", 74, 90], ["RNA", "OBSERVATION", 111, 114], ["possibly", "UNCERTAINTY", 118, 126], ["simpler", "OBSERVATION_MODIFIER", 127, 134]]], ["The latter approach is also amenable to making combinations of different epitopes and antigens for complex novel influenza virus vaccines.", [["influenza virus", "DISEASE", 113, 128], ["influenza virus", "ORGANISM", 113, 128], ["epitopes", "PROTEIN", 73, 81], ["antigens", "PROTEIN", 86, 94], ["different epitopes and antigens", "PROBLEM", 63, 94], ["complex novel influenza virus vaccines", "TREATMENT", 99, 137]]], ["Checkpoint inhibitors may be used to enhance the immune responses of immunosubdominant epitopes.", [["immunosubdominant epitopes", "PROTEIN", 69, 95], ["Checkpoint inhibitors", "TREATMENT", 0, 21], ["immunosubdominant epitopes", "PROBLEM", 69, 95]]], ["Finally, genomic vaccines may express antibodies for passive immunization instead of antigens to allow for rapid protection in the case of an emerging pandemic.BARRIER #4: NEW VACCINES AND VACCINE SAFETYADITEC Project (https://www.aditecproject.eu/) is a European initiative to organize the use of systems biology, adjuvant discovery, immunization routes, novel vaccine vectors and formulations, information about host factors, and results from animal models in order to develop novel immunization technologies and drive vaccine discovery.", [["antibodies", "PROTEIN", 38, 48], ["antigens", "PROTEIN", 85, 93], ["genomic vaccines", "TREATMENT", 9, 25], ["passive immunization", "TREATMENT", 53, 73], ["antigens", "TREATMENT", 85, 93], ["rapid protection", "TREATMENT", 107, 123], ["an emerging pandemic", "PROBLEM", 139, 159], ["NEW VACCINES", "TREATMENT", 172, 184], ["adjuvant discovery", "TREATMENT", 315, 333], ["immunization routes", "TREATMENT", 335, 354], ["novel vaccine vectors", "TREATMENT", 356, 377], ["formulations", "TREATMENT", 382, 394], ["novel immunization technologies", "TREATMENT", 479, 510], ["pandemic", "OBSERVATION", 151, 159]]], ["This consortium has published dozens of papers every year since its inception in 2011 and holds seminars and advanced courses in fields related to vaccinology.", [["advanced courses in fields", "TREATMENT", 109, 135]]], ["This project has resulted in nearly three dozen new immunization technologies, over 20 new animal and in vitro models being developed, multiple patents, and at least a dozen clinical trials.", [["new immunization technologies", "TREATMENT", 48, 77], ["multiple", "OBSERVATION_MODIFIER", 135, 143], ["patents", "OBSERVATION", 144, 151]]], ["In the United States, the Human Vaccines Project is using systems biology, artificial intelligence (AI), and cutting-edge technologies to understand how the immune system functions and responds to vaccines (44) .", [["immune system", "ANATOMY", 157, 170], ["Human", "ORGANISM", 26, 31], ["Human", "SPECIES", 26, 31], ["the Human Vaccines", "TREATMENT", 22, 40], ["cutting-edge technologies", "TREATMENT", 109, 134], ["vaccines", "TREATMENT", 197, 205]]], ["Addressing this fundamental gap in our knowledge will enable us to decode the human immune system, develop predictive markers of vaccine response, and create AI models of the immune system.", [["immune system", "ANATOMY", 84, 97], ["immune system", "ANATOMY", 175, 188], ["human", "ORGANISM", 78, 83], ["immune system", "ANATOMICAL_SYSTEM", 84, 97], ["immune system", "ANATOMICAL_SYSTEM", 175, 188], ["human", "SPECIES", 78, 83], ["human", "SPECIES", 78, 83], ["this fundamental gap", "PROBLEM", 11, 31], ["vaccine response", "PROBLEM", 129, 145]]], ["Increasingly, sophisticated computational modeling and machine learning approaches will be leveraged to understand immune function (185) , identify optimal epitopes (186), as well as design and test new vaccines (187) (188) (189) .BARRIER #4: NEW VACCINES AND VACCINE SAFETYWhile the idea of personalized medicine is making progress, very little is known why some humans are more resistant to a pathogen and others are more susceptible.", [["humans", "ORGANISM", 364, 370], ["epitopes", "PROTEIN", 156, 164], ["humans", "SPECIES", 364, 370], ["humans", "SPECIES", 364, 370], ["test new vaccines", "TEST", 194, 211], ["NEW VACCINES", "TREATMENT", 243, 255], ["VACCINE", "TREATMENT", 260, 267]]], ["Combined with a better understanding of who responds well to a particular vaccine, this knowledge will be crucial to provide adequate protection and to design novel vaccines/gene sequences for an individual.BARRIER #4: NEW VACCINES AND VACCINE SAFETYVaccine safety is also being addressed using genetic approaches-termed \"adversomics\"-using the tools of immunogenomics, systems biology, computational modeling, and bioinformatics in order to better understand both genetic and non-genetic drivers of aberrant vaccine responses at the molecular level (7, 171, 172, 176) .", [["gene sequences", "DNA", 174, 188], ["a particular vaccine", "TREATMENT", 61, 81], ["novel vaccines/gene sequences", "TREATMENT", 159, 188], ["NEW VACCINES", "TREATMENT", 219, 231], ["VACCINE SAFETYVaccine safety", "TREATMENT", 236, 264], ["computational modeling", "TEST", 387, 409]]], ["This is similar to the use of \"omic\" technologies in the field of toxicology (190, 191) .BARRIER #4: NEW VACCINES AND VACCINE SAFETYAdversomics presupposes that vaccine adverse reactions and events are not random and are predetermined genetically and in other ways.", [["NEW VACCINES", "TREATMENT", 101, 113], ["VACCINE SAFETYAdversomics presupposes", "TREATMENT", 118, 155], ["vaccine adverse reactions", "PROBLEM", 161, 186]]], ["Immune-mediated vaccine adverse events are the primary outcomes of interest for the field of adversomics (184, 192) .", [["adversomics", "DISEASE", 93, 104], ["Immune-mediated vaccine", "TREATMENT", 0, 23], ["adverse events", "PROBLEM", 24, 38]]], ["New biologic understandings, and the necessity of preventing serious adverse vaccine events, are critical to enhancing and-in some population groups-restoring public trust in vaccine safety, and for creating new knowledge applied to developing new vaccines that are both safe and effective.", [["serious adverse vaccine events", "PROBLEM", 61, 91], ["new vaccines", "TREATMENT", 244, 256]]], ["The pathway to accomplishing these goals is to understand the genetic and molecular mechanisms that determine interindividual variations in vaccine response and reactivity.", [["interindividual variations in vaccine response", "PROBLEM", 110, 156]]], ["In turn, mechanistic knowledge of underlying vaccine adverse events could allow the ability to predict serious adverse events, and to design new vaccines that reduce or even eliminate harmful vaccine-related reactions.", [["underlying vaccine adverse events", "PROBLEM", 34, 67], ["serious adverse events", "PROBLEM", 103, 125], ["new vaccines", "TREATMENT", 141, 153], ["harmful vaccine", "PROBLEM", 184, 199], ["related reactions", "PROBLEM", 200, 217]]], ["This endeavor is likely to be complementary to a more individualized approach to vaccine practice.BARRIER #4: NEW VACCINES AND VACCINE SAFETYExamples of the value of genomics in vaccine safety have been published.", [["vaccine practice", "TREATMENT", 81, 97], ["NEW VACCINES", "TREATMENT", 110, 122], ["VACCINE SAFETYExamples", "TREATMENT", 127, 149], ["genomics in vaccine", "TREATMENT", 166, 185], ["likely to be", "UNCERTAINTY", 17, 29]]], ["McKinney et al. identified an association between specific cytokines after smallpox vaccination and the development of fever (193) .", [["fever", "DISEASE", 119, 124], ["cytokines", "PROTEIN", 59, 68], ["specific cytokines", "TREATMENT", 50, 68], ["smallpox vaccination", "TREATMENT", 75, 95], ["fever", "PROBLEM", 119, 124], ["fever", "OBSERVATION", 119, 124]]], ["Stanley et al. identified the influence of specific SNP haplotypes in the IL-1A, IL4, and IL18 gene complex in the development of fever after smallpox vaccination (194) .", [["SNP", "CHEMICAL", 52, 55], ["fever", "DISEASE", 130, 135], ["smallpox", "DISEASE", 142, 150], ["IL-1A", "GENE_OR_GENE_PRODUCT", 74, 79], ["IL4", "GENE_OR_GENE_PRODUCT", 81, 84], ["IL18", "GENE_OR_GENE_PRODUCT", 90, 94], ["IL-1A, IL4, and IL18 gene complex", "DNA", 74, 107], ["specific SNP haplotypes", "TREATMENT", 43, 66], ["IL4", "PROBLEM", 81, 84], ["IL18 gene complex", "PROBLEM", 90, 107], ["fever", "PROBLEM", 130, 135], ["smallpox vaccination", "TREATMENT", 142, 162], ["IL4", "ANATOMY", 81, 84]]], ["Feenstra and colleagues identified a variety of genes and SNPs [IFI44L, CD46, SCN1A, 2A, TMEM16 (ANO3)] in the etiology of fever and febrile seizures after MMR vaccination (195) .", [["fever", "DISEASE", 123, 128], ["febrile seizures", "DISEASE", 133, 149], ["IFI44L", "GENE_OR_GENE_PRODUCT", 64, 70], ["CD46", "GENE_OR_GENE_PRODUCT", 72, 76], ["SCN1A, 2A", "GENE_OR_GENE_PRODUCT", 78, 87], ["TMEM16", "GENE_OR_GENE_PRODUCT", 89, 95], ["ANO3", "GENE_OR_GENE_PRODUCT", 97, 101], ["SNPs", "DNA", 58, 62], ["IFI44L", "DNA", 64, 70], ["CD46", "DNA", 72, 76], ["SCN1A", "DNA", 78, 83], ["TMEM16", "DNA", 89, 95], ["ANO3", "DNA", 97, 101], ["fever", "PROBLEM", 123, 128], ["febrile seizures", "PROBLEM", 133, 149], ["MMR vaccination", "TREATMENT", 156, 171], ["fever", "OBSERVATION", 123, 128]]], ["We and others have published on the association of myopericarditis after smallpox vaccine (196) (197) (198) (199) (200) .", [["myopericarditis", "DISEASE", 51, 66], ["myopericarditis", "CANCER", 51, 66], ["myopericarditis", "PROBLEM", 51, 66], ["smallpox vaccine", "TREATMENT", 73, 89], ["myopericarditis", "OBSERVATION", 51, 66]]], ["This has resulted in studies attempting to determine possible genetic associations (176, 201, 202) .BARRIER #5: NON-HERITABLE FACTORS (E.G., ENVIRONMENT AND GEOGRAPHY)In addition to host genetics, non-heritable or environmental factors (e.g., pathogenic and symbiotic microorganisms, infections, diet, smoking, geographic, and other factors) play a role in shaping biological post-vaccination responses; however, the contribution of environmental factors to vaccine-induced immune responses is less understood (93) .", [["infections", "DISEASE", 284, 294], ["studies", "TEST", 21, 28], ["environmental factors", "PROBLEM", 214, 235], ["pathogenic and symbiotic microorganisms", "PROBLEM", 243, 282], ["infections", "PROBLEM", 284, 294], ["environmental factors", "PROBLEM", 433, 454], ["vaccine", "TREATMENT", 458, 465], ["NON-HERITABLE", "OBSERVATION_MODIFIER", 112, 125]]], ["It is possible that inter-individual variation in immune responses induced by environmental factors would be significant in shaping adaptive post-vaccination responses.", [["inter-individual variation in immune responses", "PROBLEM", 20, 66], ["inter-individual", "OBSERVATION_MODIFIER", 20, 36], ["variation", "OBSERVATION_MODIFIER", 37, 46]]], ["As an example, by using a systems vaccinology approach to assess immune responses stimulated by trivalent inactivated influenza vaccination (TIV), the gene expression of TLR5 at day 3 after vaccination was found to correlate with influenza vaccination response (HAI titers) 28 days after vaccination (203) .", [["TLR5", "GENE_OR_GENE_PRODUCT", 170, 174], ["TLR5", "PROTEIN", 170, 174], ["TIV", "SPECIES", 141, 144], ["a systems vaccinology approach", "TREATMENT", 24, 54], ["immune responses", "PROBLEM", 65, 81], ["trivalent inactivated influenza vaccination", "TREATMENT", 96, 139], ["TIV", "TREATMENT", 141, 144], ["the gene expression of TLR5", "TREATMENT", 147, 174], ["vaccination", "TREATMENT", 190, 201], ["influenza vaccination response", "TREATMENT", 230, 260]]], ["While TLR5 mediates the sensing of flagellin on bacteria, it has been shown that it is also necessary to generate B cell responses and Ab production to viral vaccines (e.g., inactivated influenza and inactivated polio vaccines) (203, 204) .", [["B cell", "ANATOMY", 114, 120], ["influenza", "DISEASE", 186, 195], ["TLR5", "GENE_OR_GENE_PRODUCT", 6, 10], ["flagellin", "GENE_OR_GENE_PRODUCT", 35, 44], ["B cell", "CELL", 114, 120], ["Ab", "GENE_OR_GENE_PRODUCT", 135, 137], ["TLR5", "PROTEIN", 6, 10], ["flagellin", "PROTEIN", 35, 44], ["flagellin on bacteria", "PROBLEM", 35, 56], ["B cell responses", "TEST", 114, 130], ["Ab production", "PROBLEM", 135, 148], ["viral vaccines", "TREATMENT", 152, 166], ["influenza", "PROBLEM", 186, 195], ["inactivated polio vaccines", "TREATMENT", 200, 226]]], ["Vaccination of TLR5 \u2212/\u2212 mice with TIV has caused a substantial reduction in Ab levels and frequencies of short-lived plasma cells confirming the gut microbiota can influence the heterogeneity in vaccine responses.", [["plasma cells", "ANATOMY", 117, 129], ["gut microbiota", "ANATOMY", 145, 159], ["TIV", "CHEMICAL", 34, 37], ["TLR5", "GENE_OR_GENE_PRODUCT", 15, 19], ["Ab", "GENE_OR_GENE_PRODUCT", 76, 78], ["plasma cells", "CELL", 117, 129], ["gut microbiota", "MULTI-TISSUE_STRUCTURE", 145, 159], ["TLR5", "PROTEIN", 15, 19], ["plasma cells", "CELL_TYPE", 117, 129], ["mice", "SPECIES", 24, 28], ["mice", "SPECIES", 24, 28], ["TIV", "SPECIES", 34, 37], ["Vaccination", "TREATMENT", 0, 11], ["TLR5 \u2212/\u2212 mice", "TREATMENT", 15, 28], ["TIV", "TREATMENT", 34, 37], ["a substantial reduction", "PROBLEM", 49, 72], ["Ab levels", "TEST", 76, 85], ["short-lived plasma cells", "PROBLEM", 105, 129], ["substantial", "OBSERVATION_MODIFIER", 51, 62], ["reduction", "OBSERVATION_MODIFIER", 63, 72], ["Ab levels", "OBSERVATION", 76, 85]]], ["Hence, there is close interaction among the components of the human immune system and the host microbiota, and this interface may influence vaccine-induced immune response and affect vaccine efficacy.", [["immune system", "ANATOMY", 68, 81], ["human", "ORGANISM", 62, 67], ["immune system", "ANATOMICAL_SYSTEM", 68, 81], ["human", "SPECIES", 62, 67], ["human", "SPECIES", 62, 67], ["influence vaccine", "TREATMENT", 130, 147], ["host microbiota", "OBSERVATION", 90, 105]]], ["Such findings require systems-level omics technologies to dissect the contributions and inter-relationships between multiple factors.BARRIER #5: NON-HERITABLE FACTORS (E.G., ENVIRONMENT AND GEOGRAPHY)The effect of genetic contribution (heritability) on vaccineinduced immunity has mainly been estimated through monozygotic and dizygotic twin studies, which provided an approach to control for common environmental factors.", [["vaccineinduced immunity", "TREATMENT", 253, 276], ["dizygotic twin studies", "TEST", 327, 349], ["an approach", "TREATMENT", 366, 377], ["common environmental factors", "PROBLEM", 393, 421], ["NON-HERITABLE", "OBSERVATION_MODIFIER", 145, 158]]], ["Most of these studies have found that immune responses to many vaccines are heritable (205) (206) (207) .", [["these studies", "TEST", 8, 21], ["immune responses", "PROBLEM", 38, 54], ["many vaccines", "TREATMENT", 58, 71]]], ["For example, the estimated heritability for anti-HBs Ab concentrations after receipt of hepatitis B vaccine ranged between 61 and 91% in different studies (205, 206, 208) .", [["hepatitis B", "DISEASE", 88, 99], ["anti-HBs Ab", "GENE_OR_GENE_PRODUCT", 44, 55], ["hepatitis B", "ORGANISM", 88, 99], ["anti-HBs Ab", "PROTEIN", 44, 55], ["hepatitis B", "SPECIES", 88, 99], ["the estimated heritability", "PROBLEM", 13, 39], ["anti-HBs Ab concentrations", "PROBLEM", 44, 70], ["hepatitis B vaccine", "TEST", 88, 107]]], ["With respect to MMR vaccinations, the estimated heritability for Ab responses to measles, mumps and rubella virus vaccines has been found to be 88.5, 38.8, and 45.7%, respectively (209) .", [["measles", "DISEASE", 81, 88], ["mumps and rubella virus", "DISEASE", 90, 113], ["Ab", "GENE_OR_GENE_PRODUCT", 65, 67], ["mumps", "ORGANISM", 90, 95], ["rubella virus", "ORGANISM", 100, 113], ["mumps and rubella virus", "SPECIES", 90, 113], ["rubella virus", "SPECIES", 100, 113], ["MMR vaccinations", "TREATMENT", 16, 32], ["the estimated heritability", "PROBLEM", 34, 60], ["Ab responses", "TEST", 65, 77], ["measles", "PROBLEM", 81, 88], ["mumps", "PROBLEM", 90, 95], ["rubella virus vaccines", "TREATMENT", 100, 122]]], ["Using the frequency of the human immune cell repertoire by FACS, a large genetic study of 1,629 individuals (14-102 years old) from Sardinia, Italy, found many cell populations (that are positive for the CD93 marker) with very high heritability (>60%), including Tregs and their subsets (mean 55%) (210) .", [["immune cell", "ANATOMY", 33, 44], ["cell", "ANATOMY", 160, 164], ["Tregs", "ANATOMY", 263, 268], ["human", "ORGANISM", 27, 32], ["immune cell", "CELL", 33, 44], ["cell populations", "CELL", 160, 176], ["CD93", "GENE_OR_GENE_PRODUCT", 204, 208], ["Tregs", "CELL", 263, 268], ["CD93 marker", "PROTEIN", 204, 215], ["Tregs", "CELL_TYPE", 263, 268], ["human", "SPECIES", 27, 32], ["human", "SPECIES", 27, 32], ["a large genetic study", "TEST", 65, 86], ["many cell populations", "PROBLEM", 155, 176], ["the CD93 marker", "TEST", 200, 215], ["very high heritability", "PROBLEM", 222, 244], ["Tregs", "TEST", 263, 268], ["many cell populations", "OBSERVATION", 155, 176], ["very", "OBSERVATION_MODIFIER", 222, 226], ["high", "OBSERVATION_MODIFIER", 227, 231], ["Tregs", "ANATOMY", 263, 268]]], ["Thus, circulating immune-cell phenotypes may have measurable heritable components.", [["immune-cell", "ANATOMY", 18, 29], ["immune-cell", "CELL", 18, 29], ["cell phenotypes", "PROBLEM", 25, 40], ["measurable heritable components", "PROBLEM", 50, 81], ["cell phenotypes", "OBSERVATION", 25, 40], ["measurable", "OBSERVATION_MODIFIER", 50, 60], ["heritable", "OBSERVATION_MODIFIER", 61, 70], ["components", "OBSERVATION_MODIFIER", 71, 81]]], ["In contrast, a recent systems-level influenza-vaccine twin study by Brodin et al. used 210 healthy twins (8-82 years old) to examine 204 different parameters of the immune system, and immune response outcomes found that non-heritable factors had a greater influence than heritable factors (211) .", [["immune system", "ANATOMY", 165, 178], ["non-heritable factors", "PROTEIN", 220, 241], ["a recent systems", "TEST", 13, 29], ["level influenza-vaccine", "TREATMENT", 30, 53], ["twin study", "TEST", 54, 64], ["non-heritable factors", "PROBLEM", 220, 241]]], ["Given that many earlier vaccine investigations in twins have studied infants and young children, the authors proposed that \"many if not most of the less heritable traits that we measured in our mostly adult population may be much more heritable if measured in young children\" (211) .", [["infants", "ORGANISM", 69, 76], ["children", "ORGANISM", 87, 95], ["children", "ORGANISM", 266, 274], ["infants", "SPECIES", 69, 76], ["children", "SPECIES", 87, 95], ["children", "SPECIES", 266, 274]]], ["Similar environments may thus falsely suggest heritable traits in vaccinations of twins.", [["heritable traits", "PROBLEM", 46, 62]]], ["It was suggested that variation in the human immune response increases with age and is driven by non-heritable factors, such as frequent environmental contact with various pathogens (e.g., CMV, influenza) and microbes.", [["influenza", "DISEASE", 194, 203], ["human", "ORGANISM", 39, 44], ["CMV", "ORGANISM", 189, 192], ["non-heritable factors", "PROTEIN", 97, 118], ["human", "SPECIES", 39, 44], ["human", "SPECIES", 39, 44], ["CMV", "SPECIES", 189, 192], ["various pathogens", "PROBLEM", 164, 181], ["CMV", "PROBLEM", 189, 192], ["influenza", "PROBLEM", 194, 203]]], ["This hypothesis illustrates one of the challenges in translating findings from genetic studies (e.g., genetic variants that underline heritable immune response traits) to new vaccine development without accounting for continuously changing, non-heritable influences.CONCLUSIONS AND PERSPECTIVEVaccine development in the twenty-first century is enabled by increasingly sophisticated genetic and high-dimensional assays, aided by bioinformatics approaches (212) (213) (214) .", [["genetic studies", "TEST", 79, 94], ["genetic variants", "PROBLEM", 102, 118], ["heritable immune response traits", "PROBLEM", 134, 166], ["new vaccine development", "TREATMENT", 171, 194]]], ["This has allowed unprecedented resolution, at the whole-systems level, of how innate, adaptive, and cellular immune responses are generated, interact, and are maintained after vaccination.", [["cellular", "ANATOMY", 100, 108], ["cellular", "CELL", 100, 108], ["vaccination", "TREATMENT", 176, 187], ["unprecedented", "OBSERVATION_MODIFIER", 17, 30], ["resolution", "OBSERVATION_MODIFIER", 31, 41]]], ["These technologies are being further leveraged in understanding adverse (aberrant) vaccine responses and the durability of immunity to vaccines, which represent areas of intense investigation due to their importance to human health.", [["human", "ORGANISM", 219, 224], ["human", "SPECIES", 219, 224], ["human", "SPECIES", 219, 224], ["adverse (aberrant) vaccine responses", "PROBLEM", 64, 100], ["immunity to vaccines", "TREATMENT", 123, 143]]], ["Taken together, genetic technologies and approaches have led to a new era of genetic design of vaccines and have provided solutions to the barriers currently impeding progress in this area ( Table 1) .CONCLUSIONS AND PERSPECTIVEThese novel approaches have been driven by public health urgency, demand for vaccine safety, cost considerations, and the inability of past vaccine-development paradigms to lead to viable vaccine candidates against complex and hyper-variable pathogens quickly enough to meet public health needs at an affordable cost.", [["genetic design of vaccines", "TREATMENT", 77, 103], ["solutions", "TREATMENT", 122, 131], ["vaccine safety", "TREATMENT", 305, 319], ["past vaccine", "TREATMENT", 363, 375], ["development paradigms", "PROBLEM", 376, 397], ["viable vaccine candidates", "TREATMENT", 409, 434], ["complex and hyper-variable pathogens", "PROBLEM", 443, 479]]], ["As a result, vaccine development is being accelerated by genetic and bioinformatics approaches (186) .", [["vaccine development", "TREATMENT", 13, 32]]], ["In the last decade, new vaccines against influenza have been developed and licensed, as have vaccines against meningococcus group B, hepatitis B, and herpes zoster using genomics-based approaches.", [["influenza", "DISEASE", 41, 50], ["meningococcus group B", "DISEASE", 110, 131], ["hepatitis B", "DISEASE", 133, 144], ["herpes zoster", "DISEASE", 150, 163], ["influenza", "ORGANISM", 41, 50], ["meningococcus group B", "ORGANISM", 110, 131], ["hepatitis B", "ORGANISM", 133, 144], ["herpes zoster", "ORGANISM", 150, 163], ["meningococcus group", "SPECIES", 110, 129], ["herpes zoster", "SPECIES", 150, 163], ["hepatitis B", "SPECIES", 133, 144], ["new vaccines", "TREATMENT", 20, 32], ["influenza", "PROBLEM", 41, 50], ["vaccines", "TREATMENT", 93, 101], ["meningococcus group B", "PROBLEM", 110, 131], ["hepatitis B", "PROBLEM", 133, 144], ["herpes zoster", "PROBLEM", 150, 163]]], ["Many more vaccines are in development.CONCLUSIONS AND PERSPECTIVEGenetic approaches have enabled the identification of relationships/networks between individual genetic variants and specific aspects of vaccine-induced innate, adaptive, or cellular immune responses.", [["cellular", "ANATOMY", 239, 247], ["cellular", "CELL", 239, 247], ["Many more vaccines", "TREATMENT", 0, 18], ["individual genetic variants", "PROBLEM", 150, 177], ["vaccine", "TREATMENT", 202, 209]]], ["The promise of vaccinomics is to identify specific immune response profiles that may serve as signatures or biomarkers that accurately predict vaccine immunogenicity, efficacy, and/or safety.", [["vaccinomics", "TREATMENT", 15, 26]]], ["Furthermore, it has the potential to identify genetic variants or antigens that lead to newer and safer vaccine candidates.", [["antigens", "PROTEIN", 66, 74], ["genetic variants", "PROBLEM", 46, 62], ["antigens", "PROBLEM", 66, 74], ["safer vaccine candidates", "TREATMENT", 98, 122]]], ["We believe that the development of very large and detailed genotype:phenotype databases will eventually lead to a new model of personalized vaccine practice (i.e., the delivery of the right vaccine to the right person at the right time) that utilizes genetic and immune signatures to do the following: develop new vaccine candidates; predict the need for a vaccine and the dose needed to induce protective immunity; and to predict whether a significant adverse effect is likely to occur-in other words, personalized vaccinology.", [["person", "SPECIES", 211, 217], ["phenotype databases", "PROBLEM", 68, 87], ["personalized vaccine practice", "TREATMENT", 127, 156], ["the delivery of the right vaccine", "TREATMENT", 164, 197], ["new vaccine candidates", "TREATMENT", 310, 332], ["a vaccine", "TREATMENT", 355, 364], ["a significant adverse effect", "PROBLEM", 439, 467], ["very", "OBSERVATION_MODIFIER", 35, 39], ["large", "OBSERVATION_MODIFIER", 40, 45], ["right", "ANATOMY_MODIFIER", 205, 210]]], ["Issues of high costs for genetic-based assays, including the cost of analysis and the complexity of such data exist, as well as inertia on the part of current vaccine developers conspiring to delay the full use of these rapidly advancing new paradigms.", [["genetic-based assays", "TEST", 25, 45], ["analysis", "TEST", 69, 77], ["current vaccine", "TREATMENT", 151, 166], ["high", "OBSERVATION_MODIFIER", 10, 14]]], ["Funders of research must realize not only the promise of such vaccine development approaches but also the costs.", [["such vaccine", "TREATMENT", 57, 69]]], ["For example, the standard allowable budget for the most common NIH research funding mechanism in the USA, the R01, has not changed in the past 30 years despite massive advances in science and the cost of experiments and statistical analysis over this time period.CONCLUSIONS AND PERSPECTIVEInfectious diseases have always been-and always will bea threat to human health.", [["human", "ORGANISM", 357, 362], ["human", "SPECIES", 357, 362], ["human", "SPECIES", 357, 362], ["statistical analysis", "TEST", 220, 240], ["PERSPECTIVEInfectious diseases", "PROBLEM", 279, 309], ["not", "UNCERTAINTY", 119, 122], ["changed", "OBSERVATION_MODIFIER", 123, 130]]], ["An excellent example of this is the current COVID-19 pandemic.", [["the current COVID", "TEST", 32, 49], ["pandemic", "PROBLEM", 53, 61], ["excellent", "OBSERVATION_MODIFIER", 3, 12]]], ["This demonstrates how easily and repeatedly pathogens can emerge and affect humanity on a global scale.", [["a global scale", "TEST", 88, 102]]], ["We had ample warning that novel coronaviruses can and do jump species and cause widespread and serious disease in humans.", [["coronaviruses", "ORGANISM", 32, 45], ["humans", "ORGANISM", 114, 120], ["humans", "SPECIES", 114, 120], ["humans", "SPECIES", 114, 120], ["novel coronaviruses", "PROBLEM", 26, 45], ["jump species", "PROBLEM", 57, 69], ["widespread and serious disease in humans", "PROBLEM", 80, 120], ["widespread", "OBSERVATION_MODIFIER", 80, 90], ["serious", "OBSERVATION_MODIFIER", 95, 102], ["disease", "OBSERVATION", 103, 110]]], ["Our efforts to create vaccines against SARS and MERS resulted in products that reached clinical trials but no licensed vaccines.", [["SARS", "DISEASE", 39, 43], ["vaccines", "TREATMENT", 22, 30], ["SARS", "PROBLEM", 39, 43], ["licensed vaccines", "TREATMENT", 110, 127]]], ["Fortunately, what we learned from those outbreaks has been rapidly applied to the SARS-CoV2 and we have seen clinical trials begin within 5 months of the first reported cases.", [["SARS", "DISEASE", 82, 86]]], ["This is a tremendous achievement.", [["tremendous", "OBSERVATION_MODIFIER", 10, 20]]], ["Novel tools and paradigms allow highly directed study at levels of genetics and biology unimaginable just a handful of years ago.", [["Novel tools", "TEST", 0, 11], ["highly directed study", "TEST", 32, 53]]], ["An example is that of the CRISPR/Cas9 technology that is revolutionizing genome editing of cells and pathogens; this technology has been used to excise virulence genes and create Pseudorabies virus vaccines (215) and to create duck enteritis virus (DEV) recombinants expressing avian influenza (highly pathogenic H5N1) and duck tembusu virus (DTMUV) antigens.", [["cells", "ANATOMY", 91, 96], ["duck enteritis", "DISEASE", 227, 241], ["avian influenza", "DISEASE", 278, 293], ["Cas9", "GENE_OR_GENE_PRODUCT", 33, 37], ["cells", "CELL", 91, 96], ["Pseudorabies virus", "ORGANISM", 179, 197], ["duck enteritis virus", "ORGANISM", 227, 247], ["DEV", "ORGANISM", 249, 252], ["avian influenza", "ORGANISM", 278, 293], ["highly pathogenic H5N1", "ORGANISM", 295, 317], ["duck tembusu virus", "ORGANISM", 323, 341], ["CRISPR", "DNA", 26, 32], ["Cas9", "DNA", 33, 37], ["virulence genes", "DNA", 152, 167], ["duck tembusu virus (DTMUV) antigens", "PROTEIN", 323, 358], ["duck enteritis virus", "SPECIES", 227, 247], ["avian influenza", "SPECIES", 278, 293], ["duck tembusu virus", "SPECIES", 323, 341], ["Pseudorabies virus", "SPECIES", 179, 197], ["duck enteritis virus", "SPECIES", 227, 247], ["DEV", "SPECIES", 249, 252], ["duck tembusu virus", "SPECIES", 323, 341], ["DTMUV", "SPECIES", 343, 348], ["the CRISPR/Cas9 technology", "TREATMENT", 22, 48], ["pathogens", "PROBLEM", 101, 110], ["virulence genes", "PROBLEM", 152, 167], ["create Pseudorabies virus vaccines", "TREATMENT", 172, 206], ["duck enteritis virus", "PROBLEM", 227, 247], ["influenza", "PROBLEM", 284, 293], ["duck tembusu virus", "PROBLEM", 323, 341], ["duck", "ANATOMY", 227, 231], ["enteritis", "OBSERVATION", 232, 241]]], ["The resulting trivalent vaccine elicits protection against all three duck pathogens (216) .CONCLUSIONS AND PERSPECTIVEPerhaps Albert Camus said it best in his book The Plague:CONCLUSIONS AND PERSPECTIVEEverybody knows that pestilences have a way of recurring in the world; yet somehow we find it hard to believe in ones that crash down on our heads from a blue sky.", [["trivalent", "CHEMICAL", 14, 23], ["Plague", "DISEASE", 168, 174], ["duck", "ORGANISM", 69, 73], ["duck", "SPECIES", 69, 73], ["The resulting trivalent vaccine", "TREATMENT", 0, 31]]], ["There have been as many plagues as wars in history; yet always plagues and wars take people equally by surprise (217) .AUTHOR CONTRIBUTIONSRK, IO, and GP conceived of the topic.", [["people", "ORGANISM", 85, 91], ["people", "SPECIES", 85, 91], ["many", "OBSERVATION_MODIFIER", 19, 23], ["plagues", "OBSERVATION", 24, 31]]], ["IO, PP, and GP revised the manuscript.", [["PP", "TEST", 4, 6]]], ["RK, IO, PP, and GP approved the final manuscript.", [["PP", "TEST", 8, 10]]], ["All authors contributed to the article and approved the submitted version.GLOSSARY VaccinomicsThe integration of immunogenetics and immunogenomics with systems biology, immune profiling, and bioinformatics approaches used in the development and study of new vaccines.AdversomicsThe study of vaccine adverse reactions using immunogenetics and systems biology approaches to better understand the genetic and non-genetic drivers of vaccine adverse reactions at the molecular level.EpigenomicsThe study of the complete set of epigenetic modifications on the genetic material of a cell (i.e., the epigenome).Genome-wide association studies (GWAS)The observational study of a genome-wide set of genetic variants in different subjects to examine if any one variant is associated with a trait.Systems biologyThe study of complex systems in order to understand the networks of interactions and effects of those interactions.CRISPR-Cas-9 technologyA gene-editing technology that can be used in the development of vaccines.", [["cell", "ANATOMY", 576, 580], ["cell", "CELL", 576, 580], ["CRISPR-Cas", "GENE_OR_GENE_PRODUCT", 915, 925], ["CRISPR", "DNA", 915, 921], ["Cas", "PROTEIN", 922, 925], ["systems biology", "TEST", 152, 167], ["immune profiling", "TEST", 169, 185], ["bioinformatics approaches", "TREATMENT", 191, 216], ["new vaccines", "TREATMENT", 254, 266], ["The study", "TEST", 278, 287], ["vaccine adverse reactions", "TREATMENT", 291, 316], ["vaccine adverse reactions", "PROBLEM", 429, 454], ["The study", "TEST", 489, 498], ["epigenetic modifications", "PROBLEM", 522, 546], ["The observational study", "TEST", 641, 664], ["genetic variants", "PROBLEM", 689, 705], ["The study", "TEST", 800, 809], ["A gene-editing technology", "TREATMENT", 938, 963], ["vaccines", "TREATMENT", 1003, 1011]]]], "1543c9833c37fde8f5f3634e14012fc4c9b71553": [["IntroductionCoronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) originated in Wuhan, China, quickly became a global pandemic, and has impacted the U.S.A. at an extraordinary pace.", [["COVID-19", "CHEMICAL", 38, 46], ["acute respiratory syndrome coronavirus", "DISEASE", 65, 103], ["SARS-CoV2)", "DISEASE", 107, 117], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 58, 105], ["severe acute respiratory syndrome coronavirus", "SPECIES", 58, 103], ["SARS-CoV2)", "SPECIES", 107, 117], ["IntroductionCoronavirus Disease", "PROBLEM", 0, 31], ["COVID", "TEST", 38, 43], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 58, 103], ["a global pandemic", "PROBLEM", 161, 178], ["severe", "OBSERVATION_MODIFIER", 58, 64], ["acute", "OBSERVATION_MODIFIER", 65, 70], ["respiratory syndrome", "OBSERVATION", 71, 91]]], ["Within three months from the first diagnosed case of COVID-19 in the U.S. A. in late January 2020, the number of SARS-CoV2-infected individuals in the U.S.A. is close to a million, and the number of casualties have surpassed 45,000 [1] .", [["SARS-CoV2-infected", "DISEASE", 113, 131], ["SARS-CoV2", "ORGANISM", 113, 122], ["individuals", "ORGANISM", 132, 143], ["COVID", "TEST", 53, 58], ["SARS", "TEST", 113, 117]]], ["Globally, SARS-CoV2 has infected millions, with an overall case fatality rate of >6.5% [1] .", [["SARS", "DISEASE", 10, 14], ["SARS-CoV2", "ORGANISM", 10, 19], ["SARS-CoV2", "SPECIES", 10, 19], ["infected millions", "PROBLEM", 24, 41], ["fatality rate", "TEST", 64, 77], ["infected", "OBSERVATION", 24, 32]]], ["As rapid testing becomes more readily available in the next few weeks, it is expected that many more cases will be diagnosed, and many of them would need hospitalization for care.IntroductionThe severity of disease in those with the infection has overwhelmed healthcare systems and frontline healthcare providers, and has exhausted resources, revealing how illequipped the world was to handle this pandemic.", [["infection", "DISEASE", 233, 242], ["rapid testing", "TEST", 3, 16], ["disease", "PROBLEM", 207, 214], ["the infection", "PROBLEM", 229, 242], ["severity", "OBSERVATION_MODIFIER", 195, 203], ["disease", "OBSERVATION", 207, 214], ["infection", "OBSERVATION", 233, 242]]], ["The peak of this pandemic is expected in the next few weeks, when a surge of hospital admissions for COVID-19 will emerge globally [2, 3] .", [["COVID", "TEST", 101, 106], ["peak", "OBSERVATION_MODIFIER", 4, 8]]], ["In the U.S.A., while currently COVID-19 seems to preferentially be affecting densely populated urban areas, this pandemic will likely impact other urban as well as rural areas soon.", [["densely", "OBSERVATION_MODIFIER", 77, 84], ["populated", "OBSERVATION", 85, 94]]], ["Healthcare centers everywhere should prepare to implement measures for an efficient hospital-wide approach to manage the imminent surge in hospitalized patients with COVID-19.", [["COVID-19", "CHEMICAL", 166, 174], ["patients", "ORGANISM", 152, 160], ["patients", "SPECIES", 152, 160], ["COVID", "TEST", 166, 171]]], ["Connecticut is one of the states impacted heavily and early by COVID-19 [4] .", [["COVID-19", "CHEMICAL", 63, 71]]], ["We present an outline of how Connecticut Veterans Affairs Healthcare System prepared for this pandemic in order to share our experience, and hopefully help inform other facilities across the country and globally.Effective and accessible leadership with rapid and cohesive responseResponse to pandemic is a multi-disciplinary team effort with efficient leadership that meets several times daily to work at a quick pace in order to make effective implementation of preparatory measures before the actual arrival of the first infected patients, followed by a continuity of the same diligence to ensure modifications in plans as needed and addressing new demands as they arise.", [["patients", "ORGANISM", 532, 540], ["patients", "SPECIES", 532, 540], ["a quick pace", "TREATMENT", 405, 417], ["preparatory measures", "TREATMENT", 463, 483], ["rapid", "OBSERVATION_MODIFIER", 253, 258]]], ["This centripetal, accessible, and highly motivated approach of management, we find, has been an important reason why our preparedness was both rapid and effective.", [["management", "TREATMENT", 63, 73], ["centripetal", "OBSERVATION_MODIFIER", 5, 16]]], ["Additionally she created protocols for well-informed care of patients, enhanced the education and protective measures for HCWs including residency trainees, developed a clinical algorithm to guide judicious testing, and participated in COVID-19 treatment group meetings at other institutions to help create or modify local treatment algorithms.", [["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 61, 69], ["judicious testing", "TEST", 197, 214], ["local treatment algorithms", "TREATMENT", 317, 343]]], ["These committees included research and ethics committee, treatment committee, code and emergency response committee, discharge and post-discharge planning committee, scarce resource allocation committee, and a committee that included members of our ethics team and palliative care service to guide policy on the triaging of patients in case of bed shortages.", [["patients", "ORGANISM", 324, 332], ["patients", "SPECIES", 324, 332]]], ["Critical care staff underwent training and refreshment courses for proning, extracorporeal membrane oxygenation (ECMO), minimization of bedside personnel while still providing stateof-the-art care during high-aerosol generating procedures, etc.Effective and accessible leadership with rapid and cohesive response2.0 Gatekeeping: screenings at entrances, off-site testing, emergency room safeguards VA Connecticut was the first healthcare system in the state to enact several measures within a week of the first case reported on the East Coast and 3 days after the first case reported in the state.", [["extracorporeal membrane", "ANATOMY", 76, 99], ["refreshment courses", "TREATMENT", 43, 62], ["proning", "TREATMENT", 67, 74], ["extracorporeal membrane oxygenation", "TREATMENT", 76, 111], ["the-art care", "TREATMENT", 184, 196], ["high-aerosol generating procedures", "TREATMENT", 204, 238], ["rapid", "OBSERVATION_MODIFIER", 285, 290], ["cohesive response", "OBSERVATION", 295, 312]]], ["These measures were fully implemented sequentially within 2 weeks from initiation.Effective and accessible leadership with rapid and cohesive response2.1 All elective and non-emergent procedures were canceled or postponed.", [["non-emergent procedures", "TEST", 171, 194], ["rapid", "OBSERVATION_MODIFIER", 123, 128]]], ["VA has been a national leader in clinical video medicine to reach patients living far away from the VA hospitals and clinics, and the conversion from inperson clinic visits to video visits was effortless and immediate.", [["patients", "ORGANISM", 66, 74], ["patients", "SPECIES", 66, 74]]], ["2.2 Letters were mailed to patients advising them to call their primary care providers before arriving at hospital if they had fever or respiratory symptoms.", [["respiratory", "ANATOMY", 136, 147], ["fever", "DISEASE", 127, 132], ["respiratory symptoms", "DISEASE", 136, 156], ["patients", "ORGANISM", 27, 35], ["patients", "SPECIES", 27, 35], ["fever", "PROBLEM", 127, 132], ["respiratory symptoms", "PROBLEM", 136, 156]]], ["Physicians staffing the call centers provided stay-at-home and social distancing counseling, as well as individualized education on symptoms that should prompt a hospital visit.", [["symptoms", "PROBLEM", 132, 140]]], ["2.3 Off-site testing centers were erected to conduct outpatient drive-up testing for patients who were thought to have suggestive symptoms.", [["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93], ["suggestive symptoms", "PROBLEM", 119, 138]]], ["2.5 Our major healthcare facility, the West Haven VA, has multiple entrances for patients and employees.", [["patients", "ORGANISM", 81, 89], ["patients", "SPECIES", 81, 89]]], ["As part of the COVID response, entrance to our hospital was limited to the emergency room (ER) and two manned entrances where primary screenings were conducted on everyone entering the facility, including questions about exposure to COVID19, personal symptoms and signs, and temperature checks.", [["primary screenings", "TEST", 126, 144], ["COVID19", "TREATMENT", 233, 240], ["personal symptoms", "PROBLEM", 242, 259], ["signs", "TEST", 264, 269], ["temperature checks", "TEST", 275, 293]]], ["Those who failed primary screening received a secondary screen by a physician who examined and collected samples for testing as indicated.", [["samples", "ANATOMY", 105, 112], ["testing", "TEST", 117, 124]]], ["2.6 The ER underwent an expeditious transformation so patients could be evaluated in private rooms.", [["ER", "GENE_OR_GENE_PRODUCT", 8, 10], ["patients", "ORGANISM", 54, 62], ["ER", "PROTEIN", 8, 10], ["patients", "SPECIES", 54, 62]]], ["Every patient arriving into ER was given a mask to wear, until evaluation and triage by ER physicians.", [["patient", "ORGANISM", 6, 13], ["ER", "GENE_OR_GENE_PRODUCT", 28, 30], ["ER", "GENE_OR_GENE_PRODUCT", 88, 90], ["ER", "PROTEIN", 28, 30], ["ER", "PROTEIN", 88, 90], ["patient", "SPECIES", 6, 13], ["a mask", "TREATMENT", 41, 47], ["evaluation", "TEST", 63, 73]]], ["2.7 All HCWs as well as ancillary staff were provided surgical masks in an attempt to prevent nosocomial transmission of SARS-CoV2.", [["SARS", "DISEASE", 121, 125], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 121, 130], ["surgical masks", "TREATMENT", 54, 68], ["nosocomial transmission of SARS", "PROBLEM", 94, 125]]], ["This was implemented after a patient initially admitted to the psychiatry locked unit for non-COVID-related reasons tested positive 10 days later after the development of new cough and fever, which raised concern for pre-symptomatic phase of COVID-19 among patients, and for potential transmission of virus by asymptomatic HCWs.Effective and accessible leadership with rapid and cohesive response3.0 Droplet precautions, personal protective equipment (PPE), social distancing 3.1 CDC guidelines for respiratory isolation with airborne precautions were followed as implemented by HEIP.", [["respiratory", "ANATOMY", 499, 510], ["cough", "DISEASE", 175, 180], ["fever", "DISEASE", 185, 190], ["patient", "ORGANISM", 29, 36], ["patients", "ORGANISM", 257, 265], ["patient", "SPECIES", 29, 36], ["patients", "SPECIES", 257, 265], ["new cough", "PROBLEM", 171, 180], ["fever", "PROBLEM", 185, 190], ["COVID", "TEST", 242, 247], ["virus", "PROBLEM", 301, 306], ["Droplet precautions", "TREATMENT", 400, 419], ["respiratory isolation", "TREATMENT", 499, 520], ["airborne precautions", "TREATMENT", 526, 546], ["new", "OBSERVATION_MODIFIER", 171, 174], ["cough", "OBSERVATION", 175, 180], ["fever", "OBSERVATION", 185, 190], ["rapid", "OBSERVATION_MODIFIER", 369, 374], ["cohesive response", "OBSERVATION", 379, 396]]], ["Negative pressure rooms were used for all patients being admitted with suspicion of COVID-19 until it was ruled out by testing.", [["patients", "ORGANISM", 42, 50], ["patients", "SPECIES", 42, 50], ["pressure rooms", "TREATMENT", 9, 23], ["COVID", "TEST", 84, 89], ["pressure rooms", "OBSERVATION", 9, 23]]], ["Distinct COVID units were created in the hospital.", [["COVID units", "DNA", 9, 20], ["Distinct COVID units", "TREATMENT", 0, 20]]], ["Private rooms were also prepared for a surge of patients if needed.", [["patients", "ORGANISM", 48, 56], ["patients", "SPECIES", 48, 56]]], ["Strict protocols were instituted for any aerosol-producing procedures including nasopharyngeal sample collection, nebulizer administration, and intubation.", [["nasopharyngeal sample", "ANATOMY", 80, 101], ["Strict protocols", "TREATMENT", 0, 16], ["any aerosol-producing procedures", "TREATMENT", 37, 69], ["nasopharyngeal sample collection", "TREATMENT", 80, 112], ["nebulizer administration", "TREATMENT", 114, 138], ["intubation", "TREATMENT", 144, 154], ["nasopharyngeal", "ANATOMY", 80, 94]]], ["Full PPE [gown, gloves and either N-95 respirator with face shield, or powered air-purifying respirator (PAPR)] was ensured to prevent infection among HCWs.Effective and accessible leadership with rapid and cohesive response3.2 Regular trainings, FIT testing, and educational sessions on donning/doffing were conducted to ensure HCWs were fully conversant in PPE.", [["infection", "DISEASE", 135, 144], ["Full PPE", "TREATMENT", 0, 8], ["gloves", "TREATMENT", 16, 22], ["face shield", "TREATMENT", 55, 66], ["infection", "PROBLEM", 135, 144], ["FIT testing", "TEST", 247, 258], ["infection", "OBSERVATION", 135, 144], ["rapid", "OBSERVATION_MODIFIER", 197, 202]]], ["3.3 'Buddy system' was encouraged as a culture so that HCW would be helped and watched by another HCW while donning and doffing the PPE to ensure correct steps, and to avoid accidental contamination of self or environment.Reduction of time spent at bedside was a major goal forHCWs providing care to COVID-19 positive or person under investigation (COVID-PUI), while still ensuring state-of-the-art care and management.", [["person", "SPECIES", 321, 327], ["a culture", "TEST", 37, 46], ["the-art care", "TREATMENT", 391, 403], ["management", "TREATMENT", 408, 418]]], ["This helps protect HCWs from unnecessary exposure and save PPEs, which are still in short supply.", [["PPEs", "SIMPLE_CHEMICAL", 59, 63], ["save PPEs", "TREATMENT", 54, 63]]], ["Patient rooms were equipped for video surveillance and in-room phones so that providers could gather the bulk of history by speaking to the patient via phone while watching them on the video.", [["patient", "ORGANISM", 140, 147], ["Patient", "SPECIES", 0, 7], ["patient", "SPECIES", 140, 147], ["video surveillance", "TEST", 32, 50]]], ["I-Pads were also issued to patients so that they could interact with providers and 'virtual visitors'.", [["patients", "ORGANISM", 27, 35], ["patients", "SPECIES", 27, 35]]], ["A protocol for cleaning of I-Pads was disseminated.", [["A protocol", "TREATMENT", 0, 10], ["cleaning of I-Pads", "TREATMENT", 15, 33], ["disseminated", "OBSERVATION", 38, 50]]], ["Providers were trained to conduct team huddles to review all data they would need, examination findings they would look for, and information they would provide to the patient at bedside before one of the team members entered the COVID-PUI room.", [["patient", "ORGANISM", 167, 174], ["patient", "SPECIES", 167, 174], ["examination findings", "TEST", 83, 103]]], ["Bedside physician visit for uncomplicated patients was limited to one physician per visit per day when medically feasible.", [["patients", "ORGANISM", 42, 50], ["patients", "SPECIES", 42, 50]]], ["3.5 Nursing care was similarly streamlined with strictly enforced PPE measures and provision of care with bundled approach: carefully planned bedside nursing visit that would provide meal, medications, vital sign checks, and all other required care in the same visit if possible.", [["strictly enforced PPE measures", "TREATMENT", 48, 78], ["medications", "TREATMENT", 189, 200], ["vital sign checks", "TEST", 202, 219]]], ["Meal trays were replaced by paper service meals so that leftovers and paper plates/cups could be disposed of into trash, and nursing would not need to enter rooms multiple times to collect the used trays and have others return them for cleaning and re-use.", [["Meal trays", "TREATMENT", 0, 10], ["paper plates/cups", "TREATMENT", 70, 87]]], ["3.6 Decontamination of certain equipment with strong disinfectant wipes can reduce the shelf life of such equipment.", [["certain equipment", "TREATMENT", 23, 40], ["strong disinfectant wipes", "TREATMENT", 46, 71]]], ["Therefore, while also trying to conserve PPE, modifications were made to some usual practices.", [["PPE", "GENE_OR_GENE_PRODUCT", 41, 44], ["PPE", "TREATMENT", 41, 44]]], ["Instead of taking the computer-on-wheels to the bedside to obtain an electronically signed informed consent, consent for procedures could be obtained via phone from the patient, provided the patient could provide consent, and this conversation was witnessed by another provider.", [["patient", "ORGANISM", 169, 176], ["patient", "ORGANISM", 191, 198], ["patient", "SPECIES", 169, 176], ["patient", "SPECIES", 191, 198]]], ["Echocardiograms for COVID-PUIs and COVID+ patients were limited to critical need only; all routine echocardiograms for these patients as well as all pre-scheduled echocardiograms on stable outpatients were deferred until infected patients were COVID-19 test negative or when the pandemic eased.", [["patients", "ORGANISM", 42, 50], ["patients", "ORGANISM", 125, 133], ["outpatients", "ORGANISM", 189, 200], ["patients", "ORGANISM", 230, 238], ["patients", "SPECIES", 42, 50], ["patients", "SPECIES", 125, 133], ["patients", "SPECIES", 230, 238], ["Echocardiograms", "TEST", 0, 15], ["COVID", "TEST", 20, 25], ["PUIs", "TEST", 26, 30], ["COVID", "TEST", 35, 40], ["all routine echocardiograms", "TEST", 87, 114], ["all pre-scheduled echocardiograms", "TEST", 145, 178], ["COVID", "TEST", 244, 249]]], ["As medications used for management of COVID-19 can cause QTc prolongation (hydroxychloroquine, azithromycin, etc.), this interval was closely monitored for inpatients via telemetry and calculation of QTc from rhythm strip if possible.", [["COVID-19", "CHEMICAL", 38, 46], ["QTc prolongation", "DISEASE", 57, 73], ["hydroxychloroquine", "CHEMICAL", 75, 93], ["azithromycin", "CHEMICAL", 95, 107], ["COVID-19", "CHEMICAL", 38, 46], ["hydroxychloroquine", "CHEMICAL", 75, 93], ["azithromycin", "CHEMICAL", 95, 107], ["COVID-19", "SIMPLE_CHEMICAL", 38, 46], ["QTc", "SIMPLE_CHEMICAL", 57, 60], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 75, 93], ["azithromycin", "SIMPLE_CHEMICAL", 95, 107], ["medications", "TREATMENT", 3, 14], ["management of COVID", "TREATMENT", 24, 43], ["QTc prolongation", "PROBLEM", 57, 73], ["hydroxychloroquine", "TREATMENT", 75, 93], ["azithromycin", "TREATMENT", 95, 107], ["telemetry", "TEST", 171, 180], ["QTc", "TEST", 200, 203], ["rhythm strip", "TEST", 209, 221]]], ["This reduced unnecessary exposure by HCW in order to obtain a 12-lead ECG to calculate the QTc.", [["a 12-lead ECG", "TEST", 60, 73], ["the QTc", "TEST", 87, 94]]], ["3.7 Simulation was conducted several times for all HCWs to be fully conversant on conducting resuscitation and emergency procedures on COVID-PUIs or known COVID+ patients, as these involve high-risk aerosolgenerating maneuvers.", [["patients", "ORGANISM", 162, 170], ["patients", "SPECIES", 162, 170], ["conducting resuscitation", "TREATMENT", 82, 106], ["emergency procedures", "TREATMENT", 111, 131], ["COVID", "TREATMENT", 135, 140], ["PUIs", "TREATMENT", 141, 145]]], ["New policy was instituted that outlined how the code would be announced overhead so that responders would come prepared knowing it was a code for a COVID-PUI or COVID+ patient.", [["patient", "ORGANISM", 168, 175], ["patient", "SPECIES", 168, 175]]], ["Rapid and ensured PPE provisions were delineated carefully, measures were placed by anesthesiology for reduction of aerosol generation during code, and number of inroom personnel was streamlined significantly, with predesignated roles in the conduction of resuscitation.", [["Rapid and ensured PPE provisions", "TREATMENT", 0, 32], ["aerosol generation", "TREATMENT", 116, 134], ["resuscitation", "TREATMENT", 256, 269]]], ["Workstations were individually assigned to minimize use of shared space/keyboards.", [["shared space/keyboards", "TREATMENT", 59, 81]]], ["Containers of disinfectant wipes were placed in all workstations.Hospital bed redistribution and HCW team restructuring4.1 In order to prepare for inpatients with COVID-19, negative pressure rooms were needed on regular wards, as well as ICU.", [["disinfectant wipes", "TREATMENT", 14, 32], ["COVID", "TEST", 163, 168], ["disinfectant wipes", "OBSERVATION", 14, 32]]], ["Our facility had a total of 4 negative pressure rooms before the emergence of COVID-19.", [["COVID-19", "CHEMICAL", 78, 86], ["COVID-19", "CHEMICAL", 78, 86], ["COVID", "TEST", 78, 83]]], ["Within a week, negative pressure was created on an entire floor of the hospital.", [["pressure", "OBSERVATION_MODIFIER", 24, 32]]], ["Portable forced air system was used to create such rooms in an ICU section too that was devoted to COVID-19 patient care.", [["patient", "ORGANISM", 108, 115], ["patient", "SPECIES", 108, 115], ["Portable forced air system", "TEST", 0, 26], ["an ICU section", "TREATMENT", 60, 74]]], ["4.2 ICU and on-ward policy of care was devised and revised in real-time to continue state-of-the-art management of COVID-19 patients, with a multidisciplinary team approach, involving General Medicine, Cardiology, Infectious Diseases, Infection Prevention, Pulmonary and Critical Care Medicine, and Pharmacy.", [["Infectious Diseases", "DISEASE", 214, 233], ["Infection", "DISEASE", 235, 244], ["patients", "ORGANISM", 124, 132], ["patients", "SPECIES", 124, 132], ["Infectious", "OBSERVATION", 214, 224], ["Infection", "OBSERVATION", 235, 244], ["Pulmonary", "ANATOMY", 257, 266]]], ["4.3 Patients who had been undergoing 'blind rehabilitation'Hospital bed redistribution and HCW team restructuringwere discharged to open up a floor unit and new admissions to our community living center were stopped.", [["Patients", "ORGANISM", 4, 12], ["Patients", "SPECIES", 4, 12], ["blind rehabilitation", "TREATMENT", 38, 58]]], ["This was done to protect the veterans from acquiring this infection while residing in the hospital, and also to create more rooms for sick patients with COVID-19.", [["infection", "DISEASE", 58, 67], ["veterans", "ORGANISM", 29, 37], ["patients", "ORGANISM", 139, 147], ["patients", "SPECIES", 139, 147], ["this infection", "PROBLEM", 53, 67], ["COVID", "TEST", 153, 158], ["infection", "OBSERVATION", 58, 67]]], ["We made sure to not exclude house-staff from patient care.", [["patient", "ORGANISM", 45, 52], ["patient", "SPECIES", 45, 52]]], ["4.5 Protocols were created with back-up workforce and back-up hospital space to be deployed for anticipated COVID-19 surge in waves.", [["anticipated COVID", "TREATMENT", 96, 113]]], ["4.6 To facilitate discharge of COVID-19 patients who were not requiring inpatient services anymore, we were able to give each patient a thermometer and home pulseoximeter.", [["patients", "ORGANISM", 40, 48], ["patient", "ORGANISM", 126, 133], ["patients", "SPECIES", 40, 48], ["patient", "SPECIES", 126, 133], ["home pulseoximeter", "TREATMENT", 152, 170]]], ["We established a Hospitalist-led virtual video clinic to allow daily visits with these patients and have them transmit their home data.", [["patients", "ORGANISM", 87, 95], ["patients", "SPECIES", 87, 95]]], ["In addition, COVID-19 also has the notable predicament of a long incubation period that ranges from 5 to 14 days, and often causes a rapid respiratory/cardiac decompensation at any time during the illness [5, 6] .", [["respiratory", "ANATOMY", 139, 150], ["cardiac", "ANATOMY", 151, 158], ["respiratory/cardiac decompensation", "DISEASE", 139, 173], ["COVID-19", "CHEMICAL", 13, 21], ["cardiac", "ORGAN", 151, 158], ["a rapid respiratory/cardiac decompensation", "PROBLEM", 131, 173], ["notable", "OBSERVATION_MODIFIER", 35, 42], ["predicament", "OBSERVATION", 43, 54], ["rapid", "OBSERVATION_MODIFIER", 133, 138], ["cardiac", "ANATOMY", 151, 158], ["decompensation", "OBSERVATION", 159, 173]]], ["Therefore, asymptomatic patients who are hospitalized for reasons other than COVID-19, and who are not tested for COVID-19 upon admission, may develop symptoms during hospitalization and may also become a source of nosocomial infection.Testing criteria and order setsUntil the capacity to test widely and repeatedly becomes available widely, a clinical algorithm that can be used for outpatients as well as inpatients would be helpful.", [["nosocomial infection", "DISEASE", 215, 235], ["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32], ["COVID", "TEST", 77, 82], ["COVID", "TEST", 114, 119], ["symptoms", "PROBLEM", 151, 159], ["nosocomial infection", "PROBLEM", 215, 235], ["Testing criteria", "TEST", 236, 252], ["a clinical algorithm", "TEST", 342, 362], ["nosocomial", "OBSERVATION_MODIFIER", 215, 225], ["infection", "OBSERVATION", 226, 235]]], ["We developed a clinical algorithm to help direct providers toward testing for COVID-19 (Table 1) .", [["testing", "TEST", 66, 73], ["COVID", "TEST", 78, 83]]], ["This algorithm is based on review of clinical data from China, Italy, and within the U.S.A. [7] [8] [9] [10] [11] [12] [13] [14] .", [["U.S.A. [7] [8] [9] [10] [11] [12] [13]", "CHEMICAL", 85, 123], ["[7] [8] [9] [10] [11] [12] [13] [14]", "SIMPLE_CHEMICAL", 92, 128]]], ["It can be used by providers to help determine whether COVID-19 is a likely diagnosis for patients in outpatient setting, those being seen in ER, and those hospitalized for another reason and later developing suggestive symptoms.", [["patients", "ORGANISM", 89, 97], ["ER", "GENE_OR_GENE_PRODUCT", 141, 143], ["ER", "PROTEIN", 141, 143], ["patients", "SPECIES", 89, 97], ["COVID", "TEST", 54, 59], ["suggestive symptoms", "PROBLEM", 208, 227]]], ["However, this algorithm has been found to be helpful in our institution, and may be found to be useful at facilities when and where ample rapid testing is not available.5.2In order to ensure that the proper PPE were utilized and other specific critical care instructions for COVID-PUIs were carried out, we created a COVID-order set for use by ED providers when they admitted a patient as COVID-PUI, and for use by inpatient providers when they decided to test a hospitalized patient for COVID-19 (Table 2) .", [["patient", "ORGANISM", 378, 385], ["patient", "ORGANISM", 476, 483], ["patient", "SPECIES", 378, 385], ["patient", "SPECIES", 476, 483], ["this algorithm", "TEST", 9, 23], ["ample rapid testing", "TEST", 132, 151], ["the proper PPE", "TREATMENT", 196, 210], ["COVID", "TEST", 488, 493]]], ["These orders then ensured all necessary instructions were implemented, including COVID-19 precautions/isolation, nursing orders, nutrition specifications, COVID-relevant laboratory orders, and telemetry.Mindfulness and HCW wellnessThe toll on frontline workers of a pandemic caused by a virus that is highly transmissible and virulent, especially when combined with lack of appropriate supplies of PPEs, can be profound.", [["pandemic", "DISEASE", 266, 274], ["PPEs", "SIMPLE_CHEMICAL", 398, 402], ["COVID", "TREATMENT", 81, 86], ["telemetry", "TEST", 193, 202], ["Mindfulness", "PROBLEM", 203, 214], ["a pandemic", "PROBLEM", 264, 274], ["a virus", "PROBLEM", 285, 292], ["virulent", "PROBLEM", 326, 334], ["PPEs", "PROBLEM", 398, 402], ["virus", "OBSERVATION", 287, 292], ["virulent", "OBSERVATION_MODIFIER", 326, 334], ["profound", "OBSERVATION_MODIFIER", 411, 419]]], ["Early intervention, teamwork, self-care and enhancement of existing resilience are all critical for the healthcare providers who are involved in the fight against this pandemic.", [["Early intervention", "TREATMENT", 0, 18], ["this pandemic", "PROBLEM", 163, 176]]], ["We therefore sought help from Employee Assistance Program (EAP), Health Psychology, and Department of Psychiatry to create a robust support system.", [["a robust support system", "TREATMENT", 123, 146]]], ["This system was designed to provide critical and valuable mental health support, acute psychiatric first aid, coping strategies and tools, an app for stress-o-meter to self assess the daily stress burden, and various mindfulness and cheerfulness endeavors and workshops.", [["psychiatric", "DISEASE", 87, 98], ["critical and valuable mental health support", "TREATMENT", 36, 79], ["coping strategies", "TREATMENT", 110, 127], ["the daily stress burden", "PROBLEM", 180, 203]]], ["The COVID-19 pandemic has occurred in the age of unprecedented global a.", [["The COVID", "TEST", 0, 9], ["pandemic", "PROBLEM", 13, 21]]], ["New abnormalities in liver tests (AST/ALT >60 IU, bilirubin >2 mg/dL) b.", [["liver", "ANATOMY", 21, 26], ["bilirubin", "CHEMICAL", 50, 59], ["bilirubin", "CHEMICAL", 50, 59], ["liver", "ORGAN", 21, 26], ["AST", "SIMPLE_CHEMICAL", 34, 37], ["ALT", "SIMPLE_CHEMICAL", 38, 41], ["bilirubin", "SIMPLE_CHEMICAL", 50, 59], ["AST", "PROTEIN", 34, 37], ["ALT", "PROTEIN", 38, 41], ["bilirubin", "PROTEIN", 50, 59], ["New abnormalities", "PROBLEM", 0, 17], ["liver tests", "TEST", 21, 32], ["AST", "TEST", 34, 37], ["ALT", "TEST", 38, 41], ["bilirubin", "TEST", 50, 59], ["abnormalities", "OBSERVATION", 4, 17], ["liver", "ANATOMY", 21, 26]]], ["New elevation of: ferritin (>400 but <700) or fibrinogen (>400 but <600) c.", [["ferritin", "GENE_OR_GENE_PRODUCT", 18, 26], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 46, 56], ["ferritin", "PROTEIN", 18, 26], ["fibrinogen", "PROTEIN", 46, 56], ["New elevation of: ferritin", "PROBLEM", 0, 26], ["fibrinogen", "TEST", 46, 56], ["elevation", "OBSERVATION_MODIFIER", 4, 13]]], ["Leukopenia with TLC <4.0 k d.", [["Leukopenia", "DISEASE", 0, 10], ["Leukopenia", "PROBLEM", 0, 10], ["TLC", "TEST", 16, 19]]], ["LDH > 350 or troponin elevation 6.", [["LDH", "GENE_OR_GENE_PRODUCT", 0, 3], ["troponin", "GENE_OR_GENE_PRODUCT", 13, 21], ["LDH", "PROTEIN", 0, 3], ["LDH", "TEST", 0, 3], ["troponin elevation", "PROBLEM", 13, 31]]], ["Fever (\u2265100.4) 7.", [["Fever", "DISEASE", 0, 5], ["Fever", "PROBLEM", 0, 5]]], ["New onset unexplained anosmia or ageusia Please note: Other less common clinical features of COVID-19 include nausea, vomiting, diarrhea, abdominal pain, only rarely seen without other criteria above. connectivity, and has affected countries worldwide, turning necessity of information sharing into a blessing.", [["abdominal", "ANATOMY", 138, 147], ["anosmia", "DISEASE", 22, 29], ["COVID", "DISEASE", 93, 98], ["nausea", "DISEASE", 110, 116], ["vomiting", "DISEASE", 118, 126], ["diarrhea", "DISEASE", 128, 136], ["abdominal pain", "DISEASE", 138, 152], ["abdominal", "ORGANISM_SUBDIVISION", 138, 147], ["New onset unexplained anosmia", "PROBLEM", 0, 29], ["ageusia", "PROBLEM", 33, 40], ["COVID", "TEST", 93, 98], ["nausea", "PROBLEM", 110, 116], ["vomiting", "PROBLEM", 118, 126], ["diarrhea", "PROBLEM", 128, 136], ["abdominal pain", "PROBLEM", 138, 152], ["abdominal", "ANATOMY", 138, 147], ["pain", "OBSERVATION", 148, 152]]], ["Journals, networks, virtual meetings and conferences, governmental response dissemination systems, and the overall willingness to propagate information and experience have been a remarkable contribution to the preparedness for this pandemic.", [["this pandemic", "PROBLEM", 227, 240]]], ["Our experience with hospital preparedness at our facility has been multidisciplinary and effective, largely because of the central incident command body that ensured quick and thoughtful application of measures and helped us organize our COVID-19 response.", [["body", "ANATOMY", 148, 152], ["body", "ORGANISM_SUBDIVISION", 148, 152], ["our COVID", "TEST", 234, 243]]], ["While these are unprecedented and frightening times, a coordinated, facile, and effective response can help minimize the impact of COVID-19.", [["COVID-19", "CHEMICAL", 131, 139], ["COVID", "TEST", 131, 136]]]], "PMC7361836": [["In response to the COVID\u201019 pandemic, the UK Government developed a specification of a \u2018minimally acceptable\u2019 rapidly manufactured ventilator system (RMVS) [1].", [["ventilator system", "OBSERVATION", 131, 148]]], ["Many teams around the world began working to close the projected gap in ventilator availability and used the RMVS specification as the starting point for their efforts.", [["the RMVS specification", "TREATMENT", 105, 127]]]], "f687cb9e2cafe78bfafb5cb3316b7853b3bfed26": [["Some authors have reported the presence of cutaneous lesions related to new COronaVirusDisease 2019 (CoViD-19) caused by SARS-CoV-2, in up to 20.4% of the cases; however, these lesions are not well characterized either clinically or histopathologically.", [["cutaneous lesions", "ANATOMY", 43, 60], ["lesions", "ANATOMY", 177, 184], ["CoViD-19", "CHEMICAL", 101, 109], ["cutaneous lesions", "PATHOLOGICAL_FORMATION", 43, 60], ["SARS-CoV-2", "ORGANISM", 121, 131], ["lesions", "PATHOLOGICAL_FORMATION", 177, 184], ["SARS-CoV", "SPECIES", 121, 129], ["cutaneous lesions", "PROBLEM", 43, 60], ["new COronaVirusDisease", "PROBLEM", 72, 94], ["CoViD", "TEST", 101, 106], ["SARS", "PROBLEM", 121, 125], ["CoV", "TEST", 126, 129], ["these lesions", "PROBLEM", 171, 184], ["cutaneous", "ANATOMY", 43, 52], ["lesions", "OBSERVATION", 53, 60], ["new", "OBSERVATION_MODIFIER", 72, 75], ["lesions", "OBSERVATION", 177, 184], ["not", "UNCERTAINTY", 189, 192], ["well characterized", "OBSERVATION_MODIFIER", 193, 211]]], ["1 Recently, it has been highlighted the finding of congested and edematous blood vessels in the alveolar septum along with hyaline thrombi, and also in the heart, liver and kidney of autopsies of 3 patients deceased due to severe infection by SARS-CoV-2.", [["edematous blood vessels", "ANATOMY", 65, 88], ["alveolar septum", "ANATOMY", 96, 111], ["hyaline thrombi", "ANATOMY", 123, 138], ["heart", "ANATOMY", 156, 161], ["liver", "ANATOMY", 163, 168], ["kidney", "ANATOMY", 173, 179], ["thrombi", "DISEASE", 131, 138], ["infection", "DISEASE", 230, 239], ["SARS", "DISEASE", 243, 247], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 75, 88], ["alveolar septum", "MULTI-TISSUE_STRUCTURE", 96, 111], ["hyaline thrombi", "PATHOLOGICAL_FORMATION", 123, 138], ["heart", "ORGAN", 156, 161], ["liver", "ORGAN", 163, 168], ["kidney", "ORGAN", 173, 179], ["patients", "ORGANISM", 198, 206], ["patients", "SPECIES", 198, 206], ["SARS-CoV", "SPECIES", 243, 251], ["congested and edematous blood vessels in the alveolar septum", "PROBLEM", 51, 111], ["hyaline thrombi", "PROBLEM", 123, 138], ["severe infection", "PROBLEM", 223, 239], ["congested", "OBSERVATION", 51, 60], ["edematous", "OBSERVATION", 65, 74], ["blood vessels", "OBSERVATION", 75, 88], ["alveolar septum", "ANATOMY", 96, 111], ["hyaline", "OBSERVATION_MODIFIER", 123, 130], ["thrombi", "OBSERVATION", 131, 138], ["heart", "ANATOMY", 156, 161], ["liver", "ANATOMY", 163, 168], ["kidney", "ANATOMY", 173, 179], ["severe", "OBSERVATION_MODIFIER", 223, 229], ["infection", "OBSERVATION", 230, 239]]], ["2 Thus, anticoagulant treatment has been proposed to decrease mortality in certain cases of severe CoViD-19 disease.", [["CoViD-19", "CANCER", 99, 107], ["anticoagulant treatment", "TREATMENT", 8, 31], ["severe CoViD-19 disease", "PROBLEM", 92, 115], ["severe", "OBSERVATION_MODIFIER", 92, 98], ["19 disease", "OBSERVATION", 105, 115]]], ["3 We report a case of livedoid purple lesions along with acrocyanosis in a patient with confirmed SARS-CoV-2 infection with positive nasopharyngeal swab, showing an underlying obstructive cutaneous vasculopathy and sweat gland necrosis, both previously undescribed findings in this disease.Some authors have reported the presence of cutaneous lesions related to new COronaVirusA 61-year-old male, otherwise apparently healthy except for a history of diabetes, was accepted as an inpatient in the intensive care unit with the diagnosis of COVID-associated severe bilateral pneumonia complicated with diabetic ketoacidosis.", [["livedoid purple lesions", "ANATOMY", 22, 45], ["nasopharyngeal swab", "ANATOMY", 133, 152], ["cutaneous", "ANATOMY", 188, 197], ["sweat gland", "ANATOMY", 215, 226], ["cutaneous lesions", "ANATOMY", 333, 350], ["livedoid purple lesions", "DISEASE", 22, 45], ["acrocyanosis", "DISEASE", 57, 69], ["SARS-CoV-2 infection", "DISEASE", 98, 118], ["obstructive cutaneous vasculopathy", "DISEASE", 176, 210], ["sweat gland necrosis", "DISEASE", 215, 235], ["COronaVirusA", "CHEMICAL", 366, 378], ["diabetes", "DISEASE", 450, 458], ["COVID", "DISEASE", 538, 543], ["pneumonia", "DISEASE", 572, 581], ["diabetic ketoacidosis", "DISEASE", 599, 620], ["livedoid purple lesions", "CANCER", 22, 45], ["patient", "ORGANISM", 75, 82], ["SARS-CoV-2", "ORGANISM", 98, 108], ["nasopharyngeal swab", "MULTI-TISSUE_STRUCTURE", 133, 152], ["sweat gland", "ORGAN", 215, 226], ["cutaneous lesions", "CANCER", 333, 350], ["patient", "SPECIES", 75, 82], ["SARS-CoV-2", "SPECIES", 98, 108], ["livedoid purple lesions", "PROBLEM", 22, 45], ["acrocyanosis", "PROBLEM", 57, 69], ["SARS", "PROBLEM", 98, 102], ["CoV-2 infection", "PROBLEM", 103, 118], ["positive nasopharyngeal swab", "PROBLEM", 124, 152], ["an underlying obstructive cutaneous vasculopathy", "PROBLEM", 162, 210], ["sweat gland necrosis", "PROBLEM", 215, 235], ["this disease", "PROBLEM", 277, 289], ["cutaneous lesions", "PROBLEM", 333, 350], ["diabetes", "PROBLEM", 450, 458], ["COVID", "PROBLEM", 538, 543], ["severe bilateral pneumonia", "PROBLEM", 555, 581], ["diabetic ketoacidosis", "PROBLEM", 599, 620], ["lesions", "OBSERVATION", 38, 45], ["acrocyanosis", "OBSERVATION", 57, 69], ["nasopharyngeal swab", "ANATOMY", 133, 152], ["obstructive", "OBSERVATION_MODIFIER", 176, 187], ["cutaneous", "ANATOMY", 188, 197], ["vasculopathy", "OBSERVATION", 198, 210], ["sweat gland", "ANATOMY", 215, 226], ["necrosis", "OBSERVATION", 227, 235], ["cutaneous", "ANATOMY", 333, 342], ["lesions", "OBSERVATION", 343, 350], ["new", "OBSERVATION_MODIFIER", 362, 365], ["diabetes", "OBSERVATION", 450, 458], ["severe", "OBSERVATION_MODIFIER", 555, 561], ["bilateral", "ANATOMY_MODIFIER", 562, 571], ["pneumonia", "OBSERVATION", 572, 581], ["diabetic", "OBSERVATION_MODIFIER", 599, 607], ["ketoacidosis", "OBSERVATION", 608, 620]]], ["Simultaneously started showing cutaneous lesions.", [["cutaneous lesions", "ANATOMY", 31, 48], ["cutaneous lesions", "PATHOLOGICAL_FORMATION", 31, 48], ["cutaneous lesions", "PROBLEM", 31, 48], ["cutaneous", "ANATOMY", 31, 40], ["lesions", "OBSERVATION", 41, 48]]], ["There was no previous history of immunosuppression, new drugs or endovascular manipulation.", [["endovascular", "IMMATERIAL_ANATOMICAL_ENTITY", 65, 77], ["immunosuppression", "TREATMENT", 33, 50], ["new drugs", "TREATMENT", 52, 61], ["endovascular manipulation", "TREATMENT", 65, 90], ["no", "UNCERTAINTY", 10, 12], ["immunosuppression", "OBSERVATION", 33, 50], ["endovascular", "OBSERVATION", 65, 77]]], ["He was treated with low molecular weight heparin.Some authors have reported the presence of cutaneous lesions related to new COronaVirusPhysical examination showed purple ischemic digits involving the second and fourth distal phalanges of the right hand, and milder in the second, fourth and fifth digits of the left hand.Some authors have reported the presence of cutaneous lesions related to new COronaVirusSecond, third and fifth digits of the left foot were also involved.", [["cutaneous lesions", "ANATOMY", 92, 109], ["distal phalanges", "ANATOMY", 219, 235], ["right hand", "ANATOMY", 243, 253], ["left hand", "ANATOMY", 312, 321], ["cutaneous lesions", "ANATOMY", 365, 382], ["left foot", "ANATOMY", 447, 456], ["heparin", "CHEMICAL", 41, 48], ["He", "ORGANISM", 0, 2], ["low molecular weight heparin", "SIMPLE_CHEMICAL", 20, 48], ["cutaneous lesions", "PATHOLOGICAL_FORMATION", 92, 109], ["digits", "ORGANISM_SUBDIVISION", 180, 186], ["phalanges", "ORGAN", 226, 235], ["hand", "ORGANISM_SUBDIVISION", 249, 253], ["hand", "ORGANISM_SUBDIVISION", 317, 321], ["cutaneous lesions", "PATHOLOGICAL_FORMATION", 365, 382], ["foot", "ORGANISM_SUBDIVISION", 452, 456], ["low molecular weight heparin", "TREATMENT", 20, 48], ["cutaneous lesions", "PROBLEM", 92, 109], ["new COronaVirusPhysical examination", "TEST", 121, 156], ["purple ischemic digits", "PROBLEM", 164, 186], ["cutaneous lesions", "PROBLEM", 365, 382], ["cutaneous", "ANATOMY", 92, 101], ["lesions", "OBSERVATION", 102, 109], ["purple", "OBSERVATION_MODIFIER", 164, 170], ["ischemic digits", "OBSERVATION", 171, 186], ["second", "ANATOMY_MODIFIER", 201, 207], ["fourth", "ANATOMY_MODIFIER", 212, 218], ["distal", "ANATOMY_MODIFIER", 219, 225], ["phalanges", "ANATOMY_MODIFIER", 226, 235], ["right", "ANATOMY_MODIFIER", 243, 248], ["hand", "ANATOMY", 249, 253], ["milder", "OBSERVATION", 259, 265], ["second", "ANATOMY_MODIFIER", 273, 279], ["fourth", "ANATOMY_MODIFIER", 281, 287], ["fifth digits", "ANATOMY_MODIFIER", 292, 304], ["left", "ANATOMY_MODIFIER", 312, 316], ["hand", "ANATOMY", 317, 321], ["cutaneous", "ANATOMY", 365, 374], ["lesions", "OBSERVATION", 375, 382], ["new", "OBSERVATION_MODIFIER", 394, 397], ["COronaVirusSecond", "OBSERVATION", 398, 415], ["third", "ANATOMY_MODIFIER", 417, 422], ["fifth digits", "ANATOMY_MODIFIER", 427, 439], ["left", "ANATOMY_MODIFIER", 447, 451], ["foot", "ANATOMY", 452, 456]]], ["In addition, we observed livedoid purplish retiform and roundish patches in the other fingertips and in both, volar and dorsal areas of both feet and hands, some with angled edges (Fig 1 a) .", [["livedoid purplish retiform", "ANATOMY", 25, 51], ["roundish patches", "ANATOMY", 56, 72], ["fingertips", "ANATOMY", 86, 96], ["volar", "ANATOMY", 110, 115], ["dorsal areas", "ANATOMY", 120, 132], ["feet", "ANATOMY", 141, 145], ["fingertips", "ORGANISM_SUBDIVISION", 86, 96], ["volar", "TISSUE", 110, 115], ["feet", "ORGANISM_SUBDIVISION", 141, 145], ["livedoid purplish retiform", "TREATMENT", 25, 51], ["roundish patches", "TREATMENT", 56, 72], ["purplish", "OBSERVATION_MODIFIER", 34, 42], ["retiform", "OBSERVATION", 43, 51], ["roundish patches", "OBSERVATION", 56, 72], ["fingertips", "ANATOMY", 86, 96], ["both", "ANATOMY_MODIFIER", 104, 108], ["volar", "ANATOMY", 110, 115], ["dorsal", "ANATOMY_MODIFIER", 120, 126], ["areas", "ANATOMY_MODIFIER", 127, 132], ["both", "ANATOMY_MODIFIER", 136, 140], ["feet", "ANATOMY", 141, 145], ["hands", "ANATOMY", 150, 155], ["angled edges", "OBSERVATION", 167, 179]]], ["No cutaneous or mucosal lesions in other areas were observed.Some authors have reported the presence of cutaneous lesions related to new COronaVirusA biopsy showed a slightly necrotic upper epidermis.", [["cutaneous", "ANATOMY", 3, 12], ["mucosal lesions", "ANATOMY", 16, 31], ["cutaneous lesions", "ANATOMY", 104, 121], ["necrotic upper epidermis", "ANATOMY", 175, 199], ["necrotic", "DISEASE", 175, 183], ["mucosal lesions", "PATHOLOGICAL_FORMATION", 16, 31], ["cutaneous lesions", "PATHOLOGICAL_FORMATION", 104, 121], ["upper epidermis", "TISSUE", 184, 199], ["cutaneous or mucosal lesions in other areas", "PROBLEM", 3, 46], ["cutaneous lesions", "PROBLEM", 104, 121], ["new COronaVirusA biopsy", "TEST", 133, 156], ["a slightly necrotic upper epidermis", "PROBLEM", 164, 199], ["cutaneous", "ANATOMY", 3, 12], ["mucosal", "ANATOMY", 16, 23], ["lesions", "OBSERVATION", 24, 31], ["cutaneous", "ANATOMY", 104, 113], ["lesions", "OBSERVATION", 114, 121], ["new", "OBSERVATION_MODIFIER", 133, 136], ["slightly", "OBSERVATION_MODIFIER", 166, 174], ["necrotic", "OBSERVATION_MODIFIER", 175, 183], ["upper", "ANATOMY_MODIFIER", 184, 189], ["epidermis", "ANATOMY", 190, 199]]], ["In the papillary dermis, dilated blood vessels were found, most of them filled with hyaline thrombi and few with a mild neutrophilic component surrounding them.", [["papillary dermis", "ANATOMY", 7, 23], ["blood vessels", "ANATOMY", 33, 46], ["hyaline thrombi", "ANATOMY", 84, 99], ["thrombi", "DISEASE", 92, 99], ["papillary dermis", "TISSUE", 7, 23], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 33, 46], ["dilated blood vessels", "PROBLEM", 25, 46], ["hyaline thrombi", "PROBLEM", 84, 99], ["a mild neutrophilic component", "PROBLEM", 113, 142], ["papillary dermis", "ANATOMY", 7, 23], ["dilated", "OBSERVATION", 25, 32], ["blood vessels", "ANATOMY", 33, 46], ["hyaline", "OBSERVATION_MODIFIER", 84, 91], ["thrombi", "OBSERVATION", 92, 99], ["few", "OBSERVATION_MODIFIER", 104, 107], ["mild", "OBSERVATION_MODIFIER", 115, 119], ["neutrophilic", "OBSERVATION_MODIFIER", 120, 132], ["component", "OBSERVATION_MODIFIER", 133, 142]]], ["In some areas, larger arterial vessels located in the dermo-hypodermal interface showed focal fibrinoid necrosis surrounded by a scarce neutrophilic infiltrate (Fig 1b-d) .", [["arterial vessels", "ANATOMY", 22, 38], ["dermo-hypodermal", "ANATOMY", 54, 70], ["focal fibrinoid", "ANATOMY", 88, 103], ["neutrophilic infiltrate", "ANATOMY", 136, 159], ["necrosis", "DISEASE", 104, 112], ["arterial vessels", "MULTI-TISSUE_STRUCTURE", 22, 38], ["fibrinoid necrosis", "PATHOLOGICAL_FORMATION", 94, 112], ["neutrophilic infiltrate", "PATHOLOGICAL_FORMATION", 136, 159], ["larger arterial vessels", "PROBLEM", 15, 38], ["focal fibrinoid necrosis", "PROBLEM", 88, 112], ["a scarce neutrophilic infiltrate", "PROBLEM", 127, 159], ["some", "OBSERVATION_MODIFIER", 3, 7], ["areas", "OBSERVATION_MODIFIER", 8, 13], ["larger", "OBSERVATION_MODIFIER", 15, 21], ["arterial", "ANATOMY_MODIFIER", 22, 30], ["vessels", "ANATOMY", 31, 38], ["focal", "OBSERVATION_MODIFIER", 88, 93], ["fibrinoid", "OBSERVATION_MODIFIER", 94, 103], ["necrosis", "OBSERVATION", 104, 112], ["scarce", "OBSERVATION_MODIFIER", 129, 135], ["neutrophilic", "OBSERVATION_MODIFIER", 136, 148], ["infiltrate", "OBSERVATION", 149, 159]]], ["Orcein staining demonstrated that the larger vessel was an artery.", [["vessel", "ANATOMY", 45, 51], ["artery", "ANATOMY", 59, 65], ["Orcein", "SIMPLE_CHEMICAL", 0, 6], ["vessel", "MULTI-TISSUE_STRUCTURE", 45, 51], ["artery", "MULTI-TISSUE_STRUCTURE", 59, 65], ["Orcein staining", "TEST", 0, 15], ["larger", "OBSERVATION_MODIFIER", 38, 44], ["vessel", "ANATOMY", 45, 51], ["artery", "ANATOMY", 59, 65]]], ["Sweat gland necrosis and degeneration was present, more evident in the secretory portion of the eccrine sweat coil, with preserved eccrine ducts.", [["Sweat gland", "ANATOMY", 0, 11], ["secretory portion", "ANATOMY", 71, 88], ["eccrine sweat coil", "ANATOMY", 96, 114], ["eccrine ducts", "ANATOMY", 131, 144], ["Sweat gland necrosis", "DISEASE", 0, 20], ["Sweat gland", "MULTI-TISSUE_STRUCTURE", 0, 11], ["eccrine sweat", "MULTI-TISSUE_STRUCTURE", 96, 109], ["eccrine ducts", "MULTI-TISSUE_STRUCTURE", 131, 144], ["Sweat gland necrosis", "PROBLEM", 0, 20], ["degeneration", "PROBLEM", 25, 37], ["gland", "ANATOMY", 6, 11], ["necrosis", "OBSERVATION", 12, 20], ["degeneration", "OBSERVATION", 25, 37], ["eccrine", "ANATOMY", 96, 103], ["sweat coil", "OBSERVATION", 104, 114], ["eccrine", "ANATOMY_MODIFIER", 131, 138], ["ducts", "ANATOMY", 139, 144]]], ["Microbiological cultures from skin biopsy and blood and PCR for SARS-CoV-2 from the skin biopsy were negative.Accepted ArticleThis article is protected by copyright.", [["cultures", "ANATOMY", 16, 24], ["skin biopsy", "ANATOMY", 30, 41], ["blood", "ANATOMY", 46, 51], ["skin biopsy", "ANATOMY", 84, 95], ["skin biopsy", "MULTI-TISSUE_STRUCTURE", 30, 41], ["blood", "ORGANISM_SUBSTANCE", 46, 51], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 64, 74], ["skin biopsy", "MULTI-TISSUE_STRUCTURE", 84, 95], ["SARS-CoV", "SPECIES", 64, 72], ["Microbiological cultures", "TEST", 0, 24], ["skin biopsy", "TEST", 30, 41], ["blood", "TEST", 46, 51], ["PCR", "TEST", 56, 59], ["SARS", "TEST", 64, 68], ["CoV", "TEST", 69, 72], ["the skin biopsy", "TEST", 80, 95], ["skin", "ANATOMY", 30, 34], ["skin", "ANATOMY", 84, 88], ["biopsy", "OBSERVATION", 89, 95]]], ["All rights reserved Blood tests showed increased fibrinogen (up to 995 mg/mL) and D-dimer levels (60.83 mg/L) and leucopenia, with later progressive normalization.", [["Blood", "ANATOMY", 20, 25], ["leucopenia", "DISEASE", 114, 124], ["Blood", "ORGANISM_SUBSTANCE", 20, 25], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 49, 59], ["D-dimer", "GENE_OR_GENE_PRODUCT", 82, 89], ["fibrinogen", "PROTEIN", 49, 59], ["Blood tests", "TEST", 20, 31], ["increased fibrinogen", "PROBLEM", 39, 59], ["D-dimer levels", "TEST", 82, 96], ["leucopenia", "PROBLEM", 114, 124], ["later progressive normalization", "PROBLEM", 131, 162], ["increased", "OBSERVATION_MODIFIER", 39, 48], ["fibrinogen", "OBSERVATION", 49, 59], ["leucopenia", "OBSERVATION", 114, 124], ["progressive", "OBSERVATION_MODIFIER", 137, 148], ["normalization", "OBSERVATION", 149, 162]]], ["Coagulation tests showed a heterozygous Factor V Leiden mutation with normal antithrombin III, homocysteine, protein C and protein S levels.", [["homocysteine", "CHEMICAL", 95, 107], ["homocysteine", "CHEMICAL", 95, 107], ["Factor V Leiden", "GENE_OR_GENE_PRODUCT", 40, 55], ["antithrombin III", "GENE_OR_GENE_PRODUCT", 77, 93], ["homocysteine", "SIMPLE_CHEMICAL", 95, 107], ["protein C", "GENE_OR_GENE_PRODUCT", 109, 118], ["protein S", "GENE_OR_GENE_PRODUCT", 123, 132], ["Factor V Leiden", "PROTEIN", 40, 55], ["antithrombin III", "PROTEIN", 77, 93], ["protein C", "PROTEIN", 109, 118], ["protein S", "PROTEIN", 123, 132], ["Coagulation tests", "TEST", 0, 17], ["a heterozygous Factor V Leiden mutation", "PROBLEM", 25, 64], ["homocysteine", "TEST", 95, 107], ["protein C", "TEST", 109, 118], ["protein S levels", "TEST", 123, 139], ["antithrombin III", "OBSERVATION_MODIFIER", 77, 93]]], ["No Retiform purpura and livedoid lesions in our patient could be explained as a cutaneous manifestation of an underlying systemic coagulopathy related to COVID-19, as it has been previously described in other coagulopathies.", [["livedoid lesions", "ANATOMY", 24, 40], ["cutaneous", "ANATOMY", 80, 89], ["purpura", "DISEASE", 12, 19], ["livedoid lesions", "DISEASE", 24, 40], ["systemic coagulopathy", "DISEASE", 121, 142], ["COVID-19", "CHEMICAL", 154, 162], ["coagulopathies", "DISEASE", 209, 223], ["COVID-19", "CHEMICAL", 154, 162], ["livedoid lesions", "CANCER", 24, 40], ["patient", "ORGANISM", 48, 55], ["patient", "SPECIES", 48, 55], ["Retiform purpura", "PROBLEM", 3, 19], ["livedoid lesions", "PROBLEM", 24, 40], ["an underlying systemic coagulopathy", "PROBLEM", 107, 142], ["COVID", "TEST", 154, 159], ["other coagulopathies", "PROBLEM", 203, 223], ["Retiform", "OBSERVATION_MODIFIER", 3, 11], ["purpura", "OBSERVATION", 12, 19], ["livedoid", "OBSERVATION_MODIFIER", 24, 32], ["lesions", "OBSERVATION", 33, 40], ["systemic", "OBSERVATION_MODIFIER", 121, 129], ["coagulopathy", "OBSERVATION", 130, 142], ["coagulopathies", "OBSERVATION", 209, 223]]], ["6 Our patient heterozygous mutation of factor V Leyden is an additional known risk factor favoring thrombosis.", [["thrombosis", "DISEASE", 99, 109], ["patient", "ORGANISM", 6, 13], ["factor V Leyden", "GENE_OR_GENE_PRODUCT", 39, 54], ["patient", "SPECIES", 6, 13], ["Our patient heterozygous mutation", "PROBLEM", 2, 35], ["thrombosis", "PROBLEM", 99, 109], ["thrombosis", "OBSERVATION", 99, 109]]], ["7 Our case\u00b4s sweat gland necrosis was similar to the one present in non-drug related coma-associated bulla.", [["sweat gland", "ANATOMY", 13, 24], ["bulla", "ANATOMY", 101, 106], ["sweat gland necrosis", "DISEASE", 13, 33], ["sweat gland", "ORGAN", 13, 24], ["bulla", "PATHOLOGICAL_FORMATION", 101, 106], ["Our case\u00b4s sweat gland necrosis", "PROBLEM", 2, 33], ["non-drug related coma-associated bulla", "PROBLEM", 68, 106], ["gland", "ANATOMY", 19, 24], ["necrosis", "OBSERVATION", 25, 33], ["non-drug related", "OBSERVATION_MODIFIER", 68, 84], ["coma-associated", "OBSERVATION_MODIFIER", 85, 100], ["bulla", "OBSERVATION", 101, 106]]], ["7 But, in our case, thrombi and even fibrinoid necrosis were not only observed in the upper dermis vessels but also in all the other vessels in the biopsy, even in the dermo-hypodermal junction, an unexpected finding that could be related with a more extensive endothelial damage secondary to CoViD-19 infection, as it has been recently reported after observing viral inclusion bodies in electron microscopy of kidney, small bowel and lung of severely affected patients.", [["thrombi", "ANATOMY", 20, 27], ["fibrinoid", "ANATOMY", 37, 46], ["upper dermis vessels", "ANATOMY", 86, 106], ["vessels", "ANATOMY", 133, 140], ["biopsy", "ANATOMY", 148, 154], ["dermo-hypodermal junction", "ANATOMY", 168, 193], ["endothelial", "ANATOMY", 261, 272], ["kidney", "ANATOMY", 411, 417], ["small bowel", "ANATOMY", 419, 430], ["lung", "ANATOMY", 435, 439], ["thrombi", "DISEASE", 20, 27], ["necrosis", "DISEASE", 47, 55], ["endothelial damage", "DISEASE", 261, 279], ["CoViD-19", "CHEMICAL", 293, 301], ["infection", "DISEASE", 302, 311], ["thrombi", "PATHOLOGICAL_FORMATION", 20, 27], ["upper dermis vessels", "MULTI-TISSUE_STRUCTURE", 86, 106], ["vessels", "MULTI-TISSUE_STRUCTURE", 133, 140], ["dermo-hypodermal junction", "MULTI-TISSUE_STRUCTURE", 168, 193], ["endothelial", "TISSUE", 261, 272], ["CoViD-19", "GENE_OR_GENE_PRODUCT", 293, 301], ["kidney", "ORGAN", 411, 417], ["small bowel", "MULTI-TISSUE_STRUCTURE", 419, 430], ["lung", "ORGAN", 435, 439], ["patients", "ORGANISM", 461, 469], ["patients", "SPECIES", 461, 469], ["thrombi", "PROBLEM", 20, 27], ["fibrinoid necrosis", "PROBLEM", 37, 55], ["the biopsy", "TEST", 144, 154], ["a more extensive endothelial damage", "PROBLEM", 244, 279], ["CoViD-19 infection", "PROBLEM", 293, 311], ["viral inclusion bodies", "PROBLEM", 362, 384], ["electron microscopy", "TEST", 388, 407], ["small bowel and lung of severely affected patients", "PROBLEM", 419, 469], ["thrombi", "OBSERVATION", 20, 27], ["fibrinoid", "OBSERVATION_MODIFIER", 37, 46], ["necrosis", "OBSERVATION", 47, 55], ["not only observed", "UNCERTAINTY", 61, 78], ["upper", "ANATOMY_MODIFIER", 86, 91], ["dermis vessels", "ANATOMY", 92, 106], ["vessels", "ANATOMY", 133, 140], ["biopsy", "OBSERVATION", 148, 154], ["dermo-hypodermal junction", "ANATOMY", 168, 193], ["more", "OBSERVATION_MODIFIER", 246, 250], ["extensive", "OBSERVATION_MODIFIER", 251, 260], ["endothelial", "ANATOMY", 261, 272], ["damage", "OBSERVATION", 273, 279], ["infection", "OBSERVATION", 302, 311], ["kidney", "ANATOMY", 411, 417], ["small bowel", "ANATOMY", 419, 430], ["lung", "ANATOMY", 435, 439], ["severely", "OBSERVATION_MODIFIER", 443, 451], ["affected", "OBSERVATION", 452, 460]]], ["8 To our knowledge, this is the first report of a patient with CoViD-19 where the presence of an occlusive vasculopathy at the cutaneous level has been demonstrated.", [["occlusive", "ANATOMY", 97, 106], ["cutaneous", "ANATOMY", 127, 136], ["occlusive vasculopathy", "DISEASE", 97, 119], ["patient", "ORGANISM", 50, 57], ["patient", "SPECIES", 50, 57], ["CoViD", "TEST", 63, 68], ["an occlusive vasculopathy at the cutaneous level", "PROBLEM", 94, 142], ["occlusive", "OBSERVATION_MODIFIER", 97, 106], ["vasculopathy", "OBSERVATION", 107, 119], ["cutaneous", "ANATOMY", 127, 136]]], ["In our case, we observed also a striking sweat gland necrosis, a finding previously reported as associated with ketoacidotic coma but not with CoViD-19 infection.", [["sweat gland", "ANATOMY", 41, 52], ["sweat gland necrosis", "DISEASE", 41, 61], ["coma", "DISEASE", 125, 129], ["CoViD-19", "CHEMICAL", 143, 151], ["infection", "DISEASE", 152, 161], ["sweat gland", "ORGAN", 41, 52], ["CoViD-19", "GENE_OR_GENE_PRODUCT", 143, 151], ["a striking sweat gland necrosis", "PROBLEM", 30, 61], ["ketoacidotic coma", "PROBLEM", 112, 129], ["CoViD-19 infection", "PROBLEM", 143, 161], ["sweat gland", "ANATOMY", 41, 52], ["necrosis", "OBSERVATION", 53, 61], ["infection", "OBSERVATION", 152, 161]]], ["Additional studies are need to completely characterize the tissue damage associated to the virus, including within the gamut of lesions observed in the skin.", [["tissue", "ANATOMY", 59, 65], ["lesions", "ANATOMY", 128, 135], ["skin", "ANATOMY", 152, 156], ["tissue", "TISSUE", 59, 65], ["lesions", "CANCER", 128, 135], ["skin", "ORGAN", 152, 156], ["Additional studies", "TEST", 0, 18], ["the tissue damage", "PROBLEM", 55, 72], ["the virus", "PROBLEM", 87, 96], ["lesions", "PROBLEM", 128, 135], ["tissue", "ANATOMY", 59, 65], ["damage", "OBSERVATION", 66, 72], ["virus", "OBSERVATION", 91, 96], ["lesions", "OBSERVATION", 128, 135], ["skin", "ANATOMY", 152, 156]]]], "f981000b923965267e1dd7302ab9a90f69f1d0b9": [["IntroductionThe clinical syndrome associated with infection from the severe acute respiratory syndrome coronavirus 2019 (SARS-CoV-2) is notable for its variability, ranging from asymptomatic infection to multi-organ failure and death.", [["multi-organ", "ANATOMY", 204, 215], ["infection", "DISEASE", 50, 59], ["acute respiratory syndrome coronavirus", "DISEASE", 76, 114], ["infection", "DISEASE", 191, 200], ["multi-organ failure", "DISEASE", 204, 223], ["death", "DISEASE", 228, 233], ["SARS-CoV-2", "ORGANISM", 121, 131], ["severe acute respiratory syndrome coronavirus", "SPECIES", 69, 114], ["SARS-CoV-2", "SPECIES", 121, 131], ["The clinical syndrome", "PROBLEM", 12, 33], ["infection", "PROBLEM", 50, 59], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 65, 114], ["SARS", "TEST", 121, 125], ["CoV", "TEST", 126, 129], ["its variability", "PROBLEM", 148, 163], ["asymptomatic infection", "PROBLEM", 178, 200], ["multi-organ failure", "PROBLEM", 204, 223], ["death", "PROBLEM", 228, 233], ["infection", "OBSERVATION", 50, 59], ["severe", "OBSERVATION_MODIFIER", 69, 75], ["acute", "OBSERVATION_MODIFIER", 76, 81], ["respiratory syndrome", "OBSERVATION", 82, 102], ["asymptomatic", "OBSERVATION_MODIFIER", 178, 190], ["infection", "OBSERVATION", 191, 200], ["multi-organ failure", "OBSERVATION", 204, 223]]], ["1 In a study describing the first 393 patients with coronavirus disease at two New York City (NYC) hospitals, 77.1% had fever, a symptom driven by IL-1.", [["coronavirus disease", "DISEASE", 52, 71], ["fever", "DISEASE", 120, 125], ["patients", "ORGANISM", 38, 46], ["coronavirus", "ORGANISM", 52, 63], ["IL-1", "GENE_OR_GENE_PRODUCT", 147, 151], ["IL", "PROTEIN", 147, 149], ["patients", "SPECIES", 38, 46], ["a study", "TEST", 5, 12], ["coronavirus disease", "PROBLEM", 52, 71], ["fever", "PROBLEM", 120, 125], ["a symptom", "PROBLEM", 127, 136], ["coronavirus disease", "OBSERVATION", 52, 71]]], ["2 The clinical presentation, along with transcriptomic analysis of whole blood from COVID-19 patients demonstrating IL-1-alpha and IL-1-beta expression prior to the nadir of respiratory function, suggests that IL-1 may drive the pathophysiology of COVID-19.", [["whole blood", "ANATOMY", 67, 78], ["respiratory", "ANATOMY", 174, 185], ["COVID-19", "CHEMICAL", 248, 256], ["blood", "ORGANISM_SUBSTANCE", 73, 78], ["patients", "ORGANISM", 93, 101], ["IL-1-alpha", "GENE_OR_GENE_PRODUCT", 116, 126], ["IL-1-beta", "GENE_OR_GENE_PRODUCT", 131, 140], ["IL-1", "GENE_OR_GENE_PRODUCT", 210, 214], ["IL", "PROTEIN", 210, 212], ["patients", "SPECIES", 93, 101], ["transcriptomic analysis", "TEST", 40, 63], ["whole blood", "TEST", 67, 78], ["COVID", "TEST", 84, 89], ["IL", "TEST", 116, 118], ["IL", "TEST", 131, 133], ["respiratory function", "TEST", 174, 194], ["COVID", "TEST", 248, 253], ["respiratory function", "OBSERVATION", 174, 194]]], ["3 Cytokine storm syndrome (CSS) has been observed in patients with COVID-19 and has been proposed to contribute to severe sequelae of disease such as acute hypoxic respiratory failure (AHRF) and death.", [["respiratory", "ANATOMY", 164, 175], ["CSS", "DISEASE", 27, 30], ["COVID-19", "CHEMICAL", 67, 75], ["hypoxic respiratory failure", "DISEASE", 156, 183], ["AHRF", "DISEASE", 185, 189], ["death", "DISEASE", 195, 200], ["patients", "ORGANISM", 53, 61], ["Cytokine", "PROTEIN", 2, 10], ["patients", "SPECIES", 53, 61], ["3 Cytokine storm syndrome", "PROBLEM", 0, 25], ["COVID", "TEST", 67, 72], ["severe sequelae of disease", "PROBLEM", 115, 141], ["acute hypoxic respiratory failure", "PROBLEM", 150, 183], ["AHRF)", "PROBLEM", 185, 190], ["death", "PROBLEM", 195, 200], ["Cytokine storm syndrome", "OBSERVATION", 2, 25], ["severe", "OBSERVATION_MODIFIER", 115, 121], ["sequelae", "OBSERVATION", 122, 130], ["disease", "OBSERVATION", 134, 141], ["acute", "OBSERVATION_MODIFIER", 150, 155], ["hypoxic", "OBSERVATION_MODIFIER", 156, 163], ["respiratory failure", "OBSERVATION", 164, 183]]], ["4 In distinct clinical settings, including macrophage activation syndrome (MAS), elevated levels of pro-inflammatory cytokines and other laboratory indicators, including ferritin, Creactive protein (CRP), D-dimer, and lymphopenia, have been observed.", [["macrophage", "ANATOMY", 43, 53], ["MAS", "DISEASE", 75, 78], ["lymphopenia", "DISEASE", 218, 229], ["macrophage", "CELL", 43, 53], ["ferritin", "GENE_OR_GENE_PRODUCT", 170, 178], ["Creactive protein", "GENE_OR_GENE_PRODUCT", 180, 197], ["CRP", "GENE_OR_GENE_PRODUCT", 199, 202], ["D-dimer", "GENE_OR_GENE_PRODUCT", 205, 212], ["pro-inflammatory cytokines", "PROTEIN", 100, 126], ["ferritin", "PROTEIN", 170, 178], ["Creactive protein", "PROTEIN", 180, 197], ["CRP", "PROTEIN", 199, 202], ["D-dimer", "PROTEIN", 205, 212], ["macrophage activation syndrome", "PROBLEM", 43, 73], ["MAS)", "PROBLEM", 75, 79], ["elevated levels of pro-inflammatory cytokines", "PROBLEM", 81, 126], ["ferritin", "TEST", 170, 178], ["Creactive protein", "TEST", 180, 197], ["CRP", "TEST", 199, 202], ["D-dimer", "PROBLEM", 205, 212], ["lymphopenia", "PROBLEM", 218, 229], ["macrophage activation syndrome", "OBSERVATION", 43, 73], ["pro-inflammatory cytokines", "OBSERVATION", 100, 126], ["lymphopenia", "OBSERVATION", 218, 229]]], ["5 In the context of systemic juvenile idiopathic arthritis (SJIA), the prototypic disease for such syndromes, controlled clinical trials of an IL-1 inhibitor clearly demonstrated safety and efficacy.", [["juvenile idiopathic arthritis", "DISEASE", 29, 58], ["SJIA", "DISEASE", 60, 64], ["IL-1", "GENE_OR_GENE_PRODUCT", 143, 147], ["systemic juvenile idiopathic arthritis", "PROBLEM", 20, 58], ["SJIA)", "PROBLEM", 60, 65], ["the prototypic disease", "PROBLEM", 67, 89], ["such syndromes", "PROBLEM", 94, 108], ["an IL-1 inhibitor", "TREATMENT", 140, 157], ["systemic", "OBSERVATION_MODIFIER", 20, 28], ["juvenile", "OBSERVATION_MODIFIER", 29, 37], ["idiopathic", "OBSERVATION_MODIFIER", 38, 48], ["arthritis", "OBSERVATION", 49, 58]]], ["6 Based on the experience of clinicians, and particularly rheumatologists, IL-1 inhibition has been used in additional rare syndromes characterized by induction of hyperinflammation mediated by impaired regulation of the cytokine response.", [["hyperinflammation", "DISEASE", 164, 181], ["IL-1", "GENE_OR_GENE_PRODUCT", 75, 79], ["IL", "PROTEIN", 75, 77], ["cytokine", "PROTEIN", 221, 229], ["IL-1 inhibition", "TREATMENT", 75, 90], ["additional rare syndromes", "PROBLEM", 108, 133], ["hyperinflammation", "PROBLEM", 164, 181], ["cytokine response", "OBSERVATION", 221, 238]]], ["7, 8 Anakinra, a recombinant IL-1 receptor antagonist approved by the Food and Drug Administration for use in Neonatal-Onset Multisystem Inflammatory Disease and rheumatoid arthritis, inhibits both IL-1-alpha and IL-1-beta.", [["Anakinra", "CHEMICAL", 5, 13], ["Inflammatory Disease", "DISEASE", 137, 157], ["rheumatoid arthritis", "DISEASE", 162, 182], ["Anakinra", "SIMPLE_CHEMICAL", 5, 13], ["IL-1 receptor", "GENE_OR_GENE_PRODUCT", 29, 42], ["IL-1-alpha", "GENE_OR_GENE_PRODUCT", 198, 208], ["IL-1-beta", "GENE_OR_GENE_PRODUCT", 213, 222], ["IL-1-alpha and IL-1-beta", "PROTEIN", 198, 222], ["Anakinra", "TREATMENT", 5, 13], ["a recombinant IL-1 receptor antagonist", "TREATMENT", 15, 53], ["Multisystem Inflammatory Disease", "PROBLEM", 125, 157], ["rheumatoid arthritis", "PROBLEM", 162, 182], ["IL", "TEST", 198, 200], ["IL", "TEST", 213, 215], ["Multisystem", "OBSERVATION_MODIFIER", 125, 136], ["Inflammatory Disease", "OBSERVATION", 137, 157], ["rheumatoid arthritis", "OBSERVATION", 162, 182]]], ["Because it inhibits both IL-1 subtypes and has a short half life, anakinra could be a promising treatment for patients with severe COVID-19.", [["anakinra", "CHEMICAL", 66, 74], ["COVID-19", "CHEMICAL", 131, 139], ["IL-1", "GENE_OR_GENE_PRODUCT", 25, 29], ["anakinra", "SIMPLE_CHEMICAL", 66, 74], ["patients", "ORGANISM", 110, 118], ["IL", "PROTEIN", 25, 27], ["patients", "SPECIES", 110, 118], ["anakinra", "TREATMENT", 66, 74], ["severe COVID", "PROBLEM", 124, 136], ["both", "OBSERVATION_MODIFIER", 20, 24], ["IL", "OBSERVATION_MODIFIER", 25, 27]]], ["The objective of this study was to report a single-center preliminary experience using anakinra as part of clinical care to prevent progression to mechanical ventilation (MV) in patients with COVID-19 presenting with clinical and laboratory evidence of CSS and AHRF.Patients and study designThis was a retrospective case series of patients with COVID-19, AHRF, and signs and symptoms of CSS.", [["anakinra", "CHEMICAL", 87, 95], ["CSS", "DISEASE", 253, 256], ["AHRF", "DISEASE", 261, 265], ["AHRF", "DISEASE", 355, 359], ["CSS", "DISEASE", 387, 390], ["anakinra", "SIMPLE_CHEMICAL", 87, 95], ["patients", "ORGANISM", 178, 186], ["Patients", "ORGANISM", 266, 274], ["patients", "ORGANISM", 331, 339], ["patients", "SPECIES", 178, 186], ["Patients", "SPECIES", 266, 274], ["patients", "SPECIES", 331, 339], ["MV", "SPECIES", 171, 173], ["this study", "TEST", 17, 27], ["anakinra", "TREATMENT", 87, 95], ["clinical care", "TREATMENT", 107, 120], ["mechanical ventilation", "TREATMENT", 147, 169], ["COVID", "TEST", 192, 197], ["CSS", "PROBLEM", 253, 256], ["AHRF", "PROBLEM", 261, 265], ["COVID", "TEST", 345, 350], ["AHRF", "PROBLEM", 355, 359], ["signs", "PROBLEM", 365, 370], ["symptoms", "PROBLEM", 375, 383], ["CSS", "PROBLEM", 387, 390], ["mechanical ventilation", "OBSERVATION", 147, 169]]], ["We evaluated patients with COVID-19 through the rheumatology inpatient consult service at New York Presbyterian Hospital (NYP)-Weill Cornell Medicine and NYP-Lower ManhattanAccepted ArticleThis article is protected by copyright.", [["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21], ["NYP", "TREATMENT", 154, 157]]], ["Supplemental Table 1 presents detailed inclusion and exclusion criteria used to guide the use of anakinra to treat CSS in patients with COVID-19.", [["anakinra", "CHEMICAL", 97, 105], ["CSS", "DISEASE", 115, 118], ["anakinra", "SIMPLE_CHEMICAL", 97, 105], ["patients", "ORGANISM", 122, 130], ["patients", "SPECIES", 122, 130], ["anakinra", "TREATMENT", 97, 105], ["CSS", "TREATMENT", 115, 118], ["COVID", "TEST", 136, 141]]], ["In summary, we required that patients have molecular documentation of SARS-CoV-2, fever (documented or historical), ferritin >1,000 ng/mL with one additional laboratory marker of hyperinflammation, and AHRF.", [["SARS", "DISEASE", 70, 74], ["fever", "DISEASE", 82, 87], ["hyperinflammation", "DISEASE", 179, 196], ["patients", "ORGANISM", 29, 37], ["SARS-CoV-2", "ORGANISM", 70, 80], ["ferritin", "GENE_OR_GENE_PRODUCT", 116, 124], ["ferritin", "PROTEIN", 116, 124], ["patients", "SPECIES", 29, 37], ["SARS-CoV", "SPECIES", 70, 78], ["SARS", "PROBLEM", 70, 74], ["CoV", "TEST", 75, 78], ["fever", "PROBLEM", 82, 87], ["ferritin", "TEST", 116, 124], ["hyperinflammation", "PROBLEM", 179, 196], ["AHRF", "PROBLEM", 202, 206], ["hyperinflammation", "OBSERVATION", 179, 196]]], ["AHRF was defined as requiring either 15 liters (L) of supplemental oxygen (O 2 ) via non-rebreather (NRB) mask combined with 6L nasal cannula (NC) or \u226595% oxygen by high flow nasal cannula (HFNC).", [["nasal", "ANATOMY", 128, 133], ["nasal", "ANATOMY", 175, 180], ["oxygen", "CHEMICAL", 67, 73], ["oxygen", "CHEMICAL", 155, 161], ["oxygen", "CHEMICAL", 67, 73], ["O 2", "CHEMICAL", 75, 78], ["oxygen", "CHEMICAL", 155, 161], ["oxygen", "SIMPLE_CHEMICAL", 67, 73], ["oxygen", "SIMPLE_CHEMICAL", 155, 161], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 175, 188], ["supplemental oxygen", "TREATMENT", 54, 73], ["non-rebreather", "TREATMENT", 85, 99], ["NRB", "TREATMENT", 101, 104], ["mask", "TREATMENT", 106, 110], ["6L nasal cannula", "TREATMENT", 125, 141], ["NC", "TREATMENT", 143, 145], ["\u2265", "TREATMENT", 150, 151], ["oxygen", "TREATMENT", 155, 161], ["high flow nasal cannula (HFNC", "TREATMENT", 165, 194]]], ["Patients on invasive MV at the time of evaluation were ineligible.Accepted ArticlePatients were considered for treatment with anakinra only after they were deemed ineligible for any ongoing clinical trial for patients with COVID-19.", [["anakinra", "CHEMICAL", 126, 134], ["COVID-19", "CHEMICAL", 223, 231], ["Patients", "ORGANISM", 0, 8], ["anakinra", "SIMPLE_CHEMICAL", 126, 134], ["patients", "ORGANISM", 209, 217], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 209, 217], ["MV", "SPECIES", 21, 23], ["invasive MV", "TREATMENT", 12, 23], ["evaluation", "TEST", 39, 49], ["treatment", "TREATMENT", 111, 120], ["anakinra", "TREATMENT", 126, 134], ["COVID", "TEST", 223, 228], ["invasive MV", "OBSERVATION_MODIFIER", 12, 23]]], ["We obtained and documented verbal consent for the off-label use of anakinra in these patients.", [["anakinra", "CHEMICAL", 67, 75], ["anakinra", "SIMPLE_CHEMICAL", 67, 75], ["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93], ["anakinra", "TREATMENT", 67, 75]]], ["The Weill Cornell Medicine Institutional Review Board approved this study.Treatment with anakinraOnly subcutaneous (SQ) anakinra was available at our institution's pharmacy.", [["subcutaneous", "ANATOMY", 102, 114], ["anakinraOnly", "CHEMICAL", 89, 101], ["anakinra", "CHEMICAL", 120, 128], ["anakinraOnly", "CHEMICAL", 89, 101], ["anakinra", "SIMPLE_CHEMICAL", 120, 128], ["this study", "TEST", 63, 73], ["anakinraOnly subcutaneous (SQ) anakinra", "TREATMENT", 89, 128]]], ["Patients were started on anakinra 100 mg SQ every 6 hours; however, while a uniform treatment plan and secure supply of medication was being established, the first two patients were treated initially with doses below the proposed 100 mg every 6 hours.", [["anakinra", "CHEMICAL", 25, 33], ["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 168, 176], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 168, 176], ["anakinra", "TREATMENT", 25, 33], ["a uniform treatment plan", "TREATMENT", 74, 98], ["secure supply of medication", "TREATMENT", 103, 130]]], ["The dosing frequency of anakinra was gradually decreased to every 8, 12, and 24 hours, over a maximum treatment duration of 20 days.", [["anakinra", "CHEMICAL", 24, 32], ["anakinra", "SIMPLE_CHEMICAL", 24, 32], ["anakinra", "TREATMENT", 24, 32], ["a maximum treatment duration", "TREATMENT", 92, 120]]], ["We tapered anakinra based on decreasing oxygen requirement and clinical improvement, or in response to elevated transaminases, cytopenias, concern for new bacterial infection (based on positive cultures, increase in procalcitonin to >0.6 ng/mL, or high clinical suspicion), or worsening renal function.", [["renal", "ANATOMY", 287, 292], ["anakinra", "CHEMICAL", 11, 19], ["oxygen", "CHEMICAL", 40, 46], ["cytopenias", "DISEASE", 127, 137], ["bacterial infection", "DISEASE", 155, 174], ["oxygen", "CHEMICAL", 40, 46], ["anakinra", "SIMPLE_CHEMICAL", 11, 19], ["oxygen", "SIMPLE_CHEMICAL", 40, 46], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 216, 229], ["renal", "ORGAN", 287, 292], ["procalcitonin", "PROTEIN", 216, 229], ["anakinra", "TREATMENT", 11, 19], ["decreasing oxygen requirement", "PROBLEM", 29, 58], ["elevated transaminases", "PROBLEM", 103, 125], ["cytopenias", "PROBLEM", 127, 137], ["new bacterial infection", "PROBLEM", 151, 174], ["positive cultures", "PROBLEM", 185, 202], ["procalcitonin", "TEST", 216, 229], ["worsening renal function", "PROBLEM", 277, 301], ["tapered", "OBSERVATION_MODIFIER", 3, 10], ["anakinra", "OBSERVATION", 11, 19], ["decreasing", "OBSERVATION_MODIFIER", 29, 39], ["oxygen requirement", "OBSERVATION", 40, 58], ["elevated", "OBSERVATION_MODIFIER", 103, 111], ["transaminases", "OBSERVATION", 112, 125], ["cytopenias", "OBSERVATION", 127, 137], ["concern for", "UNCERTAINTY", 139, 150], ["new", "OBSERVATION_MODIFIER", 151, 154], ["bacterial", "OBSERVATION_MODIFIER", 155, 164], ["infection", "OBSERVATION", 165, 174], ["worsening", "OBSERVATION_MODIFIER", 277, 286], ["renal", "ANATOMY", 287, 292], ["function", "OBSERVATION", 293, 301]]], ["We continued anakinra in patients requiring MV with the goal that its use could facilitate extubation.Treatment with anakinraThere were three patients who met our eligibility criteria but were not given anakinra because it was unavailable or the patient declined it.", [["anakinra", "CHEMICAL", 13, 21], ["anakinra", "CHEMICAL", 117, 125], ["anakinra", "CHEMICAL", 203, 211], ["anakinra", "CHEMICAL", 117, 125], ["anakinra", "SIMPLE_CHEMICAL", 13, 21], ["patients", "ORGANISM", 25, 33], ["anakinra", "SIMPLE_CHEMICAL", 117, 125], ["patients", "ORGANISM", 142, 150], ["anakinra", "SIMPLE_CHEMICAL", 203, 211], ["patient", "ORGANISM", 246, 253], ["patients", "SPECIES", 25, 33], ["patients", "SPECIES", 142, 150], ["patient", "SPECIES", 246, 253], ["MV", "SPECIES", 44, 46], ["anakinra", "TREATMENT", 13, 21], ["MV", "TREATMENT", 44, 46], ["anakinra", "TREATMENT", 117, 125], ["anakinra", "TREATMENT", 203, 211], ["anakinra", "OBSERVATION", 13, 21]]], ["We considered continuing anakinra after discharge from the hospital based on clinical response and tolerability; in most cases we discontinued it because patients had improved significantly by that time and the likelihood of further decompensation was low.Background MedicationsWe allowed background methylprednisolone, empiric antibiotics and hydroxychloroquine, which were included in the clinical care protocols for COVID-19 at NYP.", [["anakinra", "CHEMICAL", 25, 33], ["decompensation", "DISEASE", 233, 247], ["methylprednisolone", "CHEMICAL", 300, 318], ["hydroxychloroquine", "CHEMICAL", 344, 362], ["methylprednisolone", "CHEMICAL", 300, 318], ["hydroxychloroquine", "CHEMICAL", 344, 362], ["patients", "ORGANISM", 154, 162], ["methylprednisolone", "SIMPLE_CHEMICAL", 300, 318], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 344, 362], ["NYP", "SIMPLE_CHEMICAL", 431, 434], ["patients", "SPECIES", 154, 162], ["continuing anakinra", "TREATMENT", 14, 33], ["further decompensation", "PROBLEM", 225, 247], ["background methylprednisolone", "TREATMENT", 289, 318], ["empiric antibiotics", "TREATMENT", 320, 339], ["hydroxychloroquine", "TREATMENT", 344, 362], ["COVID", "TEST", 419, 424], ["decompensation", "OBSERVATION", 233, 247]]], ["Several patients received anakinra together with methylprednisolone, as this was being considered for all patients with Accepted Article worsening respiratory failure at high risk for MV at our institution.", [["respiratory", "ANATOMY", 147, 158], ["anakinra", "CHEMICAL", 26, 34], ["methylprednisolone", "CHEMICAL", 49, 67], ["respiratory failure", "DISEASE", 147, 166], ["methylprednisolone", "CHEMICAL", 49, 67], ["patients", "ORGANISM", 8, 16], ["anakinra", "SIMPLE_CHEMICAL", 26, 34], ["methylprednisolone", "SIMPLE_CHEMICAL", 49, 67], ["patients", "ORGANISM", 106, 114], ["patients", "SPECIES", 8, 16], ["patients", "SPECIES", 106, 114], ["MV", "SPECIES", 184, 186], ["anakinra", "TREATMENT", 26, 34], ["methylprednisolone", "TREATMENT", 49, 67], ["Article worsening respiratory failure", "PROBLEM", 129, 166], ["worsening", "OBSERVATION_MODIFIER", 137, 146], ["respiratory failure", "OBSERVATION", 147, 166]]], ["None of these patients received remdesivir.", [["remdesivir", "CHEMICAL", 32, 42], ["remdesivir", "CHEMICAL", 32, 42], ["patients", "ORGANISM", 14, 22], ["remdesivir", "SIMPLE_CHEMICAL", 32, 42], ["patients", "SPECIES", 14, 22], ["remdesivir", "TREATMENT", 32, 42]]], ["We excluded patients with cancer receiving chemotherapy or immunotherapy and patients on other immunosuppressive biologics.", [["cancer", "ANATOMY", 26, 32], ["cancer", "DISEASE", 26, 32], ["patients", "ORGANISM", 12, 20], ["cancer", "CANCER", 26, 32], ["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 12, 20], ["patients", "SPECIES", 77, 85], ["cancer", "PROBLEM", 26, 32], ["chemotherapy", "TREATMENT", 43, 55], ["immunotherapy", "TREATMENT", 59, 72], ["other immunosuppressive biologics", "TREATMENT", 89, 122], ["cancer", "OBSERVATION", 26, 32]]], ["Supplemental Table 1 provides details regarding exclusion criteria.MonitoringWe monitored vital signs, oxygen requirement, ferritin level, complete blood count with differential, comprehensive metabolic panel, erythrocyte sedimentation rate, CRP, lactate dehydrogenase, international normalized ratio, and prothrombin time.Outcomes and timelinesThe primary outcome was prevention of MV.", [["blood", "ANATOMY", 148, 153], ["erythrocyte", "ANATOMY", 210, 221], ["oxygen", "CHEMICAL", 103, 109], ["lactate", "CHEMICAL", 247, 254], ["oxygen", "CHEMICAL", 103, 109], ["lactate", "CHEMICAL", 247, 254], ["oxygen", "SIMPLE_CHEMICAL", 103, 109], ["ferritin", "GENE_OR_GENE_PRODUCT", 123, 131], ["blood", "ORGANISM_SUBSTANCE", 148, 153], ["erythrocyte", "CELL", 210, 221], ["CRP", "GENE_OR_GENE_PRODUCT", 242, 245], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 247, 268], ["prothrombin", "GENE_OR_GENE_PRODUCT", 306, 317], ["ferritin", "PROTEIN", 123, 131], ["CRP", "PROTEIN", 242, 245], ["lactate dehydrogenase", "PROTEIN", 247, 268], ["MV", "SPECIES", 383, 385], ["vital signs", "TEST", 90, 101], ["oxygen requirement", "TEST", 103, 121], ["ferritin level", "TEST", 123, 137], ["complete blood count", "TEST", 139, 159], ["differential", "TEST", 165, 177], ["comprehensive metabolic panel", "TEST", 179, 208], ["erythrocyte sedimentation rate", "TEST", 210, 240], ["CRP", "TEST", 242, 245], ["lactate dehydrogenase", "TEST", 247, 268], ["international normalized ratio", "TEST", 270, 300], ["prothrombin time", "TEST", 306, 322]]], ["Clinical response was defined as the patient being weaned off O 2 or to 2L O 2 by NC.", [["O 2", "CHEMICAL", 62, 65], ["O 2", "CHEMICAL", 75, 78], ["patient", "ORGANISM", 37, 44], ["2L O 2", "GENE_OR_GENE_PRODUCT", 72, 78], ["patient", "SPECIES", 37, 44]]], ["Failure to respond was defined as requiring MV.", [["MV", "SPECIES", 44, 46], ["Failure to respond", "PROBLEM", 0, 18]]], ["We used the ordinal scale of the World Health Organization trials for COVID-19 (Supplemental Table 2 ) to measure respiratory outcomes.", [["respiratory", "ANATOMY", 114, 125], ["COVID", "TREATMENT", 70, 75], ["Supplemental Table 2 )", "TREATMENT", 80, 102]]], ["9 The maximum duration of treatment with anakinra was 20 days.", [["anakinra", "CHEMICAL", 41, 49], ["anakinra", "SIMPLE_CHEMICAL", 41, 49], ["treatment", "TREATMENT", 26, 35], ["anakinra", "TREATMENT", 41, 49], ["maximum", "OBSERVATION_MODIFIER", 6, 13]]], ["We followed the patients until they were able to wean off O 2 or until discharge.ResultsFourteen patients met our criteria for CSS in the setting of severe COVID-19 pneumonia and AHRF (Table 1) .", [["COVID", "DISEASE", 156, 161], ["pneumonia", "DISEASE", 165, 174], ["AHRF", "DISEASE", 179, 183], ["patients", "ORGANISM", 16, 24], ["patients", "ORGANISM", 97, 105], ["patients", "SPECIES", 16, 24], ["patients", "SPECIES", 97, 105], ["CSS", "PROBLEM", 127, 130], ["severe COVID", "PROBLEM", 149, 161], ["pneumonia", "PROBLEM", 165, 174], ["AHRF", "PROBLEM", 179, 183], ["severe", "OBSERVATION_MODIFIER", 149, 155], ["pneumonia", "OBSERVATION", 165, 174]]], ["Eleven received anakinra.", [["anakinra", "CHEMICAL", 16, 24], ["anakinra", "SIMPLE_CHEMICAL", 16, 24], ["anakinra", "TREATMENT", 16, 24], ["anakinra", "OBSERVATION", 16, 24]]], ["The initial dose of anakinra was lower for the first 2 patients treated; once we established a treatment guideline and had adequate supply of the medication the remaining patients were treated in a standardized way.", [["anakinra", "CHEMICAL", 20, 28], ["anakinra", "SIMPLE_CHEMICAL", 20, 28], ["patients", "ORGANISM", 55, 63], ["patients", "ORGANISM", 171, 179], ["patients", "SPECIES", 55, 63], ["patients", "SPECIES", 171, 179], ["anakinra", "TREATMENT", 20, 28], ["a treatment guideline", "TREATMENT", 93, 114], ["the medication", "TREATMENT", 142, 156]]], ["The majority of the patients that did not meet our AHRF definition had a less severe form of COVID-19 and improved gradually over time on their own (data not shown).", [["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28], ["COVID", "TEST", 93, 98], ["less severe", "OBSERVATION_MODIFIER", 73, 84]]], ["Table 2 shows the doses of anakinra and background medications that each patient received including the dosage and duration of methylprednisolone.", [["anakinra", "CHEMICAL", 27, 35], ["methylprednisolone", "CHEMICAL", 127, 145], ["anakinra", "CHEMICAL", 27, 35], ["methylprednisolone", "CHEMICAL", 127, 145], ["anakinra", "SIMPLE_CHEMICAL", 27, 35], ["patient", "ORGANISM", 73, 80], ["methylprednisolone", "SIMPLE_CHEMICAL", 127, 145], ["patient", "SPECIES", 73, 80], ["anakinra", "TREATMENT", 27, 35], ["background medications", "TREATMENT", 40, 62], ["the dosage", "TREATMENT", 100, 110], ["methylprednisolone", "TREATMENT", 127, 145]]], ["Patients treated with anakinra within 36 hours of meeting our O 2 supplementation threshold for eligibility (early-initiation) did not require MV (patients 1-3, 6, 8, 11) or avoided recurrent MV (patient 9).", [["anakinra", "CHEMICAL", 22, 30], ["O 2", "CHEMICAL", 62, 65], ["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 147, 155], ["patient", "ORGANISM", 196, 203], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 147, 155], ["patient", "SPECIES", 196, 203], ["MV", "SPECIES", 143, 145], ["MV", "SPECIES", 192, 194], ["anakinra", "TREATMENT", 22, 30], ["our O 2 supplementation threshold", "TREATMENT", 58, 91], ["MV", "TEST", 143, 145]]], ["All patients not requiring MV were discharged home.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["MV", "SPECIES", 27, 29], ["MV", "TREATMENT", 27, 29]]], ["Patients whose O 2 requirements met our AHRF definition for 4 or more days prior to initiating anakinra (late-initiation) required MV (patients 4, 5, 7, 10).", [["anakinra", "CHEMICAL", 95, 103], ["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 135, 143], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 135, 143], ["MV", "SPECIES", 131, 133], ["anakinra", "TREATMENT", 95, 103], ["MV", "TREATMENT", 131, 133]]], ["We continued anakinra in all late-initiation patients to facilitate extubation.", [["anakinra", "CHEMICAL", 13, 21], ["anakinra", "SIMPLE_CHEMICAL", 13, 21], ["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53], ["anakinra", "TREATMENT", 13, 21]]], ["Two patients developed infections (patients 4 and 7)Resultsprompting discontinuation of anakinra.", [["infections", "DISEASE", 23, 33], ["anakinra", "CHEMICAL", 88, 96], ["patients", "ORGANISM", 4, 12], ["patients", "ORGANISM", 35, 43], ["anakinra", "SIMPLE_CHEMICAL", 88, 96], ["patients", "SPECIES", 4, 12], ["patients", "SPECIES", 35, 43], ["infections", "PROBLEM", 23, 33], ["anakinra", "TREATMENT", 88, 96], ["infections", "OBSERVATION", 23, 33]]], ["Three of the 4 late-initiation patients were extubated and 2Accepted Articlewere discharged home (patients 7 and 10).", [["patients", "ORGANISM", 31, 39], ["patients", "ORGANISM", 98, 106], ["patients", "SPECIES", 31, 39], ["patients", "SPECIES", 98, 106]]], ["One remains in the hospital (patient 4).", [["patient", "ORGANISM", 29, 36], ["patient", "SPECIES", 29, 36]]], ["For those intubated, the duration of MV ranged from 7 to 19 days.", [["MV", "SPECIES", 37, 39], ["MV", "TEST", 37, 39]]], ["For patient 5, anakinra was initiated before blood culture results were available; once a bacterial infection was identified, anakinra was discontinued, but the patient died weeks later.", [["blood", "ANATOMY", 45, 50], ["anakinra", "CHEMICAL", 15, 23], ["bacterial infection", "DISEASE", 90, 109], ["anakinra", "CHEMICAL", 126, 134], ["patient", "ORGANISM", 4, 11], ["anakinra", "SIMPLE_CHEMICAL", 15, 23], ["blood", "ORGANISM_SUBSTANCE", 45, 50], ["anakinra", "SIMPLE_CHEMICAL", 126, 134], ["patient", "ORGANISM", 161, 168], ["patient", "SPECIES", 4, 11], ["patient", "SPECIES", 161, 168], ["anakinra", "TREATMENT", 15, 23], ["blood culture", "TEST", 45, 58], ["a bacterial infection", "PROBLEM", 88, 109], ["anakinra", "TREATMENT", 126, 134], ["bacterial", "OBSERVATION_MODIFIER", 90, 99], ["infection", "OBSERVATION", 100, 109]]], ["Three of the 14 patients meeting criteria did not receive anakinra (patients 12-14); all required MV and then received an IL-6 antagonist (after documentation of elevated IL-6).", [["anakinra", "CHEMICAL", 58, 66], ["anakinra", "CHEMICAL", 58, 66], ["patients", "ORGANISM", 16, 24], ["anakinra", "SIMPLE_CHEMICAL", 58, 66], ["patients", "ORGANISM", 68, 76], ["IL-6 antagonist", "GENE_OR_GENE_PRODUCT", 122, 137], ["IL-6", "GENE_OR_GENE_PRODUCT", 171, 175], ["IL", "PROTEIN", 171, 173], ["patients", "SPECIES", 16, 24], ["patients", "SPECIES", 68, 76], ["MV", "SPECIES", 98, 100], ["anakinra", "TREATMENT", 58, 66], ["an IL-6 antagonist", "TREATMENT", 119, 137], ["elevated IL", "PROBLEM", 162, 173]]], ["IL-6 levels were elevated only in these 3 patients; 1 was extubated and discharged home (patient 13) and 2 remain in the hospital, 1 still intubated (patient 14) and the other initially failed extubation but was successfully extubated 7 days later (patient 12) ( Table 2 ).Accepted ArticleAll eligible patients had ferritin levels over 1,000 ng/mL for 1 to 2 days before consultation ( Figure 1A ).", [["IL-6", "GENE_OR_GENE_PRODUCT", 0, 4], ["patients", "ORGANISM", 42, 50], ["patient", "ORGANISM", 89, 96], ["patient", "ORGANISM", 150, 157], ["patient", "ORGANISM", 249, 256], ["patients", "ORGANISM", 302, 310], ["ferritin", "GENE_OR_GENE_PRODUCT", 315, 323], ["IL-6", "PROTEIN", 0, 4], ["ferritin", "PROTEIN", 315, 323], ["patients", "SPECIES", 42, 50], ["patient", "SPECIES", 89, 96], ["patient", "SPECIES", 150, 157], ["patient", "SPECIES", 249, 256], ["patients", "SPECIES", 302, 310], ["IL", "TEST", 0, 2], ["ferritin levels", "TEST", 315, 330]]], ["Ferritin levels trended down, but only 2 patients achieved levels below 500 ng/mL by the study's conclusion.", [["Ferritin", "GENE_OR_GENE_PRODUCT", 0, 8], ["patients", "ORGANISM", 41, 49], ["Ferritin", "PROTEIN", 0, 8], ["patients", "SPECIES", 41, 49], ["Ferritin levels", "TEST", 0, 15], ["the study", "TEST", 85, 94]]], ["Most of the patients also had lymphocyte counts less than 1,200/uL at the time of consultation, and 5 had lymphocyte counts greater than 1,500/uL by the end of follow up ( Figure 1B ).Accepted ArticleNearly all patients had a CRP greater than 5 mg/dL, which trended down or normalized in all but one patient who developed a superimposed infection ( Figure 1C ).", [["lymphocyte", "ANATOMY", 30, 40], ["lymphocyte", "ANATOMY", 106, 116], ["infection", "DISEASE", 337, 346], ["patients", "ORGANISM", 12, 20], ["lymphocyte", "CELL", 30, 40], ["lymphocyte", "CELL", 106, 116], ["patients", "ORGANISM", 211, 219], ["CRP", "GENE_OR_GENE_PRODUCT", 226, 229], ["patient", "ORGANISM", 300, 307], ["CRP", "PROTEIN", 226, 229], ["patients", "SPECIES", 12, 20], ["patients", "SPECIES", 211, 219], ["patient", "SPECIES", 300, 307], ["lymphocyte counts", "TEST", 30, 47], ["lymphocyte counts", "TEST", 106, 123], ["a CRP", "TEST", 224, 229], ["a superimposed infection", "PROBLEM", 322, 346], ["superimposed", "OBSERVATION_MODIFIER", 324, 336], ["infection", "OBSERVATION", 337, 346]]], ["In patients 12-14, the levels of ferritin and lymphocyte counts were similar to those of the patients that received anakinra and did not fluctuate over the course of the disease and our observation period; CRP levels normalized within 2 days of receiving anti-IL-6 biologic (data not shown).DiscussionThis case series suggests that anakinra confers the greatest benefit in COVID-19 with features of CSS when patients require high levels of supplemental O 2 for <2 days and before intubation.", [["lymphocyte", "ANATOMY", 46, 56], ["anakinra", "CHEMICAL", 116, 124], ["anakinra", "CHEMICAL", 332, 340], ["O 2", "CHEMICAL", 453, 456], ["patients", "ORGANISM", 3, 11], ["ferritin", "GENE_OR_GENE_PRODUCT", 33, 41], ["lymphocyte", "CELL", 46, 56], ["patients", "ORGANISM", 93, 101], ["anakinra", "SIMPLE_CHEMICAL", 116, 124], ["CRP", "GENE_OR_GENE_PRODUCT", 206, 209], ["anti-IL-6", "GENE_OR_GENE_PRODUCT", 255, 264], ["anakinra", "SIMPLE_CHEMICAL", 332, 340], ["patients", "ORGANISM", 408, 416], ["ferritin", "PROTEIN", 33, 41], ["CRP", "PROTEIN", 206, 209], ["patients", "SPECIES", 3, 11], ["patients", "SPECIES", 93, 101], ["patients", "SPECIES", 408, 416], ["the levels of ferritin", "TEST", 19, 41], ["lymphocyte counts", "TEST", 46, 63], ["anakinra", "TREATMENT", 116, 124], ["the disease", "PROBLEM", 166, 177], ["CRP levels", "TEST", 206, 216], ["anti-IL", "TREATMENT", 255, 262], ["anakinra", "TREATMENT", 332, 340], ["COVID", "TEST", 373, 378], ["CSS", "TREATMENT", 399, 402], ["intubation", "TREATMENT", 480, 490], ["lymphocyte counts", "OBSERVATION", 46, 63], ["anakinra", "OBSERVATION", 116, 124]]], ["Our treatment strategy involved giving high doses of anakinra soon after development of AHRF followed by a slow tapering over a maximum of 20 days, guided by clinical response and tolerability.", [["anakinra", "CHEMICAL", 53, 61], ["AHRF", "DISEASE", 88, 92], ["anakinra", "SIMPLE_CHEMICAL", 53, 61], ["Our treatment strategy", "TREATMENT", 0, 22], ["anakinra", "TREATMENT", 53, 61], ["AHRF", "PROBLEM", 88, 92], ["a slow tapering", "TREATMENT", 105, 120]]], ["The goal of treating patients at risk for MV was to prevent organ damage, morbidity and, in the setting of a rapidly progressing pandemic, depletion of healthcare resources such as ventilators.", [["organ", "ANATOMY", 60, 65], ["organ damage", "DISEASE", 60, 72], ["patients", "ORGANISM", 21, 29], ["organ", "ORGAN", 60, 65], ["patients", "SPECIES", 21, 29], ["MV", "SPECIES", 42, 44], ["MV", "TREATMENT", 42, 44], ["organ damage", "PROBLEM", 60, 72], ["morbidity", "PROBLEM", 74, 83], ["a rapidly progressing pandemic", "PROBLEM", 107, 137], ["healthcare resources", "TREATMENT", 152, 172], ["ventilators", "TREATMENT", 181, 192], ["damage", "OBSERVATION", 66, 72], ["morbidity", "OBSERVATION", 74, 83], ["rapidly", "OBSERVATION_MODIFIER", 109, 116], ["progressing", "OBSERVATION_MODIFIER", 117, 128], ["pandemic", "OBSERVATION", 129, 137]]], ["Our data demonstrate that the early-initiation patients did not require MV and have been discharged home.", [["patients", "ORGANISM", 47, 55], ["patients", "SPECIES", 47, 55], ["MV", "SPECIES", 72, 74], ["Our data", "TEST", 0, 8], ["MV", "TREATMENT", 72, 74]]], ["This early aggressive treatment was likely key in improving the patients' risk for requiring MV without major risk of complications.", [["patients", "ORGANISM", 64, 72], ["patients", "SPECIES", 64, 72], ["MV", "SPECIES", 93, 95], ["This early aggressive treatment", "TREATMENT", 0, 31], ["MV", "TREATMENT", 93, 95], ["complications", "PROBLEM", 118, 131], ["complications", "OBSERVATION", 118, 131]]], ["For patients requiring MV, anakinra should be used with caution due to risk of complications such as superimposed bacterial infection.DiscussionTo date, there are several reports from Europe regarding the use of anakinra in patients with COVID-19.", [["anakinra", "CHEMICAL", 27, 35], ["bacterial infection", "DISEASE", 114, 133], ["anakinra", "CHEMICAL", 212, 220], ["patients", "ORGANISM", 4, 12], ["anakinra", "SIMPLE_CHEMICAL", 27, 35], ["anakinra", "SIMPLE_CHEMICAL", 212, 220], ["patients", "ORGANISM", 224, 232], ["patients", "SPECIES", 4, 12], ["patients", "SPECIES", 224, 232], ["MV", "SPECIES", 23, 25], ["MV", "TREATMENT", 23, 25], ["anakinra", "TREATMENT", 27, 35], ["caution", "TREATMENT", 56, 63], ["complications", "PROBLEM", 79, 92], ["superimposed bacterial infection", "PROBLEM", 101, 133], ["anakinra", "TREATMENT", 212, 220], ["COVID", "TEST", 238, 243], ["complications", "OBSERVATION", 79, 92], ["superimposed", "OBSERVATION_MODIFIER", 101, 113], ["bacterial", "OBSERVATION_MODIFIER", 114, 123], ["infection", "OBSERVATION", 124, 133]]], ["Unlike our study, they did not require that patients have severe respiratory failure in order to initiate anakinra.", [["respiratory", "ANATOMY", 65, 76], ["respiratory failure", "DISEASE", 65, 84], ["anakinra", "CHEMICAL", 106, 114], ["patients", "ORGANISM", 44, 52], ["anakinra", "SIMPLE_CHEMICAL", 106, 114], ["patients", "SPECIES", 44, 52], ["our study", "TEST", 7, 16], ["severe respiratory failure", "PROBLEM", 58, 84], ["anakinra", "TREATMENT", 106, 114], ["severe", "OBSERVATION_MODIFIER", 58, 64], ["respiratory failure", "OBSERVATION", 65, 84]]], ["[10] [11] [12] Such an approach increases the possibility of overestimating the medication's Accepted Article efficacy and confers potentially unnecessary risk of medication side effects.", [["[10] [11] [12]", "SIMPLE_CHEMICAL", 0, 14], ["the medication", "TREATMENT", 76, 90], ["medication side effects", "PROBLEM", 163, 186]]], ["Our criteria for initiating anakinra included severe respiratory failure to avoid treating patients who are more likely to improve without immunosuppression.", [["respiratory", "ANATOMY", 53, 64], ["anakinra", "CHEMICAL", 28, 36], ["respiratory failure", "DISEASE", 53, 72], ["anakinra", "SIMPLE_CHEMICAL", 28, 36], ["patients", "ORGANISM", 91, 99], ["patients", "SPECIES", 91, 99], ["anakinra", "TREATMENT", 28, 36], ["severe respiratory failure", "PROBLEM", 46, 72], ["immunosuppression", "TREATMENT", 139, 156], ["severe", "OBSERVATION_MODIFIER", 46, 52], ["respiratory failure", "OBSERVATION", 53, 72], ["more likely", "UNCERTAINTY", 108, 119]]], ["We defined a specific phenotype of patients with COVID-19, which allowed us to examine the clinical response in a group of patients with similar clinical presentation.DiscussionThree of the patients who fit this phenotype did not receive anakinra and instead received an IL-6 antagonist after documentation of elevated IL-6.", [["anakinra", "CHEMICAL", 238, 246], ["anakinra", "CHEMICAL", 238, 246], ["patients", "ORGANISM", 35, 43], ["patients", "ORGANISM", 123, 131], ["patients", "ORGANISM", 190, 198], ["anakinra", "SIMPLE_CHEMICAL", 238, 246], ["IL-6 antagonist", "GENE_OR_GENE_PRODUCT", 271, 286], ["IL-6", "GENE_OR_GENE_PRODUCT", 319, 323], ["IL-6", "PROTEIN", 319, 323], ["patients", "SPECIES", 35, 43], ["patients", "SPECIES", 123, 131], ["patients", "SPECIES", 190, 198], ["COVID", "TEST", 49, 54], ["anakinra", "TREATMENT", 238, 246], ["an IL-6 antagonist", "TREATMENT", 268, 286], ["elevated IL", "PROBLEM", 310, 321]]], ["Since IL-1 can induce IL-6, it is possible that anakinra could have prevented MV in those 3 patients.", [["anakinra", "CHEMICAL", 48, 56], ["IL-1", "GENE_OR_GENE_PRODUCT", 6, 10], ["IL-6", "GENE_OR_GENE_PRODUCT", 22, 26], ["anakinra", "SIMPLE_CHEMICAL", 48, 56], ["patients", "ORGANISM", 92, 100], ["IL-1", "PROTEIN", 6, 10], ["IL-6", "PROTEIN", 22, 26], ["patients", "SPECIES", 92, 100], ["MV", "SPECIES", 78, 80], ["anakinra", "PROBLEM", 48, 56], ["anakinra", "OBSERVATION", 48, 56]]], ["The possibility that anakinra may have improved outcomes in those patients is also supported by the presence of fever, a symptom mediated by IL-1.", [["anakinra", "CHEMICAL", 21, 29], ["fever", "DISEASE", 112, 117], ["anakinra", "SIMPLE_CHEMICAL", 21, 29], ["patients", "ORGANISM", 66, 74], ["IL-1", "GENE_OR_GENE_PRODUCT", 141, 145], ["IL-1", "PROTEIN", 141, 145], ["patients", "SPECIES", 66, 74], ["anakinra", "TREATMENT", 21, 29], ["fever", "PROBLEM", 112, 117], ["possibility", "UNCERTAINTY", 4, 15], ["anakinra", "OBSERVATION", 21, 29], ["improved", "OBSERVATION_MODIFIER", 39, 47], ["fever", "OBSERVATION", 112, 117]]], ["13 MV is a known risk factor for developing bacterial pneumonia.", [["bacterial pneumonia", "DISEASE", 44, 63], ["MV", "SPECIES", 3, 5], ["a known risk factor", "PROBLEM", 9, 28], ["developing bacterial pneumonia", "PROBLEM", 33, 63], ["bacterial", "OBSERVATION_MODIFIER", 44, 53], ["pneumonia", "OBSERVATION", 54, 63]]], ["Both patients who continued anakinra after requiring MV developed superimposed bacterial infection, which suggests anakinra may have augmented this risk.", [["anakinra", "CHEMICAL", 28, 36], ["bacterial infection", "DISEASE", 79, 98], ["anakinra", "CHEMICAL", 115, 123], ["patients", "ORGANISM", 5, 13], ["anakinra", "SIMPLE_CHEMICAL", 115, 123], ["patients", "SPECIES", 5, 13], ["MV", "SPECIES", 53, 55], ["anakinra", "TREATMENT", 28, 36], ["MV", "TREATMENT", 53, 55], ["superimposed bacterial infection", "PROBLEM", 66, 98], ["anakinra", "TREATMENT", 115, 123], ["bacterial", "OBSERVATION_MODIFIER", 79, 88], ["infection", "OBSERVATION", 89, 98], ["anakinra", "OBSERVATION", 115, 123]]], ["However, for patients who did not require MV, anakinra was well tolerated without development of major infections.", [["anakinra", "CHEMICAL", 46, 54], ["infections", "DISEASE", 103, 113], ["patients", "ORGANISM", 13, 21], ["anakinra", "SIMPLE_CHEMICAL", 46, 54], ["patients", "SPECIES", 13, 21], ["MV", "SPECIES", 42, 44], ["MV", "TREATMENT", 42, 44], ["anakinra", "TREATMENT", 46, 54], ["major infections", "PROBLEM", 97, 113], ["major", "OBSERVATION_MODIFIER", 97, 102], ["infections", "OBSERVATION", 103, 113]]], ["Elevation in transaminase levels was the most frequently observed laboratory abnormality patients developed on anakinra.", [["anakinra", "CHEMICAL", 111, 119], ["patients", "ORGANISM", 89, 97], ["anakinra", "SIMPLE_CHEMICAL", 111, 119], ["patients", "SPECIES", 89, 97], ["Elevation in transaminase levels", "PROBLEM", 0, 32], ["laboratory abnormality", "PROBLEM", 66, 88], ["anakinra", "TREATMENT", 111, 119], ["transaminase", "ANATOMY", 13, 25], ["most frequently", "OBSERVATION_MODIFIER", 41, 56]]], ["It is possible that these changes were caused by CSS itself; in all cases, the enzyme levels improved after lowering the anakinra dose, so discontinuation was not necessary.", [["anakinra", "CHEMICAL", 121, 129], ["anakinra", "SIMPLE_CHEMICAL", 121, 129], ["the enzyme levels", "TEST", 75, 92], ["lowering the anakinra dose", "TREATMENT", 108, 134], ["discontinuation", "TREATMENT", 139, 154]]], ["All patients were able to tolerate between 2 to 6 days of anakinra 100 mg every 6 hours before we decided to lower the dose.", [["anakinra", "CHEMICAL", 58, 66], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["anakinra", "TREATMENT", 58, 66]]], ["The most common reasons for decreasing the dose were clinical improvement or elevation in transaminase levels.", [["transaminase", "SIMPLE_CHEMICAL", 90, 102], ["elevation in transaminase levels", "PROBLEM", 77, 109], ["elevation", "OBSERVATION_MODIFIER", 77, 86]]], ["Only Accepted Article one individual on anakinra experienced an injection site reaction, and this was the patient with the longest duration of treatment (19 days).", [["anakinra", "CHEMICAL", 40, 48], ["patient", "ORGANISM", 106, 113], ["patient", "SPECIES", 106, 113], ["anakinra", "TREATMENT", 40, 48], ["an injection site reaction", "PROBLEM", 61, 87], ["treatment", "TREATMENT", 143, 152]]], ["Some studies of MAS used intravenous (IV) anakinra while our study used the SQ form.", [["anakinra", "CHEMICAL", 42, 50], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 25, 36], ["intravenous (IV) anakinra", "TREATMENT", 25, 50], ["our study", "TEST", 57, 66]]], ["11 The pharmacokinetics of the medication could be affected by SQ administration leading to slowed absorption, especially in obese patients.", [["SQ", "CHEMICAL", 63, 65], ["SQ", "SIMPLE_CHEMICAL", 63, 65], ["patients", "ORGANISM", 131, 139], ["patients", "SPECIES", 131, 139], ["the medication", "TREATMENT", 27, 41], ["SQ administration", "TREATMENT", 63, 80], ["slowed absorption", "PROBLEM", 92, 109]]], ["Still, our study provides insight into the use of SQ anakinra when the IV form is not available.DiscussionOur study is the first report from the U.S. to examine the use of anakinra in patients with COVID-19 and features of CSS.", [["SQ anakinra", "CHEMICAL", 50, 61], ["anakinra", "CHEMICAL", 172, 180], ["SQ anakinra", "SIMPLE_CHEMICAL", 50, 61], ["anakinra", "SIMPLE_CHEMICAL", 172, 180], ["patients", "ORGANISM", 184, 192], ["patients", "SPECIES", 184, 192], ["our study", "TEST", 7, 16], ["SQ anakinra", "TREATMENT", 50, 61], ["the IV form", "TREATMENT", 67, 78], ["anakinra", "TREATMENT", 172, 180], ["COVID", "TEST", 198, 203]]], ["A strength of our study is that we defined a narrow phenotype, which enabled us both to target a specific group of patients most likely to benefit from anakinra and to avoid risks of immunosuppression in patients more likely to recover on their own.", [["anakinra", "CHEMICAL", 152, 160], ["patients", "ORGANISM", 115, 123], ["anakinra", "SIMPLE_CHEMICAL", 152, 160], ["patients", "ORGANISM", 204, 212], ["patients", "SPECIES", 115, 123], ["patients", "SPECIES", 204, 212], ["our study", "TEST", 14, 23], ["a narrow phenotype", "PROBLEM", 43, 61], ["anakinra", "TREATMENT", 152, 160], ["immunosuppression", "TREATMENT", 183, 200]]], ["Whereas previous studies in MAS used primarily intravenous (IV) anakinra, our study showed benefit with SQ anakinra.", [["intravenous", "ANATOMY", 47, 58], ["anakinra", "CHEMICAL", 64, 72], ["anakinra", "CHEMICAL", 107, 115], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 47, 58], ["anakinra", "SIMPLE_CHEMICAL", 64, 72], ["SQ anakinra", "SIMPLE_CHEMICAL", 104, 115], ["previous studies", "TEST", 8, 24], ["intravenous (IV) anakinra", "TREATMENT", 47, 72], ["our study", "TEST", 74, 83], ["SQ anakinra", "TREATMENT", 104, 115]]], ["Our study has several limitations, including a small sample and the absence of controls.DiscussionWe were still able to examine the relevance of our selection criteria by documenting clinical progression of 3 patients who did not receive the anakinra.DiscussionOur experience provides insight regarding the use of anakinra in COVID-19 patients with severe AHRF and features of CSS.", [["anakinra", "CHEMICAL", 242, 250], ["anakinra", "CHEMICAL", 314, 322], ["AHRF", "DISEASE", 356, 360], ["patients", "ORGANISM", 209, 217], ["anakinra", "SIMPLE_CHEMICAL", 314, 322], ["patients", "ORGANISM", 335, 343], ["patients", "SPECIES", 209, 217], ["patients", "SPECIES", 335, 343], ["Our study", "TEST", 0, 9], ["a small sample", "PROBLEM", 45, 59], ["the anakinra", "TREATMENT", 238, 250], ["anakinra", "TREATMENT", 314, 322], ["severe AHRF", "PROBLEM", 349, 360], ["CSS", "PROBLEM", 377, 380], ["small", "OBSERVATION_MODIFIER", 47, 52]]], ["We identified a specific patient phenotype with COVID-19 that might benefit most from treatment with anakinra.", [["anakinra", "CHEMICAL", 101, 109], ["patient", "ORGANISM", 25, 32], ["anakinra", "SIMPLE_CHEMICAL", 101, 109], ["COVID-19", "DNA", 48, 56], ["patient", "SPECIES", 25, 32], ["COVID", "TEST", 48, 53], ["anakinra", "TREATMENT", 101, 109]]], ["It also provides guidance on a treatment strategy that employs high doses of anakinra for a minimum of 3 to 4 days followed by a slow taper based on clinical response and side effects, such as elevation in transaminases.", [["anakinra", "CHEMICAL", 77, 85], ["anakinra", "SIMPLE_CHEMICAL", 77, 85], ["transaminases", "SIMPLE_CHEMICAL", 206, 219], ["a treatment strategy", "TREATMENT", 29, 49], ["anakinra", "TREATMENT", 77, 85], ["a slow taper", "TREATMENT", 127, 139], ["side effects", "PROBLEM", 171, 183], ["elevation in transaminases", "PROBLEM", 193, 219], ["elevation", "OBSERVATION_MODIFIER", 193, 202]]], ["The results of this study suggest that anakinra should be used cautiously in patients requiring MV, as those patientsAccepted ArticleThis article is protected by copyright.", [["anakinra", "CHEMICAL", 39, 47], ["anakinra", "SIMPLE_CHEMICAL", 39, 47], ["patients", "ORGANISM", 77, 85], ["patients", "ORGANISM", 109, 117], ["patients", "SPECIES", 77, 85], ["patients", "SPECIES", 109, 117], ["MV", "SPECIES", 96, 98], ["this study", "TEST", 15, 25], ["anakinra", "TREATMENT", 39, 47], ["MV", "TREATMENT", 96, 98]]], ["All rights reserved (6) 41 days on MV as of June 2, 2020.Not applicableAll except patients 8 and 11 received hydroxychloroquine.", [["hydroxychloroquine", "CHEMICAL", 109, 127], ["hydroxychloroquine", "CHEMICAL", 109, 127], ["patients", "ORGANISM", 82, 90], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 109, 127], ["patients", "SPECIES", 82, 90], ["MV", "SPECIES", 35, 37], ["MV", "TREATMENT", 35, 37], ["hydroxychloroquine", "TREATMENT", 109, 127]]], ["All patients were off anakinra by the end of the case series.Not applicable*Patient's blood culture were drawn before anakinra was initiated and results were pending when the medication was started.", [["blood", "ANATOMY", 86, 91], ["anakinra", "CHEMICAL", 22, 30], ["anakinra", "CHEMICAL", 118, 126], ["patients", "ORGANISM", 4, 12], ["blood", "ORGANISM_SUBSTANCE", 86, 91], ["anakinra", "SIMPLE_CHEMICAL", 118, 126], ["patients", "SPECIES", 4, 12], ["Patient", "SPECIES", 76, 83], ["anakinra", "TREATMENT", 22, 30], ["Patient's blood culture", "TEST", 76, 99], ["anakinra", "TREATMENT", 118, 126], ["the medication", "TREATMENT", 171, 185]]], ["Once the results were positive, we discontinued anakinra.", [["anakinra", "CHEMICAL", 48, 56], ["anakinra", "CHEMICAL", 48, 56], ["anakinra", "SIMPLE_CHEMICAL", 48, 56], ["anakinra", "TREATMENT", 48, 56]]]]}